



β -cell-specific E2f1 deficiency impairs glucose homeostasis, β -cell identity, and insulin secretion

Frédéric Oger, Cyril Bourouh, Marika Elsa Friano, Emilie Courty, Laure Rolland, Xavier Gromada, Maeva Moreno, Charlène Carney, Nabil Rabhi, Emmanuelle Durand, et al.

► To cite this version:

Frédéric Oger, Cyril Bourouh, Marika Elsa Friano, Emilie Courty, Laure Rolland, et al.. β -cell-specific E2f1 deficiency impairs glucose homeostasis, β -cell identity, and insulin secretion. *Diabetes*, 2023, 72 (8), pp.1112-1126. 10.2337/db22-0604 . hal-04200339

HAL Id: hal-04200339

<https://hal.science/hal-04200339>

Submitted on 14 Nov 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **β-cell specific *E2f1* deficiency impairs glucose**
2 **homeostasis, β-cell identity and insulin secretion**

3
4 **Frédéric Oger^{1, 11}, Cyril Bourouh^{1, 11}, Marika Elsa Friano^{2, 11}, Emilie Courty^{3, 11}, Laure**
5 **Rolland³, Xavier Gromada¹, Maeva Moreno¹, Charlène Carney¹, Nabil Rabhi⁴,**
6 **Emmanuelle Durand¹, Souhila Amanzougarene¹, Lionel Berberian¹, Mehdi Derhourhi¹,**
7 **Etienne Blanc¹, Sarah Anissa Hannou¹, Pierre-Damien Denechaud^{5, 1}, Zohra Benfodda⁶,**
8 **Patrick Meffre⁶, Lluis Fajas⁵, Julie Kerr-Conte⁷, François Pattou⁷, Philippe Froguel^{1, 8},**
9 **Benoit Pourcet⁹, Amélie Bonnefond^{1, 8}, Patrick Collombat² and Jean-Sébastien**
10 **Annicotte^{3, 10,*}**

11
12 ¹ Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, CNRS, U1283 - UMR 8199 -
13 EGID, F-59000 Lille, France
14 ² Université Côte d'Azur, CNRS, INSERM, IBV, F-06000 Nice, France
15 ³ Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167 – RID-AGE-Facteurs de
16 risque et déterminants moléculaires des maladies liées au vieillissement, F-59000 Lille,
17 France

18 ⁴ Department of Biochemistry, Boston University School of Medicine, MA02118 Boston,
19 USA

20 ⁵ Center for Integrative Genomics, Université de Lausanne, CH-1015 Lausanne,
21 Switzerland

22 ⁶ Univ. Nîmes, UPR CHROME, F-30021 Nîmes cedex 1, France

23 ⁷ Univ. Lille, Inserm, CHU Lille, U1190 - EGID, F-59000 Lille, France

24 ⁸ Department of Metabolism, Imperial College London, Hammersmith Hospital, London
25 W12 0NN, UK

26 ⁹ Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011 - EGID, F-59000 Lille,
27 France

28 ¹⁰ Lead contact

29 ¹¹ Contributed equally to this work

30 ¹ Present address: Inserm, UMR1297, Institute of Metabolic and Cardiovascular Diseases,
31 F-31000 Toulouse, France

32 * Correspondence : jean-sebastien.annicotte@inserm.fr (J.-S. A.)

33 INSERM UMR1167-RID-AGE (INSERM / Université de Lille / CHU de Lille / Institut
34 Pasteur de Lille) - Faculté de Médecine - Pôle recherche

35 1 place de Verdun - 59045 Lille Cedex - France

36 Phone: +33 (0)3 20 97 42 54

37

38 Running title: E2F1 and beta-cell identity

39 **Abstract**

40 The loss of pancreatic β -cell identity emerges as an important feature of type 2 diabetes
41 development, but the molecular mechanisms are still elusive. Here, we explore the cell-
42 autonomous role of the cell cycle regulator and transcription factor E2F1 in the maintenance
43 of β -cell identity, insulin secretion and glucose homeostasis. We show that the β -cell-specific
44 loss of *E2f1* function in mice triggers glucose intolerance associated with defective insulin
45 secretion, an altered endocrine cell mass, a downregulation of many β -cell genes and a
46 concomitant increase of non- β -cell markers. Mechanistically, the epigenomic profiling of
47 promoters of these non- β -cell upregulated genes identified an enrichment of bivalent
48 H3K4me3/H3K27me3 or H3K27me3 marks. Conversely, promoters of downregulated
49 genes were enriched in active chromatin H3K4me3 and H3K27ac histone marks. We find
50 that specific *E2f1* transcriptional, cistromic and epigenomic signatures are associated with
51 these β -cell dysfunctions, with E2F1 directly regulating several β -cell genes at the chromatin
52 level. Finally, the pharmacological inhibition of E2F transcriptional activity in human islets
53 also impairs insulin secretion and the expression of β -cell identity genes. Our data suggest
54 that E2F1 is critical for maintaining β -cell identity and function through a sustained control
55 of β -cell and non β -cell transcriptional programs.

56

57 **Article Highlights**

- 58
- β -cell specific *E2f1* deficiency in mice impairs glucose tolerance.
 - Loss of *E2f1* function alters α -to- β -cell ratio but do not trigger β -cell conversion into
 α cells.
 - Pharmacological inhibition of E2F activity inhibits glucose-stimulated insulin secretion
and alters β - and α -cell gene expression in human islets.
 - E2F1 maintains β -cell function and identity through the control of transcriptomic and
epigenetic programs.

66 **Introduction**

67

68 Type 2 Diabetes (T2D) is a progressive metabolic disorder characterized by chronic
69 hyperglycemia due to inadequate pancreatic β -cell response to peripheral insulin resistance.
70 Usually, β -cells respond to obesity and aging-associated loss of insulin sensitivity by
71 increasing insulin secretion to compensate for rising glycemia. However, when insulin
72 secretion and action are imbalanced, the emerging chronic hyperglycemic state
73 progressively leads to massive β -cell dysfunction and decreased mass (1). Importantly,
74 single cell transcriptomic analysis of human pancreatic islet cells from T2D and healthy
75 individuals revealed the complex identity of endocrine cells associated with the
76 pathophysiology (2-4). In addition, recent studies demonstrated a loss of transcriptional
77 maturity (5) and cell-type-specific regulatory profiles underlying T2D pathogenesis (6).
78 Moreover, histology studies of human diabetic pancreata found a significant increase in bi-
79 hormonal Insulin+ (Ins+)/Glucagon+ (Glu+) cells suggesting an altered β -cell identity (7; 8).
80 Accordingly, recent studies using β -cell lineage tracing murine models have demonstrated
81 that islet cells can trans-differentiate directly toward another islet cell fate and/or de-
82 differentiate toward a progenitor-like cell (9). In this context, both genetic and epigenetic
83 mechanisms are important to maintain adult β -cell fate and function in mouse and human
84 (10-13). Yet, the molecular actors controlling β -cell mass, identity maintenance and cellular
85 plasticity still need to be identified.

86 Gene transcription and chromatin states are tightly regulated to ensure the
87 appropriate transcriptome for a specific cell type. Many transcription factors have been
88 identified as key regulators of β -cell identity and function, including Pdx1 (14), Pax6 (15),
89 Nkx6.1 (16) and Nkx2.2 (17). Interestingly, pleiotropic transcription factors are also involved
90 in the control of β -cell functions and glucose homeostasis, suggesting their important roles
91 in activating or repressing gene transcription. Amongst those, members of E2F transcription

factor (E2F1 to E2F8) family play critical roles in cell survival and proliferation, by regulating the expression of genes involved in cell-cycle progression (18). The transcriptional activity of E2F1, the founder member of the family, is regulated by several protein complexes including the retinoblastoma tumor suppressor family (pRB, p107, p130), cyclin-dependent kinases (such as CDK4) and their regulatory partner cyclins (Ccn), as well as the family of the cdk inhibitors (CDKi, such as p16^{Ink4A} encoded by the *Cdkn2a* locus). Interestingly, the role of the cell cycle machinery goes beyond the unique regulation of cell proliferation. Indeed, modulating the expression levels of these cell cycle regulators revealed an important role for these proteins in glucose homeostasis (19) and diabetes development through the control of β-cell mass and function (20; 21). We and others have recently identified a molecular crosstalk between *E2f1/pRb* and Glucagon-like peptide-1 (Glp-1) pathways (22; 23). Although *E2F1* gene expression is decreased in human T2D islets (24), the causal effect of *E2F1* deficiency on impaired β-cell mass, function and T2D development is not elucidated. In particular, the cellular and molecular mechanisms underlying the contribution of *E2F1* as a transcription factor to β-cell identity and/or plasticity in mice and humans remain unknown. We recently demonstrated that the germline deletion of *E2f1* in the obese and diabetic *db/db* mouse model, despite lowering liver steatosis, does not protect against diabetes or obesity (25). Interestingly, we observed decreased plasma insulin levels, increased plasma glucose and glucose intolerance in *db/db::E2f1^{-/-}* mice compared to *db/db::E2f1^{+/+}* controls (25). These metabolic alterations in a diabetic background raises the possibility that *E2f1* may contribute to islet morphology, cell identity and function in a cell-autonomous manner. To test this hypothesis, we generated mice lacking *E2f1* in β-cells and identified that *E2f1* is mandatory to maintain β-cell identity gene expression in both mouse models and human islets. By combining cellular and mouse models to pharmacological approaches, we identify *E2f1* as a critical transcription factor necessary to maintain proper β-cell gene expression and function, while repressing non β-cell transcriptional programs.

118 **Research design and methods**

119

120 A detailed description of the following procedures can be found in the Supplemental Material
121 section.

122 **Animal Experiments.** *In vivo* experiments were performed in compliance with the French
123 ethical guidelines for studies on experimental animals (animal house agreement no. A 59-
124 35015, Authorization for Animal Experimentation no.59-350294, project approval by our
125 local ethical committee no. CEEA 482012, APAFIS#2915-201511300923025v4). All
126 experiments were performed with male mice. *E2f1*^{-/-} (Jax Lab, stock number #002785),
127 *CMV-CDK4*^{R24C} (26), *Cdkn2a*^{-/-} (27), *db/db::E2f1*^{-/-} (25), *E2f1* floxed (*E2f1*^{flox/flox}, Taconic
128 Biosciences, NY, USA) and RIP-Cre^{+/+} mice were previously described (25; 28). MIP-CreERT
129 mice were obtained from Jax Lab (stock number #024709, (29)). For lineage tracing
130 experiments, Rosa26R-td-tomato (Jax Lab, stock number #007914) and Rosa26R-ECFP
131 (Gt(ROSA)26Sortm2(ECFP)Cos, (30)) mice were used. Intraperitoneal glucose and insulin
132 tolerance tests (ipGTT and ITT, respectively) were performed on 6, 8 and 12-week-old male
133 (*E2f1*^{fl/fl} and *E2f1*^{β/β}) or 5-month-old (*E2f1*^{fl/fl} and *E2f1*^{MIP-CreERT β/β}) littermates as previously
134 described (31) on 16-hr-fasted animals for ipGTT and 5-hr-fasted animals for ITT. Glycemia
135 was measured using the Accu-Check Performa (Roche Diagnostics). Circulating insulin
136 levels were measured using the mouse Insulin ELISA kit (Mercodia).

137

138 **Immunofluorescence, Immunohistochemistry and Morphometry.** Immunofluorescence
139 and immunohistochemistry were performed exactly as described previously (31). Briefly,
140 pancreatic tissues were fixed in 10% formalin, embedded in paraffin and sectioned at 5 µm.
141 For immunofluorescence microscopy analyses, after antigen retrieval using citrate buffer, 5-
142 µm formalin-fixed paraffin-embedded (FFPE) pancreatic sections were incubated with

143 primary antibodies as indicated. Immunofluorescence staining was revealed by using a
144 fluorescein-isothiocyanate-conjugated anti-rabbit (for cleaved caspase-3, Alexa-conjugated
145 anti-mouse (for glucagon), anti-rabbit (for Glut-2) or anti-guinea pig (for insulin) secondary
146 antibodies were used to identify specifically primary antibodies. Nuclei were stained with
147 Dapi (Sigma-Aldrich, D9542). For morphometric analysis, three to ten animals from each
148 genotype were analyzed, and images were processed and quantified using ImageJ software
149 by an observer blinded to experimental groups. Morphometric analysis including islet
150 density, β -cell fraction and mass was performed as previously described (32). β -cell size
151 was measured using immunofluorescent staining of pancreatic sections using an anti-Glut-
152 2 antibody (Merck, #07-1402-1) on 5 mice from each genotype and acquisition was done on
153 a Spinning disk confocal microscope (Zeiss). 20 islets per mice were analyzed, and 5 mice
154 from each genotype were used to analyze β -cell size. Quantification was then performed
155 using a custom-made script with ImageJ software (available upon request). β -cell
156 proliferation was measured using BrdU staining on FFPE pancreatic sections. Apoptosis
157 was quantified using an immunofluorescent staining using an anti-cleaved caspase 3.

158

159 **Cell Culture, Pancreatic Islet Studies and Pharmacological Treatments.** For mouse islet
160 studies, pancreata were digested by type V collagenase (Sigma-Aldrich, C9263; 1.5 mg/ml)
161 for 10 min at 37°C as described previously (31). Briefly, after digestion and separation in a
162 density gradient medium, islets were purified by handpicking under a macroscope and
163 cultured during 16 hours before subsequent analysis. For expression studies, mouse
164 isolated islets were snap-frozen in liquid nitrogen before RNA extraction. Human pancreatic
165 tissues were harvested from brain-dead, non-diabetic adult human donors (see
166 Supplementary Table S1 for donor information). Isolation and islets culture were performed
167 as described (33). Human islets were treated for 48 hours with DMSO 0.1% or HLM006474
168 (34; 35) at 10 μ M. Data are expressed as a ratio of total insulin content. For mRNA and

169 protein quantification, human islets were isolated as described above and snap-frozen for
170 further processing. Min6 cells (AddexBio) were cultured in DMEM (Gibco) with 15% fetal
171 bovine serum, 100 mg/mL penicillin-streptomycin, and 55 mM beta-mercaptoethanol. Min6
172 cells were treated with HLM006474 (10 μ M) or DMSO 0.1% (35) for 48 hours before GSIS
173 assay or RNA extraction.

174

175 **RNA extraction, qPCR and RNA-Sequencing.** Total RNA was extracted from cells and
176 tissues using TRIzol reagent (Life Technologies) as described previously (22). mRNA
177 expression was measured after reverse transcription by quantitative real-time PCR (qRT-
178 PCR) with FastStart SYBR Green master mix (Roche) using a LightCycler Nano or LC480
179 instruments (Roche). qRT-PCR results were normalized to endogenous cyclophilin
180 reference mRNA levels. The results are expressed as the relative mRNA level of a specific
181 gene expression using the formula $2^{-\Delta Ct}$. The complete list of primers is presented in
182 Supplementary Table S2. For RNA sequencing, total RNA was extracted from Min6 cells or
183 pancreatic islets using the RNeasy Plus Microkit (Qiagen) following manufacturer's
184 instructions. Using a $P < 0.05$ adjusted for multiple comparisons as threshold for differential
185 gene expression analyses, we then performed pathway analysis using Ingenuity Pathway
186 Analysis (Ingenuity Systems, Qiagen), Metascape (36) and Gene Set Enrichment Analysis
187 (GSEA; <http://software.broadinstitute.org/gsea/>).

188

189 **Chromatin immunoprecipitation and ChIP-Sequencing.** ChIP experiments were
190 performed on formaldehyde-fixed Min6 cells. Briefly, 20×10^6 Min6 cells or 100×10^6 Min6
191 cells (for E2f1 ChIP-seq) were treated with formaldehyde at a final concentration of 1% to
192 crosslink DNA and protein complexes during 10 min. The reaction was stopped by the
193 addition of glycine (0.125 M) during 5 min. Cells were lysed and DNA-protein complexes
194 were sheared using the Bioruptor Pico (Diagenode, ref B01060010) for 8 minutes. The

195 sheared chromatin was immunoprecipitated with either the non-specific antibody IgG (Santa
196 Cruz, sc2025), H3K4me3 (Active motif, #61379), H3K27me3 (Active motif, #61017),
197 H3K27ac (Active motif, #39685) or anti-flag (Clone M2, Sigma-Aldrich). Further
198 bioinformatic analyses of the public data sets and those of this study were performed using
199 the open web-based platform Galaxy Europe (<https://usegalaxy.eu>). A list of ChIP-seq and
200 RNA-seq data sets used in this study can be found in Supplementary Table S3. A detailed
201 description of RNA-seq and ChIP-seq procedures can be found in the Supplemental
202 Material.

203

204 **Statistical Analysis.** Data are presented as mean ± s.e.m. Data are derived from multiple
205 experiments unless stated otherwise. Statistical analysis was performed using a two-tailed
206 unpaired *t*-test or one-way or two-way ANOVA with Tukey's post hoc test comparing all
207 groups to each other, using GraphPad Prism 9.0 software. Differences were considered
208 statistically significant at p 0.05 (*p < 0.05, ** p < 0.01, and *** p < 0.001).

209

210 **Data and Resource Availability.** The datasets and resource generated during and/or
211 analyzed during the current study are available from the corresponding author upon
212 reasonable request.

213 **Results**

214

215 **β-cell specific *E2f1* deficiency impairs glucose tolerance due to defective *in vivo***
216 **glucose-stimulated insulin secretion.**

217

218 To determine whether *E2f1* regulates insulin-producing β-cell fate and function in a cell-
219 autonomous manner, we generated β-cell specific *E2f1*-deficient mice by crossing *E2f1*
220 floxed (*E2f1*^{f/f}) with RIP-Cre (Rip-Cre^{+/}) mice (28). Quantitative RT-PCR showed a 91 %
221 tissue-specific reduction in *E2f1* expression in pancreatic islets isolated from *E2f1*^{β-/-} mice
222 (Supplementary figure S1A). 12-week-old *E2f1*^{β-/-} mice displayed normal body weight
223 (Supplementary figure S1B) and fasting glycemia when fed a chow diet (Supplementary
224 figure S1C) when compared to age-matched control *E2f1* floxed (*E2f1*^{f/f}) and Rip-Cre (Rip-
225 Cre^{+/}) male littermates. No significant difference was observed between *E2f1*^{β-/-} mice and
226 *E2f1*^{f/f} control littermates for body weight, fasting glycemia, glucose tolerance or insulinemia
227 in 6-week-old (Supplementary figures S2A to S2E) and 8-week-old animals (Supplementary
228 figures S2F to S2J). However, when challenged with a bolus of glucose, 12-week-old *E2f1*^{β-/-}
229 mice exhibited glucose intolerance (Figures 1A-B), primarily due to decreased insulin
230 secretion in response to *in vivo* glucose injection (Figure 1C) rather than defective insulin
231 sensitivity (Supplementary figure S2K).

232 We next sought to evaluate the metabolic consequences of modulating *E2f1* expression in
233 adult β cells. To this end, we generated β-cell specific *E2f1* deficient mice (*E2f1*^{MIP-CreERT β-/-})
234 by crossing *E2f1*^{f/f} with the tamoxifen-inducible model MIP-Cre-ERT (MIP-CreERT^{+/}) mice
235 (29). We first confirmed efficient recombination upon tamoxifen treatment in pancreatic islets
236 isolated from *E2f1*^{f/f} and *E2f1*^{MIP-CreERT β-/-} (Supplementary figure S2L). Like *E2f1*^{β-/-} mice,
237 the genetic deletion of *E2f1* in adult β cells revealed glucose intolerance 1 month after
238 tamoxifen administration (Supplementary figures S2M and S2N), a phenotype that was

239 aggravated 3 months post-tamoxifen gavage (Figures 1D-E). Interestingly, insulinemia
240 during ipGTT was also impaired in *E2f1*^{MIP-CreERT β-/-} mice 20 minutes after glucose injection
241 (Figure 1F). Altogether, these data suggest that the β-cell specific *E2f1* deficiency, either
242 triggered early during development or in fully mature adult β cells, impairs glucose tolerance
243 and insulin secretion in response to glucose.

244

245 **Increased alpha-to-beta-cell ratio in the pancreas of *E2f1*-deficient mice.**

246

247 As *E2f1*^{β-/-} mice displayed impaired insulin secretion in response to glucose, we investigated
248 the contribution of *E2f1* to islet morphology. We observed that islet density (Figure 2A), islet
249 size (Figure 2B), β-cell fraction (Figure 2C), β-cell mass (Figure 2D) and β-cell size (Figure
250 2E and Supplementary figure S3A) were comparable between 3-month-old *E2f1*^{β-/-} and
251 *E2f1*^{fl/fl} pancreata. We then analyzed proliferation and apoptosis in *E2f1*^{β-/-} and *E2f1*^{fl/fl}
252 pancreas. Apoptotic cells were not detected in the pancreas from control and β-cell specific
253 *E2f1*-deficient mice, as shown by cleaved caspase 3 immunofluorescent staining
254 (Supplementary figures S3B-C). BrdU staining of *E2f1*^{β-/-} and *E2f1*^{fl/fl} pancreatic sections
255 revealed that the number of proliferative cells was decreased in *E2f1*^{β-/-} islets (Figure 2F and
256 Supplementary figures S3D). Remarkably, an immunofluorescence analysis of sections
257 from control and *E2f1*^{β-/-} pancreas demonstrated a significant increase of glucagon-positive
258 cells (Figures 2G-H), whereas the number of somatostatin-positive cells was not modified
259 in *E2f1*^{β-/-} islets (Figures 2I-J). These results suggest that the loss of *E2f1* expression could
260 induce an α-cell hyperplasia associated with lower endocrine cell proliferation.

261 To confirm the role of *E2f1* in maintaining physiological α-to-β-cell ratio, we performed
262 immunofluorescence staining of insulin and glucagon in the pancreas of wild-type and global
263 *E2f1* knock-out mice (*E2f1*-/-). The detailed analysis of *E2f1*-/- pancreas revealed a
264 decreased proportion of ins+ β-cell and a concomitant expansion of the glu+ α-cell

percentage per islet in chow-fed 16-week-old animals, as demonstrated by the quantification of insulin and glucagon positive cells in *E2f1*^{+/+} and *E2f1*^{-/-} pancreas (Supplementary figures S4A, S4B and S4C). To test whether *bona fide* regulators of E2F1 activity could rescue the altered α-to-β-cell ratio observed in *E2f1*^{-/-} mice, we used 2 different genetically-engineered mouse models (Supplementary figures S4D). We first used the R24C mouse model of CDK4 hyperactivation (CMV-CDK4^{R24C}) that constitutively expresses a CDK4 mutant protein that restores β-cell mass and function during diabetes development (37; 38). As previously observed (38), α-to-β-cell ratio was decreased in CMV-Cdk4^{R24C} pancreas (Supplementary figures S4C and S4E). We then generated compound mutant mouse models with both *E2f1* deficiency and overactive CDK4 (*E2f1*^{-/-}::CMV-Cdk4^{R24C}). Interestingly, the decreased α-to-β-cell ratio β-cell number observed in CMV-Cdk4^{R24C} pancreas was blunted in *E2f1*^{-/-}::CMV-Cdk4^{R24C} mice, with a concomitant increase of glucagon immunofluorescent staining (Supplementary figures S4C and S4F). To sustain such findings, we then replicated these observations in an alternative model using *Cdkn2a*-deficient mice (*Cdkn2a*^{-/-}; (27)), an upstream regulator of the E2F1-CDK4-pRb signaling pathway involved in β-cell function (39-41). Although Glu+ and Ins+ immunofluorescent positive cell staining was similar between *Cdkn2a*^{+/+} and *Cdkn2a*^{-/-} pancreas (Supplementary figures S4C and S4G), *E2f1*^{-/-}::*Cdkn2a*^{-/-} compound mutant mice displayed an altered α-to-β-cell ratio with a decrease of Ins+ and an increase Glu+ cell numbers (Supplementary figures S4C and S4H). In addition, our recent observation of decreased plasma insulin levels, increased plasma glucose and glucose intolerance in *db/db*::*E2f1*^{-/-} mice compared to *db/db*::*E2f1*^{+/+} controls (25) prompted us to evaluate islet morphology in these diabetic mouse models. Accordingly, in the *db/db* background, *E2f1* deficient mice displayed a further increase of the α-cell number per islet, while exhibiting a lower β-cell count compared to *db/db*::*E2f1*^{+/+} controls (Supplementary figures S5A-B). Altogether, these results suggest a specific role of E2f1 in maintaining pancreatic β-cell

291 numbers under normal conditions but also in a diabetic environment associated to glucose
292 intolerance, insulin resistance and obesity. We may then hypothesize that *E2f1* expression
293 in β cell may be necessary to maintain insulin secretion and glucose homeostasis
294 associated to normal α -to- β -cell ratio.

295

296 ***E2f1*-deficiency in β cells does not induce their conversion into α cells.**

297

298 To evaluate the fate of *E2f1*-deficient β cells and the potential origin of the increased number
299 of α -cells in *E2f1* ^{β -/-} mice, we performed lineage-tracing experiments. To track the destiny of
300 β -cells, the expression of the tomato tracer was monitored in Rip-Cre^{+/+::tdTomato} and *E2f1* ^{β -/-}
301 ^{+/+::tdTomato}. As expected, tomato positive (Tom+) cells were colocalized with ins+ cells in
302 controls and *E2f1* ^{β -/-}^{+/+::tdTomato} pancreata (Figure 3A). Interestingly, we could not detect any
303 colocalization of Tom+ and glu+ cells in controls, nor in β -cell specific *E2f1* deficient
304 pancreata (Figure 3B). β -cell lineage tracing results were further confirmed in *E2f1* ^{β -/-} mice
305 by using the ECFP reporter mouse strain model (30) (Figure 3C-D). These data suggest
306 that, although the number of α cells is increased upon *E2f1* deficiency, loss of *E2f1*
307 expression in β cells does not trigger their conversion into α cells.

308

309 **Loss of β -cell identity markers in *E2f1* deficient pancreatic islets.**

310

311 E2F1 is a transcription factor that controls gene expression in several cellular systems. In
312 order to get a global view of the transcriptional mechanisms associated with the loss of *E2f1*
313 expression in the β -cell, we performed RNA sequencing (RNA-seq) in control (*E2f1* ^{f/f}) and
314 *E2f1* ^{β -/-} isolated islets. As expected, the floxed region of the *E2f1* gene spanning exon 2 and
315 3 was not covered in *E2f1* ^{β -/-} isolated islets compared to *E2f1* ^{f/f} isolated islets, indicating
316 specific and efficient gene deletion through the Cre recombinase activity in *E2f1* ^{β -/-} isolated

317 islets (Supplementary figure S6A). Transcriptome analysis revealed that 692 annotated
318 genes were differentially expressed across the two groups (adjusted P Value (AdjP) <0.05).
319 Interestingly, a majority of genes were upregulated in *E2f1*^{β-/-} isolated islets (493 genes,
320 Figure 4A and Supplementary Table S4), with only 199 down-regulated genes associated
321 with the loss of *E2f1* expression in β-cells (Figure 4A and Supplementary Table S4). This
322 first observation suggests that *E2f1* expression is not only necessary to activate, but also to
323 repress gene transcription within β-cells. Analyses of the RNA-seq data of downregulated
324 genes with Ingenuity Pathway Analysis (IPA) software revealed an enrichment of gene
325 networks involved in insulin secretion pathway or Maturity Onset Diabetes of the Young
326 (MODY) signaling (Figure 4B). Conversely, upregulated genes in *E2f1*^{β-/-} isolated islets were
327 mostly associated with inflammatory response, including the hepatic fibrosis signaling
328 pathway, iNOS signaling or toll-like receptor signaling (Figure 4C). RNA-seq data were then
329 analyzed using the “upstream regulator analysis” function of IPA to identify potential
330 contributors that could be associated to the transcriptional reprogramming observed in
331 *E2f1*^{β-/-} isolated islets. Among the most significant upstream regulators of the upregulated
332 genes, Tumor Necrosis Factor, interferon gamma, Myd88 were identified (Supplementary
333 Table S5). Conversely, analysis of the downregulated genes suggested that Xbp1, Hnf1a,
334 Neurod1 and Pdx1, transcription factors previously shown to control β-cell identity or
335 function, were found to be potential upstream regulators that were predicted to be inhibited
336 (Supplementary Table S5). To better understand the relationship between the observed
337 metabolic phenotype (*i.e.* glucose intolerance and defective insulin secretion), increased
338 glu+ cells and *E2f1* deficiency, we filtered gene sets to focus on β- and α-cell-specific genes
339 being conserved between zebrafish, mouse and human (42). Notably, a total of 15 genes
340 from 109 conserved genes (82 and 27 for α-cell and β-cell genes, respectively) were
341 differentially expressed. Interestingly, most of the conserved β-cell markers were found to
342 be decreased in *E2f1*^{β-/-} isolated islets (Figure 4D and Supplementary figure S6B), whereas

343 most of the conserved α -cell genes were upregulated upon *E2f1* deficiency (Figure 4D and
344 Supplementary figure S6C). Gene Set Enrichment Analysis (GSEA) further confirmed an
345 enriched signature of increased expression of α -cell markers (Figure 4E) and conversely, a
346 decreased expression of β -cell markers in *E2f1 $^{B/-}$* isolated islets (Figure 4F). We further
347 confirmed these changes in the expression of selected α - and β -cell markers at the
348 transcriptional level by qPCR in an independent experiment: accordingly, we observed a
349 strong decrease in transcript levels of *Pdx1*, *Ins2*, *Pcsk9*, *Foxo1* and *Glp1r* in *E2f1 $^{B/-}$* islets
350 (Supplementary figure S6D). Conversely, α -cell specific Aristaless-related homeobox (*Arx*)
351 mRNA levels were increased in *E2f1 $^{B/-}$* islets (Supplementary figure S6E). Altogether these
352 results suggest that the β -cell specific deletion of *E2f1* induces a transcriptional
353 reprogramming characterized by a loss of β -cell identity genes associated to an increased
354 expression of non β -cell markers.

355

356 **The treatment with the E2F inhibitor *HLM006474* inhibits glucose-stimulated insulin
357 secretion and alters β - and α -cell gene expression in Min6 cells and human islets.**

358

359 To assess the effect of E2F1 activity on β -cell identity markers in Min6 cells and human
360 islets, we made use of the E2F pan-inhibitor HLM006474 previously shown to inhibit the
361 binding of E2Fs to their DNA target genes and E2F1 transcriptional activity (35). Consistent
362 with our previous findings in HEK293 cells (35), a 48h treatment of Min6 cells with this
363 inhibitor triggered a decrease in *E2f1* transcriptional activity, as measured by transient
364 transfection experiments using an E2F reporter gene (Figure 5A). In addition, the treatment
365 of Min6 cells with this inhibitor induced a marked decrease in glucose-stimulated insulin
366 secretion (Figure 5B) and in the expression of several β -cell markers, including *Ins1*, *Pdx1*,
367 and *Pax4* and *Nkx2.2* (Figure 5C). The treatment of human islets with the E2F inhibitor for
368 48 hours also decreased GSIS (Figure 5D) and β -cell marker expression levels with a

369 concomitant increase in the expression of α -cell genes (Figure 5E). Therefore, the
370 pharmacological inhibition of E2F activity impairs β -cell function and gene expression in both
371 mouse cell line and human islets, suggesting that E2F1 activity is also required in human
372 islets to maintain proper insulin secretion and β -cell identity genes, as observed in mice.

373

374 **Maintenance of β -cell identity is dependent on E2F1 transcriptional activity.**

375

376 Our transcriptome analysis revealed a 2.5-fold more up- than downregulation of global gene
377 expression in $E2f1^{\beta/-}$ isolated islets. Comparative analysis of log10 transcripts per million
378 levels (Log10(TPM+1)) of up- and downregulated genes values demonstrated that the
379 expression of upregulated genes in $E2f1^{\beta/-}$ islets was significantly increased upon $E2f1$
380 deficiency compared to wild-type controls whereas the expression of downregulated genes
381 was not significantly modulated (Figure 6A). Considering that $E2f1$ could play a dual role in
382 the regulation of gene expression in pancreatic β -cells, we postulated that this mechanism
383 could be related to a distinct epigenomic profile within promoter of genes that are up- and
384 down-regulated in $E2f1^{\beta/-}$ islets. Using a recently published chromatin-state segmentation
385 model (12), we probed the active/repressive level of these promoters by monitoring several
386 epigenome marks such as active and poised promoters (tri-methylation of lysine 4 in histone
387 H3 [H3K4me3]) and enhancers (acetylation of lysine 27 in histone H3 [H3K27ac]).
388 Intersecting publicly available data of chromatin immunoprecipitation followed by next-
389 generation sequencing (ChIP-seq) from healthy C57Bl6/J mouse pancreatic islets (GSE
390 110648 (12)) and our RNA-seq data, we grouped up- and down regulated genes according
391 to their chromatin state (Figure 6B and Supplementary Table S4). We observed that 61% of
392 the upregulated genes in $E2f1^{\beta/-}$ pancreatic islets were associated to a silent chromatin state
393 in healthy C57Bl6/J mouse pancreatic islets characterized by bivalent H3K4me3/H3K27me3
394 and Polycomb-repressed (H3K27me3) marks. Conversely, 82% of the down-regulated

395 genes showed an enrichment in active chromatin state characterized by RNA-Pol2
396 recruitment, H3K4me3 and H3K27ac histone marks.

397

398 While H3K4me3, H3K27ac and H3K27me3 ChIP-seq data were available for mouse islets,
399 we then performed ChIP-seq experiments in Min6 cells as a surrogate of β-cell. H3K4me3,
400 H3K27ac and H3K27me3 ChIP-seq signals were thus interrogated within promoter
401 (centered to transcription start site [TSS] +/- 1 kb) of up- and downregulated genes both in
402 Min6 cells and mouse pancreatic islets (Figures 6C-D and Supplementary figures S7A-B).
403 H3K4me3 as well as H3K27ac signals were stronger within promoter of genes that are
404 downregulated in *E2f1*^{β/-} isolated islets compared to upregulated genes, both in Min6 cells
405 and mouse pancreatic islets (Figure 6C and Supplementary figures S7A-B). Conversely,
406 H3K27me3 ChIP-seq signals were lower in the promoter region of downregulated genes
407 compared to upregulated genes (Figure 6D and Supplementary figures S7A-B). Altogether,
408 these results suggest that the transcriptome of *E2f1*^{β/-} islets is associated to a specific
409 epigenomic pattern that may be involved in the control of E2f1-mediated transcriptional
410 activation or repression.

411

412 **E2f1 cistrome profiling by ChIP-seq identifies potential direct E2f1 target genes**
413 **involved in β-cell function.**

414

415 Having demonstrated that the transcriptome of *E2f1*^{β/-} isolated islets was altered compared
416 to controls, we next asked whether these up and down regulated genes identified in isolated
417 islets from *E2f1*^{β/-} mice were direct or indirect E2f1 target genes. To reach this aim, we
418 performed ChIP-seq experiments to determine chromatin-bound E2f1 target genes.

419 In a first series of experiments, ChIP-seq experiments targeting endogenous E2f1 were
420 conducted in pancreatic islets but failed to profile the endogenous E2f1 cistrome due to lack

421 of antibody specificity (data not shown). Alternatively, E2f1 was over-expressed in Min6 cells
422 as surrogate of β -cells through transfection of a plasmid encoding E2f1 fused to Flag tag
423 (E2f1-flag). As expected, E2f1-flag protein was overexpressed in Min6 cells transfected with
424 plasmid encoding E2f1-flag compared to those transfected with empty plasmid
425 (Supplementary figure S8A). These results prompted us to perform a ChIP-seq analysis
426 using an anti-flag antibody to profile E2f1-flag cistrome at genome-wide level in Min6 cells.
427 Among the E2f1-bound genomic regions, 94.5% were localized within promoter ($\leq 1\text{kb}$)
428 whereas other genomic locations were marginally represented (Supplementary figure S8B)
429 confirming that E2f1 is a transcription factor mainly bound within GC-rich proximal promoter
430 (43). Indeed, a DNA motif enrichment analysis was performed within E2f1-enriched
431 promoter regions showing that E2f motif was the most significant enriched motif within these
432 regions suggesting that E2f1 was directly bound on promoter (Supplementary figure S8C).
433 Next, we consolidated our results in an independent experiment by performing a ChIP-qPCR
434 analysis targeting two E2f1-flag-bound promoters (from *Ezh2* and *Ccne1* genes) detected
435 by ChIP-seq (Supplementary figures S8D and E, respectively). As expected, ChIP-qPCR
436 performed with anti-Flag antibody led to a significant enrichment of E2f1-flag within both
437 *Ezh2* (Supplementary figure S8F) and *Ccne1* (Supplementary figure S8G) promoters
438 compared to ChIP-qPCR conducted with unspecific antibody (IgG). In addition, none E2f1-
439 flag enrichment was detected within an unspecific intergenic chromatin region (negative
440 control, Supplementary figure S8H), validating our E2f1 cistrome analysis.

441 After ChIP-qPCR-based validation of our anti-flag antibody approach in Min6 cells
442 (Supplementary figure S8), E2f1-flag ChIP-seq signal was interrogated within promoter
443 (centered to TSS $\pm 1\text{kb}$) of dysregulated genes identified in pancreatic islets isolated from
444 *E2f1* ^{$\beta/-$} mice to identify E2f1-bound (*i.e.*, direct E2f1 target genes) and E2f1-unbound (*i.e.*,
445 indirect E2f1 target genes) genes. Among the upregulated genes in *E2f1* ^{$\beta/-$} islets, we
446 identified 197 genes harboring E2f1-bound proximal promoters and 297 genes with E2f1-

447 unbound proximal promoters (Supplementary table S6). Among the downregulated genes,
448 95 genes harbored a E2f1-bound proximal promoter whereas 106 genes were identified as
449 E2f1-unbound proximal promoters (Supplementary table S6). This ChIP-seq and RNA-seq
450 intersecting analysis was exemplified by a series of genes including *Nkx6-1* (Supplementary
451 figure S9A) and *Tcf7* (Supplementary figure S9B) displaying E2f1 enrichment in the close
452 vicinity of TSS. Concerning E2f1-unbound promoters, we could observe that *Ins1*
453 (Supplementary figure S9C) and *Gzma* (Supplementary figure S9D), although differentially
454 regulated at the mRNA level, were not bound by E2f1 at the chromatin level. Altogether,
455 these results suggested that E2f1 could have a dual role on the regulation of gene
456 expression by acting either as a transcriptional activator or repressor in pancreatic islets,
457 through both indirect and direct mechanisms at the chromatin level.

458 To better appreciate the potential role of E2f1 in the control of gene expression, canonical
459 pathway analysis was performed using the different clusters of genes identified above. Our
460 analysis revealed that E2f1-undound downregulated genes were mostly associated to
461 insulin secretion signaling pathway (Supplementary figures S9E-H). IPA could not reveal
462 any enrichment of pathways involved in insulin secretion in E2f1-bound promoters.
463 However, a detailed analysis of ChIP-seq data from down- and upregulated genes revealed
464 that E2f1 was associated to the chromatin region of several genes involved in β-cell function,
465 such as *Glis3*, *Glp1r*, *Manf*, *Nkx6-1*, *Ppp1r1a* or *Wfs1* or β-cell dysfunction, such as *Bcl11a*
466 or *Cxcl14* (Supplementary figure S9A and Supplementary table S6).

467
468 Since E2f1-bound genes in Min6 cells are predicted to be potential E2f1 direct target genes,
469 we next investigated whether there were differences in the epigenomic activation level of
470 these promoters. Therefore, we conducted a ChromHMM analysis (Chromatin Hidden
471 Markov Model) allowing characterization of chromatin states based on differential
472 enrichment levels of histone marks as well as transcription factor at genome-wide level (44).

473 ChromHMM analysis was thus performed by combining ChIP-seq data obtained in Min6
474 cells from both E2f1-Flag and a selection of histone marks related to the active/repressive
475 state of promoter (i.e., H3K4me3, H3K9ac, H3K27ac, and H3K27me3) and enhancers (i.e.,
476 H3K4me1, H3K27ac and H3K27me3). By applying a 16-state ChromHMM analysis, we
477 demonstrated that only 3 states were enriched with E2f1-Flag (states 6, 14 and 15) (Figure
478 7A). Whereas states 14 and 15 displayed the typical features of active promoter (i.e.,
479 H3K4me3, H3K9ac and/or H3K27ac), chromatin state related to state 6 was more
480 associated with repressed promoter (H3K4me3 and H3K27me3). The TSS-centered
481 genomic distribution analysis of these 16 chromatin states confirmed that states 6, 14 and
482 15 corresponded to proximal promoter of genes (Supplementary figure S10A).

483 To go further in the characterization of the role of E2f1 in the β-cell, we next decided to
484 analyze the differential transcriptomic data from *E2f1*^{β/-} isolated islets in the light of this
485 ChromHMM analysis by determining whether the promoter of deregulated genes belonged
486 to one of the chromatin states described above. This analysis showed that 23.4% of the
487 upregulated genes (109 on 465 genes) harbored a state 6-promoter indicating that the
488 expression of these genes could be repressed by E2f1 in β-cells *in vivo* (Supplementary
489 Table S7). Conversely, promoters of downregulated genes were more associated with state
490 14 (46.5%, 87 out of 187 genes, Supplementary Table S7) and 15 (41.1%, 77 out of 187
491 genes, Supplementary Table S7) indicating that E2f1 could play a positive role in the
492 regulation of expression of these genes in β-cell. Although pathway analysis of the different
493 chromatin states of the direct down- and upregulated genes could not precisely demonstrate
494 a specific enrichment of pathways involved in insulin secretion or β-cell function
495 (Supplementary figures S10B to G), we could observe that most of the non β-cell markers,
496 such as *Cxcl12* (Figure 7B) or the β-cell disallowed genes *Gab1* (Figure 7C), *Mgll*, *Oat*
497 (Supplementary Table S7), *Slc25a33* (Figure 7D) or *Yap1* (Figure 7E), were mostly
498 associated to segment 6 and were upregulated in *E2f1*^{β/-} isolated islets (Supplementary

499 Table S7). Interestingly, genes related to β-cell function, such as *Glis3* (Figure 7F), *Glp1r*
500 (Figure 7G), *Manf* (Figure 7H), *Nkx6-1* (Supplementary Table S7), *P2ry1* (Figure 7I) or *Wfs1*
501 (Supplementary Table S7), were downregulated and associated to state 14 or 15
502 (Supplementary Table S7). Altogether, these results support a potential dual active and
503 repressive role for E2f1 on transcriptional regulation within β-cells. Importantly, our data
504 suggest that E2f1 modulates β-cell and non β-cell transcriptional programs in pancreatic
505 islets through direct, epigenomic based-mechanisms as well as indirect processes probably
506 through the upstream regulation of β-cell enriched transcriptional regulators, such as Pdx-1
507 or Hnf1a.

508 **Discussion**

509

510 In the present study, we show that the transcription factor E2F1 plays an essential role in
511 maintaining β-cell function and identity through the control of transcriptomic and epigenetic
512 programs within the pancreatic islets. Our study is the first one to demonstrate a direct, cell-
513 autonomous contribution of *E2f1* in controlling not only *in vivo* insulin secretion but also β-
514 cell identity maintenance, without affecting the pancreatic islet cell number and β-cell mass.

515 The role of E2F1 in the control of cell cycle and proliferation has been extensively studied,
516 particularly in the context of cancer (18). However, its function in non-proliferating fully
517 differentiated cells, including β-cells, remains to be precisely deciphered. The observation
518 that cell cycle regulators, including E2F1, are expressed in cells that are not proliferating,
519 suggest that they may be involved in adaptive pathways that are independent of cellular
520 proliferation. We and others have demonstrated that this pathway plays a key role in post-
521 natal β-cell proliferation (45-47), glucose homeostasis and insulin secretion (20; 48; 49).

522 Studies also revealed that the Cdk4-E2F1-pRb pathway controls the fate of pancreatic
523 progenitors through the transcriptional control of the expression of *Ngn3* and *Pdx1* as well
524 as *Pdx1* protein stability (50; 51). Most of these studies were performed using germline *E2f1*
525 deficient mice, which precludes to ascertain a cell-autonomous role of *E2f1* in the endocrine
526 pancreas and β-cell functions. To better appreciate the specific role of E2F1 in β-cells, we
527 specifically knocked-down *E2f1* in the β-cell using the Cre/loxP technology. Although we
528 cannot rule out an early role for *E2f1* in pancreatic progenitors due to the use of the RIP-
529 Cre mice (28), our data demonstrate that *E2f1* expression within the β-cell is necessary to
530 maintain a proper gene expression program to regulate insulin secretion and glucose
531 homeostasis. Moreover, we observe that the specific *E2f1* deficiency in adult, mature β-cells
532 results in glucose homeostasis impairments and failure in glucose-stimulated insulin
533 secretion. Since E2F1 overexpression stimulates β-cell proliferation and function (48), our

534 results further suggest that targeting *E2f1* might be of interest to maintain β-cell functions in
535 the context of diabetes.

536

537 The complexity of *E2f1* biology resides in the fact that it can positively or negatively regulate
538 the expression of its target genes. Our data suggest that *E2f1* may be part of a repressor
539 complex that regulates β-cell identity. In line with this, we observe that genes mostly
540 upregulated in *E2f1*^{β-/-} isolated islets, including *Gab1*, *Slc25a33* or *Yap1*, were identified as
541 β-cell “ disallowed ” genes, *i.e.* genes that are repressed in β cells (52), or genes involved
542 in the inflammatory response such as *Cxcl12*, *Cxcl14* or *Irf5*. This suggests that the
543 repressive effects of *E2f1* are key in maintaining β-cell identity and subsequent β-cell
544 function. Accordingly, repression of non β-cell programs is crucial for maintaining β-cell
545 identity. *Pdx1* (14), *Pax6* (15), *Nkx6.1* (16) and *Nkx2.2* (17) are key transcription factor
546 required to maintain gene repression of non-β-cell programs. Interestingly, *Nkx6.1* mRNA
547 levels are decreased in *E2f1*^{β-/-} isolated islets, and *Nkx6.1* promoter is directly bound by
548 *E2f1*, suggesting that *E2f1* could modulate β-cell functions through *Nkx6.1* regulation.
549 Chromatin regulators and epigenomic features play important roles in the control of β-cell
550 identity and plasticity (53-55). Indeed, the modulation of islet-enriched transcription factor
551 activity, including *Pdx1* or *Nkx2.2*, involves their interaction with coregulators such as
552 *Dnmt1*, *Dmnt3a* or *Hdac1* (56-58) or their accessibility to chromatin, as demonstrated for
553 the β-cell specific deletion of protein arginine methyltransferase 1 (*Prmt1*) that results in the
554 loss of β-cell identity and diabetes development (59). In addition, recent studies also indicate
555 that loss of Polycomb silencing in human and mouse β-cells contributes to the loss of β-cell
556 identity in diabetes (12). Indeed, the β-cell specific deletion of *Eed*, a component of the
557 Polycomb repressive complex (PRC)-2, triggers β-cell dysfunction, dedifferentiation and
558 diabetes development associated to chromatin-state-associated transcriptional
559 dysregulation (12). In addition, as PRC2 loss induces β-cell plasticity through epigenomic

560 reprogramming at both active and silent genes suggest that maintaining proper and specific
561 histone marks and chromatin state at precise loci is crucial to maintain normal β -cell
562 functions and avoid T2D development. Interestingly, most of the upregulated genes in $E2f1^{\beta^-}$
563 pancreatic islets were characterized by bivalent H3K4me3/H3K27me3 and Polycomb-
564 repressed (H3K27me3) marks. In addition, epigenomic interventions triggering ectopic
565 acetylation and gene derepression contribute to β -cell dysfunctions. Indeed, blocking HDAC
566 activity through the use of the HDAC inhibitor SAHA, impairs glucose intolerance in mice
567 fed a HFD (12). Here we show that the loss of $E2f1$ function triggers transcriptional
568 dysregulation of specific genes that are in a bivalent (*i.e.* H3K4me3/H3K27me3 and
569 Polycomb-repressed (H3K27me3) marks) and active (*i.e.* RNA-Pol2 recruitment, H3K4me3
570 and H3K27ac histone marks) state in healthy pancreatic islets. This suggests a potential
571 ectopic acetylation in the promoter region of upregulated genes in $E2f1^{\beta^-}$ islets and
572 decreased activation of the promoter region of downregulated genes. Interestingly, we
573 demonstrate in this study that *Ezh2*, a member of the PRC2 complex, is also a direct $E2f1$
574 target gene. Although $E2f1$ is a ubiquitous transcription factor that is weakly expressed
575 within β -cell compared to *bona fide* β -cell genes, we speculate that this transcriptional
576 regulator may cooperate with β -cell transcription factors and/or the chromatin machinery
577 such as HDAC or the PRC2 complex to integrate some signals necessary for β -cell
578 maintenance in physiological conditions. Since $E2f1$ regulates gene expression through its
579 interaction with repressor complexes including pRb, SWI/SNF and HDACs (18), our finding
580 that $E2f1$ mediates repression of non β -cell programs deserves deeper investigations to
581 identify the $E2f1$ complexes that can trigger these transcriptomic and epigenomic effects in
582 the β -cell and their patho(physio)logical consequences.

583 The current study has a number of limitations. First, the use of RipCre transgenic mice to
584 delete $E2f1$ in the β cells may also contribute to side-effects on glucose homeostasis.
585 Although we observed that these mice do not have a metabolic phenotype (Figure 1 and

586 (22; 31)), it cannot be excluded that the transgene *per se* could exert specific deleterious
587 functions in β cells.

588 Second, over-expression studies in Min6 and pharmacological treatment with the E2F
589 inhibitor may display adverse side-effects and induce off-target actions, such as non-specific
590 inhibition of other cell-cycle/E2f related proteins or modulation of cofactor activity due to
591 overexpression of transcription factors (60).

592 Third, the use of bulk RNA-seq on total pancreatic islets does not allow to perfectly address
593 the effect of *E2f1* deletion on the β -cell transcriptome. Transcriptomic analyses using sorted
594 β cells or single-cell RNA-sequencing will provide direct evidences regarding the alteration
595 of β -cell identity within specific pancreatic cell populations.

596 Finally, we observe increased α -cell positive staining associated with decreased endocrine
597 cell proliferation in *E2f1 $^{ \beta/-}$* islets, and lineage tracing experiments demonstrate that α -cells
598 do not originate from β -cell. The origin of the supernumerary α cells observed in *E2f1 $^{ \beta/-}$*
599 islets remains unknown and requires further investigations.

600 In summary, the present data highlight that E2f1 transcriptional activity within pancreatic
601 islets is key for maintaining glucose homeostasis and insulin secretion through the
602 regulation of key β -cell identity genes and the repression of non β -cell programs, both in
603 mouse and human islets. The observation that E2F1 levels are decreased in human T2D
604 islets (24) suggests that a reduced E2F1 expression or activity may contribute to β -cell
605 failure in diabetes.

606

607 **Author contributions.** F.O., C.B., M.E.F., E.C., L.R., X.G., M.M., C.C., N.R., E.B. and
608 S.A.H. contributed to the *in vivo* and cellular experiments. F.O., M.M., C.B., E.D., S.A., L.B.,
609 M.D. and A.B. performed the RNA-seq and ChIP-seq experiments and analysis. P.D.D.,
610 Z.B., P.M., L.F., J.K.C., F.P., B.P. and P.C. provided reagents and data and discussed the
611 results from the study. J.-S.A. designed the study, supervised the project and contributed to
612 experiments and/or their analysis and the funding of this project. F.O., C.B., M.E.F., E.C.,
613 N.R., P.F., A.B. and J.-S.A. wrote and/or edited the manuscript. F.O., C.B., M.E.F. and E.C.
614 contributed equally to this work. J.-S.A. is the guarantor of this work and, as such, had full
615 access to all of the data in the study and take responsibility for the integrity of the data and
616 the accuracy of the data analysis.

617

618 **Acknowledgements.** We thank Dr Raphael Scharfmann and members of the INSERM
619 UMR1167 and U1283 for helpful discussions, and Céline Gheeraert for excellent help with
620 ChIP experiments. Human islets were provided through the JDRF award 31-2008-416 (ECIT
621 Islet for Basic Research program). The authors thank the Experimental Resources platform
622 from Université de Lille, especially Cyrille Degraeve, Yann Lepage, Mélanie Besegher and
623 Julien Devassine for animal care. We thank the Department of Histology from the Lille
624 Medicine Faculty, particularly M.H. Gevaert and R.M. Siminski, for histological preparations.
625 We thank “France Genomique” consortium (ANR-10-INSB-009). This work was supported
626 by grants from « European Genomic Institute for Diabetes » E.G.I.D, ANR-10-LABX-46 and
627 Equipex 2010 ANR-10-EQPX-07-01; 'LIGAN-PM' Genomics platform, a French State fund
628 managed by the Agence Nationale de la Recherche under the frame program
629 Investissements d’Avenir I-SITE ULNE / ANR-16-IDEX-0004 ULNE (to J.K.C., F.P., P.F.,
630 A.B. and J-S. A), Agence Nationale pour la Recherche (BETAPLASTICITY, ANR-17-CE14-
631 0034 to P.F., P.C. and J-S. A.), European Foundation for the Study of Diabetes (EFSD, to
632 J-S.A.), European Commission, INSERM, CNRS, Institut Pasteur de Lille (CPER CTRL

633 Melodie, to E.C., B.P. and J-S.A.), Fondation pour la Recherche Médicale (FRM Grant
634 EQU202103012732 to J-S.A.), Association pour la Recherche sur le Diabète (to J-S.A.),
635 Université de Lille (to F.O., C.B., X.G., N.R. and J-S.A.), I-SITE ULNE (EpiRNAdiab Sustain
636 grant to J-S.A.), Conseil Régional Hauts de France and Métropole Européenne de Lille (to
637 X.G., N.R. and J-S.A.), F.E.D.E.R. (Fonds Européen de Développement Régional, to N.R.,
638 P.F. and J-S.A.) and Société Francophone du Diabète (to S.A.H. and J-S.A.).

639

640 **Conflict of interest.** The authors declare no competing financial interests.

641

642 **References**

643

- 644 1. Weir GC, Bonner-Weir S: Five stages of evolving beta-cell dysfunction during progression
645 to diabetes. *Diabetes* 2004;53 Suppl 3:S16-21
- 646 2. Segerstolpe A, Palasantza A, Eliasson P, Andersson EM, Andreasson AC, Sun X, Picelli
647 S, Sabirsh A, Clausen M, Bjursell MK, Smith DM, Kasper M, Ammala C, Sandberg R: Single-
648 Cell Transcriptome Profiling of Human Pancreatic Islets in Health and Type 2 Diabetes. *Cell*
649 *Metab* 2016;24:593-607
- 650 3. Wang YJ, Schug J, Won KJ, Liu C, Naji A, Avrahami D, Golson ML, Kaestner KH: Single-
651 Cell Transcriptomics of the Human Endocrine Pancreas. *Diabetes* 2016;65:3028-3038
- 652 4. Xin Y, Kim J, Okamoto H, Ni M, Wei Y, Adler C, Murphy AJ, Yancopoulos GD, Lin C,
653 Gromada J: RNA Sequencing of Single Human Islet Cells Reveals Type 2 Diabetes Genes.
654 *Cell Metab* 2016;24:608-615
- 655 5. Avrahami D, Wang YJ, Schug J, Feleke E, Gao L, Liu C, Consortium H, Naji A, Glaser B,
656 Kaestner KH: Single-cell transcriptomics of human islet ontogeny defines the molecular
657 basis of beta-cell dedifferentiation in T2D. *Molecular metabolism* 2020;42:101057
- 658 6. Rai V, Quang DX, Erdos MR, Cusanovich DA, Daza RM, Narisu N, Zou LS, Didion JP,
659 Guan Y, Shendure J, Parker SCJ, Collins FS: Single-cell ATAC-Seq in human pancreatic
660 islets and deep learning upscaling of rare cells reveals cell-specific type 2 diabetes
661 regulatory signatures. *Molecular metabolism* 2020;32:109-121
- 662 7. White MG, Marshall HL, Rigby R, Huang GC, Amer A, Booth T, White S, Shaw JA:
663 Expression of mesenchymal and alpha-cell phenotypic markers in islet beta-cells in recently
664 diagnosed diabetes. *Diabetes Care* 2013;36:3818-3820
- 665 8. Spijker HS, Song H, Ellenbroek JH, Roefs MM, Engelse MA, Bos E, Koster AJ, Rabelink
666 TJ, Hansen BC, Clark A, Carlotti F, de Koning EJ: Loss of beta-Cell Identity Occurs in Type
667 2 Diabetes and Is Associated With Islet Amyloid Deposits. *Diabetes* 2015;64:2928-2938
- 668 9. Talchai C, Xuan S, Lin HV, Sussel L, Accili D: Pancreatic β cell dedifferentiation as a
669 mechanism of diabetic β cell failure. *Cell* 2012;150:1223-1234
- 670 10. Collombat P, Xu X, Ravassard P, Sosa-Pineda B, Dussaud S, Billestrup N, Madsen OD,
671 Serup P, Heimberg H, Mansouri A: The ectopic expression of Pax4 in the mouse pancreas
672 converts progenitor cells into alpha and subsequently beta cells. *Cell* 2009;138:449-462
- 673 11. Bramswig NC, Everett LJ, Schug J, Dorrell C, Liu C, Luo Y, Streeter PR, Naji A, Grompe
674 M, Kaestner KH: Epigenomic plasticity enables human pancreatic alpha to beta cell
675 reprogramming. *J Clin Invest* 2013;123:1275-1284
- 676 12. Lu TT, Heyne S, Dror E, Casas E, Leonhardt L, Boenke T, Yang CH, Sagar, Arrigoni L,
677 Dalgaard K, Teperino R, Enders L, Selvaraj M, Ruf M, Raja SJ, Xie H, Boenisch U, Orkin
678 SH, Lynn FC, Hoffman BG, Grun D, Vavouris T, Lempradl AM, Pospisilik JA: The Polycomb-

- 679 680 Dependent Epigenome Controls beta Cell Dysfunction, Dedifferentiation, and Diabetes. *Cell Metab* 2018;27:1294-1308 e1297
- 681 682 13. Lawlor N, Stitzel ML: (Epi)genomic heterogeneity of pancreatic islet function and failure in type 2 diabetes. *Molecular metabolism* 2019;27S:S15-S24
- 683 684 14. Gao T, McKenna B, Li C, Reichert M, Nguyen J, Singh T, Yang C, Pannikar A, Doliba N, Zhang T, Stoffers DA, Edlund H, Matschinsky F, Stein R, Stanger BZ: Pdx1 maintains beta cell identity and function by repressing an alpha cell program. *Cell Metab* 2014;19:259-271
- 687 688 15. Swisa A, Avrahami D, Eden N, Zhang J, Feleke E, Dahan T, Cohen-Tayar Y, Stolovich-Rain M, Kaestner KH, Glaser B, Ashery-Padan R, Dor Y: PAX6 maintains beta cell identity by repressing genes of alternative islet cell types. *J Clin Invest* 2017;127:230-243
- 690 691 16. Schaffer AE, Taylor BL, Benthuysen JR, Liu J, Thorel F, Yuan W, Jiao Y, Kaestner KH, Herrera PL, Magnuson MA, May CL, Sander M: Nkx6.1 controls a gene regulatory network required for establishing and maintaining pancreatic Beta cell identity. *PLoS Genet* 2013;9:e1003274
- 694 695 17. Gutierrez GD, Bender AS, Cirulli V, Mastracci TL, Kelly SM, Tsirigos A, Kaestner KH, Sussel L: Pancreatic beta cell identity requires continual repression of non-beta cell programs. *J Clin Invest* 2017;127:244-259
- 697 698 18. Kent LN, Leone G: The broken cycle: E2F dysfunction in cancer. *Nat Rev Cancer* 2019;19:326-338
- 699 700 19. Denechaud PD, Fajas L, Giralt A: E2F1, a Novel Regulator of Metabolism. *Frontiers in endocrinology* 2017;8:311
- 701 702 20. Annicotte JS, Blanchet E, Chavey C, Iankova I, Costes S, Assou S, Teyssier J, Dalle S, Sardet C, Fajas L: The CDK4-pRB-E2F1 pathway controls insulin secretion. *Nat Cell Biol* 2009;11:1017-1023
- 704 705 21. Salas E, Rabhi N, Froguel P, Annicotte JS: Role of Ink4a/Arf locus in beta cell mass expansion under physiological and pathological conditions. *J Diabetes Res* 2014;2014:873679
- 707 708 22. Bourouh C, Courty E, Rolland L, Pasquetti G, Gromada X, Rabhi N, Carney C, Moreno M, Boutry R, Caron E, Benfodda Z, Meffre P, Kerr-Conte J, Pattou F, Froguel P, Bonnefond A, Oger F, Annicotte JS: The transcription factor E2F1 controls the GLP-1 receptor pathway in pancreatic beta cells. *Cell Rep* 2022;40:111170
- 711 712 23. Cai EP, Luk CT, Wu X, Schroer SA, Shi SY, Sivasubramaniyam T, Brunt JJ, Zacksenhaus E, Woo M: Rb and p107 are required for alpha cell survival, beta cell cycle control and glucagon-like peptide-1 action. *Diabetologia* 2014;57:2555-2565
- 714 715 24. Lupi R, Mancarella R, Del Guerra S, Bugiani M, Del Prato S, Boggi U, Mosca F, Filipponi F, Marchetti P: Effects of exendin-4 on islets from type 2 diabetes patients. *Diabetes Obes Metab* 2008;10:515-519

- 717 25. Denechaud PD, Lopez-Mejia IC, Giralt A, Lai Q, Blanchet E, Delacuisine B, Nicolay BN,
718 Dyson NJ, Bonner C, Pattou F, Annicotte JS, Fajas L: E2F1 mediates sustained lipogenesis
719 and contributes to hepatic steatosis. *J Clin Invest* 2016;126:137-150
- 720 26. Sotillo R, Dubus P, Martin J, de la Cueva E, Ortega S, Malumbres M, Barbacid M: Wide
721 spectrum of tumors in knock-in mice carrying a Cdk4 protein insensitive to INK4 inhibitors.
722 *EMBO J* 2001;20:6637-6647
- 723 27. Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, DePinho RA: Role of the INK4a
724 locus in tumor suppression and cell mortality. *Cell* 1996;85:27-37
- 725 28. Herrera PL: Adult insulin- and glucagon-producing cells differentiate from two
726 independent cell lineages. *Development* 2000;127:2317-2322
- 727 29. Wicksteed B, Brissova M, Yan W, Opland DM, Plank JL, Reinert RB, Dickson LM,
728 Tamarina NA, Philipson LH, Shostak A, Bernal-Mizrachi E, Elghazi L, Roe MW, Labosky
729 PA, Myers MG, Jr., Gannon M, Powers AC, Dempsey PJ: Conditional gene targeting in
730 mouse pancreatic ss-Cells: analysis of ectopic Cre transgene expression in the brain.
731 *Diabetes* 2010;59:3090-3098
- 732 30. Srinivas S, Watanabe T, Lin CS, William CM, Tanabe Y, Jessell TM, Costantini F: Cre
733 reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus.
734 *BMC Dev Biol* 2001;1:4
- 735 31. Rabhi N, Denechaud PD, Gromada X, Hannou SA, Zhang H, Rashid T, Salas E, Durand
736 E, Sand O, Bonnefond A, Yengo L, Chavey C, Bonner C, Kerr-Conte J, Abderrahmani A,
737 Auwerx J, Fajas L, Froguel P, Annicotte JS: KAT2B is required for pancreatic beta cell
738 adaptation to metabolic stress by controlling the unfolded protein response signaling. *Cell Reports*
739 2016;In press
- 740 32. Courty E, Besseiche A, Do TTH, Liboz A, Aguid FM, Quilichini E, Buscato M, Gourdy P,
741 Gautier JF, Riveline JP, Haumaitre C, Buyse M, Feve B, Guillemain G, Blondeau B: Adaptive
742 beta-Cell Neogenesis in the Adult Mouse in Response to Glucocorticoid-Induced Insulin
743 Resistance. *Diabetes* 2019;68:95-108
- 744 33. Kerr-Conte J, Vandewalle B, Moerman E, Lukowiak B, Gmyr V, Arnalsteen L, Caiazzo
745 R, Sterkers A, Hubert T, Vantyghem MC, Pattou F: Upgrading pretransplant human islet
746 culture technology requires human serum combined with media renewal. *Transplantation*
747 2010;89:1154-1160
- 748 34. Ma Y, Kurtyka Ca, Boyapalle S, Sung S-S, Lawrence H, Guida W, Cress WD: A small-
749 molecule E2F inhibitor blocks growth in a melanoma culture model. *Cancer research*
750 2008;68:6292-6299
- 751 35. Rosales-Hurtado M, Lebeau A, Bourouh C, Cebrian-Torrejon G, Albalat M, Jean M,
752 Naubron JV, Annicotte JS, Benfodda Z, Meffre P: Improved synthesis, resolution, absolute
753 configuration determination and biological evaluation of HLM006474 enantiomers. *Bioorg
754 Med Chem Lett* 2019;29:380-382
- 755 36. Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, Benner C,
756 Chanda SK: Metascape provides a biologist-oriented resource for the analysis of systems-
757 level datasets. *Nat Commun* 2019;10:1523

- 758 37. Miyawaki K, Inoue H, Keshavarz P, Mizuta K, Sato A, Sakamoto Y, Moritani M, Kunika
759 K, Tanahashi T, Itakura M: Transgenic expression of a mutated cyclin-dependent kinase 4
760 (CDK4/R24C) in pancreatic beta-cells prevents progression of diabetes in db/db mice.
761 Diabetes research and clinical practice 2008;82:33-41
- 762 38. Rane SG, Dubus P, Mettus RV, Galbreath EJ, Boden G, Reddy EP, Barbacid M: Loss
763 of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in beta-
764 islet cell hyperplasia. Nat Genet 1999;22:44-52
- 765 39. Pal A, Potjer TP, Thomsen SK, Ng HJ, Barrett A, Scharfmann R, James TJ, Bishop DT,
766 Karpe F, Godsland IF, Vasan HF, Newton-Bishop J, Pijl H, McCarthy MI, Gloyn AL: Loss-
767 of-Function Mutations in the Cell-Cycle Control Gene CDKN2A Impact on Glucose
768 Homeostasis in Humans. Diabetes 2016;65:527-533
- 769 40. Ndiaye FK, Ortalli A, Canouil M, Huyvaert M, Salazar-Cardozo C, Lecoer C, Verbanck
770 M, Pawlowski V, Boutry R, Durand E, Rabearivelo I, Sand O, Marselli L, Kerr-Conte J,
771 Chandra V, Scharfmann R, Poulain-Godefroy O, Marchetti P, Pattou F, Abderrahmani A,
772 Froguel P, Bonnefond A: Expression and functional assessment of candidate type 2
773 diabetes susceptibility genes identify four new genes contributing to human insulin
774 secretion. Molecular metabolism 2017;6:459-470
- 775 41. Helman A, Klochendler A, Azazmeh N, Gabai Y, Horwitz E, Anzi S, Swisa A, Condiotti
776 R, Granit RZ, Nevo Y, Fixler Y, Shreibman D, Zamir A, Tornovsky-Babeay S, Dai C, Glaser
777 B, Powers AC, Shapiro AM, Magnuson MA, Dor Y, Ben-Porath I: p16(INK4a)-induced
778 senescence of pancreatic beta cells enhances insulin secretion. Nat Med 2016;22:412-420
- 779 42. Tarifeno-Saldivia E, Lavergne A, Bernard A, Padamata K, Bergemann D, Voz ML,
780 Manfrid I, Peers B: Transcriptome analysis of pancreatic cells across distant species
781 highlights novel important regulator genes. BMC Biol 2017;15:21
- 782 43. Fulciniti M, Lin CY, Samur MK, Lopez MA, Singh I, Lawlor MA, Szalat RE, Ott CJ, Avet-
783 Loiseau H, Anderson KC, Young RA, Bradner JE, Munshi NC: Non-overlapping Control of
784 Transcriptome by Promoter- and Super-Enhancer-Associated Dependencies in Multiple
785 Myeloma. Cell Rep 2018;25:3693-3705 e3696
- 786 44. Ernst J, Kellis M: ChromHMM: automating chromatin-state discovery and
787 characterization. Nat Methods 2012;9:215-216
- 788 45. Iglesias A, Murga M, Laresgoiti U, Skoudy A, Bernales I, Fullaondo A, Moreno B, Lloreta
789 J, Field SJ, Real FX, Zubiaga AM: Diabetes and exocrine pancreatic insufficiency in
790 E2F1/E2F2 double-mutant mice. J Clin Invest 2004;113:1398-1407
- 791 46. Fajas L, Annicotte JS, Miard S, Sarruf D, Watanabe M, Auwerx J: Impaired pancreatic
792 growth, beta cell mass, and beta cell function in E2F1 (-/-) mice. J Clin Invest
793 2004;113:1288-1295
- 794 47. Li FX, Zhu JW, Tessem JS, Beilke J, Varella-Garcia M, Jensen J, Hogan CJ, DeGregori
795 J: The development of diabetes in E2f1/E2f2 mutant mice reveals important roles for bone
796 marrow-derived cells in preventing islet cell loss. Proc Natl Acad Sci U S A 2003;100:12935-
797 12940

- 798 48. Grouwels G, Cai Y, Hoebeke I, Leuckx G, Heremans Y, Ziebold U, Stange G, Chintinne
799 M, Ling Z, Pipeleers D, Heimberg H, Van de Castele M: Ectopic expression of E2F1
800 stimulates beta-cell proliferation and function. *Diabetes* 2010;59:1435-1444
- 801 49. Boni-Schnetzler M, Hauselmann SP, Dalmas E, Meier DT, Thienel C, Traub S, Schulze
802 F, Steiger L, Dror E, Martin P, Herrera PL, Gabay C, Donath MY: beta Cell-Specific Deletion
803 of the IL-1 Receptor Antagonist Impairs beta Cell Proliferation and Insulin Secretion. *Cell
804 Rep* 2018;22:1774-1786
- 805 50. Kim SY, Rane SG: The Cdk4-E2f1 pathway regulates early pancreas development by
806 targeting Pdx1+ progenitors and Ngn3+ endocrine precursors. *Development*
807 2011;138:1903-1912
- 808 51. Kim YC, Kim SY, Mellado-Gil JM, Yadav H, Neidermyer W, Kamaraju AK, Rane SG: RB
809 regulates pancreas development by stabilizing Pdx1. *EMBO J* 2011;30:1563-1576
- 810 52. Pullen TJ, Huisng MO, Rutter GA: Analysis of Purified Pancreatic Islet Beta and Alpha
811 Cell Transcriptomes Reveals 11beta-Hydroxysteroid Dehydrogenase (Hsd11b1) as a Novel
812 Disallowed Gene. *Front Genet* 2017;8:41
- 813 53. Campbell SA, Hoffman BG: Chromatin Regulators in Pancreas Development and
814 Diabetes. *Trends Endocrinol Metab* 2016;27:142-152
- 815 54. Avrahami D, Li C, Zhang J, Schug J, Avrahami R, Rao S, Stadler MB, Burger L,
816 Schubeler D, Glaser B, Kaestner KH: Aging-Dependent Demethylation of Regulatory
817 Elements Correlates with Chromatin State and Improved beta Cell Function. *Cell Metab*
818 2015;22:619-632
- 819 55. Arda HE, Li L, Tsai J, Torre EA, Rosli Y, Peiris H, Spitale RC, Dai C, Gu X, Qu K, Wang
820 P, Wang J, Grompe M, Scharfmann R, Snyder MS, Bottino R, Powers AC, Chang HY, Kim
821 SK: Age-Dependent Pancreatic Gene Regulation Reveals Mechanisms Governing Human
822 beta Cell Function. *Cell Metab* 2016;23:909-920
- 823 56. Spaeth JM, Walker EM, Stein R: Impact of Pdx1-associated chromatin modifiers on islet
824 beta-cells. *Diabetes Obes Metab* 2016;18 Suppl 1:123-127
- 825 57. Papizan JB, Singer RA, Tschen SI, Dhawan S, Friel JM, Hipkens SB, Magnuson MA,
826 Bhushan A, Sussel L: Nkx2.2 repressor complex regulates islet beta-cell specification and
827 prevents beta-to-alpha-cell reprogramming. *Genes Dev* 2011;25:2291-2305
- 828 58. Dhawan S, Georgia S, Tschen SI, Fan G, Bhushan A: Pancreatic beta cell identity is
829 maintained by DNA methylation-mediated repression of Arx. *Dev Cell* 2011;20:419-429
- 830 59. Kim H, Yoon BH, Oh CM, Lee J, Lee K, Song H, Kim E, Yi K, Kim MY, Kim H, Kim YK,
831 Seo EH, Heo H, Kim HJ, Lee J, Suh JM, Koo SH, Seong JK, Kim S, Ju YS, Shong M, Kim
832 M, Kim H: PRMT1 Is Required for the Maintenance of Mature beta-Cell Identity. *Diabetes*
833 2020;69:355-368
- 834 60. Schmidt SF, Larsen BD, Loft A, Mandrup S: Cofactor squelching: Artifact or fact?
835 *Bioessays* 2016;38:618-626
- 836

837 **Figure legends**

838

839 **Figure 1. The β cell-specific deletion of *E2f1* impairs glucose tolerance and insulin**
840 **secretion in mice. (A)** Intraperitoneal glucose tolerance test (IPGTT) was performed on
841 $E2f1^{\beta-/-}$ (n=12), RIP-Cre^{+/+} (n=7) and $E2f1^{fl/fl}$ (n=8) male mice at 12 weeks of age. **(B)** Area
842 under the curve (AUC) calculated from (B). **(C)** Plasma insulin levels at 0 and 30 min after
843 intraperitoneal glucose injection in $E2f1^{\beta-/-}$ (n=12), RIP-Cre^{+/+} (n=7) and $E2f1^{fl/fl}$ (n=8) male
844 mice at 12 weeks of age. **(D)** IPGTT was performed on 5-month-old adult $E2f1^{MIP-CreERT \beta-/-}$
845 (n=12) and $E2f1^{fl/fl}$ (n=8) male mice 3 months after tamoxifen administration. **(E)** Area under
846 the curve (AUC) calculated from (D). **(F)** Plasma insulin levels at 0 and 20 min after
847 intraperitoneal glucose injection in $E2f1^{MIP-CreERT \beta-/-}$ (n=11) and $E2f1^{fl/fl}$ (n=11) male mice at
848 5 months of age 3 months post tamoxifen treatment. All values are expressed as mean \pm
849 s.e.m. and were analysed by one-way analysis of variance (ANOVA) with Tukey's test (B,
850 C), two-way ANOVA with Tukey's test (A, D, F) or two-tailed unpaired *t*-test (E). *p < 0.05;
851 **p<0.01.

852

853 **Figure 2. Normal β -cell mass but altered α -to- β cell ratio in β cell-specific *E2f1***
854 **deficient mice. (A to D)** Morphometric analysis revealed comparable islet density (A), mean
855 islet size (B), β -cell fraction (C), and mass (D), area (E) and proliferation (F) in pancreata of
856 3-month-old $E2f1^{\beta-/-}$ (n=5) and control $E2f1^{fl/fl}$ (n=5) male mice. **(G)** Representative
857 immunofluorescent staining of insulin and glucagon in pancreatic sections from 3-month-old
858 $E2f1^{\beta-/-}$ and control $E2f1^{fl/fl}$ male mice. **(H)** Ratio of glucagon labelled cells (Glucagon +) over
859 pancreatic islets in $E2f1^{\beta-/-}$ and $E2f1^{fl/fl}$ male mice calculated from (F) (n=5). **(I)**
860 Representative immunofluorescent staining of insulin and somatostatin in pancreatic
861 sections from 3-month-old $E2f1^{\beta-/-}$ and control $E2f1^{fl/fl}$ male mice. **(J)** The ratio of
862 somatostatin labelled cells over pancreatic islets in $E2f1^{\beta-/-}$ and $E2f1^{fl/fl}$ male mice was

863 calculated from (G) (n=5). All values are expressed as mean \pm s.e.m. and were analysed by
864 two-tailed unpaired Mann-Whitney test (A, B, C, D, E, F, G, H, J). *p < 0.05; **p<0.01.

865

866 **Figure 3. Lineage tracing of β cells reveals that *E2f1*-deficient β cells are not converted**
867 **into α cells. (A-B)** Representative immunofluorescent staining of Dapi, Tomato, insulin (A)
868 and Dapi, Tomato, glucagon (B) in pancreatic sections from 12-week-old Rip-
869 Cre^{+/+::E2f1^{+/+::tdTomato}} (*E2f1* $\beta^{+/+}$) and *E2f1^{β-/-::tdTomato}* (*E2f1^{β-/-}*) mice. **(C-D)**
870 Representative immunofluorescent staining of Dapi, red fluorescent protein (RFP), insulin
871 (C) and Dapi, RFP, glucagon (D) in pancreatic sections from 12-week-old *E2f1^{β-/-::ECFP}*
872 (*E2f1^{β-/-}*) mice.

873

874 **Figure 4. RNA-seq analysis of *E2f1* β cell-specific knockout islets reveal altered**
875 **transcriptional programs. (A)** Volcano plot providing adjusted P value (i.e., FDR, false
876 discovery rate) and fold change for all gene transcripts in islets from *E2f1^{β-/-}* mice. Genes
877 that are differentially expressed compared to *E2f1^{fl/fl}* with an AdjP<0.05 are indicated by two-
878 level color coding. 199 downregulated protein-coding genes are highlighted in red. 493
879 upregulated protein-coding genes are highlighted in green (n=3 per genotype for RNA-seq
880 analysis). **(B-C)** Ingenuity Pathway Analysis of downregulated (B) and upregulated (C)
881 genes in *E2f1^{β-/-}* compared to *E2f1^{fl/fl}*. Histogram of enriched terms across input gene lists
882 are shown. **(D)** Evolutionary conserved α - and β -cell markers were recovered from Tarifeno-
883 Saldivia E *et al.* (42) and were used to filter our RNA-seq dataset. Volcano plots provides
884 AdjP values (i.e., FDR, false discovery rate) and fold change for both α - and β -cell marker
885 transcripts in islets from *E2f1^{β-/-}* mice. The α - and β -cell markers are displayed as orange
886 square and blue triangle, respectively. Gene symbols of differentially expressed α - and β -
887 cell markers are displayed (AdjP<0.05). **(E-F)** Enrichment plot from Gene Set Enrichment

888 Analysis (GSEA) was conducted with 82 probe sets specifically expressed in α -cells (E) and
889 with 26 probe sets specifically expressed in β -cells (F).

890

891 **Figure 5. The pharmacological inhibition of E2f transcription factor activity induces a**
892 **loss of β -cell function in mouse and human islets.** **(A)** Min6 cells were transiently co-
893 transfected with the E2F-RE-Tk promoter luciferase construct in the absence (PCDNA3) or
894 presence of E2F1:DP1 heterodimer (E2F1/DP1) and were subsequently treated with DMSO
895 (0.1 %, 48h) or HLM006474-treated (10 μ M, 48h). Raw data for luciferase activity were
896 normalized to β -galactosidase activity. **(B)** Glucose stimulated insulin secretion (GSIS) at
897 indicated glucose concentration on DMSO (0.1 %, 48h) or HLM006474-treated (10 μ M, 48h)
898 Min6 cells (n=6). **(C)** qPCR-based analysis of β -cell specific mRNA expression in DMSO
899 (0.1 %, 48h) or HLM006474-treated (10 μ M, 48h) Min6 cells (n=3). **(D)** Glucose stimulated
900 insulin secretion (GSIS) at indicated glucose concentration on human islets treated with
901 DMSO (0.1 %, 48h) or HLM006474 (10 μ M, 48h) (n=3) (see supplementary Table S1 for
902 donor information). **(E)** qPCR-based analysis of β -cell specific (*INS*, *PDX1*, *PAX4*, *MAFA*
903 and *NEUROD1*) and α -cell specific (*ARX* and *GCG*) mRNA expression in DMSO (0.1 %,
904 48h) or HLM006474-treated (10 μ M, 48h) human islets (n=3). Data are represented as mean
905 \pm s.e.m. and were analyzed by two-way ANOVA with Tukey's test (A, B, D) and two-tailed
906 unpaired *t*-test (C, E). *p < 0.05; **p<0.01; ***p<0.001.







907











908 **Figure 6. The transcriptome of *E2f1* ^{β -/-} islets is associated to a specific epigenomic**
909 **pattern.** **(A)** Expression level of *E2f1* ^{β -/-} up- and down- regulated genes both in pancreatic
910 islets from control (WT) and *E2f1* knock-out (*E2f1* ^{β -/-}) mice. Results are displayed as
911 Log10(TPM+1) calculated from TPM obtained from RNA-seq data. Data are represented as
912 mean s.e.m and were analyzed by unpaired *t*-test (**** p<0.0001). **(B)** Pie-chart displaying
913 chromatin state of *E2f1* ^{β -/-} up- and down- regulated genes according to pancreatic islets





914 genes-associated chromatin state stratification from Lu TT *et al.* (12) **(C)** H3K4me3 and
915 H3K27ac ChIP-seq mean signal within promoter (centered to TSS +/- 1kb) of *E2f1*^{β-/-}-up- and
916 down- regulated genes both in Min6 cells and mouse pancreatic islets (12). **(D)** H3K27me3
917 ChIP-seq mean signal within promoter (centered to TSS +/- 1kb) of *E2f1*^{β-/-}-up- and down-
918 regulated genes both in Min6 cells and mouse pancreatic islets (12).







919






920 **Figure 7. Integrating ChIP-seq and RNA-seq data reveals that E2f1 modulates β-cell**
921 **and non-β-cell genes associated to different epigenomic marks. (A)** ChromHMM model
922 based on Min6 cells. Heatmap displays ChromHMM 16-state model obtained with ChIP-seq
923 data sets for H3K4me3, H3K27ac, H3K9ac, H3K4me1, H3K27me3 and E2f1. ChromHMM
924 identifies functionally distinct chromatin states representing both repressive, bivalent and
925 active domains. **(B to I)** Integrated Genome Browser profiles displaying H3K4m3, H3K27ac
926 and H3K27me3 ChIP-seq signal intensities from Min6 cells and mouse pancreatic islets and
927 E2f1 ChIP-seq signal intensity at selected promoters of *E2f1*^{β-/-} upregulated (B to E) and
928 downregulated (F to I) genes.





A**B****C****D****E****F**










A**B****C****D****E****F****G****H****I**



A**B****C****D****E****F**

A**B****C****D****E**

A**B****C****D**

A**B****F****C****G****D****H****E****I**

Supplemental material

Supplementary methods

Materials and Oligonucleotides. Anti-BrdU (ab6326), anti-insulin (guinea pig, ab7842), anti-glucagon (rabbit, ab92517), anti-RFP (ab124754) and IgG (ab37415 ChIP grade for ChIP-seq experiments) antibodies were from Abcam; H3K4me3 (#61379), H3K27ac (#39685) and H3K27me3 (#61017) antibodies were from Active motif; anti-Glut2 (#07-1402-1) was from Merck; anti-cleaved caspase 3 antibody (#9661S) was from Cell Signaling; anti-PC1/3 (AB10553) was from Millipore. Anti-glucagon (mouse, G2654) and anti-FLAG (clone M2) were from Sigma-Aldrich. The HLM006474 compound was first described in (1) and synthetized as previously described (2). The list of primers used in this study is presented in Supplementary Table S2.

Animal Experiments. Mice were maintained according to European Union guidelines for the use of laboratory animals. Mice were housed under a 12-hr light/dark cycle and given a regular chow (A04;Safe).

E2f1^{-/-} (B6; 129S4-*E2f1tm1Meg/J*) mice and *db*/⁺ mice (Janvier Labs) were crossed to obtain *db/db::E2f1*^{+/+} and *db/db::E2f1*^{-/-} mice and were previously described in (3). CMV-CDK4^{R24C} (4) and *Cdkn2a*^{-/-} (5) were described elsewhere and were crossed with *E2f1*^{-/-} mice to obtain *E2f1*^{-/-::CMV-CDK4^{R24C} and *E2f1*^{-/-::Cdkn2a^{-/-}.}}

The congenic mice carrying the floxed *E2f1* allele were thereafter mated with rat insulin II promoter (RIP)-Cre (6) to generate RIPcre^{Tg/+::E2f1}^{fl/fl} mice. To delete E2f1 in adult β cells, we developed a mouse model allowing targeted recombination of E2f1 in

β cells through the use of a tamoxifen inducible strategy. To this end, $E2f1^{flox/flox}$ were crossed with MIP-CreERT mice (Jax Lab, stock number #024709). $E2f1^{flox/flox}$, Rip-Cre^{+/+} and MIP-CreERT were intercrossed to generate pure mutant *Rip-Cre*^{Tg/+}/ $E2f1^{flox/flox}$ and *MIP-CreERT*^{Tg/+}/ $E2f1^{flox/flox}$ mice. A PCR genotyping strategy was subsequently used to identify RIP-cre^{Tg/+}:: $E2f1^{+/+}$ (*Rip-Cre*^{+/+}), Rip-cre^{+/-}:: $E2f1^{flox/flox}$ or *MIP-CreERT*^{+/-}:: $E2f1^{flox/flox}$ ($E2f1^{fl/fl}$), RIPcre^{Tg/+}:: $E2f1^{flox/flox}$ ($E2f1^{\beta/\beta^-}$) and *MIP-CreERT*^{Tg/+}:: $E2f1^{flox/flox}$ ($E2f1^{MIP-CreERT \beta/\beta^-}$) mice. Tamoxifen was dissolved in corn oil (stock solution, 20mg/mL) at 52°C in agitation for 15min and was then administrated to both 2-month-old $E2f1^{fl/fl}$ control and $E2f1^{MIP-CreERT \beta/\beta^-}$ transgenic animals by gavage once per day for 7 days at the dose of 4mg/day. After gavage, a stock solution of 1 mg/mL (stored at 4°C) was prepared in advance by dissolving 100mg of Tamoxifen Citrate (Biogaran) in 100 mL of drinking water. This solution was then diluted 1:20 in drinking water and provided to the animals for 1 week after the gavage induction in black bottles to prevent any alteration of the drug.

Metabolic phenotyping experiments were performed according to the EMPRESS protocols. For in vivo insulin secretion, $E2f1^{fl/fl}$ and $E2f1^{MIP-CreERT \beta/\beta^-}$ mice were starved for 5/6 hours prior Glucose-Stimulated Insulin Secretion (GSIS) to evaluate the basal insulinemia. Blood was collected from mice anesthetized with isoflurane delivered in oxygen at a flow rate of 1L/min. Whole blood samples were collected from the retro-orbital cavity into blood collection tubes containing EDTA, using sterile glass capillaries. To assess insulin secretion level, a second blood sample was collected 20 minutes after an intraperitoneal injection of 2g/kg of body weight of D-(+)-glucose. Plasma was obtained by centrifuging at 2000g for 10 minutes at 4°C. Thereafter, it was transferred into pre-cooled tubes and directly frozen in liquid nitrogen and then stored at -80°C.

Plasma insulin concentration was evaluated by using Enzyme-Linked Immunosorbent Assay (ELISA) Ultrasensitive immunoassay (Mercodia, Uppsala, Sweden), following manufacturer's instructions. All reagents and samples were pre-warm at room temperature before use. The optical density was read at 450 nm, using a spectrophotometer ELISA reader (Sunrise BasicTecan, Crailsheim, Germany), supported by the Tecan's Magellan data analyses software. Insulin concentration was calculated using the online analyses software (myAssay.com), as suggested from the provider.

Measurement of cell proliferation, apoptosis and β-cell size. To assess cellular proliferation, 5-bromo-2'-deoxyuridine (BrdU, B9285, Sigma Aldrich) was administrated to 4 *E2f1*^{β-/-} mice and 4 *E2f1*^{f/f} control littermates. BrdU was dissolved in drinking water (1mg/ml) and provided to mice in dark bottles to protect the solution from the light. The solution was prepared fresh and it was changed every two days for 8 days prior to analyses. Pancreata were harvested, embedded in paraffin, and sectioned at 5 µm. The pancreatic sections were co-stained with anti-BrdU and anti-PC1/3, and slides were mounted with DAPI mounting-medium for nuclei-staining. Islet numbers and area were calculated with Axiovision software in squared-Pixel (PC1/3 positive area), and BrdU+/DAPI+ nuclei were counted. To measure apoptosis and β-cell size, pancreatic tissues were fixed with 10% formalin solution, dehydrated and embedded in paraffin. Immunofluorescence analysis were performed on 5 µm tissue sections. The sections were first de-paraffinized and re-hydrated, followed by a heat-induced antigen retrieval in citrate buffer. Sections were then incubated with blocking buffer for 30minutes and primary anti-Glut2 (for measuring β-cell size) or anti-cleaved caspase 3 antibodies (for measuring apoptosis) diluted at 1:100 in blocking buffer solution over night at +4°C. Immunofluorescent stainings were revealed using an

alexa-conjugated anti-rabbit secondary antibody (for Glut-2) or fluorescein-isothiocyanate-conjugated anti-rabbit (for cleaved caspase-3). Nuclei were stained with Dapi (SigmaAldrich, D9542). For cleaved caspase 3 immunostaining, intestinal FFPE sections from murine trinitrobenzene sulphonic acid (TNBS)-induced model of colitis (a kind gift of Dr Laurent Dubuquoy, Lille) was a positive control. Image acquisitions were done using a Spinning disk confocal microscope (Zeiss). 20 islets per mice were analyzed and 5 mice from each genotype were used to analyze β-cell size and apoptosis. Analysis and quantification were performed on ImageJ software using a macro program (developed in the lab and available upon request).

RNA-Sequencing. RNA quality was verified using RNA 6000 nanochips (Agilent, 5067-1511) on the Agilent 2100 bioanalyzer (Agilent, G2939A). Purified RNA (50ng) with RNA integrity number ≥6.5 was subsequently used for library preparation (TruSeq Stranded mRNA Library Preparation Kit, #20020594, Illumina) and sequenced on a HiSeq2500 system (Illumina). 3 biological replicates per condition were sequenced using paired-end mode. The demultiplexing of sequence data (from BCL files generated by Illumina sequencing systems to standard FASTQ file formats) was performed using bcl2fastq Conversion Software (Illumina; version 2.19.1). Trimming of residuals adapters and low-quality reads was performed using Cutadapt software (version 1.7.1). A mean of 54 million paired-end reads of 75 bp were generated for each sample. After initial checks and validation of sequence quality, RNA-seq reads were aligned to the mouse reference genome (mm10) using TopHat2 or STAR Aligner (version 2.5.2b). Subsequently, both quantification and annotation of the reads were performed using Bioconductor package Rsubread. The counting of the different genes

and isoforms was performed using RSEM (version 1.3). Finally, the differential gene expression analyses were performed using Bioconductor package DESeq2.

ChIP sequencing. 1 ng of eluted and purified DNA was used to prepare DNA sequencing library with the Nextflex rapid DNA seq kit 2.0 (Perkin Elmer, NOVA-5188-01) on the NextSeq 500 system (Illumina) using single read 100 base pairs mode. Sequence reads from FASTQ files were mapped to the mouse genome (mm10) using Bowtie2 Aligner (version 2.3.5.1). The demultiplexing of sequence data (from BCL files generated by Illumina sequencing systems to standard FASTQ file formats) was performed using bcl2fastq Conversion Software (Illumina; version 2.20). Trimming of residuals adapters and low-quality reads was performed using TrimGalore (version 0.4.5). Finally, peak-calling was performed with MACS2 software (version 2.2.7.1).

Bioinformatic analysis. Bioinformatic analysis were mainly performed using the open web-based platform Galaxy Europe (<https://usegalaxy.eu>). Motif search was performed using Pscan Web Interface (7).

Supplementary References

1. Ma Y, Kurtyka Ca, Boyapalle S, Sung S-S, Lawrence H, Guida W, Cress WD: A small-molecule E2F inhibitor blocks growth in a melanoma culture model. *Cancer research* 2008;68:6292-6299
2. Rosales-Hurtado M, Lebeau A, Bourouh C, Cebrian-Torrejon G, Albalat M, Jean M, Naubron JV, Annicotte JS, Benfodda Z, Meffre P: Improved synthesis, resolution, absolute configuration determination and biological evaluation of HLM006474 enantiomers. *Bioorg Med Chem Lett* 2019;29:380-382
3. Denechaud PD, Lopez-Mejia IC, Giralt A, Lai Q, Blanchet E, Delacuisine B, Nicolay BN, Dyson NJ, Bonner C, Pattou F, Annicotte JS, Fajas L: E2F1 mediates sustained lipogenesis and contributes to hepatic steatosis. *J Clin Invest* 2016;126:137-150
4. Sotillo R, Dubus P, Martin J, de la Cueva E, Ortega S, Malumbres M, Barbacid M: Wide spectrum of tumors in knock-in mice carrying a Cdk4 protein insensitive to INK4 inhibitors. *EMBO J* 2001;20:6637-6647
5. Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, DePinho RA: Role of the INK4a locus in tumor suppression and cell mortality. *Cell* 1996;85:27-37
6. Herrera PL: Adult insulin- and glucagon-producing cells differentiate from two independent cell lineages. *Development* 2000;127:2317-2322
7. Zambelli F, Pesole G, Pavesi G: Pscan: finding over-represented transcription factor binding site motifs in sequences from co-regulated or co-expressed genes. *Nucleic Acids Res* 2009;37:W247-252

8. Nicol JW, Helt GA, Blanchard SG, Jr., Raja A, Loraine AE: The Integrated Genome Browser: free software for distribution and exploration of genome-scale datasets. *Bioinformatics* 2009;25:2730-2731
9. Lu TT, Heyne S, Dror E, Casas E, Leonhardt L, Boenke T, Yang CH, Sagar, Arrigoni L, Dalgaard K, Teperino R, Enders L, Selvaraj M, Ruf M, Raja SJ, Xie H, Boenisch U, Orkin SH, Lynn FC, Hoffman BG, Grun D, Vavouri T, Lempradl AM, Pospisilik JA: The Polycomb-Dependent Epigenome Controls beta Cell Dysfunction, Dedifferentiation, and Diabetes. *Cell Metab* 2018;27:1294-1308 e1297
10. Ernst J, Kellis M: ChromHMM: automating chromatin-state discovery and characterization. *Nat Methods* 2012;9:215-216

Supplementary figures and legends

Supplementary Figure S1, related to Figure 1. Validation of the *E2f1^{β/-}* mouse model. (A) qPCR-based analysis of *E2f1* mRNA expression in different tissues (pancreatic islets, hypothalamus (Hypo), heart, epididymal white adipose tissue (eWAT), brown adipose tissue (BAT) and muscle) isolated from 3-month-old male *E2f1^{β/-}*, RIP-Cre^{+/} and *E2f1^{f1/f1}* control mice (n=3-6). (B and C) Body weight (B, n=5-8) and fasting glycaemia (C, n=7-12) of 3-month-old male *E2f1^{β/-}*, RIP-Cre^{+/} and control *E2f1^{f1/f1}* mice. Statistical analysis were performed using one-way analysis of variance (ANOVA) with Tukey's test. **p<0.01. Results are represented as mean ± s.e.m.

Supplementary Figure S2, related to Figure 1. Metabolic phenotyping of the *E2f1^{β/-}* and *E2f1MIP-CreERT β/-* mouse models. Body weight (A, F, n=5-7), fasting

glycaemia (**B**, **G**, n=5-7), ipGTT (**C**, **H**, n=5-7) and its corresponding AUC (**D**, **I**, n=5-7), and plasma insulin levels at 0 and 30 min after intraperitoneal glucose injection (**E**, **J**, n=5-7) of 6-week-old (**A** to **E**) and 8-week-old (**F** to **J**) male *E2f1^{β-/-}* and control *E2f1^{fl/fl}* mice. (**K**) Intraperitoneal insulin tolerance test (IPITT) of *E2f1^{β-/-}* (n=8), RIP-Cre^{+/+} (n=8) and *E2f1^{fl/fl}* (n=8) male mice at 12 weeks of age. (**L**) qPCR-based analysis of *E2f1* mRNA expression in pancreatic islets isolated from 5-month-old male *E2f1^{MIP-CreERT β-/-}* and *E2f1^{fl/fl}* control mice 3 months after tamoxifen administration (n=9-10). (**M-N**) ipGTT (**M**, n=9-10) and its corresponding AUC (**N**, n=9-10) was performed one month after tamoxifen administration in *E2f1^{MIP-CreERT β-/-}* and *E2f1^{fl/fl}* control mice. All values are expressed as mean ± s.e.m. and were analysed by two-tailed unpaired Mann-Whitney test (A, B, D, F, G, I, L, N) or two-way ANOVA with Bonferroni's multiple comparisons test (C, H, K, M). *p < 0.05; **p<0.01; ***p<0.001.

Supplementary Figure S3, related to Figure 2. The E2f1-CDK4-Cdkn2a pathway is required to maintain normal α-to-β cell ratio. (A) Representative immunofluorescent staining of Glut-2 in pancreatic sections from 3 months old *E2f1^{β-/-}* and control *E2f1^{fl/fl}* male mice. Quantification of β-cell size was performed as described in the supplemental material using confocal images from 20 islets and 5 mice per genotype and ImageJ macro. **(B-D)** Representative immunofluorescent staining of cleaved caspase 3 (B-C) and BrdU staining (D) in pancreatic sections from 3 months old *E2f1^{β-/-}* and control *E2f1^{fl/fl}* male mice (B-D). Small intestine FFPE sections from control C57bl6/J mice treated with TNBS were used as a positive control for apoptotic cell detection through cleaved caspase 3 staining (C). Nuclei were stained with Dapi.

Supplementary Figure S4, related to Figure 2. The E2f1-CDK4-Cdkn2a pathway is required to maintain normal α-to-β cell ratio. (A, B). Representative immunofluorescent staining of insulin and glucagon in pancreatic sections from 16-week-old global *E2f1* knockout male mice (*E2f1*^{-/-}, B) compared to littermate controls (*E2f1*^{+/+}, A). **(C)** Quantification of glucagon (Glucagon +) and insulin (Insulin +) labelled cells from the different mouse models (n=3 per genotype). **(D)** Scheme representing the different genetically-engineered mouse models used in this study. **(E to H)** Representative immunofluorescent staining of insulin and glucagon in pancreatic sections from male CMV-CDK4^{R24C} (E), *E2f1*^{-/-}::CMV-CDK4^{R24C} (F), *Cdkn2a*^{-/-} (G), *E2f1*^{-/-}::*Cdkn2a*^{-/-} (H) mice. Values in C are expressed as mean ± s.e.m. and were analysed by one-way ANOVA with Tukey's test. ***p<0.001 and ****p<0.0001 compared to *E2f1*^{+/+}; #####p<0.0001 compared to *E2f1*^{-/-}.

Supplementary Figure S5, related to Figure 2. Altered α-to-β cell ratio in germline *E2f1*-deficient mice. (A) Representative immunofluorescent staining of insulin and glucagon in pancreatic sections from 14 to 15 week old global *E2f1* knockout male mice in a *Db/Db* background (*Db/Db*::*E2f1*^{-/-}) compared to littermate control (*Db/Db*::*E2f1*^{+/+}). **(B)** Quantification of glucagon (Glucagon +) and insulin (Insulin +) labelled cells in *Db/Db*::*E2f1*^{-/-} and *Db/Db*::*E2f1*^{+/+} mice calculated from C (n=4 per genotype). Values in B are expressed as mean ± s.e.m. and were analysed by two-tailed unpaired *t*-test. *p < 0.05; **p<0.01.

Supplementary Figure S6, related to Figure 4. Gene expression analysis of pancreatic islets isolated from β cell-specific *E2f1* knockout mouse (*E2f1*^{β-/-}) compared to littermate controls (*E2f1*^{f/f}). **(A)** Aligned reads and sequencing

coverage of *E2f1* gene exons in *E2f1^{fl/fl}* and *E2f1^{β-/-}* isolated islets in RNA-sequencing experiments. **(B and C)** Heatmap from gene set enrichment analysis (GSEA) displaying differentially expressed β-cell specific genes **(B)** and α-cell specific genes **(C)** in islets isolated from *E2f1^{β-/-}* and *E2f1^{fl/fl}* mice. **(D)** qPCR-based analysis of *E2f1*, *Pcsk9*, *Foxo1* and some β-cell specific genes (*Pdx1*, *Mafa*, *Ins2*, *Glp1r*) in islets isolated from 6-month-old *E2f1^{β-/-}* and *E2f1^{fl/fl}* control male mice (n=5-11). **(E)** qPCR-based analysis of *Arx* (α-cell specific gene) in islets isolated from 6-month-old *E2f1^{β-/-}* and *E2f1^{fl/fl}* control male mice (n=3-5). Results are represented as mean ± s.e.m. Statistical analysis for D and E were performed using one-way ANOVA with Tukey's test. *p < 0.05; **p<0.01; ***p<0.001.

Supplementary Figure S7, related to Figure 6. Chromatin state of specific examples of *E2f1^{β-/-}* up- and down- regulated genes in pancreatic islets and Min6 cells. (A-B) Integrated Genome Browser (IGB, (8)) was used to visualize H3K4m3, H3K27ac and H3K27me3 ChIP-seq signal intensities from Min6 cells and mouse pancreatic islets (9) within a series of **(A)** *E2f1^{β-/-}* down-regulated genes and **(B)** *E2f1^{β-/-}* up-regulated genes.

Supplementary Figure S8, related to Figure 7. E2f1 ChIP-seq validation. (A) Western blot assay showing efficacy of pCMV-hE2F1-Flag plasmid transfection using a Flag antibody in Min6 cells transfected during 24h with the empty pCMV plasmid (Empty plasmid) and pCMV-hE2F1-Flag (E2f1 Flag) plasmid during 24h and 48h. **(B)** Pie-chart showing localization of E2F1 binding in the genome divided in proximal promotor (<1kb), distal promotor (between 1 and 3 kb), gene body, downstream and distal intergenic region. **(C)** Transcription factor binding motifs enriched in ChIP-Seq

from Min6 cells transfected with pCMV-hE2F1-Flag plasmid. **(D)** Integrated genome browser (IGB) representation of hE2F1-Flag fixation site in the promoter region of *Ezh2* in Min6 cells transfected with pCMV plasmid (Empty-Flag) or pCMV-hE2F1-Flag (E2f1-Flag) plasmid (n=2). **(E)** Representation of hE2F1-Flag fixation site in the promotor of *Ccne1* in Min6 cells transfected with pCMV plasmid or pCMV-hE2F1-Flag plasmid realized using IGB software (n=2). **(F, G, H)** ChIP-qPCR showing fixation of hE2F1-Flag in *Ezh2* (F), *Ccne1* (G) and an intergenic region in Min6 cells transfected with pCMV plasmid or pCMV-hE2F1-Flag after an immunoprecipitation with IgG or Flag antibodies (n=2).

Supplementary Figure S9, related to Figure 7. Pathway analysis of direct and indirect E2f1 target genes. **(A-D)** IGB profiles of E2f1 bound (A-B) and unbound (C-D) genes identified through E2f1-Flag Chip-seq analysis. **(E-H)** Ingenuity Pathway Analysis (IPA) of E2f1 bound and unbound downregulated (E-G) and upregulated (F-H) genes in *E2f1^{β/-}* compared to *E2f1^{f/f}*. Histogram of the 10 top enriched canonical pathways across input gene lists are shown.

Supplementary Figure S10, related to Figure 7. Pathway analysis of E2f1 direct and indirect target genes. **(A)** Genomic localisation of 16-state ChromHMM model. Heatmap displays the fold enrichment for each state for each 200-bp bin position within 2 kb around a set of transcription start sites (TSSs). **(B to G)** Ingenuity pathway analysis identified 10 top canonical pathways of *E2f1^{β/-}* up- and down-regulated genes belonging to segment 6 (B-C), 14 (D-E) and 15 (F-G).

Supplementary Table S1, related to Figure 5. Donor information.

Supplementary Table S2, related to Figures 5, S1, S2, S6 and S8. List of oligonucleotides used in this study.

Supplementary Table S3, related to Figures 4, 6, 7, S6, S7, S8, S9 and S10. List of ChIP-seq and RNA-seq data sets used in this study.



Supplementary Table S4, related to Figures 4, 6 and S6. List of transcripts differentially regulated in *E2f1*^{β/-} and *E2f1*^{fl/fl} pancreatic islets identified by RNA-sequencing and their chromatin state.


Supplementary Table S5, related to figure 4. Pathway analysis of RNA-sequencing data in pancreatic islets isolated from control *E2f1*^{fl/fl} and β-cell specific *E2f1*^{β/-} deficient mice identifies potential upstream regulators associated to *E2f1* deficiency.


Supplementary Table S6, related to figure 7, S9 and S10. E2f1-flag ChIP-seq in Min6 cells reveals direct and indirect E2f1 target genes involved in beta cell function. Download the excel file at : <https://nextcloud.univ-lille.fr/index.php/s/ATYtizjgHkQCEpb>


Supplementary Table S7, related to figure 7 and S10. List of the up- and downregulated genes that are bound by E2f1 at the chromatin level identified through ChromHMM 16-state segmentation (10). Chromatin state of E2f1 target genes were identified through intersecting E2f1-flag ChIP sequencing and RNA-sequencing data in pancreatic islets isolated from control *E2f1*^{fl/fl} and β-cell specific *E2f1*^{β/-} deficient mice. Genes belonging to segment 6, 14 and 15 are listed with their corresponding



adjPval and Log2FC. Download the excel file at: <https://nextcloud.univ-lille.fr/index.php/s/cgxD5gQjqKbwZpQ>























A**B**









A**B****C**




Low expression
High expression

D**E**




A**B****C****D****E****G****H****F**



A**Downregulated, E2F1 bound****B****Upregulated, E2f1 bound****C****Downregulated, E2f1 not bound****D****Upregulated, E2f1 not bound****E****Downregulated, E2F1 bound****F****Upregulated, E2f1 bound****G****Downregulated, E2f1 not bound****H****Upregulated, E2f1 not bound**

A**B****C****D**


Segment 14, downregulated genes

**E**

Segment 14, upregulated genes

**F****G**

Segment 15, upregulated genes





Supplementary Table S1, related to Figure 5. Donor informations.

Checklist for Reporting Human Islet Preparations Used in Research

Adapted from Hart NJ, Powers AC (2018) Progress, challenges, and suggestions for using human islets to understand islet biology and human diabetes. *Diabetologia* <https://doi.org/10.1007/s00125-018-4772-2>

Continues on the next page

RECOMMENDED INFORMATION								
Donor cause of death	Hémorragie Méningée	AVC	AVC					
Warm ischaemia time (h)	0	0	0					
Cold ischaemia time (h)	3H38	6H20	6H35					
Estimated purity (%)	80	80	80					
Estimated viability (%)	98,1	93,7	95,3					
Total culture time (h) ^d	18	18	36					
Glucose-stimulated insulin secretion or other functional measurement ^e	1,18	3,67	1,56					
Handpicked to purity? Please select yes/no from drop down list	No	No	No					
Additional notes								

^aIf you have used more than eight islet preparations, please complete additional forms as necessary

^bFor example, IIDP, ECIT, Alberta IsletCore

^cPlease specify the therapy/therapies

^dTime of islet culture at the isolation centre, during shipment and at the receiving laboratory

^ePlease specify the test and the results

Supplementary Table S2, related to Figure 5, S1, S2, S5 and S7. List of oligonucleotide used in this study. (To modify for publication)

Gene Name	Gene symbol	Species	Primer
<i>Cyclophilin</i>	<i>Cyclo</i>	Mouse	ATGGCAGTGGGGCAGGTCC
			TTGCCATTCTGGACCCAAA
<i>E2f1</i>	<i>E2f1</i>	Mouse	GATCGAAGCTTAATGGAGCG
			CCCTTGCTTCAGAGAACAGG
<i>E2f1 Exon3</i>	<i>E2f1 Exon3</i>	Mouse	ACAGCTGCAACTGCTTCGGAG
			AGCTTGAGTTGGTCTCAGGAGG
<i>Paired Box 4</i>	<i>Pax4</i>	Mouse	GTGTACCCCTAGCTGCCCTG
			ATAGGCCTGGGATGAGGTGT
<i>Pancreatic and duodenal homeobox 1</i>	<i>Pdx1</i>	Mouse	ATTGTCGGTACCTCGGGC
			GATGCTGGAGGGCTGTGGCG
<i>Aristaless-related homeobox</i>	<i>Arx</i>	Mouse	GCGGGCTTCCAGAACAGC
			CTGAAACCACACTGGACTCGG
<i>Homeobox protein Nkx2.2</i>	<i>Nkx2.2</i>	Mouse	GTGCAAGGGAGTATTGGAGGC
			GAAGGGCCAGAGGAGGAGA
<i>Forkhead box protein O1</i>	<i>Foxo1</i>	Mouse	TGCCAACCAAAGCTTCCCACA
			TGGACTGCTCTCAGTTCTGCT
<i>Insulin1</i>	<i>Ins1</i>	Mouse	GCCAAACAGCAAAGTCAGG
			GTTGAAACAATGACCTGCTTC
<i>Insulin2</i>	<i>Ins2</i>	Mouse	CAGCAAGCAGGAAGCTTACT
			CAGGTGGGAAACCACAAAGGT
<i>Glucagon</i>	<i>Gcg</i>	Mouse	AGGCCAGGAAGCGGAGACT
			GGAGCCATCAGGTGCTGC
<i>Potassium voltage-gated channel subfamily J member 11</i>	<i>Kcnj11</i>	Mouse	CACAAGCTGGGTTGGGGCTC
			TGCCCCTAGCTGGTTCTGC
<i>Dihydrofolate reductase</i>	<i>Dhfr</i>	Mouse	ATGGTTCGACCATTGAACTGCATCG
			TCTTCTCAGGAATGGAGAACAGG
<i>Glucokinase</i>	<i>Gck</i>	Mouse	GCTCACTGAACCCGGTCAGC
			TGTGCGCAGCTGCTCTGAGG
<i>v-maf musculoaponeurotic fibrosarcoma oncogene family, protein A</i>	<i>MafA</i>	Mouse	OCTGTAGAGGAAGCCGAGGAA
			CTCTCCCCAGTGTGAGTATAGC
<i>v-maf musculoaponeurotic fibrosarcoma oncogene family, protein B</i>	<i>MafB</i>	Mouse	TTAGGGCAGACAGAGCTACCGAAA
			ATACTCTTACACTCCCACCCCTG
<i>Solute carrier family 2 (facilitated glucose transporter)</i>	<i>Slc2a2</i>	Mouse	AACCGGGATGATTGGCATGT
			GGCGAATTATCCAGCAGCA
<i>Proprotein convertase subtilisin/kexin type1</i>	<i>Pcsk1</i>	Mouse	CCGGAGGGCAAGAAGCTGCC
			TGTTCACTGGCGCTGCAACAAG
<i>Proprotein convertase subtilisin/kexin type2</i>	<i>Pcsk2</i>	Mouse	AAAGATGGCGCTGCAACAAG
			TTGCCAGTGTTGAACAGGT
<i>Proprotein convertase subtilisin/kexin type9</i>	<i>Pcsk9</i>	Mouse	TTGCAGCAGCTGGAACTT
			CCGACTGTGATGACCTGGA
<i>Urocortin 3</i>	<i>Ucn3</i>	Mouse	TGATGCCACCTACTTCTG
			CTGTGTTGAGGCACTGAAAG
<i>Hepatocyte nuclear factor 1 homeobox a</i>	<i>Hfn1a</i>	Mouse	ACCGTACACCGTGGACCTTA
			CTGAGATCTACAGCACCTG

<i>Glucagon like peptide 1 receptor promoter</i>	<i>Glp1r</i>	Mouse	CTGGGCTCTTAAACCTGAG CTGCCCTCTCCGCTGG
<i>Enhancer of zeste homolog 2 promoter</i>	<i>Ezh2</i>	Mouse	TTCCGCCCTCTGATTTGGAC CATGCCTTTATTGGCCCC
<i>Cyclin E1 promoter</i>	<i>Ccne1</i>	Mouse	GTTCTTAACCTGGGGCCT CAAGTGAATGTCAGCAGGG
			ACTCTGCCGTGACCCCTTT GGTGTCAAGAGAGTGTGGGA

<i>E2F1</i>	<i>hE2F1</i>	Human	ATGGCAGTGGGGCAGGTCC TTGCCATTCTGGACCCAAA
<i>Paired Box 4</i>	<i>hPAX4</i>	Human	AGCAGAGGCACTGGAGAAAGAGTT CAGCTGCATTTCACCTTGAGCTT
<i>Pancreatic and duodenal homeobox 1</i>	<i>hPDX1</i>	Human	CGTCCAGCTGCCCTTCCAT CCGTGAGATGACTTGTGAATAGGA
<i>Aristaless-related homeobox</i>	<i>hARX</i>	Human	CTGCTGAAACGCAAACAGAGGG CTCGGTCAAGTCCAGCCTCATG
<i>v-maf musculoaponeurotic fibrosarcoma oncogene family, protein A</i>	<i>hMAFA</i>	Human	TTGTACAGGTCCGCTCTT AGCAGAGGCACTGGAGAAAGAGTT
<i>Neurogenic Differentiation</i>	<i>hNEUROD1</i>	Human	GCCCCAGGGTTATGAGACTAT GAGAACTGAGACACTGTCCTGT
<i>Insulin</i>	<i>hINS</i>	Human	AGCCTTGTGAACCAACACC GCTGGTAGAGGGAGCAGATG
<i>Glucagon</i>	<i>hGCG</i>	Human	CATTACAGGGCACATTCAAC CGGCCAAGTCTCAACAT

Supplementary Table S3, related to Figures 4, 5, 6, 7, S5, S6, S7, S8 and S9 . List of ChIP-seq and RNA-seq data sets used in this study.

References	Experiment	Mouse strain	Genotype	Biological samples	Antibody	Accession number	Database	Related figures
Lu et al., Cell Metab, 2018	ChIP-seq	C57B6/J (8-10 weeks)	WT	Pancreatic islets	H3K4me3 H3K27ac H3K27me3	GSE110648	Gene expression omnibus (https://www.ncbi.nlm.nih.gov/geo/)	Figure 6, Figure 7 and Figure S6 Figure 6, Figure 7 and Figure S6 Figure 6, Figure 7 and Figure S6
This study	ChIP-seq	N/A	N/A	Min6 cells (DMSO)	H3K4me3 H3K27ac H3K27me3 Flag M2	In progress In progress In progress In progress		Figure 6, Figure 7 and Figure S6 Figure 6, Figure 7 and Figure S6 Figure 6, Figure 7 and Figure S6 Figure 7, Figures S7, S8 and S9
This study	RNA-seq	C57B6/J (12 weeks) C57B6/J (12 weeks) N/A	E2f1 ^{+/+} (ctrl) E2f1 ^{β/−} (KO) N/A	Pancreatic islets (n=3) Pancreatic islets (n=3) Min6 cells (n=3)	N/A	In progress In progress In progress		Figure 4, Figure 6, Figure 7, Figures S5, S6, S8 and S9 Figure 4, Figure 6, Figure 7, Figures S5, S6, S8 and S9 Figure 6

Supplementary Table S4, related to Figures 4 and S5. List of transcripts differentially regulated in E2f1beta-/ and E2f1fl/fl pancreatic islets identified by RNA-seq and their chromatin state.

baseMean	log2FoldChange	IfCS	stat	pvalue	padj	ensembl_genetss_chromatine_state	A	Active TSS (-1)
ENSMUSG00000096515	493.7382422	25.67664338	9.06855555	6.57220187	4.9577E-11	8.2973E-06	ENSMUSG00000096515	ENSMUSG00000096515
ENSMUSG00000028255	15.93590967	2.81784241	7.43275581	1.0636E-13	3.2634E-10	ENSMUSG00000028255	B	Active TSS (+1)
ENSMUSG00000076576	484.1335785	12.46127603	2.93493697	4.2458411	2.1777E-05	0.02885572	ENSMUSG00000076576	ENSMUSG00000076576
ENSMUSG00000095335	12.38863751	3.01346965	4.11108753	3.938E-05	0.00439385	ENSMUSG00000095335	C	TSS Flank Cis-reg
ENSMUSG00000095630	697.2342764	11.34603634	3.58965915	3.16075959	0.0015736	0.04449198	ENSMUSG00000095630	ENSMUSG00000095630
ENSMUSG00000076556	75.3782068	9.778196893	2.77504099	3.523623251	0.00024569	0.02014642	ENSMUSG00000076556	ENSMUSG00000076556
ENSMUSG00000095442	55.29094767	9.331579038	1.63397948	5.71095239	1.1235E-08	7.3867E-06	ENSMUSG00000095442	ENSMUSG00000095442
ENSMUSG00000053977	46.12129767	9.263777657	1.69696397	5.45903024	4.7874E-08	2.3821E-05	ENSMUSG00000053977	ENSMUSG00000053977
ENSMUSG000000106797	19.09370507	7.797063646	1.60276462	4.86475903	1.146E-06	0.00031488	ENSMUSG000000106797	ENSMUSG000000106797
ENSMUSG00000024798	38.37098841	8.772852677	1.63515241	5.365159	8.0878E-08	3.7224E-05	ENSMUSG00000024798	ENSMUSG00000024798
ENSMUSG00000023123	17.16189854	8,59154443	4.97724218	6.4497E-07	0.00019465	ENSMUSG00000023123	D	Proximal Cis-reg/elongation
ENSMUSG00000093861	917.6157786	8.246225838	2.26741157	3.63684561	0.000276	0.01520599	ENSMUSG00000093861	ENSMUSG00000093861
ENSMUSG00000053977	26,91486434	8.240684634	2.78786603	3.28047392	0.000103633	0.03487899	ENSMUSG00000053977	ENSMUSG00000053977
ENSMUSG000000106797	19.09370507	7.797063646	1.60276462	4.86475903	1.146E-06	0.00031488	ENSMUSG000000106797	ENSMUSG000000106797
ENSMUSG00000041449	17,52769147	7.789610914	1.67896295	4.645073037	3.3996E-06	0.00073631	ENSMUSG00000041449	ENSMUSG00000041449
ENSMUSG00000071716	16,184112609	7,64681725	2.0317004	3.76102183	0.00016921	0.01098087	ENSMUSG00000071716	ENSMUSG00000071716
ENSMUSG00000076652	16,09526081	7,551529017	2.2050798	3.45129189	0.00055207	0.02410638	ENSMUSG00000076652	ENSMUSG00000076652
ENSMUSG00000015619	15,53730619	7,489807109	1.89146109	3.95979972	7.5013E-05	0.00663934	ENSMUSG00000015619	ENSMUSG00000015619
ENSMUSG00000076522	15,27985042	7,475489061	2.27878660	3.28047392	0.000103633	0.03487899	ENSMUSG00000076522	ENSMUSG00000076522
ENSMUSG00000009185	14,62072498	7,1413407455	1.80191873	4.11471414	3.8857E-05	0.00438867	ENSMUSG00000009185	ENSMUSG00000009185
ENSMUSG00000095130	13,771217619	7,327103007	2.14705234	3.121623365	0.00064338	0.02632154	ENSMUSG00000095130	ENSMUSG00000095130
ENSMUSG00000083161	11,91656623	7,2899345392	1.78717353	4.07903007	4.5224E-06	0.00489749	ENSMUSG00000083161	ENSMUSG00000083161
ENSMUSG00000094808	13,19071697	7,261489589	4.17000793	4.17000949	3.0459E-05	0.00373383	ENSMUSG00000094808	ENSMUSG00000094808
ENSMUSG00000024291	12,83740959	7,224913162	2.31028185	3.12782646	0.00176428	0.04797693	ENSMUSG00000024291	ENSMUSG00000024291
ENSMUSG00000028167	9,510678808	7,160571738	2.18726504	3.82161612	0.00013015	0.00914559	ENSMUSG00000028167	ENSMUSG00000028167
ENSMUSG00000024211	9,201281748	7,117088093	2.21102662	3.218858414	0.00128704	0.03909866	ENSMUSG00000024211	ENSMUSG00000024211
ENSMUSG00000023739	9,406954178	6,910462926	1.92088394	3.59754319	0.00032124	0.01656576	ENSMUSG00000023739	ENSMUSG00000023739
ENSMUSG00000090264	10,15501244	6,886247967	2.384532887	3.73173061	0.00019017	0.01178808	ENSMUSG00000090264	ENSMUSG00000090264
ENSMUSG00000011384	6,934962891	6,810322486	1.87818381	3.62601491	0.00028783	0.01572382	ENSMUSG00000011384	ENSMUSG00000011384
ENSMUSG00000044103	8,797831001	6,680655999	2.02194368	3.30407624	0.0009529	0.03303743	ENSMUSG00000044103	ENSMUSG00000044103
ENSMUSG00000096375	8,30968383	6,596255546	1.97089253	3.34683674	0.00081739	0.03040838	ENSMUSG00000096375	ENSMUSG00000096375
ENSMUSG00000033882	7,814807895	6,528156565	1.090065653	3.12422221	0.00178761	0.04839694	ENSMUSG00000033882	ENSMUSG00000033882
ENSMUSG00000081665	7,80586912	6,50681988	1.98237638	3.28236456	0.0010294	0.03483701	ENSMUSG00000081665	ENSMUSG00000081665
ENSMUSG00000022132	8,13504613	6,437333031	1.76788904	3.2531673	0.0014126	0.03660392	ENSMUSG00000022132	ENSMUSG00000022132
ENSMUSG00000026069	7,2821081594	6,375359854	2.04272579	3.12100619	0.00180234	0.04851522	ENSMUSG00000026069	ENSMUSG00000026069
ENSMUSG000000100001	23,87743635	6,3464663386	1.52490963	4.16186393	3.1566E-05	0.00378433	ENSMUSG000000100001	ENSMUSG000000100001
ENSMUSG00000035775	22,69017844	6,05170726	1.54455046	3.91810266	8.9249E-06	0.00733513	ENSMUSG00000035775	ENSMUSG00000035775
ENSMUSG00000058119	121,7412868	5,970186761	0.70309687	8.49127199	2.0439E-17	1.2543E-13	ENSMUSG00000058119	ENSMUSG00000058119
ENSMUSG00000026012	27,42073306	5,675154935	1.57411845	3.60529726	0.0003118	0.01630453	ENSMUSG00000026012	ENSMUSG00000026012
ENSMUSG00000020588	13,19171246	5,370625992	1.62602609	3.02534944	0.0009581	0.03315537	ENSMUSG00000020588	ENSMUSG00000020588
ENSMUSG00000079455	18,31529583	5,280215983	1.58338789	3.33475834	0.00085374	0.0317295	ENSMUSG00000079455	ENSMUSG00000079455
ENSMUSG00000026622	30,695657216	5,252353208	1.46811052	3.57767292	0.00034673	0.01753636	ENSMUSG00000026622	ENSMUSG00000026622
ENSMUSG000000094561	47,65603487	5,084640809	1.8137559	4.29534568	1.7442E-05	0.00248922	ENSMUSG000000094561	ENSMUSG000000094561
ENSMUSG00000021835	39,27876404	5,064484846	1.42572224	3.55222394	0.00038199	0.0186366	ENSMUSG00000021835	ENSMUSG00000021835
ENSMUSG00000024670	3,284226678	4,845004518	1.09388204	4.42918371	9,459E-06	0.00155483	ENSMUSG00000024670	ENSMUSG00000024670
ENSMUSG00000071519	1206,790689	4,729010537	0.8001376	5,91024661	3.416E-09	3.3099E-06	ENSMUSG00000071519	ENSMUSG00000071519
ENSMUSG00000044179	24,78766966	4,709533933	1.18819762	3.96361165	7,3824E-05	0.0065976	ENSMUSG00000044179	ENSMUSG00000044179
ENSMUSG00000071517	71,07657696	4,640182909	0.99812784	4.6491123	3.3335E-06	0.00073059	ENSMUSG00000071517	ENSMUSG00000071517
ENSMUSG00000029188	17,14644104	4,601826481	1.43877985	3.19842299	0.00138181	0.04099798	ENSMUSG00000029188	ENSMUSG00000029188
ENSMUSG00000066513	82,0812124	4,444719588	0.81310564	5,46634946	4,5945E-08	2,3493E-05	ENSMUSG00000066513	ENSMUSG00000066513
ENSMUSG00000042195	89,05745752	4,35131527	0.73813425	5,89494692	3,748E-09	3,4501E-06	ENSMUSG00000042195	ENSMUSG00000042195
ENSMUSG00000076490	30,62424688	4,165058627	1.30584028	3,18956207	0.00142489	0,04150655	ENSMUSG00000076490	ENSMUSG00000076490
ENSMUSG00000032083	50,82340123	4,104863984	1.24840507	3,28808651	0.00100871	0,03451686	ENSMUSG00000032083	ENSMUSG00000032083
ENSMUSG0000000782	208,8707391	4,054063538	1.21380776	3,3399552	0.00083792	0,03103841	ENSMUSG0000000782	ENSMUSG0000000782
ENSMUSG00000078249	283,4976504	3,874701905	0.3719978	4,1051927	2,0974E-25	3,8614E-21	ENSMUSG00000078249	ENSMUSG00000078249
ENSMUSG00000053219	57,84121675	3,853250899	0.85103444	4,52773432	5,5619E-08	0,00109759	ENSMUSG00000053219	ENSMUSG00000053219
ENSMUSG00000024857	142,543771	3,822303937	0.86522742	4,41769334	9,976E-06	0,00159702	ENSMUSG00000024857	ENSMUSG00000024857
ENSMUSG00000005232	42,7377981	3,739944627	1.17940737	3,17101719	0,00151896	0,04336333	ENSMUSG00000005232	ENSMUSG00000005232
ENSMUSG00000016283	271,7240211	3,66789053	5,42352573	5,48345E-08	2,831E-05	0,005NSMUSG00000016283	ENSMUSG00000016283	ENSMUSG00000016283
ENSMUSG000000290982	59,80842846	3,619322334	1.04708432	3,45141481	0,00055766	0,02410638	ENSMUSG000000290982	ENSMUSG000000290982
ENSMUSG00000066512	197,12442422	3,514914591	0.76102028	4,62415851	3,7613E-06	0,00077803	ENSMUSG00000066512	ENSMUSG00000066512
ENSMUSG00000042817	3,488822331	3,098647042	1.96947995	3,53689945	0,00040485	0,01966585	ENSMUSG00000042817	ENSMUSG00000042817
ENSMUSG0000000527375	72,50075675	3,26570878	0.878464219	3,22345673	0,00032735	0,01674051	ENSMUSG0000000527375	ENSMUSG0000000527375
ENSMUSG00000044882	83,678620379	3,480698754	0.786464042	4,24575715	9,6105E-06	0,01556555	ENSMUSG00000044882	ENSMUSG00000044882
ENSMUSG00000027715	48,06128795	3,459486926	1.05015541	3,29426187	0,00098681	0,03395717	ENSMUSG00000027715	ENSMUSG00000027715
ENSMUSG00000027358	157,1916444	3,324850588	0,84890058	4,031711703	5,4112E-05	0,00538488	ENSMUSG00000027358	ENSMUSG00000027358
ENSMUSG00000040300	63,67700275	3,40152024	0,96733920	3,51636934	0,00043749	0,02054046	ENSMUSG00000040300	ENSMUSG00000040300
ENSMUSG00000066687	25,18429488	3,395426509	1.01781276	3,33600307	0,00084992	0,03117295	ENSMUSG00000066687	ENSMUSG00000066687
ENSMUSG000000207863	107,3001113	3,267693733	1.01313344	3,22533402	0,00125826	0,03886665	ENSMUSG000000207863	ENSMUSG000000207863
ENSMUSG0000000359015	1							

ENSMUSG000000041119	67,01857038	2,088617716	0.53502009	3,90381177	9,4689E-05	0,00751393	ENSMUSG0C_Pde9a	L
ENSMUSG000000087259	158,3311445	2,043865315	0.3534007	5,79615516	6,7852E-09	5,3867E-06	ENSMUSG0C_2610035D17L	O
ENSMUSG000000030144	330,2249677	2,044381428	0.51230741	3,99053648	6,5924E-05	0,0060683	ENSMUSG0C_Cle4cd	O
ENSMUSG000000005008	220,9186651	2,036095107	0.37037315	5,49741552	3,854E-08	2,0272E-05	ENSMUSG0C_Cav2	L
ENSMUSG000000078920	347,6375101	2,031301269	0.50991102	3,98363866	6,7868E-05	0,00621617	ENSMUSG0C_Grp1747	K
ENSMUSG000000070337	121,8999231	2,028076486	0.61690968	3,28704559	0,00121244	0,04351686	ENSMUSG0C_Grp179	D
ENSMUSG000000026994	250,9688539	2,018715418	0.64069347	3,15082879	0,00162808	0,04568081	ENSMUSG0C_Galt3	L
ENSMUSG000000073489	232,2905104	2,017279673	0.51126287	3,94567995	7,9574E-05	0,00694291	ENSMUSG0C_Irf204	P
ENSMUSG000000106634	94,3659941	2,011179764	0.5434113	3,70102679	0,00021473	0,0100042	ENSMUSG0C_Gmd43042	S
ENSMUSG000000026639	386,4440786	1,995023604	0.51034779	3,90914522	9,2623E-05	0,0074263	ENSMUSG0C_Lamb3	O
ENSMUSG00000008090	103,9437039	1,994336308	0.53677083	3,7154333	0,00020286	0,01248458	ENSMUSG0C_Fgrf1	L
ENSMUSG000000071714	466,055316	1,993672862	0.52649131	3,00015265	0,01014555	ENSMUSG0C_Cs2rb2	N	
ENSMUSG00000029771	212,6141134	1,969989738	0.54231156	3,75158374	0,00017572	0,01107885	ENSMUSG0C_Irf5	L
ENSMUSG00000015396	274,9966671	1,952864979	0.51777475	3,771649793	0,00016217	0,010552215	ENSMUSG0C_Cd83	L
ENSMUSG00000024043	90,8503816	1,949157393	0.57037251	3,41734105	0,00063236	0,02604418	ENSMUSG0C_Arhgap28	B
ENSMUSG000000161353	1415,013159	1,946329921	0.29391853	6,62200474	3,5436E-11	6,8859E-08	ENSMUSG0C_Cxc12	L
ENSMUSG00000024778	203,2718547	1,934088169	0.51114607	3,78382672	0,00015444	0,01022718	ENSMUSG0C_Fas	L
ENSMUSG00000032854	207,3849468	1,923336793	0.57819474	3,32645157	0,00087959	0,0315265	ENSMUSG0C_Ugt8a	O
ENSMUSG00000046056	111,716243	1,920500131	0.56896934	3,37540181	0,00073708	0,02862793	ENSMUSG0C_Sbsn	O
ENSMUSG00000037370	189,1189288	1,919581361	0.60244045	3,18634095	0,00144085	0,041905	ENSMUSG0C_Enp1	B
ENSMUSG00000027864	650,9162172	1,857941736	0.33616153	5,52691513	3,2588E-08	1,8149E-05	ENSMUSG0C_Ptgrfn	B
ENSMUSG00000034463	725,9330609	1,84932063	0.41791363	4,42512607	9,6386E-06	0,00156555	ENSMUSG0C_Scara3	L
ENSMUSG000000053559	86,91063235	1,847291883	0.47794878	3,86504155	0,00011107	0,0082048	ENSMUSG0C_Smagp	B
ENSMUSG00000006731	508,0715103	1,839221422	0.52163679	3,525866	0,0004221	0,02007283	ENSMUSG0C_B4galnt1	L
ENSMUSG00000045994	111,3807352	1,837926632	0.41821706	4,39467163	1,1094E-05	0,0017607	ENSMUSG0C_B3ga1	N
ENSMUSG00000041734	373,7412006	1,824416959	0.48374711	3,77142707	0,00016232	0,01052215	ENSMUSG0C_Kirrel	L
ENSMUSG00000023348	136,6993142	1,821911185	0.52366032	3,42039925	0,002581086	ENSMUSG0C_Trip6	M	
ENSMUSG00000038128	176,5794909	1,81379695	0.50838523	3,56776094	0,00036004	0,0180611	ENSMUSG0C_Camk4	L
ENSMUSG00000006628	218,9622236	1,801216937	0.56534533	3,19735844	0,00138692	0,04099798	ENSMUSG0C_Hck2	L
ENSMUSG0000001761	227,4459375	1,792863736	0.42190919	4,24940667	2,1434E-05	0,00284414	ENSMUSG0C_Smo	L
ENSMUSG00000040206	117,801305	1,778324649	0.33537765	3,02044955	1,1426E-07	4,7807E-05	ENSMUSG0C_Saa3	M
ENSMUSG00000020282	296,0072115	1,767676451	0.27685528	6,38483921	1,7158E-10	2,1058E-07	ENSMUSG0C_Rhbd1f	L
ENSMUSG00000048070	160,66973	1,735354612	0.55417154	3,13174548	0,000173771	0,0475544	ENSMUSG0C_Pirt	N
ENSMUSG00000032625	292,8382	1,724026072	0.39468611	4,36809404	1,2534E-05	0,00195545	ENSMUSG0C_Thsd7a	L
ENSMUSG00000046818	135,9375471	1,715615211	0.43977862	3,9010883	9,5761E-05	0,0075507	ENSMUSG0C_Ddt4l	L
ENSMUSG00000079363	1718,259507	1,711183535	0.26512382	6,452193795	1,1028E-10	1,4502E-07	ENSMUSG0C_Gbp4	K
ENSMUSG00000029338	307,6649706	1,711186401	0.44824262	3,81754195	0,00013479	0,0092938	ENSMUSG0C_Antr2	L
ENSMUSG00000035314	138,283519	1,709159371	0.437899376	4,5082455	6,4881E-06	0,00115971	ENSMUSG0C_Gdp5	L
ENSMUSG00000021097	390,444565	1,707649706	0.25580337	6,67553417	2,4617E-11	5,6649E-08	ENSMUSG0C_Crrn	B
ENSMUSG00000028982	183,0787657	1,701846893	0.39104978	4,36203473	1,2886E-05	0,00197328	ENSMUSG0C_Slc25a3	L
ENSMUSG00000061132	403,8863407	1,687688551	0.52780046	3,13812146	0,00017029	0,04678963	ENSMUSG0C_Blnk	K
ENSMUSG00000095115	1023,118109	1,680526932	0.31431323	5,34666159	8,9591E-08	4,0229E-05	ENSMUSG0C_Itprip2	L
ENSMUSG00000039981	307,3551955	1,674920834	0.44218877	3,78777592	0,00015199	0,0103815	ENSMUSG0C_Zc3h12d	L
ENSMUSG00000020303	237,8109374	1,674692458	0.44541745	3,75982674	0,00017003	0,01090687	ENSMUSG0C_Stc2	L
ENSMUSG00000028937	456,5955846	1,672639767	0,40683092	4,11138797	3,9329E-05	0,00439385	ENSMUSG0C_Acot7	O
ENSMUSG00000039997	277,1492292	1,660249919	0.48851083	3,89589387	0,00067733	0,02725051	ENSMUSG0C_Ifl203	O
ENSMUSG00000002930	456,2590756	1,654270928	0.51492954	3,20912047	0,00131142	0,03994561	ENSMUSG0C_Ppp1r17	O
ENSMUSG000000065159	554,3481545	1,652521571	0.45350571	3,64328753	0,00026918	0,01507156	ENSMUSG0C_Cyba	L
ENSMUSG00000026712	82,37929831	1,651273125	0.52249417	3,16036661	0,001449198	ENSMUSG0C_Mrc1	N	
ENSMUSG00000024511	162,7269012	1,649933936	0.49054045	4,02874472	5,6075E-05	0,0054905	ENSMUSG0C_Rab27b	L
ENSMUSG00000024349	250,5500285	1,649710312	0.52929541	3,11680472	0,000182823	0,04906366	ENSMUSG0C_Tmem173	K
ENSMUSG00000047180	3056,9544944	1,645621007	0.25332977	6,49454275	8,3286E-11	1,1795E-07	ENSMUSG0C_Neur13	L
ENSMUSG00000002010	191,8621798	1,643263737	0.47493097	3,24812956	0,0016166	0,03687281	ENSMUSG0C_Wrd16	C
ENSMUSG00000003997	190,2595441	1,632116681	0.50619516	3,22428344	0,00126288	0,03894419	ENSMUSG0C_Hs17b13	X
ENSMUSG0000000454200	524,4161614	1,632116681	0.40093316	4,05681576	4,9746E-05	0,00516133	ENSMUSG0C_Prom2	M
ENSMUSG000000207376	135,7091757	1,630977889	0.40203383	4,05681576	4,9746E-05	0,00512095	ENSMUSG0C_Bmp6	M
ENSMUSG00000039004	103,4474047	1,62822264	0.46504453	3,50121888	0,00046314	0,02120975	ENSMUSG0C_Tinaq1	L
ENSMUSG00000020592	1053,337664	1,625415163	0.38507068	4,22108257	4,2313E-05	0,00313011	ENSMUSG0C_Sdc1	L
ENSMUSG00000072812	212,205377	1,61567904	0.47930067	3,37090923	0,00074921	0,02891587	ENSMUSG0C_Ahak2	N
ENSMUSG00000020510	553,7025633	1,611373271	0,46067137	3,4978802	0,00046697	0,02130702	ENSMUSG0C_Pik3ap1	L
ENSMUSG00000041889	191,8621798	1,610626612	0.46154582	3,48634941	0,00048368	0,02177155	ENSMUSG0C_Shisa4	L
ENSMUSG00000063873	141,5828868	1,603606782	0.42780887	3,75485615	0,00017344	0,01104862	ENSMUSG0C_Slc24a3	L
ENSMUSG00000034957	172,3354614	1,589522388	0.44209493	3,595543744	0,00032385	0,01665369	ENSMUSG0C_Celba	L
ENSMUSG00000051855	165,956506	1,576286516	0.30994094	5,08576394	3,6615E-07	0,000121719	ENSMUSG0C_Mest	M
ENSMUSG00000037679	131,8124647	1,569780183	0.47193594	3,32625694	0,00088021	0,0315265	ENSMUSG0C_Inf2	L
ENSMUSG0000001256	214,8282829	1,560522105	0.4235024	3,60812354	0,00020842	0,01619899	ENSMUSG0C_Adam19	R
ENSMUSG00000024538	237,5764176	1,556459688	0.43988988	3,53822069	0,00040283	0,01961947	ENSMUSG0C_Pcpic	C
ENSMUSG000000207074	281,2521528	1,551211908	0.3808038	3,99991728	6,3365E-05	6,8859E-08	ENSMUSG0C_Wwc1	L
ENSMUSG00000070530	190,2595441	1,542637377	0.47493097	3,24812956	0,0016166	0,03687281	ENSMUSG0C_Wrd16	C
ENSMUSG000000124248	1202,22227	1,53881175	0.17860443	8,6157535	3,6483E-18	6,3959E-14	ENSMUSG0C_Steap4	A
ENSMUSG00000006064	156,8133723	1,510807787	0.46123269	3,27558693	0,000105443	0,03523048	ENSMUSG0C_Tcea3	L
ENSMUSG00000033174	157,9600307	1,508991985	0.33134411	4,54331728	5,5376E-06	0,00104697	ENSMUSG0C_Mgjil	L
ENSMUSG00000049521	412,4460040	1,5014242197	0.2782577	3,45362033	6,4472E-08	3,0434E-05	ENSMUSG0C_Hspb1	L
ENSMUSG00000045763	1796,5303103	1,496224543	0.29565362	5,045604435	4,5209E-07	0,00014602	ENSMUSG0C_Basp1	L
ENSMUSG00000020010	1020,934982	1,461522214	0.32127666	4,54910796	5,3874E-06	0,00104402	ENSMUSG0C_Vnn3	K
ENSMUSG00000024302	216,297008	1,460864218	0.3018272	4,84006809	1,2979E-06	0,00034136	ENSMUSG0C_Dtna	L
ENSMUSG00000026604	478,4227093	1,456027411	0.38312461	3,80040173	0,00014446	0,0097419	ENSMUSG0C_Ptpn14	L
ENSMUSG00000029860	2041,707821	1,454645935	0.28132564	5,17086376	2,3324E-07	8,9457E-05	ENSMUSG0C_Zyx	A
ENSMUSG00000032068	1108,420223	1,44233874	0.35656153	4,0440562	5,2534E-05	0,00528501	ENSMUSG0C_Plet1	D
ENSMUSG00000048905	159,848067	1,43070629	0.2921665	4,929975	8,224E-07	0,00024032	ENSMUSG0C_4903539E081K	L
ENSMUSG00000032776	6							

ENSMUSG000000041859	403,9687236	1,287250447	0,38462537	3,34676426	0,00081761	0,03040838	ENSMUSG0C McM3	L
ENSMUSG000000043930	466,2419077	1,276359141	0,21839699	5,84421573	5,0896e-09	4,2591e-06	ENSMUSG0C Rtnk	L
ENSMUSG000000042677	2381,683954	1,270069689	0,21368853	5,94355582	2,789e-09	2,8526e-06	ENSMUSG0C Zc3h12a	A
ENSMUSG000000040717	397,4977149	1,269128765	0,30908653	4,106063	4,0246e-05	0,00446342	ENSMUSG0C lI17rd	B
ENSMUSG000000105383	257,640768	1,266065727	0,38056545	3,23680561	0,00087848	0,03152365	ENSMUSG0C NA	
ENSMUSG000000075010	525,3482214	1,257678087	0,37403472	3,36246352	0,0007725	0,0294216	ENSMUSG0C AV112010	K
ENSMUSG000000047281	857,5274312	1,248913694	0,39082899	3,19555029	0,00139564	0,04104444	ENSMUSG0C Sfn	L
ENSMUSG000000031825	5496,929793	1,241791057	0,18125526	6,85106208	7,3304e-12	1,9279e-08	ENSMUSG0C CrispId2	M
ENSMUSG000000003153	325,5033009	1,235025745	0,28926239	4,26958989	1,9858e-05	0,00271099	ENSMUSG0C Slc2a3	L
ENSMUSG000000040249	2838,032494	1,225859571	0,24235875	5,05818401	4,2327e-07	0,0001406	ENSMUSG0C Lrp1	L
ENSMUSG000000066800	229,9969996	1,220097317	0,36256179	3,36521206	0,00076485	0,0292134	ENSMUSG0C Rnasel	K
ENSMUSG000000028028	501,1049743	1,217365635	0,37250606	3,26804255	0,00018294	0,03560168	ENSMUSG0C Alpk1	N
ENSMUSG000000026980	819,513466	1,199311806	0,3096907	3,87261163	0,00010768	0,00812419	ENSMUSG0C Ly75	L
ENSMUSG000000037012	1333,903084	1,19678631	0,26848327	4,45758239	2,8889e-06	0,00138826	ENSMUSG0C Hk1	N
ENSMUSG000000021700	858,6387973	1,196041272	0,26108694	5,58100768	4,6274e-06	0,00091603	ENSMUSG0C Rab3c	L
ENSMUSG00000001333	358,323353	1,190380075	0,2872362	4,44252550	3,4092e-05	0,00399767	ENSMUSG0C Sync	B
ENSMUSG000000050721	656,1617705	1,188890252	0,36269017	3,27797761	0,00104554	0,03506072	ENSMUSG0C Plekho2	A
ENSMUSG000000052920	191,0064624	1,18779709	0,36368945	3,26596523	0,00109092	0,03573625	ENSMUSG0C Prng1	L
ENSMUSG000000038067	2307,697039	1,184221729	0,24207659	4,89192994	9,9852e-07	0,00028281	ENSMUSG0C Cst3	K
ENSMUSG000000037405	5789,658683	1,176574415	0,18414476	7,942059	1,9885e-15	9,1522e-12	ENSMUSG0C Icam1	M
ENSMUSG000000036718	592,9082672	1,173622922	0,25938765	4,52459058	6,0513e-06	0,00110301	ENSMUSG0C Micall2	K
ENSMUSG00000018774	1081,605756	1,170254171	0,38130404	3,36153916	0,00077509	0,0294216	ENSMUSG0C Cd68	F
ENSMUSG00000027583	150,0648953	1,166897148	0,35773036	3,26194307	0,00110651	0,0360222	ENSMUSG0C Zbb46	
ENSMUSG00000074457	601,4570005	1,155686406	0,32402193	5,56691518	0,00036152	0,01808565	ENSMUSG0C S100a16	K
ENSMUSG00000044986	121,1118964	1,151520005	0,3631942	3,17053526	0,00152158	0,04336333	ENSMUSG0C Tst	B
ENSMUSG00000001750	535,4453459	1,149771112	0,31585502	3,64052185	0,00027209	0,01508766	ENSMUSG0C Tcrg1	L
ENSMUSG000000047261	552,313033	1,137507267	0,29441788	3,86358076	0,00011174	0,00820408	ENSMUSG0C Gap43	M
ENSMUSG000000045348	409,5376867	1,126787098	0,31279033	3,60237186	0,00031532	0,01630665	ENSMUSG0C Nypap1	L
ENSMUSG000000056596	686,1646432	1,125873337	0,27115393	4,15215573	3,2996e-05	0,00388685	ENSMUSG0C Trnp1	L
ENSMUSG000000059401	993,2867895	1,120290026	0,26108694	5,58100768	4,6274e-06	0,00091603	ENSMUSG0C Mamld1	
ENSMUSG00000030257	611,3706485	1,115659789	0,34640929	3,22604051	0,00127904	0,03902319	ENSMUSG0C Srgap3	B
ENSMUSG00000020019	611,3342067	1,112924603	0,29664475	3,75170655	0,00017563	0,01107885	ENSMUSG0C Ntn4	L
ENSMUSG000000040409	267,8152783	1,108044009	0,33371502	3,23033073	0,00088911	0,03189323	ENSMUSG0C Lck	O
ENSMUSG000000034127	3002,11689	1,097648554	0,28172126	3,89622197	9,7705e-05	0,00760635	ENSMUSG0C Tspan8	L
ENSMUSG000000035864	808,6587635	1,091321335	0,30702338	5,55452188	0,00037867	0,01856366	ENSMUSG0C Syt1	L
ENSMUSG000000028073	277,4641033	1,081652155	0,33085963	3,26922308	0,00017843	0,03516889	ENSMUSG0C Pear1	W
ENSMUSG000000055805	529,1171583	1,080220174	0,33122248	3,26131295	0,00108986	0,0360222	ENSMUSG0C Fmn1l	L
ENSMUSG00000012519	768,8170811	1,076565633	0,28569933	3,75701005	0,00017196	0,01099202	ENSMUSG0C Milk	B
ENSMUSG00000090877	458,9004681	1,074853453	0,28960640	3,71142228	0,0002061	0,01260553	ENSMUSG0C Hspab1	A
ENSMUSG00000019851	977,2435451	1,06891275	0,31594974	3,38317338	0,00017653	0,02834773	ENSMUSG0C Perp	A
ENSMUSG000000605050	1936,217918	1,060987897	0,33476319	3,16936842	0,00152771	0,04346997	ENSMUSG0C H2-Q7	L
ENSMUSG00000063531	1061,513588	1,059274541	0,28900254	3,66143658	0,00024817	0,01439485	ENSMUSG0C Semame3	L
ENSMUSG000000110386	2725,066453	1,056027181	0,29189455	3,617838	0,00029707	0,015945	ENSMUSG0C Grn42031	
ENSMUSG000000027533	1403,844985	1,046865199	0,31666501	3,30590741	0,00094669	0,03288421	ENSMUSG0C Fabp5	B
ENSMUSG00000027398	739,7175875	1,037783667	0,30683393	3,38223244	0,00017849	0,02834773	ENSMUSG0C lI1b	O
ENSMUSG00000000078	205,887264	1,036441029	0,22991039	3,40802296	5,6343e-06	0,0115971	ENSMUSG0C Kif6	A
ENSMUSG000000035385	3292,031895	1,035317613	0,30411041	3,40441358	0,000366306	0,02692823	ENSMUSG0C Cdc2	N
ENSMUSG000000038849	1067,644241	1,032739785	0,31550313	3,27331069	0,00016296	0,03529294	ENSMUSG0C Ngc1	D
ENSMUSG000000029260	267,0301027	1,014364486	0,261365394	3,86363047	0,00011186	0,00820408	ENSMUSG0C Olm12b	L
ENSMUSG000000070639	1421,174589	1,005093964	0,23290337	4,29617646	1,7377e-05	0,00248922	ENSMUSG0C Rrrc8b	A
ENSMUSG000000045312	978,0733109	0,997353131	0,30991607	3,21813949	0,00012905	0,03913264	ENSMUSG0C Lhp1p2	L
ENSMUSG000000073409	2306,179091	0,997148411	0,31772133	3,13842709	0,00016981	0,04678963	ENSMUSG0C H2-Q5	L
ENSMUSG00000031453	659,6741476	0,996096158	0,29952809	3,22555175	0,00088244	0,03154499	ENSMUSG0C Rasa3	B
ENSMUSG000000606206	333,6487635	0,991101701	0,26486437	3,74192154	0,00018262	0,01139663	ENSMUSG0C Dhrs3	L
ENSMUSG000000031943	586,328222	0,990900931	0,31691694	3,12668968	0,000176786	0,04800351	ENSMUSG0C Panx1	L
ENSMUSG0000000003032	709,7560929	0,988468846	0,31742904	3,60567045	5,537e-07	0,00016989	ENSMUSG0C Kif4	A
ENSMUSG000000027347	583,4735932	0,98526962	0,27236624	3,61346339	0,00030213	0,0161244	ENSMUSG0C Rasgrp1	
ENSMUSG000000091387	484,7289705	0,985184073	0,297946107	3,30615988	0,00094584	0,03288421	ENSMUSG0C Gcnt4	B
ENSMUSG000000030934	1176,886824	0,979759541	0,291110475	3,36524355	0,00076476	0,0292134	ENSMUSG0C Oat	L
ENSMUSG000000604477	791,1432954	0,970225426	0,217614749	4,46212883	8,1194e-06	0,0188826	ENSMUSG0C IraK2	A
ENSMUSG00000019889	1943,976985	0,97085881	0,24631664	3,94150712	8,0971e-05	0,00697732	ENSMUSG0C Ptkr	L
ENSMUSG000000031925	564,7736695	0,967507575	0,23933915	4,04241329	5,2904e-05	0,00529236	ENSMUSG0C Mam2l	D
ENSMUSG0000000404044	685,7837321	0,965029367	0,30104184	3,20563205	0,00012476	0,04025087	ENSMUSG0C Cavin1	
ENSMUSG000000019850	862,0184822	0,960857241	0,28470466	3,86347473	0,0001118	0,00820408	ENSMUSG0C Rcn2	M
ENSMUSG000000047963	1060,564858	0,957828186	0,27472844	3,48645445	0,00048947	0,02192486	ENSMUSG0C Stdhd1	A
ENSMUSG0000000309962	450,501155	0,956313486	0,27200677	3,51577089	0,00038848	0,02054046	ENSMUSG0C Dtx4	B
ENSMUSG000000049382	3705,885885	0,955222177	0,267611703	3,40582296	5,45080229	0,00012905	ENSMUSG0C Lhp1p2	L
ENSMUSG000000104713	8600,034222	0,953524695	0,26160399	3,61696974	8,2894e-11	0,0188826	ENSMUSG0C Krt8	A
ENSMUSG0000000224989	3705,885885	0,957771159	0,25070009	3,64114794	0,00027143	0,01508766	ENSMUSG0C Lats2	B
ENSMUSG0000000303837	805,5878092	0,953777159	0,25070009	3,64114794	0,00027143	0,01508766	ENSMUSG0C Rras	B
ENSMUSG000000043489	2810,568899	0,942465125	0,26788493	3,45167653	0,00055712	0,02410638	ENSMUSG0C Tnfafp3	E
ENSMUSG000000085952	388,1179892	0,94262781	0,29364433	3,41498874	2,83188e-05	0,00388685	ENSMUSG0C Cd81	L
ENSMUSG000000041599	696,9989842	0,919955566	0,21044395	3,28576596	2,5158e-05	5,1212e-05	ENSMUSG0C Csf1	A
ENSMUSG000000024816	958,0315116	0,91554084	0,25534398	3,58551952	0,00036641	0,01715587	ENSMUSG0C Frmd8	B
ENSMUSG000000032000	7737,926095	0,907804843	0,13976724	3,61954475	8,2954e-11	1,1795e-07	ENSMUSG0C Bir3c	B
ENSMUSG000000035954	993,517032	0,903835936	0,24529983	3,68461561	0,00022905	0,0136025	ENSMUSG0C Dock4	A
ENSMUSG000000029298	3064,196944	0,901207523	0,20136236	4,47553935	7,6219e-06	0,01336337	ENSMUSG0C Gbp9	K
ENSMUSG000000047501	1426,169912	0,899538843	0,17589966	3,15937193	3,1552e-07	0,00011171	ENSMUSG0C Cln3d4	A
ENSMUSG000000038740	474,5688412	0,89167654	0,24642064	3,39794984	0,00067893	0,02725051	ENSMUSG0C Mvb12b	M
ENSMUSG000000008661	389,9284086	0,894636459	0,24765992	3,61235867	0,00030342	0,0161244</td		

ENSMUSG00000026421	3785,429203	0,753833175	0,22843935	3,29992696	0,0009671	0,0333414	ENSMUSG0C_Csrp1	A
ENSMUSG00000006435	4419,975017	0,748139984	0,17225418	4,3432327	1,0404-05	0,00218168	ENSMUSG0C_Neur1a	C
ENSMUSG00000037411	13897,63324	0,7432801	0,22994509	3,23242434	0,00122745	0,03823568	ENSMUSG0C_Serpine1	C
ENSMUSG0000048218	3840,742564	0,741983903	0,18277257	4,05960201	4,9156E-05	0,00511633	ENSMUSG0C_Amigo2	A
ENSMUSG00000037434	1313,609049	0,739985085	0,22885919	3,23336414	0,00122342	0,03823568	ENSMUSG0C_Slc30a1	A
ENSMUSG00000039115	452,473176	0,738978579	0,20392775	3,62372734	0,00092039	0,01581668	ENSMUSG0C_Itg9	L
ENSMUSG00000028701	802,560705	0,735835398	0,22425539	3,28123834	0,000130352	0,03484883	ENSMUSG0C_Lrap1	L
ENSMUSG000000040093	672,5164557	0,727056235	0,21911302	3,31817902	0,00090606	0,03201658	ENSMUSG0C_Bmf	B
ENSMUSG000000086841	737,7874245	0,726155291	0,22452759	3,23414727	0,000122007	0,03823	ENSMUSG0C_24n1000H16Rik	
ENSMUSG00000046711	4679,133652	0,723456773	0,17874236	3,85140381	0,00011744	0,0084789	ENSMUSG0C_Hmgc1	A
ENSMUSG00000020227	1023,534669	0,719653709	0,22656386	3,17638311	0,00149124	0,04289641	ENSMUSG0C_Irk3	L
ENSMUSG00000042228	2396,393218	0,71794553	0,19428557	3,66365109	0,00024865	0,01439485	ENSMUSG0C_Lyn	B
ENSMUSG00000005973	2201,68985	0,711379706	0,20630714	3,44815845	0,00056442	0,02428363	ENSMUSG0C_Rcn1	B
ENSMUSG0000039835	2022,292619	0,710167155	0,14981255	4,74037154	2,1333E-06	0,00051004	ENSMUSG0C_Nhs1	L
ENSMUSG0000042331	1133,545488	0,696245133	0,19714293	3,53167697	0,00041293	0,01979715	ENSMUSG0C_Spec1	A
ENSMUSG0000039195	514,3061008	0,692516152	0,22024566	3,14449585	0,000166373	0,0461979	ENSMUSG0C_Camk1d	B
ENSMUSG0000024066	1400,05722	0,689022426	0,21558921	3,1959673	0,000139349	0,04104444	ENSMUSG0C_Xdh	K
ENSMUSG00000039960	2809,842054	0,688190542	0,12404294	5,54800253	2,8895E-08	1,6624E-05	ENSMUSG0C_Rhou	A
ENSMUSG00000028469	705,0401645	0,686806371	0,21355912	3,21600118	0,0012999	0,03929592	ENSMUSG0C_Npr2	L
ENSMUSG0000042129	558,487444	0,686475836	0,1748992	5,92513685	8,668E-05	0,00725358	ENSMUSG0C_Rassf4	A
ENSMUSG0000023905	2627,192605	0,681121165	0,16748183	4,06683628	4,7656E-05	0,00507279	ENSMUSG0C_Tnfrsf12a	A
ENSMUSG0000104346	1730,512126	0,676379475	0,20379537	3,3189122	0,00090369	0,03199404	ENSMUSG0C_Pcdha3	S
ENSMUSG0000038508	1353,992334	0,675482979	0,20828686	3,24304167	0,00118261	0,03740865	ENSMUSG0C_Gdf15	X
ENSMUSG0000021087	2149,483762	0,672498599	0,18286933	3,6793781	0,00023605	0,0192985	ENSMUSG0C_Rtn1	L
ENSMUSG0000021876	35026,24833	0,670112603	0,18345248	3,6527858	0,00025941	0,04877772	ENSMUSG0C_Rnase4	B
ENSMUSG0000020407	525,917214	0,669408444	0,1810625	3,69711258	0,00021807	0,01307684	ENSMUSG0C_Upp1	B
ENSMUSG0000048087	1140,468676	0,666589408	0,19734755	3,77774355	0,00073083	0,02856606	ENSMUSG0C_Gna737	S
ENSMUSG0000022965	2645,589857	0,665460442	0,19308061	3,44654207	0,00056781	0,02436686	ENSMUSG0C_ifngr2	A
ENSMUSG0000018417	3078,222163	0,664284393	0,18197941	3,65032731	0,00026191	0,01497421	ENSMUSG0C_Myo1b	L
ENSMUSG0000009585	2945,936756	0,659122478	0,17988029	3,66422837	0,00024809	0,01439485	ENSMUSG0C_Apopb3	B
ENSMUSG0000069805	2053,285209	0,649190827	0,185355111	3,5024922	0,00046093	0,02116127	ENSMUSG0C_Fbp1	L
ENSMUSG0000047648	652,4183483	0,64368009	0,16448143	3,91339071	9,1009E-05	0,00736341	ENSMUSG0C_Fbxo30	A
ENSMUSG00000090035	1094,119682	0,64182055	0,17128005	3,74719977	0,00017882	0,01119752	ENSMUSG0C_Sun2	A
ENSMUSG0000026425	2214,641251	0,638548191	0,1435095	4,44953095	8,6058E-06	0,00142732	ENSMUSG0C_Galnt4	B
ENSMUSG00000040525	2765,403669	0,638144521	0,20293483	3,14457863	0,00166326	0,0461979	ENSMUSG0C_Srgap2	B
ENSMUSG0000021025	9684,254012	0,629244881	0,1914026	3,28754513	0,00101065	0,03451686	ENSMUSG0C_Cblc	B
ENSMUSG00000021895	1695,0604	0,622779741	0,10016778	3,67126598	5,0557E-05	5,8172E-07	ENSMUSG0C_Nfbka	A
ENSMUSG0000028413	2250,364335	0,614760443	0,14404075	4,1222E-05	0,00212872	0,012872	ENSMUSG0C_Arhgef3	
ENSMUSG0000027994	1189,940427	0,604623279	0,1590336	3,80185863	0,00014361	0,00972039	ENSMUSG0C_B4gal1t	A
ENSMUSG0000040659	3776,159532	0,603123131	0,15752557	3,82872161	0,00012881	0,00910744	ENSMUSG0C_Mcub	
ENSMUSG0000024048	5277,080849	0,605025019	0,15005309	4,00208361	6,2787E-05	0,00592775	ENSMUSG0C_Ehd2	A
ENSMUSG00000030042	717,163505	0,592103556	0,16756214	3,5336356	0,00040898	0,01970234	ENSMUSG0C_Pole4	A
ENSMUSG0000036908	4884,26537	0,587448958	0,14200702	4,13676001	5,32542E-05	0,00410431	ENSMUSG0C_Unc93b1	D
ENSMUSG0000021823	4760,383473	0,585343282	0,16881074	3,46745295	0,00052542	0,0233082	ENSMUSG0C_Vcl	A
ENSMUSG0000021996	11455,73734	0,58226953	0,15250606	3,8180084	0,00013454	0,0092938	ENSMUSG0C_Esd	F
ENSMUSG0000034917	2521,475146	0,579266385	0,16048571	3,60945701	0,00030684	0,01619939	ENSMUSG0C_Tjp3	C
ENSMUSG0000023036	1424,739139	0,576445068	0,1811266	3,18255335	0,000145983	0,04232346	ENSMUSG0C_Pcdhg4	#NA
ENSMUSG0000041135	2900,218972	0,573995744	0,14049113	4,08563676	4,39556E-05	0,00478835	ENSMUSG0C_Ripk2	A
ENSMUSG00000240520	1959,961636	0,563175137	0,12416341	4,53575777	5,7397E-06	0,00106735	ENSMUSG0C_Lpn2	B
ENSMUSG0000024661	7025,204933	0,55781099	0,17407217	3,20488384	0,00135117	0,04025087	ENSMUSG0C_Fth1	A
ENSMUSG0000052684	5574,423264	0,556329774	0,14140236	3,93437412	8,3414E-05	0,00706762	ENSMUSG0C_Gucal1t	A
ENSMUSG0000034462	2250,364335	0,550408307	0,160404396	3,35524876	0,00079294	0,02991385	ENSMUSG0C_Parp14	B
ENSMUSG0000019947	2055,182047	0,539384864	0,13756895	3,92083278	8,8243E-05	0,00730646	ENSMUSG0C_Arid5b	L
ENSMUSG00000203030	7772,112677	0,506052509	0,15005309	4,00208361	6,2787E-05	0,00592775	ENSMUSG0C_Ehd2	A
ENSMUSG0000032786	2948,649781	0,508975452	0,15720579	3,7376675	0,00074174	0,02868785	ENSMUSG0C_Aldh2	B
ENSMUSG0000002500	4316,464458	0,532184753	0,14785496	3,45429879	0,00055172	0,02410638	ENSMUSG0C_Marcks	A
ENSMUSG00000040128	8074,875922	0,530226067	0,15751256	3,85583746	0,00040898	0,01970234	ENSMUSG0C_Relb	A
ENSMUSG0000006818	1722,528025	0,527614909	0,15099148	3,49433554	0,00047524	0,02149688	ENSMUSG0C_Sod2	A
ENSMUSG0000018340	19504,63145	0,52511555	0,16762884	4,87894857	1,0665E-06	0,0002975	ENSMUSG0C_Anxa6	
ENSMUSG000005104304	2900,190086	0,521723739	0,16716796	3,12097704	0,00180252	0,04851522	ENSMUSG0C_Gprc5c	B
ENSMUSG0000048464	3084,367388	0,520882681	0,16146821	3,225590894	0,00125573	0,03886665	ENSMUSG0C_Ankrd50	
ENSMUSG00000608030	25611,63141	0,519355829	0,15200579	3,41668447	0,00063389	0,02604879	ENSMUSG0C_Gstp1	A
ENSMUSG0000029455	2453,996351	0,512356358	0,15186925	3,73736675	0,000459606	0,02564504	ENSMUSG0C_Aldh2	B
ENSMUSG000006662	4918,734717	0,510725351	0,14785496	3,45429879	0,00055172	0,02410638	ENSMUSG0C_Marcks	A
ENSMUSG000002983	2105,624371	0,50898445	0,14500472	3,5101241	0,00044749	0,02087543	ENSMUSG0C_Pcdhg4	A
ENSMUSG00000050912	4070,006174	0,50538249	0,16247003	3,99660514	6,4404E-05	0,00598827	ENSMUSG0C_Tmem123	A
ENSMUSG0000016182	3883,820564	0,503241149	0,15357238	3,26789887	0,000104954	0,03513095	ENSMUSG0C_Pl53	
ENSMUSG000003020303	3197,737238	0,502578095	0,1605426	3,13049515	0,00174512	0,0475965	ENSMUSG0C_Dusp16	A
ENSMUSG0000035356	8865,468683	0,499378575	0,15363878	3,45528162	1,501-05	0,00221443	ENSMUSG0C_Nfbka	A
ENSMUSG0000032835	10131,97588	0,498855077	0,14561572	3,42582363	0,00061292	0,02564504	ENSMUSG0C_F11r	A
ENSMUSG0000005070870	136184,542	0,498418957	0,13055497	3,81769435	0,00013437	0,0092938	ENSMUSG0C_Ft1	A
ENSMUSG0000008859	2703,720363	0,495106858	0,14873043	3,32888738	0,00087194	0,03152656	ENSMUSG0C_Mgat4b	B
ENSMUSG00000033545	2156,805536	0,492743683	0,13345808	3,69212472	0,00022239	0,01329276	ENSMUSG0C_Znf1	B
ENSMUSG000005050847	9483,344542	0,486333446	0,15153444	3,20939161	0,00133016	0,03994561	ENSMUSG0C_Cdd44	L
ENSMUSG0000034573	4240,931349	0,480274155	0,13739108	3,49567196	0,00047287	0,02142419	ENSMUSG0C_Ptpn13	B
ENSMUSG0000026479	5554,417345	0,47770834	0,11751023	4,0578074	7,47872E-05	0,00507279	ENSMUSG0C_Lamc2	B
ENSMUSG0000039943	3178,787284	0,47131184	0,13564702	3,47454135	0,00051173	0,0227558	ENSMUSG0C_Plcb4	I
ENSMUSG00000069681	4647,182979	0,47131184	0,14135232	3,28765954	0,00010124	0,03451686	ENSMUSG0C_Pgd	A
ENSMUSG00000027668	4616,6202007	0,40989152	0,13136353	3,26202076	0,00010621	0,03602222	ENSMUSG0C_Cebpd	
ENSMUSG0000028788	2149,568888	0,418134567	0,1166894	3,58329986	0,00033928	0,01724548	ENSMUSG0C_Gsto1	B
ENSMUSG00000042688	8847,901884	0,40989152	0,11239079	3,64702071</				

ENSMUSG00000028926	2810,638068	-0,970737149	0,1884006	-5,1525161	2,5701E-07	9,6493E-05	ENSMUSG0C_Cdk14	B
ENSMUSG000000105263	8287,220339	-0,969909547	0,23541155	-4,1200593	3,7877E-05	0,0043628	ENSMUSG0C_Gm42427	
ENSMUSG00000039628	734,6382013	-0,960140017	0,3083600	-3,113698	0,00184758	0,049439301	ENSMUSG0C_Hs3t16	B
ENSMUSG00000073791	184,4739954	-0,944319948	0,29974172	-3,1504455	0,00169022	0,04568081	ENSMUSG0C_Efcab7	E
ENSMUSG00000030785	1631,938161	-0,937222907	0,29107305	-3,219888	0,0012824	0,03902319	ENSMUSG0C_Cox6z2	H
ENSMUSG00000042797	652,9884155	-0,936042471	0,22027764	-4,2493757	2,1437E-05	0,0284414	ENSMUSG0C_Aqp11	B
ENSMUSG000000051435	681,6915899	-0,92676326	0,28315037	-3,2730427	0,00106396	0,03529294	ENSMUSG0C_Fhad1	A
ENSMUSG00000037843	5970,418924	-0,916070892	0,25318875	-3,6181343	0,00029673	0,015945	ENSMUSG0C_Vstm2l	A
ENSMUSG00000059824	746,7541073	-0,898189384	0,28256880	-3,1786572	0,00147959	0,04262792	ENSMUSG0C_Dbpp	A
ENSMUSG00000036800	772,4370102	-0,894646734	0,27757281	-3,2237173	0,0012678	0,03902319	ENSMUSG0C_Fam135b	L
ENSMUSG00000016179	272,8207984	-0,875807177	0,23794831	-3,6806615	0,00023263	0,0377078	ENSMUSG0C_Camk1g	L
ENSMUSG00000057069	81456,37061	-0,874627724	0,21997159	-3,976094	7,0056E-05	0,0063534	ENSMUSG0C_Ero1lb	A
ENSMUSG00000027487	857,7664583	-0,870466072	0,28171169	-3,4999002	0,00046543	0,02126206	ENSMUSG0C_Cdk5rap1	A
ENSMUSG00000035299	1310,349301	-0,867340958	0,27535055	-3,1499517	0,00163297	0,04568507	ENSMUSG0C_Mid1	
ENSMUSG00000028825	561,6371392	-0,867303947	0,2607245	-3,3263561	0,00087933	0,0315265	ENSMUSG0C_Rhd	Q
ENSMUSG00000053733	1925,580749	-0,865794203	0,26384639	-3,2814328	0,00103281	0,0348483	ENSMUSG0C_Mitxpl	A
ENSMUSG00000021287	404,807743	-0,863383062	0,24192877	-3,5687489	0,00035868	0,0180423	ENSMUSG0C_Xrcx3	B
ENSMUSG00000038058	1623,420677	-0,862463612	0,20564795	-4,1938838	2,7422E-05	0,00345778	ENSMUSG0C_Nod1	D
ENSMUSG00000021071	1255,94453	-0,849562613	0,21056208	-4,03473	5,4664E-05	0,00541051	ENSMUSG0C_Trim9	B
ENSMUSG00000022235	845,4250531	-0,848535698	0,26039751	-3,2586168	0,00111957	0,03616008	ENSMUSG0C_Cmbl	L
ENSMUSG00000024553	1343,051801	-0,815976106	0,25515158	-3,1980052	0,00138382	0,04099798	ENSMUSG0C_Gar1	B
ENSMUSG00000027984	18235,37686	-0,817156169	0,2589783	-3,593466	0,00032631	0,01673352	ENSMUSG0C_Hadh	A
ENSMUSG00000097530	681,5678173	-0,808122058	0,25948923	-3,1142798	0,00184395	0,04941344	ENSMUSG0C_Kans12-ps	
ENSMUSG00000240207	714,335379	-0,806171402	0,25064941	-3,9201251	8,8503E-05	0,07030646	ENSMUSG0C_Glp1r	A
ENSMUSG0000031026	536,8382021	-0,802702344	0,25050876	-3,2042886	0,00135397	0,04026903	ENSMUSG0C_Trim66	L
ENSMUSG00000034218	3095,615055	-0,798771384	0,13794773	-5,7903916	7,0223E-06	5,3867E-06	ENSMUSG0C_Atm	B
ENSMUSG00000024972	57,5412522	-0,796767195	0,22425312	-3,5529816	0,00038089	0,01865366	ENSMUSG0C_Lgals12	L
ENSMUSG00000742072	4071,950756	-0,794488671	0,2119561	-3,7482643	0,00017799	0,01113871	ENSMUSG0C_Adh2	A
ENSMUSG00000441239	57317,62881	-0,787997278	0,20423821	-3,8582265	0,00011421	0,00834388	ENSMUSG0C_Prs53	A
ENSMUSG0000058248	4901,878824	-0,77826955	0,16668871	-4,668998	3,0267E-06	0,00068792	ENSMUSG0C_Kcnh1	L
ENSMUSG00000095246	1952,470866	-0,773548737	0,23929073	-3,2326732	0,00122638	0,03823568	ENSMUSG0C_Tpm5	K
ENSMUSG0000030761	1294,919401	-0,771882992	0,1768894	-4,6030385	4,1637E-06	0,0008332	ENSMUSG0C_Myo7a	N
ENSMUSG0000036402	53072,5212	-0,756331509	0,180517	-4,1885546	2,8074E-05	0,0351589	ENSMUSG0C_Gng12	B
ENSMUSG0000037279	642,9904923	-0,753935098	0,23447793	-3,2153777	0,00130273	0,03931681	ENSMUSG0C_Ovo1	L
ENSMUSG0000031255	12802,42819	-0,75039097	0,17207957	-4,3670208	1,2963E-05	0,01917238	ENSMUSG0C_Sytl4	
ENSMUSG00000026185	7384,797511	-0,746561707	0,14432811	-5,1726701	2,3077E-07	8,9457E-05	ENSMUSG0C_lgfbp5	L
ENSMUSG00000227027	2136,854056	-0,743837372	0,15089447	-4,7063579	2,5218E-06	0,00059521	ENSMUSG0C_Hira	A
ENSMUSG0000027314	861,6576648	-0,743230849	0,16995963	-4,3720586	1,2308E-05	0,00193668	ENSMUSG0C_Dl14	L
ENSMUSG0000044645	287,481789	-0,73830317	0,22716014	-3,250144	0,0015347	0,03638096	ENSMUSG0C_Gnt334	
ENSMUSG00000516158	3569,286629	-0,735376281	0,21492904	-3,421484	0,00026228	0,02576589	ENSMUSG0C_Car110	A
ENSMUSG0000097908	688,7545295	-0,729992781	0,22484183	-3,2466947	0,00116754	0,0369954	ENSMUSG0C_49334040128	B
ENSMUSG000013089	2396,154732	-0,726299039	0,13270785	-5,8710284	4,2326E-09	3,7956E-06	ENSMUSG0C_Etv5	I
ENSMUSG00000070880	3095,521111	-0,721828946	0,20709033	-3,4863939	0,00048858	0,02192486	ENSMUSG0C_Gad1	A
ENSMUSG00000000215	915786,996	-0,709676093	0,19359267	-3,658821	0,00024655	0,01439485	ENSMUSG0C_Ins12	A
ENSMUSG00000055409	11017,1338	-0,708512055	0,15314053	-4,6265484	3,7181E-06	0,00077784	ENSMUSG0C_Nell1	B
ENSMUSG0000106133	434,734907	-0,707928548	0,22757464	-3,1107532	0,00186611	0,04977022	ENSMUSG0C_Gm3724	
ENSMUSG0000049971	1242,083972	-0,698021657	0,2024661	-3,451339	0,00055781	0,02410638	ENSMUSG0C_Glt1d1	A
ENSMUSG0000079620	7582,19844	-0,689701873	0,20676052	-3,357528	0,0008506	0,03117295	ENSMUSG0C_Muc4	D
ENSMUSG0000022479	11056,3572	-0,679308285	0,20107682	-3,7835251	0,00027922	0,02856356	ENSMUSG0C_Vdr	A
ENSMUSG00000055254	19604,4819	-0,676960689	0,19428133	-3,4884361	0,00049318	0,02203727	ENSMUSG0C_Ntrk2	L
ENSMUSG00000441842	4606,442282	-0,675794096	0,20986874	-3,2200798	0,00120591	0,03902319	ENSMUSG0C_Fhd1	A
ENSMUSG0000035804	3759,391361	-0,66356976	0,20754307	-3,1972629	0,00138738	0,04099798	ENSMUSG0C_Ins1	C
ENSMUSG0000020169	1155,376083	-0,662953385	0,19785633	-3,3506807	0,00080613	0,03022584	ENSMUSG0C_Best3	L
ENSMUSG0000041895	12913,85929	-0,662362588	0,19561924	-3,3859788	0,00070925	0,02814066	ENSMUSG0C_Wip1	A
ENSMUSG0000042638	3859,924727	-0,657821798	0,18660161	-3,525274	0,00042304	0,02007283	ENSMUSG0C_Gucy2c	L
ENSMUSG0000070348	13490,28492	-0,65616414	0,13821833	-4,7473019	2,0615E-06	0,00049937	ENSMUSG0C_Cnd1	L
ENSMUSG00000025140	5783,033348	-0,646346808	0,1694442	-3,8145789	0,00013642	0,00937092	ENSMUSG0C_Pycr1	A
ENSMUSG0000026443	786,2616553	-0,641878012	0,1962551	-3,37113	0,00107118	0,03534136	ENSMUSG0C_Lrrn2	L
ENSMUSG0000037106	2648,201143	-0,641554878	0,18898761	-3,3946927	0,00068706	0,02743756	ENSMUSG0C_Fer116	O
ENSMUSG00000465939	15666,82085	-0,638839765	0,16513266	-3,8686455	0,00010944	0,00819032	ENSMUSG0C_Tmem215	A
ENSMUSG00000261899	1603,542421	-0,637564488	0,17272669	-3,3081328	0,0009392	0,03280971	ENSMUSG0C_Pecr	B
ENSMUSG0000096956	531,4360911	-0,634889446	0,17965306	-3,5339773	0,00040936	0,01970234	ENSMUSG0C_Snf18	B
ENSMUSG00000444535	8959,490984	-0,626983538	0,19768824	-3,9264328	8,6125E-05	0,00724757	ENSMUSG0C_Ffar1	B
ENSMUSG0000019876	576,2191923	-0,621166351	0,19696736	-3,1579802	0,000158866	0,04472064	ENSMUSG0C_Pkb	X
ENSMUSG0000026920	4126,487245	-0,613585248	0,16877712	-3,6119357	0,00030922	0,0161244	ENSMUSG0C_Gpsm1	C
ENSMUSG0000028445	5679,972936	-0,612633369	0,1732206	-3,5356732	0,00040674	0,01970234	ENSMUSG0C_Enho	C
ENSMUSG0000025036	3747,972807	-0,60940247	0,18797485	-3,2419669	0,00018708	0,0374856	ENSMUSG0C_Sfn2	A
ENSMUSG0000034584	3733,346337	-0,607674488	0,19465045	-3,121875	0,000179703	0,04850923	ENSMUSG0C_Exph5	B
ENSMUSG0000020614	2338,469872	-0,60515059	0,15481072	-3,9087417	9,4417E-05	0,0074263	ENSMUSG0C_Fam20a	A
ENSMUSG0000033635	3595,349955	-0,602843317	0,15510036	-3,8867952	0,00010058	0,00779176	ENSMUSG0C_Vps8	I
ENSMUSG00000202602	2064,695148	-0,596011129	0,14307724	-4,1656601	3,1045E-05	0,00378106	ENSMUSG0C_Adrb1	A
ENSMUSG00000024240	1563,013973	-0,59202939	0,16962951	-3,7114235	0,00016232	0,01052215	ENSMUSG0C_Fkb11	A
ENSMUSG00000351937	3555,526468	-0,591533977	0,15684634	-3,7714235	0,00012052215	0,01052215	ENSMUSG0C_Fkb11	B
ENSMUSG0000039601	2368,258798	-0,591169974	0,18802782	-3,4483747	2,1872E-05	0,00285572	ENSMUSG0C_Gm20634	
ENSMUSG0000031626	13680,41829	-0,5753974337	0,17530154	-3,2171671	0,001220463	0,03920093	ENSMUSG0C_Rcan2	A
ENSMUSG0000061911	1767,467763	-0,575425027	0,17989027	-3,1729488	0,000176031	0,04793376	ENSMUSG0C_Sorbs2	D
ENSMUSG0000008811	1820,569354	-0,559772955	0,16310463	-3,4317233	0,00059976	0,02532891	ENSMUSG0C_Dlg3	B
ENSMUSG0000036599	2230,513745	-0,558007361	0,16466996	-4,0888664	4,3349E-05	0,00477874	ENSMUSG0C_Cht12	A
ENSMUSG0000034171	2105,461458	-0,554514383	0,17405343	-3,1858857	0,000144312	0,041905	ENSMUSG0C_Faa	B
ENSMUSG0000030515	1292,840753	-0,554350744	0,15201114	-3,646777	0,00026555	0,01503866	ENSMUSG0C_Tars12	A
ENSMUSG0000029656	1603,374929	-0,553437158	0,11864902	-4,6647785	3,0985E-06	0,00069362	ENSMUSG0C_Ift57	A
ENSMUSG00000								

ENSMUSG00000042203	5472,431258	-0,423803738	0,1266124	-3,3472531	0,00081617	0,03040838	ENSMUSG0C Tbc1d22b	A
ENSMUSG00000029467	91654,93969	-0,420004883	0,13163128	-3,1907681	0,00141895	0,0413992	ENSMUSG0C Atp2a2	A
ENSMUSG00000032557	7881,072312	-0,416455263	0,12993674	-3,2050617	0,00135034	0,04025087	ENSMUSG0C Uba5	C
ENSMUSG00000017764	1951,666245	-0,415361445	0,12765493	-3,253783	0,00113879	0,03655842	ENSMUSG0C Zswim1	C
ENSMUSG00000020260	14551,26937	-0,413337849	0,11369729	-3,635424	0,00027752	0,01520599	ENSMUSG0C Pofut2	A
ENSMUSG00000066900	5646,041715	-0,412707629	0,130862	-3,1537623	0,0016118	0,04530275	ENSMUSG0C Suds3	A
ENSMUSG00000039263	8166,600461	-0,41124954	0,10065138	-4,0858080	4,391E-05	0,00478835	ENSMUSG0C Npep1	A
ENSMUSG00000029629	2563,479544	-0,410790866	0,12147788	-3,3816089	0,00072063	0,02834773	ENSMUSG0C Phf14	A
ENSMUSG00000023915	4774,617527	-0,403332537	0,12400434	-3,2525679	0,00114367	0,03661742	ENSMUSG0C Tnfrs21	A
ENSMUSG00000042178	4184,20181	-0,401835106	0,12229858	-3,285689	0,000101733	0,0346194	ENSMUSG0C Armc5	B
ENSMUSG00000052942	5713,177341	-0,400983075	0,1202595	-3,3343152	0,0008551	0,03117295	ENSMUSG0C Gls3	A
ENSMUSG00000067924	4911,838402	-0,398071725	0,09960195	-3,9966257	6,4252E-05	0,00598827	ENSMUSG0C Rt8b	
ENSMUSG00000032120	7883,8877	-0,397379363	0,10718423	-3,7074425	0,00020936	0,01276282	ENSMUSG0C C2cd2l	A
ENSMUSG00000022769	10645,89718	-0,395391387	0,11129131	-3,5527607	0,00038121	0,01865366	ENSMUSG0C Sdf2l1	A
ENSMUSG00000032839	2979,579928	-0,39196468	0,11525528	-3,4008391	0,00067179	0,0271818	ENSMUSG0C Trpc1	A
ENSMUSG00000023921	2998,880766	-0,388505658	0,09994953	-3,8870182	0,00010148	0,00779176	ENSMUSG0C Mut	A
ENSMUSG00000030780	2842,428676	-0,388439003	0,10682712	-3,6361461	0,00027675	0,01520599	ENSMUSG0C BC017158	B
ENSMUSG00000034850	12587,35693	-0,38443241	0,11255733	-3,4154365	0,0006368	0,02611017	ENSMUSG0C Tmem127	A
ENSMUSG00000041891	50559,83839	-0,382473545	0,10077414	-3,7953541	0,00014743	0,0090598	ENSMUSG0C Lman1	A
ENSMUSG00000029086	18314,63456	-0,380380144	0,11619043	-3,2737649	0,00106125	0,03529294	ENSMUSG0C Prom1	B
ENSMUSG00000028976	19224,79516	-0,379554251	0,09891521	-3,8371677	0,00012446	0,00888115	ENSMUSG0C Slc2a5	D
ENSMUSG00000057530	46918,95336	-0,375862178	0,09537694	-3,9408077	8,1208E-05	0,00697732	ENSMUSG0C Ece1	A
ENSMUSG00000039474	21446,612834	-0,375383165	0,1014726	-3,699355	0,00021615	0,0130042	ENSMUSG0C Wif1	B
ENSMUSG00000020256	20384,87856	-0,373202713	0,11684915	-3,1938846	0,00140372	0,04121615	ENSMUSG0C Aldh12	A
ENSMUSG00000031634	6575,89164	-0,372847598	0,11477619	-3,248475	0,00116025	0,03687281	ENSMUSG0C Ufsp2	A
ENSMUSG00000007594	23405,25567	-0,370032438	0,10471225	-3,5338026	0,00040963	0,01970234	ENSMUSG0C Hapln4	L
ENSMUSG00000061306	38242,00441	-0,367326377	0,08790362	-4,1787274	2,9314E-05	0,00362201	ENSMUSG0C Slc38a10	
ENSMUSG00000041997	7979,776404	-0,367221429	0,11385062	-3,2254672	0,00125767	0,03886665	ENSMUSG0C Tk1	A
ENSMUSG00000018102	7365,912236	-0,360880958	0,11308403	-3,1912637	0,00141652	0,04139384	ENSMUSG0C Hist1h2bc	A
ENSMUSG00000028032	7794,246647	-0,35198861	0,10154982	-3,4661666	0,00052794	0,0233637	ENSMUSG0C Papss1	A
ENSMUSG00000032575	34023,93709	-0,349883098	0,09193823	-3,8056323	0,00014144	0,00964427	ENSMUSG0C Manf	A
ENSMUSG00000022685	4281,02553	-0,348980733	0,1011102	-3,451489	0,0005575	0,02410638	ENSMUSG0C Pam	A
ENSMUSG00000003500	10383,75467	-0,347431309	0,10108855	-3,4369000	0,00058841	0,0251165	ENSMUSG0C Impdh1	A
ENSMUSG00000032743	2602,916463	-0,34623877	0,10607501	-3,2640939	0,00109815	0,03590927	ENSMUSG0C D430042009	A
ENSMUSG00000042298	2422,136369	-0,344725972	0,10893669	-3,1644615	0,0015537	0,04414145	ENSMUSG0C Ttc19	A
ENSMUSG00000027230	8366,127433	-0,341784841	0,10448123	-3,2712555	0,00107071	0,03534136	ENSMUSG0C Creb3l	A
ENSMUSG00000043733	20117,70888	-0,341021998	0,10586577	-3,2212592	0,00127629	0,03902319	ENSMUSG0C Ptgn1	A
ENSMUSG00000035227	2617,87793	-0,340455569	0,09448867	-3,6031366	0,0003144	0,01630453	ENSMUSG0C Spcs2	A
ENSMUSG00000025935	29617,13461	-0,33999618	0,0938783	-3,6216693	0,00029271	0,01589604	ENSMUSG0C Tram1	A
ENSMUSG00000002845	5684,630611	-0,332542156	0,09342382	-3,5595000	0,00037156	0,01848763	ENSMUSG0C Tmem39a	N
ENSMUSG00000045752	7764,694737	-0,332314013	0,10320283	-3,2200088	0,00128187	0,03902319	ENSMUSG0C Tscs4	A
ENSMUSG00000032042	69776,49007	-0,329953801	0,08732525	-3,7784465	0,00015781	0,01038523	ENSMUSG0C Srp	A
ENSMUSG00000029472	14016,66516	-0,319355737	0,05921643	-3,3539984	0,00079653	0,02987971	ENSMUSG0C Anapc5	A
ENSMUSG00000026307	12454,39985	-0,308271842	0,08476792	-3,6366569	0,0002762	0,01520599	ENSMUSG0C Scy	A
ENSMUSG00000074102	4761,144515	-0,307006184	0,09619548	-3,1914823	0,00141545	0,04139384	ENSMUSG0C Rbm15b	A
ENSMUSG00000079487	7484,02724	-0,297935911	0,0913629	-3,2610162	0,00111014	0,0360222	ENSMUSG0C Med12	
ENSMUSG00000028173	13310,53768	-0,295379867	0,09378537	-3,1495302	0,00163533	0,04568507	ENSMUSG0C Wif5	A
ENSMUSG00000034586	27057,80754	-0,293478881	0,09071823	-3,2350597	0,00121617	0,03823	ENSMUSG0C Hdj1	A
ENSMUSG00000030282	11812,57743	-0,276735176	0,08295817	-3,33584	0,00085042	0,03117295	ENSMUSG0C Cmas	A

Supp Table S5. Pathway analysis of RNA-seq data in pancreatic islets isolated from control E2f1fl/fl and beta-cell specific E2f1beta-/- deficient mice ider

Upstream Regulator	Expr Log Ratio	Molecule Type	Predicted	Activation	Notes	Bias Term	Bias-corrected z-score	p-value of
XBP1		transcription regulator	Inhibited	-2.581	bias	-0.771	0.462	1.7E-11
HNF1A		transcription regulator	Inhibited	-3.955	bias	-0.915	-0.337	2.33E-10
NEUROD1		transcription regulator	Inhibited	-2.762	bias	-0.947	-0.145	3.93E-09
DHTKD1		enzyme					8.21E-09	
FDP	-0.576	transcription regulator	Inhibited	-2.442	bias	-0.795	-0.501	9.35E-09
NEUROG3		transcription regulator	Inhibited	-2.423	bias	-1	0	1.08E-07
FAM3A		other					3.4E-06	
PAX6		transcription regulator		-1.759	bias	-0.316	-0.822	4.68E-06
GUS3	-0.401	transcription regulator					1.18E-05	
ERN1		kinase	Inhibited	-2.135	bias	-0.57	-0.549	1.21E-05
G protein alpha		group	Inhibited	-2.648	bias	-0.828	-0.455	1.27E-05
ERCC1		enzyme					1.81E-05	
THRA		ligand-dependent nuclear receptor		0.2		-0.132	0.489	0.0000933
CD38		enzyme	Inhibited	-2.804	bias	-0.907	-0.262	3.72E-05
BAD		other					6.58E-05	
NKK2-2		transcription regulator					8.32E-05	
CGA		other		0.896		0.103	0.645	9.42E-05
TCF4		transcription regulator		-1.265		-0.237	-0.515	9.63E-05
PCSK2		peptidase					0.00011	
MAFA		transcription regulator					0.000142	
MED1		transcription regulator	Inhibited	-2.2	bias	-0.905	-0.21	0.00143
MGAAT4A		enzyme					0.00145	
METTL14		enzyme					0.000224	
TCE3		transcription regulator	Inhibited	-2.779	bias	-0.446	-1.54	0.000238
ACACB		enzyme					0.000274	
SLC13A5		transporter					0.000339	
SOX6		transcription regulator					0.000395	
MAP4K4		kinase		0.816	bias	0.932	-1.466	0.000395
SPOP		other					0.000466	
LEP		growth factor		-0.333		-0.202	0.222	0.000479
ATF6		transcription regulator					0.000486	
Histone h3		group					0.000507	
ISL1		transcription regulator	Inhibited	-2.213		-0.146	-1.889	0.000554
HTT		transcription regulator					0.000577	
SREBF1		transcription regulator		-1.601	bias	-0.739	0.382	0.000609
OGT		enzyme		-0.277		0.125	-0.451	0.000618
CET		enzyme					0.000647	
TAF10		transcription regulator					0.000657	
TRPC3		ion channel					0.000677	
IL5		cytokine	Inhibited	-2.646	bias	-0.956	-0.118	0.000718
PBLR	-0.983	transmembrane receptor					0.000944	
SST		other					0.000944	
ERCC3		enzyme					0.000966	
ERCC4		enzyme					0.000966	
GHR	-0.488	transmembrane receptor					0.00127	
NTRK2	-0.677	kinase					0.00127	
FGRFR4		kinase					0.00134	
Hedgehog		group					0.00134	
CCNT1		transcription regulator					0.00134	
SHCBP1		other					0.00134	
SLC2A2		transporter					0.00134	
TRH		other					0.00134	
P2RY14		g-protein coupled receptor					0.00149	
A1PSF1		other					0.00153	
CCDC80		other					0.00178	
Cathepsin A		group					0.00178	
MUC1		other		-1.044	bias	-0.472	-0.104	0.00184
BCL12		other					0.00195	
PHE21A		other					0.00228	
SHANK3		other					0.00228	
PTCH1		transmembrane receptor					0.00241	
CX3CL1		cytokine					0.00255	
FGF8		growth factor		-0.485		-0.171	-0.152	0.00255
PPARG		ligand-dependent nuclear receptor	Inhibited	-2.917	bias	-0.342	-1.92	0.00278
LAMTOR5		other					0.00284	
RELN		peptidase					0.00284	
DIO3		enzyme		-1.741		0.135	-2.066	0.00297
CAV1		transmembrane receptor					0.00302	
NRA4A1		ligand-dependent nuclear receptor	Activated	2.449		0.246	1.847	0.00311
CCAR2		peptidase					0.00335	
THRB		ligand-dependent nuclear receptor		-0.659		-0.079	-0.484	0.00362
DLX4-AS1		other					0.00345	
KLB		enzyme					0.00345	
NR2C2		ligand-dependent nuclear receptor					0.00345	
TAE1		transcription regulator					0.00345	
TAE5		transcription regulator					0.00345	
NCOA1		transcription regulator		1	bias	0.415	0.17	0.00366
IR52		enzym					0.00362	
TGS1		enzyme					0.00369	
CIC		transcription regulator					0.00411	
INHBB		growth factor					0.00411	
NKKX6-1	-0.538	transcription regulator					0.00411	
STK24		kinase					0.00411	
PTTG1		transcription regulator		1.067	bias	0.487	0.102	0.00414
Histone h4		group					0.00439	
F2		peptidase					0.00449	
F7AR3		g-protein coupled receptor					0.00454	
RNF40		other					0.00454	
STK11		kinase		-0.447		-0.202	0.005	0.00544
MEN1		transcription regulator					0.00548	
EPCAM		other					0.00561	
PIK3CB		kinase					0.00561	
TMBIM6		other					0.00561	
PTX2		transcription regulator	Inhibited	-2	bias	-0.553	-0.895	0.00568
MED13		transcription regulator					0.00621	
MAPK22		kinase					0.00644	
MAPK13		kinase					0.00644	
NAE1		enzyme					0.00644	
PRKDC		kinase					0.00644	
RBMS-AS1		other					0.00644	
SMC1A		transporter					0.007	
MAC		transcription regulator					0.00732	
STIM1		other					0.00742	
FCP21		other					0.00741	
CYP19A1		enzyme		-1.729		-0.089	-1.578	0.00758
FOXA2		transcription regulator	Inhibited	-2.219		-0.206	-1.762	0.00772
5430416N02Rik		other					0.00813	
ABCG5		transporter					0.00813	
ABHD11		enzyme					0.00813	
AIDA		other					0.00813	
ALG10		enzyme					0.00813	
ALG5		enzyme					0.00813	
ALG6		enzyme					0.00813	
ALG8		enzyme					0.00813	
ARFGEF3		other					0.00813	
BAIAP2L1		other					0.00813	
CALCCOCO1		transcription regulator					0.00813	
COL5A3		other					0.00813	
CSH1/CSH2		other					0.00813	
CXKC1		other					0.00813	
Gst16/Cest1c		enzyme					0.00813	
DDOST		enzyme					0.00813	
DRAIXN		other					0.00813	
ENHO	-0.613	other					0.00813	
FBXO31		enzyme					0.00813	
FBXO4		enzyme					0.00813	
FKHR		group					0.00813	
FRMPD1		other					0.00813	
FXN		kinase					0.00813	
GPR142		g-protein coupled receptor					0.00813	
HADH	-0.812	enzyme					0.00813	
HADHA		enzyme					0.00813	
INSRR		kinase					0.00813	
KHK		kinase					0.00813	
LMCUC1370		other					0.00813	
MARK3		kinase					0.00813	
MGAAT4C		enzyme					0.00813	

MKRN1	enzyme				0.00813		
MGDS	enzyme				0.00813		
Mannosidase2	group				0.00813		
Mkm1	enzyme				0.00813		
NNAT	transporter				0.00813		
PCBD1	transcription regulator				0.00813		
PHP11	phosphatase				0.00813		
PLAC1	other				0.00813		
PNLIP	enzyme				0.00813		
RHAG	peptidase				0.00813		
RHOXF2/RHOXF2B	transcription regulator				0.00813		
Ras	group				0.00813		
Rhox11	other				0.00813		
Rhoq	other				0.00813		
SLC17A9	-0.548	transporter			0.00813		
SLC19A2	transporter				0.00813		
SLC30A8	transporter				0.00813		
SLC5A1	transporter				0.00813		
SLC5A10	transporter				0.00813		
SLC9B2	transporter				0.00813		
TOB2	other				0.00813		
UBE2D3	enzyme				0.00813		
UCN3	other				0.00813		
WDR13	other				0.00813		
mir-500	micromia				0.00813		
DNMT3B	enzyme	0.447	bias	0.456	-0.572	0.00815	
AQP7	transporter					0.00825	
ATK	kinase					0.00825	
ATM	enzyme					0.00825	
IGF1BP5	-0.747	other				0.00825	
RPS6KA3	kinase					0.00825	
FMR1	transcription regulator	1.34	bias	0.339	0.59	0.00883	
MBD1	transcription regulator					0.00924	
RAPGEF3	other					0.00924	
RASSF1	other					0.00924	
IGF1R	transmembrane receptor	Inhibited	-2.577	bias	-0.629	-0.955	0.0098
MFAP5	other					0.00968	
ELL2	transcription regulator					0.0107	
PTPN11	-0.341	phosphatase				0.0107	
SMARCA2	transcription regulator					0.0107	
NFATC1	transcription regulator					0.0112	
ATKN1	transcription regulator					0.0113	
MED30	transcription regulator					0.0113	
SPZ1	transcription regulator					0.0113	
IL6ST	transmembrane receptor					0.0123	
miR-30c-5p (and other n	mature micromia					0.0123	
NRK8 (complex)	complex	Inhibited	-2.588	bias	-0.837	-0.421	0.0128
KAT2A	enzyme	Inhibited	-2	bias	-0.446	-1.107	0.0141
LDLR	transporter					0.0145	
MYCN	transcription regulator					0.0145	
LCAT	enzyme					0.0149	
MPZ	other					0.0149	
SREBF2	transcription regulator					0.016	
IGF1	growth factor	-0.841	bias	-0.329	-0.136	0.016	
Akr1b7	enzyme					0.0162	
BCAT2	enzyme					0.0162	
BCLAF1	transcription regulator					0.0162	
CALM1 (includes others)	other					0.0162	
CDC27	other					0.0162	
CERT1	kinase					0.0162	
Ces1a	enzyme					0.0162	
DAXX3	kinase					0.0162	
Eif4H	transcription regulator					0.0162	
GCKR	other					0.0162	
GOPC	transporter					0.0162	
GPC3	other					0.0162	
GPD2	enzyme					0.0162	
GPR119	g-protein coupled receptor					0.0162	
GPR68	g-protein coupled receptor					0.0162	
INSL3	growth factor					0.0162	
IP6K1	kinase					0.0162	
KCNQ2	ion channel					0.0162	
LCLAT1	enzyme					0.0162	
LRIG3	other					0.0162	
NEIL1	enzyme					0.0162	
NPFFR2	g-protein coupled receptor					0.0162	
PAPPA	peptidase					0.0162	
PAPD	peptidase					0.0162	
PASK	kinase					0.0162	
PDHA1	enzyme					0.0162	
PLAA3	enzyme					0.0162	
PRDX3	enzyme					0.0162	
PRHL	cytokine					0.0162	
PTPRF	phosphatase					0.0162	
REM2	enzyme					0.0162	
RPRD1B	other					0.0162	
RRAD	enzyme					0.0162	
SLC9A6	transporter					0.0162	
SLURP1	cytokine					0.0162	
SNCB	other					0.0162	
SNIP1	other					0.0162	
SRI	transporter					0.0162	
SRPK2	kinase					0.0162	
STX4	transporter					0.0162	
Skp	other					0.0162	
TP53INP1	other					0.0162	
VCAM1	transmembrane receptor					0.0162	
VENTX	transcription regulator					0.0162	
ZNF322	transcription regulator					0.0162	
miR-101-5p (mRNAs w/s	mature micromia					0.0162	
miR-185-3p (and other n	mature micromia					0.0162	
miR-501-3p (and other n	mature micromia					0.0162	
p38 Sapk	group					0.0162	
ARNTL	transcription regulator					0.0166	
BCL2L11	other					0.0175	
FGF19	growth factor					0.0175	
JARID2	transcription regulator					0.0175	
RNF20	enzyme					0.0175	
BDNF	growth factor					0.0177	
UNDN3A	enzyme	0.152		0.2	-0.244	0.0186	
CASR	g-protein coupled receptor	Inhibited	-2	bias	-0.593	-0.813	0.0187
GPBAR1	protein coupled receptor					0.0188	
WNT1	cytokine					0.0216	
ADIPORO	other	-0.413		-0.178	-0.081	0.0218	
CRTC2	other					0.0231	
RPS6KB1	kinase					0.0231	
TCF7L2	transcription regulator	Inhibited	-2.592	bias	-0.88	-0.312	0.0238
AGAP2	enzyme					0.0242	
ANK1	other					0.0242	
ATAD2	enzyme					0.0242	
ATOX1	transporter					0.0242	
BANP	other					0.0242	
CACNA1B	ion channel					0.0242	
CARTPT	other					0.0242	
DACT3	other					0.0242	
DNAJ3	other					0.0242	
ELavl	other					0.0242	
FRBM1	other					0.0242	
GNG3	enzyme					0.0242	
GPC6	transmembrane receptor					0.0242	
GRIP1	transcription regulator					0.0242	
HINT2	enzyme					0.0242	
HOXB13	transcription regulator					0.0242	
HSPBP1	other					0.0242	
INPP5K	phosphatase					0.0242	
Irsp4	other					0.0242	
KHLH2	other					0.0242	
KMT2B	transcription regulator					0.0242	
LHX5	transcription regulator					0.0242	
LINC01006	other					0.0242	
MAT2B	enzyme					0.0242	
MBD5	other					0.0242	

MCHR1	g-protein coupled receptor				0.0242
MOGAT2	enzyme				0.0242
NDUFAF3	other				0.0242
NIBAN2	transcription regulator				0.0242
NOP58	enzyme				0.0242
NPTX1	other				0.0242
NSD3	enzyme				0.0242
NUCKS1	kinase				0.0242
OLA1	enzyme				0.0242
PSMD14	peptidase				0.0242
PTGDS	enzyme				0.0242
PUGT11P	other				0.0242
RAB40	enzyme				0.0242
RANBP9	cilia				0.0242
RDXH16	enzyme				0.0242
RIMS2	other				0.0242
SERP1	other				0.0242
SERTAD1	transcription regulator				0.0242
SH2B2	other				0.0242
SLC39A4	transporter				0.0242
SNW1	transcription regulator				0.0242
SRGAP1	other				0.0242
THRSP	other				0.0242
U2AF2	other				0.0242
WAPL	other				0.0242
WIF1	other				0.0242
ZIC1	transcription regulator				0.0242
EGR2	growth factor				0.0245
AUAAM10	peptidase				0.0246
BTG2	transcription regulator				0.0246
GTF2B	transcription regulator				0.0246
SFRP1	transmembrane receptor				0.0246
RETNLB	other				0.0258
ROR2	kinase				0.0258
Hmgn3	other				0.0262
IHH	enzyme				0.0267
TCF	group				0.0267
INS	-0.71 other	-0.277	-0.041	-0.197	0.0276
Nrlh	group	0.152	bias	-0.606	0.0276
A2M	transporter				0.0278
CTNNB1	transcription regulator	-1.147	bias	-0.507	-0.152
EIF2AK3	kinase	-1.969	bias	-0.843	-0.31
HIF1A	transcription regulator	-1.352	bias	-0.444	-0.198
CXCR4	g-protein coupled receptor				0.0294
DLX1	other				0.0311
FAK	kinase				0.0314
MAPK1	kinase	-0.816		0.088	-1.033
ADRA2B	g-protein coupled receptor				0.0321
AGAP2-AS1	other				0.0321
AGRTRAP	g-protein coupled receptor				0.0321
AKAP5	other				0.0321
AP2M1	other				0.0321
ARP1	enzyme				0.0321
ATP2A1	transporter				0.0321
BRS3	g-protein coupled receptor				0.0321
CACNA1D	ion channel				0.0321
CDC25B	phosphatase				0.0321
CINP	other				0.0321
CPT1	group				0.0321
Cathepsin	group				0.0321
DDX9B	group				0.0321
DKK2	other				0.0321
FFA32	g-protein coupled receptor				0.0321
GALR1	-0.816 g-protein coupled receptor				0.0321
GH2	other				0.0321
IGFBP4	other				0.0321
ITPRID2	other				0.0321
Irs3	other				0.0321
KRT10	other				0.0321
LAMB1	other				0.0321
MIH3626	microRNA				0.0321
MUC1	other				0.0321
MYBPC3	other				0.0321
NASP	other				0.0321
NR2F1-AS1	other				0.0321
ORA15	other				0.0321
PTPIP3A	transporter				0.0321
PPBP F3C	phosphatase				0.0321
PRKAkB2	kinase				0.0321
RA811A	kinase				0.0321
SEMA3E	other				0.0321
SGMS1	enzyme				0.0321
SHBG	other				0.0321
SIDT2	transporter				0.0321
SLC2A8	transporter				0.0321
SLC01B3	transporter				0.0321
SNRK	kinase				0.0321
STEAP4	enzyme				0.0321
SUFU	transcription regulator				0.0321
TACSTD2	other				0.0321
TBC1D4	other				0.0321
TCF7LEF	group				0.0321
TEX15	other				0.0321
VTCN1	other				0.0321
ZFP42	transcription regulator				0.0321
msc184	microRNA				0.0321
GSK3B	kinase				0.0321
IGF2	growth factor				0.0328
Mapk	group				0.0328
FOXA1	transcription regulator	-1.982	0.02	-2.023	0.0329
HMGAA1	transcription regulator				0.0341
PTH	other				0.0341
SMAD2	transcription regulator				0.0341
PDPK1	kinase				0.0364
GLI1	transcription regulator	-0.227	0.204	-0.792	0.0369
IL10RA	transmembrane receptor	-1.633	-0.024	-1.575	0.0369
DSCAML1	other				0.0371
GH1	growth factor				0.0382
KDM3A	transcription regulator				0.0382
MLX	transcription regulator				0.0382
MYBL2	transcription regulator				0.0382
miR-30	microRNA				0.0382
SLC13A1	transporter				0.0382
ACACA	enzyme				0.04
AKRIRN2	other				0.04
APBB1	transcription regulator				0.04
ARAF	kinase				0.04
AXIN1	other				0.04
CDH16	enzyme				0.04
CHRM3	g-protein coupled receptor				0.04
CXCL14	cytokine				0.04
FZR1	kinase				0.04
GATM	enzym				0.04
GNAO1	enzyme				0.04
GPR39	g-protein coupled receptor				0.04
GYSG2	enzyme				0.04
HOC1	transcription regulator				0.04
HINFP	transcription regulator				0.04
HTR2C	g-protein coupled receptor				0.04
INSLS	other				0.04
LGALS12	-0.797 other				0.04
MIR336HG	other				0.04
Muc1	transmembrane receptor				0.04
NDN	transcription regulator				0.04
Nisch	other				0.04
PITX1	transcription regulator				0.04
PORCN	enzyme				0.04
PRMT2	enzyme				0.04
PXN	other				0.04
RAD51C	enzyme				0.04
RBBP8	enzyme				0.04
RNF187	enzyme				0.04

RUVBL2	transcription regulator					0.04
SIX3	transcription regulator					0.04
STX2	transporter					0.04
TPPP2	other					0.04
WFS1	-0.375 enzyme					0.04
WNT7B	other					0.04
WRN	enzyme					0.04
ZM22	transcription regulator					0.04
miR-193a-3p (and other)	mature microRNA					0.04
miR-455-3p (mRNAs w/s)	mature microRNA					0.04
mir-455	microRNA					0.04
mir-481	microRNA					0.04
LDL cholesterol	complex					0.04
LGAL3S	other					0.0463
CYP1A1	enzyme					0.0414
CYP27B1	enzyme					0.0419
DRD2	g-protein coupled receptor					0.0419
AKT1	kinase					0.0425
DSCAM	other					0.0425
TSC2	other					0.0427
EGFR	kinase	-1.503 bias	-0.714	0.061	0.0427	
MECP2	transcription regulator					0.0435
SLC25A13	transporter					0.0436
PIK3CA	kinase					0.0438
Creb	group					0.044
IFNG	cytokine	0.43 bias	-0.474	1.887	0.0454	
SNAI2	transcription regulator					0.0458
TOB1	transcription regulator					0.0458
NRG1	growth factor					0.0459
KLF4	transcription regulator	Inhibited	-2.19 bias	-0.598	-0.88	0.0461
EIF2S1	translation regulator					0.0478
ACOT13	enzyme					0.0478
AKAP12	transporter					0.0478
ANGPTL6	other					0.0478
ANKHD1/ANKHD1-EIF4	other					0.0478
CBR3-AS1	other					0.0478
CCND2	other					0.0478
CDK5R1	kinase					0.0478
CTNNBIP1	other					0.0478
DLX1	transcription regulator					0.0478
DMTF1	transcription regulator					0.0478
EOGT	enzyme					0.0478
ERWW-1	other					0.0478
FSTL3	other					0.0478
GOLGR	-0.802 g-protein coupled receptor					0.0478
GPAM						0.0478
GUCY2C	-0.658 kinase					0.0478
HPR1	enzyme					0.0478
IGFBP7	transporter					0.0478
MC3R	g-protein coupled receptor					0.0478
METTL1	enzyme					0.0478
MRAS	enzyme					0.0478
Npy4r	g-protein coupled receptor					0.0478
OBP2B	transporter					0.0478
PDCD5	other					0.0478
PDE3A	enzyme					0.0478
PLSCR1	enzyme					0.0478
PRKAB1	kinase					0.0478
PRKG2	kinase					0.0478
P65f Ab	complex					0.0478
SH2D5	other					0.0478
SLC2A11-AS1	other					0.0478
TFF2	other					0.0478
VGF	growth factor					0.0478
mir-637	microRNA					0.0478
PI3K (complex)	complex	-1.091 bias	-0.714	0.312	0.0486	
Raf	group					0.0498

Supp Table S5. Pathway analysis of RNA-seqencing data in pancreatic islets isolated from control E2f1fl/fl and beta-cell specific E2f1beta-/deficient mice identifies potential upstream regulators associated to E2f1 deficiency.

Upstream Regulator	Exon Log Ratio	Molecule Type	Predicted Activation	z-Flags	p-value of ov Target Molecules in Dataset	Mechanistic N
TNF		cytokine	Activated	6.542	bias	9.24E-05
IFNG		cytokine	Activated	6.621	bias	7.25E-33
lipopolysaccharide		chemical drug	Activated	8.302	bias	3.99E-31
TGFB1		growth factor	Activated	3.805	bias	1.05E-23
dexamethasone		chemical drug	Activated	1.039	bias	1.07E-19
L1B	1.038	cytokine	Activated	5.905	bias	1.30E-22
NFKBIA	0.623	transcription regulator	Activated	2.801	bias	9.07E-19
TNFSF11		cytokine	Activated	5.699	bias	2.84E-18
beta-estradiol		chemical - endogenous mammal	Activated	2.051	bias	3.85E-17
CSF2		cytokine	Activated	5.651	bias	4.93E-17
IL4		cytokine	Activated	3.078	bias	5.78E-17
IKZF1		transcription regulator	Inhibited	4.354	bias	ACOD01ADAM19.1ALAS1ALD1HANXA6.B4GALNT1.BCL11A.CAMK1D.CAP3.CCR7
thrombin		chemical drug	Activated	2.202	bias	1.72E-16
MMP9		other	Activated	4.463	bias	1.04E-16
LDL		enzyme	Activated	4.465	bias	1.05E-16
DGA		enzyme	Activated	9.331	bias	1.75E-16
cisplatin		chemical drug	Activated	6.136	bias	2.04E-15
decitabine		chemical drug	Activated	3.610	bias	6.35E-15
IKBKB		kinase	Activated	3.454	bias	7.53E-15
cyclosporin A		biologic drug	Activated	0.308	bias	7.94E-15
IL10		cytokine	Activated	0.825	bias	1.16E-14
TICAM1		chemical drug	Activated	4.566	bias	2.89E-14
IL2		cytokine	Activated	5.046	bias	3.44E-14
IKBKB		enzyme	Activated	4.465	bias	4.11E-14
aztreonam		chemical drug	Activated	3.637	bias	4.15E-14
vancomycin		biologic drug	Activated	3.483	bias	2.84E-14
STAT3		transcription regulator	Activated	1.803	bias	2.95E-13
KRAS		enzyme	Activated	1.188	bias	3.94E-12
IL1A		cytokine	Activated	4.591	bias	4.06E-12
resiquimod		chemical drug	Activated	3.556	bias	4.58E-12
puromycin aminonucleoside		chemical reagent	Activated	2.621	bias	4.61E-12
progesterone		chemical - endogenous mammal	Activated	-0.054	bias	5.14E-12
donibonoxin		chemical drug	Activated	4.451	bias	5.44E-12
IL-2B lipopolysaccharide		chemical - endogenous non-mam	Activated	1.043	bias	6.05E-12
IL33		cytokine	Activated	4.282	bias	6.76E-12
EP300		transcription regulator	Activated	0.647	bias	1.07E-11
PPARG		ligand-dependent nuclear recep	Activated	0.760	bias	1.41E-11
CHUK		kinase	Activated	4.203	bias	1.69E-11
ZBTB16	3.395	transcription regulator	Activated	0.209	bias	1.77E-11
TP53		transcription regulator	Activated	4.025	bias	2.85E-11
tretinoin		chemical - endogenous mammal	Activated	4.606	bias	2.89E-11
CG		complex	Activated	4.388	bias	3.04E-11
STAT1		transcription regulator	Activated	4.401	bias	3.04E-11
gentamicin C		chemical drug	Activated	3.729	bias	4.12E-11
lomustine		chemical drug	Activated	3.742	bias	4.12E-11
ERK1/2		group	Activated	3.040	bias	6.30E-11
Alpha catenin		group	Inhibited	4.059	bias	6.41E-11
STAT5A		transcription regulator	Activated	0.745	bias	7.46E-11
CD40LG		cytokine	Activated	3.119	bias	8.19E-11
IL10RA		transmembrane receptor	Activated	-1.612	bias	9.20E-11
ICAM1		transmembrane regulator	Activated	0.988	bias	9.64E-11
prostaglandin E2		chemical - endogenous mammal	Activated	4.183	bias	1.07E-10
TCF3		transcription regulator	Activated	1.213	bias	1.08E-10
ERBB2		kinase	Activated	2.690	bias	1.08E-10
milreptone		chemical drug	Activated	-1.001	bias	1.10E-10
PI3K (complex)		complex	Activated	3.094	bias	1.29E-10
Jnk		group	Activated	3.528	bias	1.56E-10
methylprednisolone		chemical drug	Activated	1.908	bias	1.75E-10
ID9	0.768	transcription regulator	Activated	0.549	bias	1.90E-10
VCAN		other	Activated	3.049	bias	1.98E-10
E, colI B4 lipopolysaccharide		chemical reagent	Activated	3.434	bias	2.04E-10
ethionine		chemical toxicant	Activated	3.764	bias	2.62E-10
SP1		transcription regulator	Activated	2.720	bias	2.67E-10
CD40	0.881	transmembrane receptor	Activated	3.352	bias	2.70E-10
MYB		transcription regulator	Activated	-1.340	bias	3.07E-10
ESR1		ligand-dependent nuclear recep	Activated	0.647	bias	3.26E-10
NOTCH1		transcription regulator	Activated	2.581	bias	3.34E-10
SIR		transcription regulator	Activated	0.07	bias	3.45E-10
SMARCA4		transcription regulator	Activated	3.991	bias	3.76E-10
SP1		transcription regulator	Activated	2.737	bias	4.91E-10
Interferon alpha		group	Activated	3.825	bias	3.98E-10
BCL6		transcription regulator	Activated	-1.468	bias	6.44E-10
IL3		cytokine	Activated	3.459	bias	7.60E-10
bleomycin		chemical drug	Activated	4.260	bias	8.81E-10
ADR8		group	Inhibited	-3.154	bias	9.41E-10
ERCCBP		transcription regulator	Activated	0.239	bias	1.03E-09
ICAM1		ligand-dependent nuclear recep	Activated	2.977	bias	1.05E-09
ATF3		transcription regulator	Inhibited	2.496	bias	1.25E-09
IL13		cytokine	Activated	3.073	bias	1.26E-09
TCR		complex	Activated	2.535	bias	1.33E-09
KLF2		transcription regulator	Activated	-1.899	bias	1.42E-09
APOE		transporter	Activated	-1.448	bias	1.46E-09
CpG oligonucleotide		chemical drug	Activated	3.749	bias	1.48E-09
JUN	0.556	transcription regulator	Activated	3.524	bias	1.49E-09
DDIT3		transcription regulator	Activated	2.010	bias	1.49E-09
prostaglandin B2		chemical drug	Activated	3.171	bias	1.56E-09
LY284002		chemical - kinase inhibitor	Inhibited	-3.867	bias	1.62E-09
hexachlorobenzene		chemical toxicant	Activated	3.464	bias	1.65E-09
IgE		complex	Activated	4.097	bias	1.78E-09
APP		ether	Activated	1.618	bias	1.83E-09
GFI1		transcription regulator	Inhibited	-3.260	bias	1.85E-09
camplothecin		chemical drug	Activated	1.879	bias	1.89E-09
TLR4		transmembrane receptor	Activated	4.671	bias	2.03E-09
DUSP1		phosphatase	Activated	4.661	bias	2.04E-09
FZD9		opponent	Activated	4.769	bias	2.16E-09
5-O-mycetyl-beta-araf(1>1>5)		chemical - endogenous non-mam	Activated	3.695	bias	2.20E-09
IL17A		cytokine	Activated	3.673	bias	2.21E-09
lactoferrin		chemical drug	Activated	0.392	bias	2.39E-09
thiacetamide		chemical toxicant	Activated	3.961	bias	2.39E-09
NFE2L2		transcription regulator	Activated	3.785	bias	2.73E-09
RELA		transcription regulator	Activated	4.274	bias	2.73E-09
SB2580		chemical - kinase inhibitor	Inhibited	4.228	bias	3.01E-09
TRAF3IP2		transcription regulator	Activated	4.622	bias	3.04E-09
IL11		chemical drug	Activated	3.429	bias	3.09E-09
Pam3-Cys-Ser-Lys4		chemical - kinase inhibitor	Inhibited	-3.867	bias	3.26E-09
cigarette smoke		chemical toxicant	Activated	3.477	bias	4.41E-09
OSM		cytokine	Activated	2.583	bias	5.37E-09
hydrocortisone		chemical - endogenous mammal	0.731	bias	5.99E-09	
CEBPA	1.590	transcription regulator	Activated	2.552	bias	6.41E-09
cycloheximide		chemical reagent	Activated	2.524	bias	6.44E-09
DDIT3		growth factor	Activated	1.035	bias	7.04E-09
RNA polymerase II		transcription regulator	Activated	2.620	bias	8.12E-09
PRKCD		kinase	Activated	2.619	bias	8.98E-09
hydrogen peroxide		chemical - endogenous mammal	Activated	4.082	bias	9.57E-09
PD80859		chemical - kinase inhibitor	Inhibited	-3.828	bias	1.06E-08
phenacetin		chemical drug	Activated	3.148	bias	1.08E-08
etoposide		chemical drug	Activated	3.095	bias	1.13E-08
calcitol		chemical drug	Activated	2.383	bias	1.27E-08
Tnf (family)		group	Activated	2.524	bias	1.39E-08
EGF		transcription regulator	Activated	3.371	bias	1.40E-08
RNA polymerase II		complex	Activated	3.029	bias	1.62E-08
Tkr		kinase	Activated	2.910	bias	1.75E-08
YAP1	1.318	transcription regulator	Activated	1.832	bias	2.04E-08
IKZF3		transcription regulator	Inhibited	-3.464	bias	2.30E-08
FAS	1.934	transmembrane receptor	Activated	-1.237	bias	2.38E-08
SOCS1		other	Inhibited	-3.118	bias	2.95E-08
IRF8		transcription regulator	Activated	3.385	bias	3.63E-08
TNFRSF1A		transmembrane receptor	Activated	3.525	bias	4.30E-08
TRAF3		transmembrane receptor	Activated	0.041	bias	4.10E-08
forskolin		chemical toxicant	Activated	1.643	bias	4.21E-08
Hsp70		group	Activated	0.400	bias	4.29E-08
IL18		cytokine	Activated	4.090	bias	4.55E-08
FOXO1		transcription regulator	Activated	2.522	bias	4.74E-08
MAP3K14		kinase	Activated	3.261	bias	5.08E-08
captopril		chemical drug	Activated	2.354	bias	5.08E-08
fligrastim		biologic drug	Activated	-1.444	bias	5.49E-08

Sn50 peptide		chemical toxicant	Inhibited	-2.942	bias	6.54E-06	BCL2A1.BIRC3.Cd2.FAS.ICAM1.JFNGR2.IL1B.RACK1.SERPINE1	140 (14)
SOD1		enzyme	Inhibited	-1.982	bias	6.56E-06	BMP4.BUB1.CASP3.CD14.CP.FAS.FTH1.GSTP1.HSPB1.ICAM1	191 (17)
BMP2	3.424	growth factor	Activated	2.593	bias	6.74E-06	BMP2.BMP4.BTG3.Cal1.CAMK4.CSF1.CXL12.GADD45B.Hamp/Hamp2.ID1	185 (19)
RARA		ligand-dependent nuclear receptor	Inhibited	0.258	bias	6.76E-06	APOA1.CCN2.ACD14.CD44.CD9.CD9.CEPA.CLPN.COB8.CP.CS.F3	230 (22)
PRDM1		transcription regulator	Inhibited	-1.661	bias	6.78E-06	BCL2A1.Ccd2.CCR7.CD44.CD86.CRISPL.D2.CSF3.DUSP16.FOSL1.FTH1	232 (18)
cephalondine		chemical drug	Activated	3.283	bias	6.79E-06	APOA1.CCN2.ACD14.CD44.CD9.CD9.CEPA.CLPN.COB8.CP.CS.F3	221 (19)
PP21/G179 tyrosine kinase inhibitor		kinase - kinase inhibitor	Inhibited	-2.383	bias	6.82E-06	BIRCA1.CXGK-16.ICAM1.ID1.IL1B.JUP2.CP.LV.N.SERPIN1.S.002	102 (10)
MTPN		transcription regulator	Activated	3.130	bias	6.84E-06	BCL2A1.CAS3.C02.CCN2.CEPA.CP.FSTP1.IBM3.MCM3.NQO1.PIR.RND1	94 (7)
oxazolone		chemical reagent	Inhibited	1.289	bias	6.85E-06	Cd2.Glycam1.CAM1.IL1B.SDC1.SDC4	171 (18)
CD44	0.486	other	Activated	2.897	bias	6.86E-06	BIRCA1.C2.CCR7.CD44.CD8A.CXR3.FAS.JL1B.IRAK3.JUN	180 (18)
BMP4	5.064	growth factor	Activated	2.817	bias	6.86E-06	BMP2.BMP4.Cal1.CCR7.CEPA.CS.F3.DEPF1.GATA3.Hamp/Hamp2.ID1	43 (3)
TFRC		transporter	Inhibited	-1.726	bias	6.85E-06	CAS3.CCN2.FTH1.FTL.JUN.LY11.SCL12.2TC.TNFRSF12A	124 (11)
infliximab		biologic drug	Inhibited	-3.000	bias	6.84E-06	ADAM19.BATF2.Cd28.GATA3.G2MA.ICAM1.LAG3	160 (17)
Vegf		group	Activated	4.094	bias	6.81E-06	BCL2A1.BMP2.BUB1.CAS3.C02.CCN2.CD44.CXKL12.FAF.FOSL1	165 (17)
SP2509		chemical reagent	Inhibited	-0.447	bias	6.74E-06	BCL2A1.BMP2.BUB1.CAS3.C02.CCN2.CD44.CXKL12.FAF.FOSL1	166 (17)
MMT-HG		other	Inhibited	-0.637	bias	6.73E-06	BCL2A1.BMP2.BUB1.CAS3.C02.CCN2.CD44.CXKL12.FAF.FOSL1	161 (16)
PKC α		kinase	Inhibited	0.569	bias	6.71E-06	BCL2A1.CAS3.C02.CCN2.CEPA.CP.FSTP1.IBM3.MCM3.NQO1.PIR.RND1	203 (23)
cetcoxib		chemical drug	Inhibited	1.768	bias	6.70E-06	BCL2A1.CAS3.C02.CCN2.CD44.FAS.GDF15.CAM1.ID1.IL1B.RIPK2	197 (20)
valproic acid		chemical drug	Inhibited	0.347	bias	6.79E-06	AMPD3.ANTX2.APOA1.B4GALT1.CAS3.CD44.CD83.CDC4.CEPA	207 (20)
ITK		kinase	Inhibited	0.708	bias	6.71E-06	CD44.CRIM1.Fas.GATA3.HA-LYNN.PREX3 (includes others).SRGPAP3.ZBTB16	138 (8)
PTGS2		enzyme	Activated	3.642	bias	6.93E-06	ANG.B9.C03.C2.CCR7.CD44.CD86.CSF3.CXKL12.CXKL14.ICAM1	175 (19)
IKZF2		transcription regulator	Inhibited	-2.646	bias	6.94E-06	BATF.CD2.CD28.GATA3.G2MA.ICAM1.LAG3	119 (21)
ATP-gamma-S		chemical reagent	Inhibited	-2.646	bias	6.92E-06	BCL2A1.BMP2.BUB1.CAS3.C02.CCN2.CD44.CXKL12.FAF.FOSL1	165 (17)
Nif1 (family)		group	Activated	3.000	bias	6.97E-06	BCL2A1.CCC1.COCO1.COCO1.FAF.FSTP1.IBM3.MCM3.NQO1.PIR.RND1	178 (21)
XAV-931		enzyme	Inhibited	-4.156	bias	6.98E-06	BCL2A1.CAS3.C02.CCN2.CEPA.CP.FSTP1.IBM3.MCM3.NQO1.PIR.RND1	164 (18)
sinilimus		chemical drug	Inhibited	2.124	bias	6.94E-06	BCL2A1.BMP2.CAS3.CCN2.CCR7.CD44.CD86.CSF3.CXKL12.FAF.FOSL1	139 (18)
nitrofurantoin		chemical drug	Inhibited	1.437	bias	6.92E-06	CAS3.CFLC.FAS.GSTP1.HMGCS2.IBM3.MCM3.NQO1.PIR.RND1	120 (7)
IgG		complex	Inhibited	0.822	bias	1.03E-05	Cd2.CD40.CD86.C99.CEBPD.CLDNA.CSF1.FABP5.HSPB1.IL1B	119 (14)
histamine		chemical - endogenous mammal	Activated	2.283	bias	1.04E-05	BMP2.BMP4.Cal1.CCR7.CEPA.CS.F3.DEPF1.GATA3.Hamp/Hamp2.ID1	219 (21)
CAV1		transmembrane receptor	Activated	2.621	bias	1.06E-05	CAV2.CAVIN1.CD41.FAS.HK2.ICAM1.ID1.KRT19.KRT8.NQO1	199 (22)
VDR		transcription regulator	Inhibited	1.291	bias	1.06E-05	ARHGEF3.C02.CCD14.CD44.Cle2 (includes others).CSF1.GATA3.HK2.ICAM1.ID1	188 (20)
BCL3		transcription regulator	Inhibited	0.105	bias	1.08E-05	BCL2A1.CCC1.COCO1.COCO1.FAF.FSTP1.IBM3.MCM3.NQO1.PIR.RND1	152 (14)
irofloxacin		chemical reagent	Inhibited	0.114	bias	1.09E-05	BCL2A1.CCC1.COCO1.COCO1.FAF.FSTP1.IBM3.MCM3.NQO1.PIR.RND1	167 (16)
CYLD		transcription regulator	Activated	2.433	bias	1.09E-05	BIRCA1.CXGK-16.ICAM1.ID1.IL1B.JUN.NQO1.RHOH.SERPINB1	119 (14)
ADOR2A2		G-protein coupled receptor	Inhibited	-0.114	bias	1.14E-05	Cod2.CD96.I16.KL1F4.MRC1.RUNX2.SERPIN1	151 (19)
FGF1		growth factor	Inhibited	0.996	bias	1.16E-05	AKR1B10.CD2.CD86.GSTP1.IBM3.MCM3.NQO1.PIR.RND1	167 (17)
arachidonic acid		chemical - endogenous mammal	Inhibited	0.092	bias	1.16E-05	BCL2A1.CD40.CD86.C99.CEBPD.CLDNA.CSF1.FABP5.HSPB1.IL1B	175 (18)
HDAC1		transcription regulator	Inhibited	-1.141	bias	1.17E-05	AMPD3.APOA1.BMF.CCN2.CD44.CEPA.FAS.GSTP1.ID1.KLK3	215 (21)
androgen		chemical drug	Inhibited	-1.671	bias	1.22E-05	BMP4.BMP2.Cd2.CTS.FOSL1.JUN.KL3.NFKBIA.PTP4A2.PTRK	199 (20)
SP3		transcription regulator	Activated	2.195	bias	1.23E-05	BMP2.Cd2.CD40.CEPA.DMO.FAS.FOSL1.GDF15.JUN.KLF4	216 (20)
JAK1		kinase	Activated	2.937	bias	1.23E-05	BMP2.CD40.CD86.C99.CEBPD.CCD14.CD44.Cle2	179 (19)
IRAK3	0.720	kinase	Activated	2.429	bias	1.24E-05	BMP2.CD40.CD86.C99.CEBPD.CCD14.CD44.Cle2	160 (16)
GS3	0.920	oxidoreductase	Inhibited	-0.243	bias	1.25E-05	BIRCA1.CXGK-16.I16.JUN.NQO1.RHOH.SERPINB1	173 (19)
clopitantazone		chemical drug	Activated	2.340	bias	1.29E-05	BIRCA1.C2.CD86.CD88.CLDNA.CP.GAD45B.HMGCS2.IBM3.NQO1.PIR.RND1	171 (19)
LDLR		transporter	Inhibited	2.078	bias	1.30E-05	ALCAM.BMP2.Cd2.CN2.CCN2.CD40.CD86.CSF3.CXKL12.FAF.FOSL1	172 (16)
LIF		cytokine	Activated	2.341	bias	1.30E-05	BATF.BMP2.Cd2.CCN2.CD40.CD86.CSF3.CXKL12.FAF.FOSL1	217 (22)
PPPARA		ligand-dependent nuclear receptor	Inhibited	0.230	bias	1.30E-05	ALDH2.APOA1.C1R.C92.CCN2.CEPA.CPEPD.CHL.CXKL12.CYBA	192 (17)
lenalidomide		chemical drug	Activated	3.183	bias	1.32E-05	ANTXR1.BLK2.CAV2.CD86.CEPA.CP.FSTP1.IBM3.MCFR8.KLF4.PTRK8.KLF4	35 (3)
Histone h3	group		Inhibited	0.372	bias	1.35E-05	BMP2.BT3.Cd2.CCN2.CD40.CD9.CEPA.DUSP1.GATA3.GCNT4	210 (19)
S1PR3		G-protein coupled receptor	Inhibited	0.372	bias	1.35E-05	Cd2.CCD14.CAM1.IL1B.JUN	192 (19)
WNT5A		cytokine	Inhibited	1.403	bias	1.36E-05	BMP2.CD40.CD86.C99.CEBPD.CCD14.CD44.Cle2	226 (21)
SOX11	0.920	oxidoreductase	Activated	3.18	bias	1.37E-05	Cd2.CD40.CD86.C99.CEBPD.CCD14.CD44.Cle2	202 (21)
transferrin		chemical drug	Inhibited	0.292	bias	1.39E-05	CFS1.GSTP1.I16.I1B.I16.JUN.NQO1.SERPIN1.P110	125 (14)
thioguanine		chemical toxicant	Activated	2.340	bias	1.39E-05	BIRCA1.C2.CD86.CD88.CLDNA.CP.GAD45B.HMGCS2.IBM3.NQO1.PIR.RND1	171 (19)
GL2		transcription regulator	Activated	2.000	bias	1.39E-05	ALCAM.BMP2.Cd2.CN2.CCN2.CD40.CD86.CSF3.CXKL12.FAF.FOSL1	164 (10)
MYOC		other	Inhibited	1.416	bias	1.41E-05	CDD4.JDP2.LAMA2.PDXN.RUNX27.RUNX27.SCL2.CTC2.UPP1	219 (21)
TGFB1R1		kinase	Inhibited	1.541	bias	1.41E-05	BMP2.CCR7.CD40.CD86.DOCK4.Hamp/Hamp2.JAG1.KLF4.PTRK.PSERPIN1	219 (21)
MTOR		kinase	Inhibited	1.389	bias	1.45E-05	BMP2.CCR7.CD40.CD86.CEPA.CEPBP.DAFB5.GPAT3.GATA3.GAT3	242 (21)
MAP3K8		kinase	Inhibited	1.101	bias	1.65E-05	Apo7 (includes others).BIRCA1.C130.02621.Rnk (includes others).C6r722.Cd2.CEBPD.CLIC5.CSF3.GAB1.IL	187 (18)
KDM1A		enzyme	Inhibited	-0.285	bias	1.69E-05	BCL2A1.CAM1.BMP2.CD40.CD86.CSF3.CXKL12.FAF.FOSL1.I16	120 (7)
furafrafan		chemical drug	Inhibited	1.234	bias	1.70E-05	BCL2A1.CAM1.BMP2.CD40.CD86.CSF3.CXKL12.FAF.FOSL1.I16	165 (14)
benzylbenzene		chemical toxicant	Inhibited	0.778	bias	1.72E-05	AKR1B10.CD2.CD86.GSTP1.IBM3.MCM3.NQO1.PIR.RND1	225 (22)
lazemotstatol		chemical drug	Inhibited	0.229	bias	1.73E-05	BCL2A1.CD2.CD86.GSTP1.IBM3.MCM3.NQO1.PIR.RND1	174 (13)
ZFPFM1		transcription regulator	Inhibited	1.755	bias	1.75E-05	BLNK.CEPA.ENPP1.GATA3.KL6.JUN.KL1.JAG1.KLK3.RUNX2	21 (2)
GnRH-A		chemical reagent	Activated	2.971	bias	1.75E-05	AKR1B10.D68.GSTP1.IBM3.MCM3.NQO1.PIR.RND1	212 (18)
TREM1		transmembrane receptor	Activated	2.438	bias	1.75E-05	Cd2.CCR7.CD41.CD9.CD86.CSF3.CXKL12.FAF.FOSL1	186 (15)
deferoxamine		chemical drug	Activated	3.539	bias	1.75E-05	ALDH2.ALP2.CD40.CD86.CSF3.CXKL12.FAF.FOSL1	204 (21)
CHD1		enzyme	Activated	2.236	bias	1.78E-05	BCL2A1.BMP2.ICAM1.IL1B.SD2	136 (18)
cytokine		group	Activated	3.028	bias	1.89E-05	ANG.BMF.CCR7.CD40.CD86.CSF3.CXKL12.FAF.FOSL1	149 (17)
GDF2		growth factor	Activated	3.050	bias	1.90E-05	ANG.BMF.CCR7.CD40.CD86.CSF3.CXKL12.FAF.FOSL1	142 (17)
ACTR1		G-protein coupled receptor	Inhibited	0.118	bias	1.90E-05	BCL2A1.CAM1.BMP2.CD40.CD86.CSF3.CXKL12.FAF.FOSL1	167 (20)
peftin		chemical drug	Inhibited	0.776	bias	1.93E-05	BDB2.BMF.BUB1.CD2.CEBPD.FOSL1.GDF15.HSPB1.ID1.KRT19	179 (16)
ES. coli lipopolysaccharide		chemical - endogenous non-mam	Activated	2.414	bias	1.96E-05	BMP12.APOA1.BMF.CCN2.CD40.CD86.CSF3.CXKL12.FAF.FOSL1	150 (17)
PAX7		transcription regulator	Activated	2.759	bias	1.96E-05	CDM1.Cd2.C424.FAD3.G8p8.Hamp/Hamp2.KRT27.NOO1.PT2B.SERPINB1.SERPIN2	219 (21)
peptidoglycan		chemical - endogenous non-mam	Activated	3.246	bias	1.98E-05	BCL2A1.CAS3.C02.CD40.CD86.CSF3.CXKL12.FAF.FOSL1	140 (16)
ciprofloxacin		chemical drug	Inhibited	1.571	bias	1.98E-05	ALDH2.ALP1.B61.CAL4.GAL4.NTR1.GH3.GSTA4.HSP1A.ICAM1	162 (13)
PTEN		phosphatase	Inhibited	0.065	bias	1.99E-05	Cd2.C86.CCR7.CD40.CD86.CSF3.CXKL12.FAF.FOSL1	140 (16)
nfobt		transcription regulator	Activated	2.355	bias	2.10E-05	B3GAT1.BC21.CA21.COCO1.COCO1.FAF.FSTP1.IBM3.MCM3.NQO1.PIR.RND1	113 (9)
PSMB9		residase	Inhibited	1.067	bias	2.11E-05	BCL2A1.CAM1.BMP2.CD40.CD86.CSF3.CXKL12.FAF.FOSL1	87 (7)
AHR		ligand-dependent nuclear receptor	Inhibited	0.873	bias	2.16E-05	BIRCA1.CD86.CD88.CLDNA.CP.GAD45B.HMGCS2.IBM3.NQO1.PIR.RND1	190 (19)
Hbb-b1		transporter	Inhibited	1.408	bias	2.28E-05	ADAM19.ALTH2.ATOH8.CDN2.CD44.CEPA.CF3.GATA3.HA-LYNN.PREX3	226 (21)
PGR		ligand-dependent nuclear receptor	Inhibited	1.985	bias	2.34E-05	ACOD1.BIRCA1.CD2.CD40.CD86.CSF3.CXKL12.FAF.FOSL1	235 (21)
FGF2		growth factor	Activated	3.465	bias	2.38E-05	AKR1B10.ANG.BMF.CCD1.COCO1.COCO1.FAF.FSTP1.IBM3.MCM3.NQO1.PIR.RND1	206 (25)
peftin		chemical drug	Inhibited	0.316	bias	2.42E-05	ALDH2.ALP2.CD2.CD86.GSTP1.IBM3.MCM3.NQO1.PIR.RND1	245 (21)
PTEN		enzyme	Activated	3.040	bias	2.43E-05	ALDH2.ALP2.CD2.CD86.GSTP1.IBM3.MCM3.NQO1.PIR.RND1	142 (18)
GPD1		enzyme	Inhibited	3.040	bias	2.53E-05	CLCA1.CPN6.FAD3.G8p8.Hamp/Hamp2.KRT27.NOO1.PT2B.SERPINB1.SERPIN2	128 (12)
PAEP		other	Inhibited	-0.277	bias	2.57E-05	C8D3.CXKL12.CXCR3.GATA3.IL1R1	194 (17)
superoxide		chemical - endogenous mammal	Activated	0.849	bias	2.57E-05	CYBA1.CAM1.D3.ILB2.SD2	194 (17)
S100A8		other	Inhibited	0.737	bias	2.64E-05	BMF.C2.CP2.CSF2.RBL.CXCR3.GATA2.IL1R1	145 (14)
trans-hydroxytamoxifen		chemical drug	Inhibited	-1.994	bias	2.65E-05	ANXA3.BLK8.CMP2.CCN2.CD40.CD86.CSF3.CXKL12.FAF.FOSL1	125 (7)
ARNT2		transcription regulator	Activated	3.860	bias	2.79E-05	ANG.BST1.CD86.CD88.CDN2.CD40.CD86.CSF3.CXKL12.FAF.FOSL1	127 (16)
isobutylmethylxanthine		chemical toxicant	Activated	2.774	bias	3.12E-05	ALDOA1.CD40.CD86.CSF3.CXKL12.FAF.FOSL1	222 (21)
Ap1		complex	Activated	1.673	bias	3.25E-05	BCL2A1.CNA1.CD44.CD4.CDX12.FOSL1.GATA1.IL1B.NK1.KL3	189 (21)
dihydromaleate		chemical toxicant	Inhibited	-0.600	bias	3.42E-05	GSTP1.I1B.NKFBIA.NQO1.TNFNA1P3	182 (16)
GNPAT		enzyme	Inhibited	-1.732	bias	3.48E-05	Cd2.CD60.CD66.CAM1.IL1B.MRC1	136 (18)
CBX5		transcription regulator	Inhibited	-3.317	bias	3.51E-05	BCL2A1.CAM1.LAMB2.PROM2.RUNX2.SCL2.CA3.SYTLC2.TM4SF1	188 (10)
oleolecalciferol		chemical - endogenous mammal	Inhibited	1.548	bias	3.52E-05	BCL2A1.CAM1.BMP2.CD40.CD86.CSF3.CXKL12.FAF.FOSL1	198 (23)
IL5		cytokine	Activated	4.130	bias	3.56E-05	ANXAK2.CPT2.CD40.CD86.CSF3.CXKL12.FAF.FOSL1	189 (19)
lamivudine		chemical drug	Inhibited	1.264	bias	3.56E-05	ANG.BMP2.CP2.CAV2.CN2.CD40.CD86.CSF3.CXKL12.FAF.FOSL1	228 (24)
CSAR1		G-protein coupled receptor	Activated	2.778	bias	3.60E-05	Cd2.CD28.CD40.CD86.CSF3.I1B.LTB2.PSERPIN1	138 (15)
TNFSF14		cytokine	Activated	2.180	bias	3.64E-05	BIRCA1.CD2.CD40.CD86.CSF3.CXKL12.FAF.FOSL1	151 (18)
clodronate		chemical drug	Inhibited	0.721	bias	3.		

tributryl	chemical drug	Activated	2.157	bias	5.75E-05	BCL2A1.BIRC3.CASP3.ID3.IL1.B.3LC30A1.SOD2.TNFAIP3	
CpG ODN 2395	chemical reagent	Activated	2.236	bias	5.79E-05	Cdc2.CD44.CD40.CD66.IL1B	141 (15)
CYP2J2	enzyme		0.785	bias	5.79E-05	Cdc2.CD44.ICAM1.IL1B.NFKBIA	127 (17)
fulvestrant	chemical drug		0.233	bias	5.84E-05	APOA1.BMP2.BMP4.CAV2.C62.CCN2A.CSF1.CXCL12.G3B2.GSTP1	210 (20)
raloxifene	chemical drug		0.033	bias	6.08E-05	ANXA3.BLNK.BMP2.BMP4.CSF1.CXCL12.JUN.KLF6.LITAF.Y01B	221 (22)
PPARD	ligand-dependent nuclear receptor		0.022	bias	6.26E-05	ALDH2.CD2.CD44.ICAM1.Saps2.SERPINE1	197 (18)
NOA10	enzyme	Activated	2.253	bias	6.31E-05	BIRCA1.KLF4.NFKB1.ZOASL.SOD2.SERPINE1.SOD2	183 (18)
PAF1	other	Activated	2.646	bias	6.35E-05	BCL2A1.DCD44.CAM1.Saps2.SERPINE1	127 (17)
MAPK7	kinase	Activated	2.580	bias	6.35E-05	BCL2A1.DY1.IL1B.JUN.KLF4.NQO1.STEP4	212 (23)
Mafg3k7	kinase		1.616	bias	6.42E-05	BMP4.CASP3.C22.IL1B.JUN.NFKB2.ZNOD2.Vn3	181 (17)
SMARCB1	transcription regulator		1.933	bias	6.46E-05	CNA2.CD44.CSF1.CYP3A7.DOCK4.F11R.FAS.FBP1.GJB2.JF16	193 (11)
mycophenolic acid	chemical drug	Activated	2.121	bias	6.67E-05	BIRCA1.D3.IL1.B.KRT19.RUNX2.SERPINE1.SLC30A1.SOD2.TNFAIP3	142 (14)
docosahexaenoic acid	chemical drug		0.367	bias	6.85E-05	BCL2A1.Ce2.CD40.CD44.CD83.CD86.SF1.FAS.IL1B.MRC1	143 (15)
IRF2	transcription regulator	Activated	2.277	bias	6.91E-05	ANG.CD14.HK2.ID1.I47.IL1B.I6ST.KLF4.MAPK6.PSMB10	156 (18)
Gsp	other		0.707	bias	7.16E-05	ANG.ARX.FABP5.FBP1.Hamp2.Hamp2.TNFASE4.SDC1	
TGF- β 2	transcription regulator	Activated	2.249	bias	7.17E-05	ANG.CD2.GDF15.ICAM1.IL1B.RELB.SERPINB1.SERPINE1	138 (7)
NRIH3	ligand-dependent nuclear receptor		1.309	bias	7.26E-05	APOA1.Cd2.Cd4.CN42.CCR7.CD40.CSF3.CXCL10.FBP1.JGP1.GSTP1	193 (15)
LYN	kinase		1.177	bias	7.31E-05	BCL2A1.C22.CCN2A.CD40.CD49.CSF1.IL1B.NFKB1A.NFKB2	178 (15)
L-butiothione (SR)-sulfoxime	chemical drug		0.000	bias	7.36E-05	CASP3.NFKB1A.NQO1.SERPINE1.TNFaIP3	165 (11)
lactacystin	chemical - protease inhibitor		0.320	bias	7.45E-05	Cdc2.CD9.ID1.FBP1.FOS1.LFTL.GATA3.GSTP1.HLA.A.HSPB1	188 (20)
KRIT1	other		0.000	bias	7.90E-05	BMP2.JUN.KLF4.SOD2	
PIK3CA	kinase		1.941	bias	7.97E-05	ALCAM.Cd2.Cd4.Cd24.Cd44.CEBPD.JAG1.SERpine1	211 (23)
PLAU	peptidase		0.186	bias	7.97E-05	ANG.Cd2.GDF15.ICAM1.IL1B.RELB.SERPINB1.SERPINE1	232 (24)
CCS	cytokine		1.401	bias	8.01E-05	C22.CD40.CD44.CEBPD.CSF1.IL1B.NFKB1A.ZC3H12A	159 (17)
FADD	other		0.333	bias	8.03E-05	BCL2A1.C22.FAS.CC22A5(ICAM1).PRK1.JUN.KLF6.TNFaIP3	146 (18)
BRD2	kinase		1.000	bias	8.26E-05	CBL.C22.IL1B.LT70.Y90.NQO1.PRK1.JUN.KLF6.TNFaIP3	
SREBF1	transcription regulator	Activated	2.466	bias	8.34E-05	CAMK1.CD14.CEBPA.CEBPD.CF1.CSPR1.DEPP1.FABP5.HAS.HK2	186 (20)
TMPSRSS6	peptidase		1.309	bias	8.58E-05	BMP6.Hamp/Hamp2.ID1	
Wifdc17	other		0.588	bias	8.58E-05	Cdc2.IL1B.MRC1	
IKBKE	kinase		0.594	bias	8.76E-05	ACOD1.BIRC3.Cd2.CSF3.CXCL12.HLA-A.FI16.NFKB1A.SLC2A3	175 (15)
RARG	ligand-dependent nuclear receptor		1.230	bias	8.76E-05	APOA1.BMP2.DHRS3.GAP43.JUN.KLF4.KLK3.KRT20.ZNF703	160 (10)
FASLG	cytokine		0.692	bias	8.82E-05	CASP3.CD44.FAS.FTH1.IL1B.RUNX2	187 (18)
PFA	cytokine	Activated	2.401	bias	8.82E-05	CASP3.CD44.FAS.FTH1.IL1B.RUNX2	137 (18)
NGF	growth factor		0.268	bias	8.82E-05	AKR1B10.CC27.CD44.CD86.CD88.FAS.FOS1.JUN.KLF4.GAP43.ID1.JUN	149 (18)
NORAD	other		0.244	bias	8.98E-05	ALCAM.ANTXR2.C098.FTL.GAP3.3.CSPN1	
insl3	other		1.020	bias	9.38E-05	ALCAM.ANTXR2.C098.FTL.GAP3.3.CSPN1	
hemin	chemical - endogenous mammal		0.838	bias	9.38E-05	Cdc2.F051.FTH1.FTL.GSTP1.IL1B.JUN.MRC1.NQO1	205 (18)
KITLG	growth factor		1.344	bias	9.57E-05	CIR2.CF051.1CAM1.IL1B.JUN.LT52S.NEK2.NFKB1A.NPKB1	181 (17)
lysophosphatidylcholine	chemical - other		1.692	bias	9.57E-05	FOS1.FTH1.FTL.GSTA3.GSTP1.JUN.NQO1.PRK1.UGT1A7 (includes others)	186 (19)
17-alpha-ethynodioladiol	chemical drug		1.863	bias	9.75E-05	Cdc2.CCR7.C08.CXCR2.CD45.F15.F16.JUN.KRT19.MRC1	247 (20)
SYK	kinase		0.256	bias	9.80E-05	BIRCA1.CCR7.CD44.DOCK10.FOS1.JUN.KLF4.KLK3.KRT20.ZNF703	192 (22)
wortmannin	chemical - kinase inhibitor	Inhibited	2.689	bias	1.02E-04	CASP3.Cd2.Cd4.Cd44.CEBPD.JAG1.SERpine1	206 (20)
SAA	group	Activated	2.403	bias	1.03E-04	Cd2.CD44.CSF1.CSF2.CSF3.CSF4.CSF5	
NORAD	other	Activated	2.449	bias	1.03E-04	Cd2.CD44.CSF1.CSF2.CSF3.CSF4.CSF5	
insl3	other		1.020	bias	1.04E-04	ALAS1.APOA1.CEBPA.CEBPD.CSF1.CAT3.GSTP1.HK2.IL1B.LT6ST.JUN	99 (17)
RAC1	chemical - endogenous mammal		0.838	bias	1.04E-04	Cd2.CD68.FTH1.FTL.GSTP1.IL1B.JUN.MRC1.NQO1	220 (19)
CDP36	growth factor		1.344	bias	1.04E-04	CASP3.C2.CD2.CCN2A.CD42.C42a.CD68.CEBPA.CSF1.CXCL12.FABP5	142 (16)
tert-butylhydroquinone	chemical - other		2.740	bias	1.05E-04	Cdc2.FabP5.JCAM1.IL1B.JUN.RP1.NOD2.SERPINE1	202 (20)
Bav 11-7082	chemical - kinase inhibitor	Inhibited	2.789	bias	1.09E-04	BCL2A1.BMP2.Cd2.CD4.CD44.CD83.ICAM1.IL1B.SOD2	141 (15)
PLA2G2D	enzyme		-1.000	bias	1.12E-04	Cd2.CD81.IL1B.MRC1	
BCR (complex)	complex		1.354	bias	1.12E-04	B4GALT1.BLC2A1.CASP3.CCN2A.CCR7.CD44.GD86.FAS.KLF4.LCK	140 (16)
JUNB	transcription regulator		1.109	bias	1.12E-04	Cd2.CD68.CDX2.CD44.CD86.CD88.FAS.FOS1.JUN.KLF4.GAP43.ID1.JUN	133 (13)
APD1	enzyme	Inhibited	-2.121	bias	1.14E-04	Cd2.CD44.CD45.CD46.CD47.CD48.CD49.CD50.CD51.CD52.CD53.CD54.CD55.CD56.CD57.CD58.CD59.CD60.CD61.CD62.CD63.CD64.CD65.CD66.CD67.CD68.CD69.CD70.CD71.CD72.CD73.CD74.CD75.CD76.CD77.CD78.CD79.CD80.CD81.CD82.CD83.CD84.CD85.CD86.CD87.CD88.CD89.CD90.CD91.CD92.CD93.CD94.CD95.CD96.CD97.CD98.CD99.CD100.CD101.CD102.CD103.CD104.CD105.CD106.CD107.CD108.CD109.CD110.CD111.CD112.CD113.CD114.CD115.CD116.CD117.CD118.CD119.CD120.CD121.CD122.CD123.CD124.CD125.CD126.CD127.CD128.CD129.CD130.CD131.CD132.CD133.CD134.CD135.CD136.CD137.CD138.CD139.CD140.CD141.CD142.CD143.CD144.CD145.CD146.CD147.CD148.CD149.CD150.CD151.CD152.CD153.CD154.CD155.CD156.CD157.CD158.CD159.CD159.CD160.CD161.CD162.CD163.CD164.CD165.CD166.CD167.CD168.CD169.CD170.CD171.CD172.CD173.CD174.CD175.CD176.CD177.CD178.CD179.CD180.CD181.CD182.CD183.CD184.CD185.CD186.CD187.CD188.CD189.CD190.CD191.CD192.CD193.CD194.CD195.CD196.CD197.CD198.CD199.CD199.CD200.CD201.CD202.CD203.CD204.CD205.CD206.CD207.CD208.CD209.CD210.CD211.CD212.CD213.CD214.CD215.CD216.CD217.CD218.CD219.CD220.CD221.CD222.CD223.CD224.CD225.CD226.CD227.CD228.CD229.CD229.CD230.CD231.CD232.CD233.CD234.CD235.CD236.CD237.CD238.CD239.CD239.CD240.CD241.CD242.CD243.CD244.CD245.CD246.CD247.CD248.CD249.CD249.CD250.CD251.CD252.CD253.CD254.CD255.CD256.CD257.CD258.CD259.CD259.CD260.CD261.CD262.CD263.CD264.CD265.CD266.CD267.CD268.CD269.CD269.CD270.CD271.CD272.CD273.CD274.CD275.CD276.CD277.CD278.CD279.CD279.CD280.CD281.CD282.CD283.CD284.CD285.CD286.CD287.CD288.CD289.CD289.CD290.CD291.CD292.CD293.CD294.CD295.CD296.CD297.CD298.CD299.CD299.CD300.CD301.CD302.CD303.CD304.CD305.CD306.CD307.CD308.CD309.CD309.CD310.CD311.CD312.CD313.CD314.CD315.CD316.CD317.CD318.CD319.CD319.CD320.CD321.CD322.CD323.CD324.CD325.CD326.CD327.CD328.CD329.CD329.CD330.CD331.CD332.CD333.CD334.CD335.CD335.CD336.CD337.CD338.CD339.CD339.CD340.CD341.CD342.CD343.CD344.CD345.CD346.CD347.CD348.CD349.CD349.CD350.CD351.CD352.CD353.CD354.CD355.CD356.CD357.CD358.CD359.CD359.CD360.CD361.CD362.CD363.CD364.CD365.CD366.CD367.CD368.CD369.CD369.CD370.CD371.CD372.CD373.CD374.CD375.CD376.CD377.CD378.CD379.CD379.CD380.CD381.CD382.CD383.CD384.CD385.CD385.CD386.CD387.CD387.CD388.CD389.CD389.CD390.CD390.CD391.CD392.CD393.CD394.CD395.CD395.CD396.CD397.CD397.CD398.CD399.CD399.CD400.CD401.CD402.CD403.CD404.CD405.CD406.CD407.CD408.CD409.CD409.CD410.CD411.CD412.CD413.CD414.CD415.CD416.CD417.CD418.CD419.CD420.CD421.CD422.CD423.CD424.CD425.CD426.CD427.CD428.CD429.CD429.CD430.CD431.CD432.CD433.CD434.CD435.CD435.CD436.CD437.CD438.CD438.CD439.CD439.CD440.CD441.CD442.CD443.CD444.CD445.CD445.CD446.CD447.CD448.CD448.CD449.CD449.CD450.CD451.CD452.CD453.CD453.CD454.CD455.CD455.CD456.CD457.CD457.CD458.CD458.CD459.CD459.CD460.CD461.CD462.CD463.CD463.CD464.CD465.CD465.CD466.CD467.CD467.CD468.CD468.CD469.CD469.CD470.CD470.CD471.CD472.CD472.CD473.CD473.CD474.CD474.CD475.CD475.CD476.CD476.CD477.CD477.CD478.CD478.CD479.CD479.CD480.CD480.CD481.CD481.CD482.CD482.CD483.CD483.CD484.CD484.CD485.CD485.CD486.CD486.CD487.CD487.CD488.CD488.CD489.CD489.CD490.CD490.CD491.CD491.CD492.CD492.CD493.CD493.CD494.CD494.CD495.CD495.CD496.CD496.CD497.CD497.CD498.CD498.CD499.CD499.CD500.CD500.CD501.CD501.CD502.CD502.CD503.CD503.CD504.CD504.CD505.CD505.CD506.CD506.CD507.CD507.CD508.CD508.CD509.CD509.CD510.CD510.CD511.CD511.CD512.CD512.CD513.CD513.CD514.CD514.CD515.CD515.CD516.CD516.CD517.CD517.CD518.CD518.CD519.CD519.CD520.CD520.CD521.CD521.CD522.CD522.CD523.CD523.CD524.CD524.CD525.CD525.CD526.CD526.CD527.CD527.CD528.CD528.CD529.CD529.CD530.CD530.CD531.CD531.CD532.CD532.CD533.CD533.CD534.CD534.CD535.CD535.CD536.CD536.CD537.CD537.CD538.CD538.CD539.CD539.CD540.CD540.CD541.CD541.CD542.CD542.CD543.CD543.CD544.CD544.CD545.CD545.CD546.CD546.CD547.CD547.CD548.CD548.CD549.CD549.CD550.CD550.CD551.CD551.CD552.CD552.CD553.CD553.CD554.CD554.CD555.CD555.CD556.CD556.CD557.CD557.CD558.CD558.CD559.CD559.CD560.CD560.CD561.CD561.CD562.CD562.CD563.CD563.CD564.CD564.CD565.CD565.CD566.CD566.CD567.CD567.CD568.CD568.CD569.CD569.CD570.CD570.CD571.CD571.CD572.CD572.CD573.CD573.CD574.CD574.CD575.CD575.CD576.CD576.CD577.CD577.CD578.CD578.CD579.CD579.CD580.CD580.CD581.CD581.CD582.CD582.CD583.CD583.CD584.CD584.CD585.CD585.CD586.CD586.CD587.CD587.CD588.CD588.CD589.CD589.CD590.CD590.CD591.CD591.CD592.CD592.CD593.CD593.CD594.CD594.CD595.CD595.CD596.CD596.CD597.CD597.CD598.CD598.CD599.CD599.CD600.CD600.CD601.CD601.CD602.CD602.CD603.CD603.CD604.CD604.CD605.CD605.CD606.CD606.CD607.CD607.CD608.CD608.CD609.CD609.CD610.CD610.CD611.CD611.CD612.CD612.CD613.CD613.CD614.CD614.CD615.CD615.CD616.CD616.CD617.CD617.CD618.CD618.CD619.CD619.CD620.CD620.CD621.CD621.CD622.CD622.CD623.CD623.CD624.CD624.CD625.CD625.CD626.CD626.CD627.CD627.CD628.CD628.CD629.CD629.CD630.CD630.CD631.CD631.CD632.CD632.CD633.CD633.CD634.CD634.CD635.CD635.CD636.CD636.CD637.CD637.CD638.CD638.CD639.CD639.CD640.CD640.CD641.CD641.CD642.CD642.CD643.CD643.CD644.CD644.CD645.CD645.CD646.CD646.CD647.CD647.CD648.CD648.CD649.CD649.CD650.CD650.CD651.CD651.CD652.CD652.CD653.CD653.CD654.CD654.CD655.CD655.CD656.CD656.CD657.CD657.CD658.CD658.CD659.CD659.CD660.CD660.CD661.CD661.CD662.CD662.CD663.CD663.CD664.CD664.CD665.CD665.CD666.CD666.CD667.CD667.CD668.CD668.CD669.CD669.CD670.CD670.CD671.CD671.CD672.CD672.CD673.CD673.CD674.CD674.CD675.CD675.CD676.CD676.CD677.CD677.CD678.CD678.CD679.CD679.CD680.CD680.CD681.CD681.CD682.CD682.CD683.CD683.CD684.CD684.CD685.CD685.CD686.CD686.CD687.CD687.CD688.CD688.CD689.CD689.CD690.CD690.CD691.CD691.CD692.CD692.CD693.CD693.CD694.CD694.CD695.CD695.CD696.CD696.CD697.CD697.CD698.CD698.CD699.CD699.CD700.CD700.CD701.CD701.CD702.CD702.CD703.CD703.CD704.CD704.CD705.CD705.CD706.CD706.CD707.CD707.CD708.CD708.CD709.CD709.CD710.CD710.CD711.CD711.CD712.CD712.CD713.CD713.CD714.CD714.CD715.CD715.CD716.CD716.CD717.CD717.CD718.CD718.CD719.CD719.CD720.CD720.CD721.CD721.CD722.CD722.CD723.CD723.CD724.CD724.CD725.CD725.CD726.CD726.CD727.CD727.CD728.CD728.CD729.CD729.CD730.CD730.CD731.CD731.CD732.CD732.CD733.CD733.CD734.CD734.CD735.CD735.CD736.CD736.CD737.CD737.CD738.CD738.CD739.CD739.CD740.CD740.CD741.CD741.CD742.CD742.CD743.CD743.CD744.CD744.CD745.CD745.CD746.CD746.CD747.CD747.CD748.CD748.CD749.CD749.CD750.CD750.CD751.CD751.CD752.CD752.CD753.CD753.CD754.CD754.CD755.CD755.CD756.CD756.CD757.CD757.CD758.CD758.CD759.CD759.CD760.CD760.CD761.CD761.CD762.CD762.CD763.CD763.CD764.CD764.CD765.CD765.CD766.CD766.CD767.CD767.CD768.CD768.CD769.CD769.CD770.CD770.CD771.CD771.CD772.CD772.CD773.CD773.CD774.CD774.CD775.CD775.CD776.CD776.CD777.CD777.CD778.CD778.CD779.CD779.CD780.CD780.CD781.CD781.CD782.CD782.CD783.CD783.CD784.CD784.CD785.CD785.CD786.CD786.CD787.CD787.CD788.CD788.CD789.CD789.CD790.CD790.CD791.CD791.CD792.CD792.CD793.CD793.CD794.CD794.CD795.CD795.CD796.CD796.CD797.CD797.CD798.CD798.CD799.CD799.CD800.CD800.CD801.CD801.CD802.CD802.CD803.CD803.CD804.CD804.CD805.CD805.CD806.CD806.CD807.CD807.CD808.CD808.CD809.CD809.CD810.CD810.CD811.CD811.CD812.CD812.CD813.CD813.CD814.CD814.CD815.CD815.CD816.CD816.CD817.CD817.CD818.CD818.CD819.CD819.CD820.CD820.CD821.CD821.CD822.CD822.CD823.CD823.CD824.CD824.CD825.CD825.CD826.CD8	

Foer1	complex	1.802	bias	3.19E-04	BCL2A1.Cc2.Cd83.CSF1.IL1.B.JUN.MRC1	160 (17)	
IL25	cytokine	1.608	bias	3.19E-04	Cd2.CSF3.F11R.GATA3.IL1.B.IJRL1.JAG1	179 (17)	
CSF3	1,184	cytokine	1.146	bias	3.20E-04	BATF.BIRC3.Cc2.CCR7.CD14.CD44.CEBPA.CXL12.GADD45B.ICAM1	141 (15)
reactive oxygen species	chemical toxicant	1.824	bias	3.20E-04	CASP3.CSF3.FAS.ICAM1.IL1.B.JUN.KLF6.SERPINE1.SOD2.TNFAIP3	205 (18)	
cardotoxin	chemical - other	2.828	bias	3.21E-04	CASP3.Cc2.CCN42.CSF2RL.FLT3.II.B.IJL7.RTGB7.MCM5.MEST		
geldanamycin	chemical - endogenous non-met	2.724	bias	3.21E-04	CASP3.CSF3.FAS.ICAM1.IL1.B.JUN.KLF6.SERPINE1.SOD2.TNFAIP3	123 (11)	
TRAF2	enzyme	1.022	bias	3.22E-04	BIRK1.FAS.ICAM1.Mnd.PTPN14.RB1BP1.SerP190L.TNFAIP3	100 (12)	
zinc	other	0.167	bias	3.25E-04	AKR1B1.CD8.FAS.IL1.B.NFKBIA.SLC11A2.SLC30A1.SLC30A4	182 (17)	
IL22	cytokine	1.334	bias	3.41E-04	CLCA1.CXCL12.CYBA.FTH1.HSPB1.II.B.IJL6.Muc1.SCD2.TGM3	154 (12)	
lanesepivin	chemical drug	1.770	bias	3.41E-04	BCL2A1.BIRC3.FAS.FLT3.JUN.KRB8.LYN.SERPINE1.SOD2.TNFAIP3	132 (17)	
medroxyprogesterone acetate	chemical drug	1.019	bias	3.41E-04	CAMK4.CAP3.Cc2.CD44.FAS.ICAM1.II.B.JUN.NEK2.Nrg1	218 (25)	
PTX3	other	1.571	bias	3.48E-04	Cd2.CSF3.GATA3.II.B.JUN		
ACSL4	enzyme	1.342	bias	3.48E-04	CAMK1.DNP1.FERM1.PRK1.RHOU		
vinblastine	chemical drug	2.213	bias	3.48E-04	CD40.CD86.HLA.A.II.B.SOD2	142 (17)	
Cyp22c3	enzyme	0.883	bias	3.50E-04	Cd2.CD82.CD83.II.B.JUN		
PPI4C5C	other	2.000	bias	3.50E-04	CDA40.CD86.HLA.A.II.B.SERPINE1		
P2X7R	G-protein coupled receptor	Inhibited		3.50E-04	Cd2.CD82.CD83.II.B.JUN		
DAXX	transcription regulator	1.982	bias	3.50E-04	CASP3.ISPB1.KLK3.SERPINE1	208 (19)	
SP1B	transcription regulator	2.813	bias	3.52E-04	BLNK.BMP6.CD86.Hgap1b.KLF6.KLK3.LILRB3.P2RY10		
HMG1B	transcription regulator	1.963	bias	3.52E-04	CASP3.CD40.CD83.CD86.ICAM1.B.IJRC1.RELB	161 (19)	
SMAD1	transcription regulator	2.429	bias	3.56E-04	CFS1.GADD45B.Hamp/Hamp2.ICAM1.III.IJRUNX2	158 (13)	
PROC	peptidase	0.294	bias	3.56E-04	BCL2A1.Cc2.ICAM1.III.IJRUNX2	154 (16)	
stallimycin	biologic drug	2.449	bias	3.56E-04	CSF1.IF16.II.B.IJL6.RTGP1.TNFAIP3	97 (7)	
Nrlh1	group	2.723	bias	3.59E-04	BCL2A1.CD82.CD83.II.B.IJL6.RTGP1.TNFAIP3	169 (19)	
SNAI1	transcription regulator	0.066	bias	3.59E-04	BMP4.COCO.CDN4.FOS3.I.GOF1.III.IJRT8.LAPGP1.RUNX2.SDC1	225 (19)	
dimeithyl sulfoxide	chemical drug	2.578	bias	3.86E-04	BMP2.BMP4.CP2.CD83.CSF3.NFKBIA.SOD2	106 (22)	
Gs-6976	chemical - kinase inhibitor	2.607	bias	3.87E-04	BMP2.BMP4.CP2.CD83.CSF3.NFKBIA.SOD2	144 (16)	
MET	kinase	0.633	bias	3.89E-04	BMP4.CD44.Hsp1.II.B.JUN.KLF4.NFKBIA.SOD2	173 (18)	
Creb	group	1.929	bias	3.91E-04	ANTXR1.ANTXR2.BMP6.CD14.CEBPA.CEBPD.CLMN.CSRP1.FAS.POSL1	159 (11)	
obeticholic acid	chemical drug	1.347	bias	4.01E-04	APOA1.Cc2.CD86.CEBPA.ICAM1.III.IJRUNX2	144 (17)	
NGFR	transmembrane receptor	0.895	bias	4.07E-04	CCNA2.CD86.HLA.A.II.B.JUN.SERPINE1	162 (12)	
TNFSF15	cytokine	2.200	bias	4.07E-04	BIRC3.CCR7.CD40.CD83	155 (16)	
crocidolite asbestos	chemical toxicant	1.985	bias	4.07E-04	CASP3.CD40.CD86.II.B.JUN		
prostaglandin inhibitor PS1	chemical - protease inhibitor	1.442	bias	4.07E-04	BMP2.BMP4.CP2.CD83.CSF3.NFKBIA.SOD2	110 (16)	
Tsf1b1a	group	1.334	bias	4.09E-04	BASP1.Cc2.CCR7.CSF1.CSF3.GADD45B.GATA3.IID3.IJL1B	216 (20)	
EIF2AK3	kinase	1.846	bias	4.17E-04	ANG.BIRC3.Cc2.FOS3.II.B.JUN.KLF4.RELB.RNASEL	182 (18)	
VIP	other	0.009	bias	4.17E-04	Cd2.CD40.CD86.CEBPD.GATA3.III.IJL1B.IJRK2.NFKBIA	153 (17)	
aspirin	chemical drug	Inhibited		4.17E-04	APOA1.Cc2.CD40.CD86.CSF1.CSF3.GDF15.CAM1.III.IJRUNX2	122 (16)	
1,2-dihydro-3-throne	chemical reagent	3.560	bias	4.24E-04	AKR1B10.ALAS1.ANG.B4.GALNT1.III.IJL1B.IJRT8.GSTA3.GSTP1.MGGL.NQO1	45 (3)	
vitamin E	chemical drug	1.941	bias	4.26E-04	APOA1.Cc2.CD86.CEBPA.ICAM1.III.IJRUNX2	177 (19)	
LEF1	transcription regulator	0.371	bias	4.26E-04	CASP3.CD40.FAS.GATA3.III.IJLCK.RUNX2	160 (12)	
MBD2	transcription regulator	0.115	bias	4.26E-04	AM2Y2.BIRC3.GSTP1.HK2.OAT.PL2G16.RELB		
IL7RD2	transmembrane receptor			4.26E-04	CD2.CAM1.III.IJRUNX2		
ZNFX5B	other			4.26E-04	FAS.PDGF		
FARM1	other			4.29E-04	BMP2.BMP4		
diaziquone	chemical drug			4.29E-04	CD40.II.B		
cobimetinib	chemical drug			4.29E-04	CD44.CSF3		
cyclic AMP	chemical - endogenous mammal	Activated	2.925	bias	4.37E-04	ANTXR1.ANTXR2.BMP2.CD86.CEBPA.CEBPD.GAP3.GATA3.III.IJRUNX2	230 (22)
mannitol	chemical - endogenous mammal	1.231	bias	4.43E-04	CASP3.II.B.IJL6.RTGP1.SOD2	174 (21)	
NR113	Igand-dependent nuclear receptor	Activated	2.759	bias	4.46E-04	ALAS1.APOA1.CYP3A7.GADD45B.GSTP1.HK1.ICAM1.PGD.STEAP4	139 (10)
PGR1C1	transcription regulator	2.449	bias	4.50E-04	BMP6.GDF15.HK2.LAMB3.NFKBIA.SOD2		
GATA3	transcription regulator	1.117	bias	4.57E-04	BMP6.GDF15.CEBPA.CXR3.ENPP1.GATA3.II.B.IJL1L.IJL6T7.RTGP2		
EPH4B	cytokine	-0.404	bias	4.64E-04	ATOH8.CMP4.CD85.CTSZ.CXCL2.FABP5.PAS.GATA3.GDF15.Hamp/Hamp2	210 (16)	
butyl N-[3-(4-(indazol-1-yl)methyl	chemical reagent			4.58E-04	CASP3.III.IJL1B		
CD5L	transmembrane receptor			4.58E-04	Cd2.C86.II.B	83 (7)	
FEM1A	transcription regulator			4.58E-04	Cd2.CD86.II.B	143 (13)	
GIPR	G-protein coupled receptor			4.58E-04	Cd2.C86.Tcf7		
MIA-602	chemical reagent			4.58E-04	CASP3.Cc2.III.IJRUNX2		
GSK34	chemical reagent			4.58E-04	CD40.CD83.CD86		
Fc gamma receptor	group	Activated	2.200	bias	4.75E-04	CCNA2.CD86.CD85.ICAM1.TNFAIP3	117 (17)
TRAF6	transmembrane receptor	0.468	bias	4.75E-04	CDM4.COCO.CDN4.FAS.GATA3		
2-hydroxy-AMP	chemical reagent	0.731	bias	4.75E-04	CASp1.CD40.CD86.II.B.JUN	164 (19)	
ATN1	transcription regulator			4.91E-04	BASP1.BTG3.CAMK4.C24a.II.B.JUN.LJTB2.Parks.TIAM1.TM4SF1		
glucocorticoid	chemical drug	0.268	bias	4.92E-04	BMP6.CD2.CD44.CEBPD.CSF1.CSF3.ZYPA7.FAS.ICAM1.III.IJRUNX2	170 (15)	
PTPN6	phosphatase	Inhibited	2.412	bias	5.04E-04	Cd2.CCR7.CD44.CSF6.II.B.IJL6.RTGP2	155 (16)
zymosan	chemical - endogenous non-met	1.988	bias	5.12E-04	Cd2.CD40.CD86.CSF1.CSF3.DEP1.III.IJRUNX2	134 (15)	
3,3'-dimethylmethane	chemical drug	1.937	bias	5.12E-04	FAS.GDF15.HLA.A.II.B.KRT19.NFKBIA.NQO1	215 (21)	
PI3K (family)	group	1.510	bias	5.15E-04	AKR1B10.BIRC3.CXL12.FTH1.HK1.II.B.IJL6.NQO1.PREX1.SERPINE1	195 (20)	
IL36A	cytokine	Activated	2.200	bias	5.50E-04	CDM4.COCO.CDN4.FAS.GATA3	
prostaglandin E1	chemical - endogenous mammal	-1.192	bias	5.51E-04	CDM4.COCO.CDN4.FAS.GATA3	210 (19)	
TMGB4	group	1.964	bias	5.76E-04	ALDH2.APOA1.BMP2.CP2.FAS.GSTP1.II.B.JUN.KRT8.NOO1	232 (12)	
ADRB3	G-protein coupled receptor			5.81E-04	BMP2.BMP4.RUNX2.SERPINE1		
BIRC2	enzyme			5.81E-04	Cd2.CXCL2.II.B.IJL6		
Usp17la (includes others)	peptidase	1.987	bias	5.81E-04	Cd2.CD44.II.B.KLF4	87 (7)	
ethoxyquine	chemical toxicant	1.934	bias	5.81E-04	FTH1.GSTA3.GSTP1.NGO1		
metryrapone	chemical drug	0.000	bias	5.81E-04	ALAS1.CXL12.ICAM1.III.IJRUNX2	124 (11)	
CD38	enzyme	1.964	bias	5.83E-04	ANXA6.CD4.CD86.CSF2RB.HGIG10.ICAM1.IJTB7.NEK2.PDLIM1.SDC1		
Raf1	group			5.89E-04	FOSL1.GOF1.II.B.IJL6.RTGP1.SOD2	220 (20)	
TSC2D9	other			5.89E-04	CDM4.COCO.CDN4.FAS.GATA3		
TMW1	other			5.95E-04	CDM4.COCO.CDN4.FAS.GATA3	147 (16)	
TBX21	transcription regulator	0.180	bias	6.15E-04	CXCR3.GATA3.CAMK4.II.B.IJL6.IJL7.RTGP2	159 (15)	
ADAM10	receptase			6.32E-04	CFS1.CXCL12.CXL16.DTNA.II.B.IJL6.RTGP2		
NLRX1	other	Inhibited	2.449	bias	6.32E-04	CDR1.CD40.CD86.II.B.NFKBIA.RELB.TNFAP3	158 (13)
sphingosine-1-phosphate	chemical - endogenous mammal	Activated	2.044	bias	6.60E-04	Cd2.CD4.FAS.GAP43.ICAM1.III.IJRUNX2	167 (19)
PDX1	transcription regulator	1.066	bias	6.60E-04	Cd2.CD4.GAP43.HK1.III.IJL1B.IJL6.KRT8	120 (7)	
RIPK2	kinase	0.574	bias	6.61E-04	ACOD1.Cc2.CD40.CD86.ICAM1.RASGP1.SOD2	132 (17)	
TERT	enzym	-0.686	bias	6.19E-04	ICAM1.IF16.II.B.JUN.KLK2.IJRT9.NFKBIA.PCDHGAA.RASA3.SOD2	191 (14)	
TSC2D9	transcription regulator	-1.053	bias	6.27E-04	CDM4.COCO.CDN4.FAS.GATA3	161 (19)	
TMW1	other	1.418	bias	6.27E-04	CDM4.COCO.CDN4.FAS.GATA3		
CD38	transporter	1.185	bias	6.27E-04	CDM4.COCO.CDN4.FAS.GATA3	203 (16)	
ADAM10	other	1.185	bias	6.27E-04	CDM4.COCO.CDN4.FAS.GATA3	153 (19)	
OSCAR	other	1.342	bias	6.34E-04	CD40.CD83.CD86.ICAM1.RRAS	153 (15)	
GATA3	transcription regulator	0.470	bias	6.34E-04	BATF.BCL11A.BMP.CEBPA.GATA3.GZMA.ICAM1.III.IJL1L.IJL6T7.KLF4	180 (16)	
UCP1	transporter	-0.194	bias	6.45E-04	ALAS1.CASp3.Cc2.CD40.CD86.GDF15.GSTO1.III.IJL6.RGDS.NFKBIA.SERpine1	85 (7)	
CD36	transmembrane receptor	1.970	bias	6.52E-04	AP0A1.CD86.CSF3.FAS.ICAM1.III.IJL1B.IJLP1.SERPINE1	162 (18)	
AG490	chemical - kinase inhibitor	Inhibited	2.792	bias	6.52E-04	BIRC3.CSF3.Cc2.CD40.CD86.ICAM1.RASGP1.SOD2	224 (21)
CCND1	transcription regulator	0.132	bias	6.57E-04	CCNA2.CD4.CD86.CD87.ICAM1.DSONSON.HOMER2.HSPB1.IID1.IJL3.KLK3	137 (7)	
melatonin	chemical - endogenous mammal	1.768	bias	6.60E-04	BMP2.CASp1.FAS.GJB2.II.B.IJL6.NQO1.RUNX2.SOD2	181 (19)	
nicotine	chemical drug	1.115	bias	6.60E-04	BMP2.CD2.CD4.CD86.II.B.IJL6.NQO1.RUNX2.SOD2	148 (16)	
gamm polysphosphocholine	chemical - endogenous mammal			6.77E-04	Cd2.ICAM1.III.IJRUNX2	165 (19)	
C9	complex			6.77E-04	Cd2.ICAM1.III.IJRUNX2	137 (6)	
SLC16A3	transporter			6.77E-04	CASp3.HK2.II.B		
salmonella typhimurium lipopolysaccharide	chemical - endogenous non-met			6.77E-04	Cd2.CD86.II.B		
TNFRS17	transmembrane receptor			6.77E-04	CD40.CD86.ICAM1	136 (15)	
ATG16L1	enzyme			6.77E-04	IL1B.NFKBIA.SOD2	112 (9)	
RTKN	other	1.276	bias	6.77E-04	BCL2A1.BIRC3.TNFAIP3	91 (9)	
C7	other			6.77E-04	Cd2.ICAM1.III.IJRUNX2	107 (9)	
DEK	transcription regulator			6.77E-04	CDM4.COCO.CDN4.FAS.GATA3	90 (6)	
putumin	chemical reagent			6.77E-04	CAV2.GOF1.III.IJL6.KLK3	107 (7)	
TP53COP1	chemical - endogenous non-met			6.78E-04	CASp3.CD40.III.IJL6.SERpine1	188 (23)	
CD40	other	2.000	bias	6.78E-04	CD40.CD86.III.IJL6.SERpine1	136 (15)	
Pk3s	group	2.673	bias	6.89E-04	AP0A1.DMD.FAS.FOSL1.GADD45B.GAP43.III.IJL6.KRT8	207 (19)	
PRKAQ3	other			7.14E-04	ALAS1.DOT1L.FTL1.IJL1.KLF4.PLN3.POLE4.RHOU.SLC2A3.TSPAN8		
GNA14	enzyme			7.24E-04	ANXA3.BMP2.CM8.CYBA.III.IJL6.XDHD		
andropharolide	chemical drug	0.447	bias	7.27E-04	CASP3.GATA3.GSTP1.III.IJL6	150 (21)	
SN-38	chemical drug	1.162	bias	7.27E-04	CD14.CD8.CEBPA.CEBPD.CSF2RB	183 (14)	
DDIT3	transcription regulator	1.054	bias	7.48E-04	CEBP2.CEBPD.DOCK4.GALNT1.HBDP.II.B.IJL6.NQO1.RUNX2.SOD2	210 (16)	
miR-146a-5p (and other miRNA)	mature microRNA	Inhibited	2.791	bias	7.52E-04	ATOH8.CCN2.ACD40.III.IJL6.SERLP2.RF5.NFKBIA.SY11	91 (6)
Rock	group	1.664	bias	7.73E-04	BMP2.CAVIN1.DMD.ICAM1.Nes	217 (22)	
NOG	growth factor	-1.634	bias	7.73E-04	BMP2.BMP4.CD2.FAS.D3.RUNX2	189 (23)	
PTPRJ	phosphatase	Activated	2.236	bias	7.73E-04	CCNA2.CEBPD.NFKBIA.OASL.Vn3.ZC3H12A	
minocycline	chemical drug	-1.775	bias	7.87E-04	CASP3.Cc2.CD86.GATA3.ICAM1.III.IJL6T7	174 (17)	
YY1	transcription regulator	0.447	bias	8.01E-04	ALCM.BLNK.BMP4.BMP6.CNA2.CXL12.DM.FAS.III.IJL3.IB	202 (19)	
HDAC3	transcription regulator	-0.751	bias	8.07E-04	CDR3.BM2.III.IJL6.IJL7.KLK3.IJL8.NFKBIA.RELB.SERpine1	218 (23)	
Pka	complex	1.915	bias	8.07E-04	ANXA3.CM8.CYBA.III.IJL6	203 (20)	
Prostagmogen	complex	1.929	bias	8.24E-04	Cd2.CD40.CAM1.III.IJL6	133 (17)	
ITGA9	other	2.000	bias	8.24E-04	Cd2.CXL12.II.B.IJL6	146 (12)	
NP56K5A	kinase			8.24E-04	CCR7.FOSL1.III.IJL6	191 (21)	
PCDH11Y	other	Activated	2.000	bias	8.24E-04	BMP4.CD44.FOSL1.JUN	130 (7)
IL37	cytokine	-1.938	bias	8.24E-04	BMP2.CSF1.CSF3.II.B.IJL6.XDHD	148 (15)	
CRNDE	other	Activated	2.236	bias	8.30E-04	GAB1.GADD45B.RASA3.R	

xanthohumol		chemical drug	-0.218	bias	9.44E-04	BIRC3,ICAM1,IL1B,NQO1,RUNX2	142 (10)	
XDH	0.689	enzyme	-0.094	bias	9.44E-04	Cd2,CEBPA,ICD3,IL1B,SERpine1	224 (24)	
CD80		transmembrane receptor		bias	9.44E-04	CASP3,CD28,FAS,ICAM1,IL1B	161 (20)	
frp		group		bias	9.52E-04	FTH1,FTL,SLC11A2		
RBPJL		transcription regulator		bias	9.52E-04	AMY2A,CPR2A,CTR82		
SEL		enzyme		bias	9.52E-04	COP9,SLC11A1B	148 (17)	
RANBP9		enzyme		bias	9.52E-04	GAP43,JUN,KT2B	130 (7)	
FTH1	0.558	transmembrane receptor		bias	9.52E-04	COR86,FTH1,FTL	36 (3)	
TFR2		transporter		bias	9.52E-04	BMP6,GDF5,Hamp/Hamp2	120 (6)	
sodium dodecyl sulfate		chemical drug		bias	9.52E-04	FABP5,IL1B,SERpine2		
clomipramine		chemical drug		bias	9.52E-04	DEPP1,HPN,SLC2A3		
tin mesoporphyrin		chemical drug		bias	9.52E-04	Cd2,ICAM1,IL1B	99 (7)	
pepsatrin		chemical - protease inhibitor		bias	9.52E-04	BMP2,CD9,STC2		
perilla alcohol		chemical drug		bias	9.52E-04	BCL2A1,IL1B,NFKBIA	116 (11)	
NRAS		enzyme	Inhibited	-2.804	bias	9.56E-04	COP9,SLC11A1A,IFI16,IL1B,MCM3,MEST,NQO1,PERP,SDC1	159 (17)
L22		cytokine	1.444	bias	9.60E-04	CD14,CD20,COP9,CEPBP1,GATA3,HLA4,ICAM1,IL1B,LAG3,MRC1	150 (7)	
Im-gamma		ligand	Activated	2.226	bias	9.60E-04	CASP3,Ce2,C9R9,CXK16,CXR3,FAS,ICAM1,IL1B	157 (20)
lectoceramide		chemical - endogenous mammal		bias	9.61E-04	Cd2,ICAM1,REL,B	144 (15)	
Pkq		group	1.067	bias	9.61E-04	HCK2,JUN,SOD2,VCL	180 (16)	
EIF4G2		translation regulator	1.000	bias	9.61E-04	JUN,NFLK1,KRT19,SERpine2		
LRPAP1		ether	-0.308	bias	9.61E-04	Cd2,IL1B,LRP1,SERpine1	144 (16)	
EPCAM		other	-0.762	bias	9.61E-04	FABP5,FOSL1,IDI1,JUN	164 (13)	
GRN		growth factor		bias	9.61E-04	Cd2,CTSD,ICAM1,IL1B	212 (19)	
ketamine		chemical drug		bias	9.61E-04	COP9,SLC11A1,KLF6,IL1B	102 (7)	
apicidin		chemical - endogenous non-mam	0.000	bias	9.61E-04	AMP3,FAF1,IFI16,IL1B,TGF697		
IFI16	2.317	transcription regulator	1.815	bias	1.00E-03	C2B8,CD81,ICAM1,IFI16,IL1B,ILTR,NFKBIA	211 (20)	
HTF		transcription regulator	1.372	bias	1.00E-03	APOA1,BAS1,BTG3,CIR,CAMK4,CASP3,Cd24a,C9J,CEBPA,FOSL1	232 (21)	
PARP1		enzyme	0.537	bias	1.00E-03	Cd2,CXL12,EAS,GBP6,GDF15,ICAM1,IL1B,JUN,KLK3	215 (20)	
lithium chloride		chemical drug	0.923	bias	1.00E-03	B4GALT1,BMP2,BMP4,CD44,GATA3,GF15,KLK3,KRT20,Marcks	219 (26)	
CBL		transcription regulator		bias	1.04E-03	CSF2RB,FLT3,IL1B,LCK,LYN,RUNX2	110 (7)	
cholesterol		chemical - endogenous mammal	1.021	bias	1.04E-03	CAMK1,CAV1,CD2,CD4,CDC4,CSE1,ICAM1,IL1B,SMO	137 (17)	
KMT2D		transcription regulator	1.372	bias	1.04E-03	BTP3,CCDC7,JIB,CEPBP1,KLF4,KRT23,LAMB3,LCK,POLE4,PPC		
TLR2		transmembrane receptor	Activated	3.226	bias	1.04E-03	BSP2,COP9,CEPBP1,COP9,CEPBP1,CSE1,GATA3,ICAM1,IL1B,IRAK3	148 (18)
Mg2+/-phosphatic acid		chemical - other	Activated	2.741	bias	1.04E-03	Cd2,CSE1,ICAM1,IL1B,JUN,SERpine1	149 (19)
NOO1	1.033	enzyme	1.387	bias	1.07E-03	BIRC3,C9B,CEPBA,CXK12,Z,CXR3	105 (7)	
IGCM		transmembrane receptor	0.577	bias	1.07E-03	Cod2,C9B6,FAS,IL1B,JUN	191 (20)	
mevalonic acid		chemical - endogenous mammal	1.477	bias	1.07E-03	APOA1,CDO4,ICAM1,IL1B,SERpine1	171 (19)	
CLDN7		other	0.990	bias	1.07E-03	ANXA3,B4GALT1,CD68,FADS3,FOSL1,PLA2G16,SERPINB1,SYTL2,TINAGL1		
Growth hormone		group	1.098	bias	1.08E-03	ARD5B,BMP2,BMP4,CEBPA,CEPBD,FTH1,GF15,GST1,IDI1,JUN	227 (18)	
Notch		group	1.144	bias	1.08E-03	B4GALT7,AOD455,GATA3,ICAM1,IDI1,JAG1,Nes	123 (14)	
Sos		group		bias	1.09E-03	B4GALT1,CD4,DOCK1,HPGD,L36G,KLF6,MAPK6,Nrg1,SEMA3B,SEMA3E		
2-(4-amino-1-isopropyl-1H-pyraz		chemical reagent	0.859	bias	1.10E-03	BMP2,C1R,CD4,DOCK1,HPGD,L36G,KLF6,MAPK6,Nrg1,SEMA3B,SEMA3E	118 (12)	
estrogen		chemical drug	Activated	2.032	bias	1.10E-03	B4GALT1,CD4,DOCK1,HPGD,L36G,KLF6,MAPK6,Nrg1,SEPINB1	118 (20)
theophylline		chemical - endogenous mammal	0.394	bias	1.10E-03	B4GALT1,CD4,DOCK1,HPGD,L36G,KLF6,MAPK6,Nrg1,SEPINB1	110 (14)	
CLECA9		other	0.816	bias	1.10E-03	CDC,CDC4,ICAM1,IL1B,Ser3,SERpine1	197 (21)	
PAX5		transcription regulator	0.730	bias	1.10E-03	BLNK,CD40,CSF1,FLT3,HK2,SOD2,SLC2A3		
FOSL2		transcription regulator	Activated	2.219	bias	1.14E-03	Cod2,FAS,IL1B,IL6,RELB,RUNX2	130 (11)
isocinchamate		chemical - endogenous mammal	-1.698	bias	1.14E-03	BCL2A1,CD14,CD4,CXL12,ICAM1,SLC34A2	149 (15)	
CTR9		other	1.000	bias	1.18E-03	CXCL12,RASGRIP1,SDC1,TIAM1		
epicatechin gallate		chemical drug		bias	1.18E-03	GDF15,CAM1,LYN,PERP	96 (7)	
evodiamine		chemical - endogenous non-ma	-1.715	bias	1.18E-03	BCL2A1,BIRC3,CASF3,ICAM1	86 (7)	
chlenylylthymine		chemical drug	4.000	bias	1.18E-03	CDC,CDC4,CXK12,Z,CXR3,IFI16,TNFNAIP3		
TNFRSF1B		transmembrane receptor	1.869	bias	1.20E-03	CASP3,CXK12,FAS,ICAM1,JUN,SERpine1,SOD2,TNFNAIP3	134 (16)	
MEOX2		transcription regulator	-1.400	bias	1.21E-03	ICAM1,IDI1,DOI1,LRP1,TNFNAIP3		
NR2F1		lipid-dependent nuclear recep	0.000	bias	1.21E-03	ALDH2,APCA1,FNPB1,GF15,JAG1		
mitoxantrone		chemical drug	1.067	bias	1.21E-03	FAS,F110,IL1B,KLK3,PERP	167 (13)	
pancalcitol		chemical drug	-1.000	bias	1.21E-03	BMP2,Cd2,CYP3A7,ICAM1,IL1B	155 (17)	
SIRT6		enzyme		bias	1.25E-03	BIRC3,Cd2,CSF1,IL1R1,IRAK3,SOD2	212 (16)	
miR-145-5p (and other miRNAs)		mature microRNA	Inhibited	-2.411	bias	1.25E-03	CNAQ2,F11R,LFL4,RTKN,SERpine1,SOD2	
CD14	1.316	transmembrane receptor	Activated	2.226	bias	1.25E-03	BSP2,COP9,CEPBP1,ICAM1,IL1B,IRAK3,SOD2	144 (16)
MMP2K12		group	1.772	bias	1.25E-03	Cod2,FOSL1,HCK,HSF1,IL1B,JAG1,JUN	189 (21)	
PTPN11		phosphatase	-1.254	bias	1.26E-03	CD14,CDB8,CD40,CDB8,CD40,CS6,ICAM1	194 (23)	
SETPA1		transporter	-1.087	bias	1.26E-03	Cod2,GP88B,IL1B,IL1R1,MRC1,SERpine1,TCEA3	138 (15)	
galactosylceramide		chemical - endogenous mammal		bias	1.27E-03	CD40,CDB8		
C1QTNF12		other	1.27E-03	bias	1.27E-03	Cod2,IL1B,IL6,RELB,RUNX2	103 (7)	
NIPBL		transcription regulator		bias	1.27E-03	KLF4,POLE4		
ASH1L		transcription regulator		bias	1.27E-03	IRAK3,TNFNAIP3		
KHLH21		other		bias	1.27E-03	INFKBIA,NFKBIZ		
CNDP2		peptidase		bias	1.27E-03	CD44,CXCR3		
Ap1 gamma		group		bias	1.27E-03	CD44,IL1A		
CARD9		other		bias	1.27E-03	CD44,IL1B,IL1R1		
ETMT		enzyme		bias	1.27E-03	FTH1,FTL		
STRAP		other		bias	1.27E-03	JUN,SERpine1		
Defb2		other		bias	1.27E-03	CD24a,CD40		
TIGAR		enzyme		bias	1.27E-03	Cod2,TNFNAIP3	142 (10)	
1-hexanol		chemical reagent		bias	1.27E-03	CD40,CD86		
ellipticine		chemical reagent		bias	1.27E-03	CD40,CD86		
prostatin		chemical - endogenous non-ma	-1.715	bias	1.27E-03	CAM1,CD2,CD4,CD40,CEPBD,CEPBP1,HMGCS2,MRC1,NFKBIA	95 (7)	
Mn2+		chemical - endogenous mammal		bias	1.27E-03	CD40,CEPBD,CEPBP1,HMGCS2,MRC1,NFKBIA		
tenofoviride		chemical drug		bias	1.27E-03	FAS,ICAM1,IL1B	126 (11)	
Tsl19		other		bias	1.28E-03	Cod2,COD4,CDB8	135 (11)	
GPR132		G-protein coupled receptor		bias	1.29E-03	CAMK4,CAP3,CEBPA,HLA4,ICAM1,NFKBIA,RUNX2	175 (13)	
ACVR2A		kinase		bias	1.29E-03	Hamp/Hamp2,ICAM1,IDI1	97 (4)	
APOH		transporter		bias	1.29E-03	CD40,CD86,CSE1,ICAM1,IL1B,JUN	156 (18)	
MAS1		G-protein coupled receptor		bias	1.29E-03	BATF,GATA3,G2MA1,L7RL,LYN	179 (17)	
NDFP1		other		bias	1.29E-03	CD1L,BYL,SLC11A2		
Hmgb1		enzyme	0.000	bias	1.34E-03	CASP3,C2,Cd2,Cd14,CXK12,ICAM1,IDI1,IL3,IL6,NQO1	119 (8)	
ERG		transcription regulator	1.000	bias	1.34E-03	ARHGAP28,BIRC1,CAM10,CNA2,DOCK1,DOCK10,ICAM1,KLK3,MYO12,RRAS	197 (21)	
TSLP		cytokine	1.966	bias	1.35E-03	CVR7,CD40,CD8,CD86,ICAM1	154 (16)	
CEACAM1		transporter	1.342	bias	1.35E-03	ANG,CD40,CDB6,CSE1,ICAM1	176 (18)	
Tcf7	4.054	transcription regulator	-1.167	bias	1.35E-03	BATF,GATA3,G2MA1,L7RL,TGM3		
monocrotaline		chemical toxicant	0.600	bias	1.35E-03	Cd2,GAP4,IDI1,IL3,IL6,NQO1	103 (7)	
RETNL8		other	Activated	2.630	bias	1.36E-03	CASP3,C2,Cd8,CSE1,ICAM1,IL1B,SLC11A2	197 (18)
Gsk3		group	0.911	bias	1.36E-03	CASP3,C2,Cd8,CSE1,ICAM1,IL1B,SLC11A2		
JUND		transcription regulator		bias	1.36E-03	CD40,CEPBD,CEPBP1,HSPB1,KLK3,NEK2,NQO1,PERP,SERpine2	188 (17)	
aztreonam		chemical - endogenous non-ma	-9.832	bias	1.36E-03	Cd2,Cd2,CD40,CD86,ICAM1,IL1B,IL6,RELB,RUNX2	101 (10)	
Nf- <i>kappa</i> -B1-leucine		chemical - protease inhibitor	-0.506	bias	1.36E-03	CAMK4,CAP3,CEBPA,HLA4,ICAM1,NFKBIA,RUNX2	232 (22)	
dehydroisoandrosterone		chemical - endogenous mammal	-0.742	bias	1.36E-03	BMP4,Cd2,ICAM1,KLK3,NFKBIA,RACK1,Sla3a	197 (22)	
cytokine			1.525	bias	1.37E-03	Cod2,Cd2,CSE1,ICAM1,IL1B,PLK3AP1	182 (18)	
TCF12		transcription regulator	0.655	bias	1.37E-03	BLNK,FLT3,GATA3,JIB2,L7RL,ZC3H12A	30 (2)	
TFAP2A		chemical drug	1.400	bias	1.37E-03	CEBPA,FTL1,GADD45B,HSPB1,RITAF	187 (18)	
transcription regulator		-1.623	bias	1.37E-03	ALCAM,BIRC3,CEBPA,FLA2G16,RAB27B,SERpine1,SOD2	195 (16)		
INSIG1		other	Inhibited	-2.828	bias	1.37E-03	C8B,C9T,CD9,CEPBD,CEPBP1,HMGCS2,MRC1,NFKBIA	
BRCA1		transcription regulator	Activated	2.319	bias	1.37E-03	CDC,CDC4,CXK12,Z,CXR3,IFI16,TNFNAIP3	185 (16)
JUN		transcription regulator		bias	1.37E-03	ALSP,C2,Cd2,Cd4,Cd40,CEPBD,CEPBP1,HSPB1,KLK3,NEK2,RUNX2	90 (7)	
zeta-1,4-beta-D-glucuronidase		chemical drug	9.509	bias	1.38E-03	CAV2,Cd2,Cd6,CEPBD,CEPBP1,HSPB1,KLK3,NEK2,SERpine1	247 (24)	
N-f_{kappa}-B1-leucine		chemical - protease inhibitor	-0.506	bias	1.38E-03	CAMK4,CAP3,CEBPA,HLA4,ICAM1,NFKBIA,RUNX2		
USF1		transcription regulator	1.925	bias	1.38E-03	Cod2,CSE1,ICAM1,IL1B,PLK3AP1,TNFNAIP3	217 (22)	
EN1		transcription regulator		bias	1.38E-03	ICAM1,IDI1,IL1B,PLK3AP1,TNFNAIP3		
NCOA3		kinase		bias	1.39E-03	EMPP1,GALT3,IL1B,NQO1,RUNX1,SLC11A2		
KLF6	1.036	transcription regulator	1.303	bias	1.39E-03	Cd2,IL1B,MRC1,NFKBIA,SDC1,TNFNAIP3,TNIP1	151 (11)	
PRNP		other	0.059	bias	1.46E-03	CASP3,CD44,FOSL1,HSPB1,KLK3,NEK2,NQO1	154 (16)	
STAT2		transcription regulator	1.980	bias	1.49E-03	Cd2,CD40,CDB6,GBP6,I47,IRF5	137 (10)	
GPS2		transcription regulator	-1.706	bias	1.49E-03	BLNK,Cd2,CD4,CD40,IL1B,NEK2,NQO1,PERP,SERpine2		
diphenyleneodonium		chemical reagent	Inhibited	-2.400	bias	1.49E-03	Cd2,CD40,CD86,ICAM1,IL1B,IL6,NQO1,PERP,SERpine2	189 (18)
DICER1		transcription regulator	Activated	2.527	bias	1.49E-03	Cd2,AT1,Cd2,Cd24a,CSE1,FAS,JIP,KLF4,KLK3,KRT19,MEST	139 (7)
CD202A		transmembrane receptor	2.359	bias	1.49E-03	CDC,CDC4,CXK12,Z,CXR3,IFI16,TNFNAIP3	215 (22)	
EN1		transcription regulator	1.571	bias	1.49E-03	Cd2,Cd2,CSE1,ICAM1,IL1B,IL6,NQO1,PERP,SERpine1	228 (22)	
RNAseH2A		enzyme		bias	1.52E-03	CAMK4,CAP3,CEBPA,HLA4,ICAM1,IL1B,IL6,NQO1,PERP,SERpine1	215 (17)	
TLR7/8		group	Activated	2.000	bias	1.52E-03	BCL2A1,NFKBIA,SDC1,TNFNAIP3	107 (7)
TNFSF12		cytokine	Activated	2.747	bias	1.55E-03	BST1,Cd2,Cd6,CLE4,ICAM1,IL1B,NFKBIA,TNFRSF12A	174 (17)
PTGER2		G-protein coupled receptor	1.725	bias	1.55E-03	COR7,FAS,CD16,CP2,ICAM1,IL1B,IL6,NFKBIA	157 (17)	
TNFRSF8		transmembrane receptor	0.816	bias	1.63E-03	COR7,FAS,CD16,CP2,ICAM1,IL1B,IL6,NFKBIA		
NODAL		growth factor	-1.000	bias	1.63E-03	COR7,CD40,CD86,MRC1	94 (7)	
SLC11A2		other	-0.762	bias	1.63E-03	CDC,CDC4,CXK12,Z,CXR3,IFI16,NFKBIA	126 (16)	
NFKBIZ	0.499	transcription regulator	1.969	bias	1.63E-03	COR7,CD40,CD86,SERpine1	169	

SR144528		chemical reagent		1.69E-03	ICAM1,IL1B,NFKBIA	187 (16)
5-fluorouracil		chemical drug	Activated	2.031	1.70E-03 CASP3,CD40,CD81,CD86,FAS,GAP43,GDF15,IL1B,JUN,RHDF2	207 (19)
5-N-ethylcarboxamido adenosine		chemical reagent		0.707	1.75E-03 Ccd2,CEBDP,CSF2RB,DUSP16,HK2,IL1B,KLF6,SERpine1	177 (15)
TSC2		other	Inhibited	2.355	bias 1.75E-03 Ccd2,CD86,Hamp/Hamp2,ICAM1,IL1B,SDCA4	198 (19)
EGLN1		enzyme		1.000	1.77E-03 Ccd2,CD86,Hamp/Hamp2,ICAM1,IL1B,SDCA4	196 (19)
RHO		G-protein coupled receptor		0.447	1.78E-03 Ccd2,CD86,Hamp/Hamp2,ICAM1,IL1B,SDCA4	196 (19)
SIN3A		transcription regulator		1.000	1.77E-03 Ccd2,CD86,Hamp/Hamp2,ICAM1,IL1B,SDCA4	196 (19)
IRP1		transcription regulator	Activated	3.056	bias 1.79E-03 Ccd2,CD86,Hamp/Hamp2,ICAM1,IL1B,SDCA4	162 (11)
CDH1		other		0.051	1.80E-03 BMP2,CD44,FOSL1,JUN,JUP,KRT19,RAF1	168 (16)
CFTTR		ion channel		0.896	1.80E-03 BLNK,CRL,FAS,NFKBIA,NFKBIZ,Saa3,TNFaIP3	213 (22)
phytohemagglutinin		chemical drug	Activated	2.750	bias 1.81E-03 ALDH2,CASP3,CCR7,CD44,CD83,CSF1,CXCL12,FAS,GATA3,ICAM1	133 (14)
CD24		other		1.050	1.81E-03 AP08ECB3,CDF15,ICAM1,JUN,OASL,RELB,SLC30A1,SLC44	173 (19)
ACKR2		G-protein coupled receptor	Inhibited	2.236	bias 1.85E-03 ACOD1,F11B,IL1B,JUN,OASL	135 (7)
D-galactosamine		chemical - endogenous mammal	Activated	2.219	bias 1.88E-03 CD14,GDF15,ICAM1,JUN,SOD2	148 (17)
TAF4B		transcription regulator		1.000	1.90E-03 JUN,NFKBIA,TNFaIP3,ZB1816	148 (17)
DS3		transmembrane receptor		1.969	bias 1.90E-03 JUN,NFKBIA,TNFaIP3,ZB1816,Serpin3g (includes others)	175 (18)
USF2		transcription regulator		1.000	bias 1.92E-03 Ccd2,GATA3,Hamp/Hamp2,KLK3,PROK1,SERpine1	158 (16)
HDAC4		transcription regulator		1.000	2.04E-03 DMD,FOSL1,HOMER2,JUN,RAB32,RTN1,RUNX2,SYN,TNFRSF12A	116 (9)
LCN2		transporter		0.163	2.06E-03 BMP2,Cd2,C9B,IL1B,MRC1,RUNX2,TINAGL1	106 (7)
amphetamine		chemical drug		1.050	2.06E-03 ALDH2,CASP3,CCR7,CD44,CD83,CSF1,CXCL12,FAS,GATA3,ICAM1	150 (18)
ATP		chemical - endogenous mammal	Activated	2.515	bias 2.08E-03 Ccd2,Ccr7,CD14,C9B,ICAM1,JUN,OASL,RELB,SLC30A1,SLC44	151 (7)
EGLN		group	Inhibited	-3.109	bias 2.09E-03 CAVIN1,Cdc2,FTL,GATA3,Hamp/Hamp2,HK2,RNASE4,Serpin3g (includes others),SERPINE1,STC2	134 (16)
resatorvid		chemical drug		2.17E-03	AP08ECB3,Cdc2,IL1B	1
perhexiline		chemical drug		2.17E-03	DEPD,CEBDP,SLC2A3	1
LILR2A2		other		2.17E-03	CD40,CSP3,CD44,CD86,ICAM1,IL1B,SDCA4	1
ERS		other		2.17E-03	ATOH8,Hamp/Hamp2,IDE1	1
mir-373		microRNA		2.17E-03	CD44,LATS2,SERpine1	1
FSTL1		other		2.17E-03	Ccd2,GDF15,IL1B	146 (16)
ATXN3		peptidase		2.17E-03	CXCL12,IL1R1,SOD2	1
KRT8	0.955	other		2.17E-03	KRT19,KRT20,Reg3d	1
CCL3L3		cytokine		2.17E-03	Cd2,CD40,IL1B	135 (13)
SIRPA		phosphatase		2.17E-03	Cd2,Csf3,IL1B	150 (17)
hydroquinone		chemical - endogenous mammal		2.17E-03	IL1B,IL1R1,SLC2A3	148 (12)
MTRTA2		transcription regulator		0.946	2.19E-03 Cxcl12,IL1R1,IL1R2,HLA-A,ICAM1,IL1D1,RAB27B,Saa3,TST,VCL	201 (20)
UTX		chemical - endogenous mammal		2.19E-03	Cd2,CO14,ICAM1,SERpine1	161 (18)
PROCR		other		2.19E-03	Cd2,GPF6,ICAM1,IL1B	169 (19)
BCAP31		transporter		2.19E-03	Cd2,C081,C9B,IL1B	220 (22)
BGN		other		2.19E-03	BMP2,IL1B,RUNX2,SERpine1	1
Saa3	1.778	other		2.19E-03	AP0A01,BMP2,Csf3,RUNX2	1
SLC9A3		ion channel		2.19E-03	Ifit7,Reg3d,Saa3,UPP1	1
BMPRIB		kinase		2.19E-03	ID1,D3,RUNX2,SERpine1	176 (17)
dialyl disulfide		chemical - endogenous non-mar		2.19E-03	CASP3,QDF15,GSTA3,NOQ1	169 (21)
centromere		chemical - endogenous mammal		2.19E-03	CD44,CSP3,CD44,CD86,ICAM1,IL1B	196 (16)
NCOA2		transcription regulator		0.964	2.20E-03 BMP2,Ccs,CSF3,CD44,CD86,ICAM1,IL1B,NOQ1	217 (22)
aspirin		chemical toxicant		2.20E-03	ESD,GSTP1,Heps1b,HSPB1,JUN,NOQ1,PRK31,SERpine1	111 (7)
FOXA2		transcription regulator		1.668	2.24E-03 ALAS1,AP0A1,C08,CERPA,CLCA1,CLDN4,EHD2,FABP5,GPRC5C,HK2	184 (19)
mir-21		microRNA	Inhibited	-3.219	bias 2.25E-03 C1R,CCNA2,FAS,GATA3,GPB6,ICAM1,IL1B,IL1B,IL36G	1
FOXL2		transcription regulator	Activated	2.429	bias 2.26E-03 BCL2A1,BMP2,FAS,ICAM1,SCD2,TNFaIP3	1
BCL2L1		other		2.26E-03	CASP3,Cdc2,CD44,FAS,IL1B,NOQ1	160 (18)
CASR		G-protein coupled receptor		1.667	bias 2.26E-03 ARHEGE3,CD44,Clec2d (includes others),CSF1,GATA3,ID1,ITGB7,VCL,ZYX	132 (7)
TLR8		transmembrane receptor	Activated	2.235	bias 2.31E-03 CCR7,CD40,CD86,ICAM1,IL1B	146 (18)
A2A		transporter		2.372	bias 2.31E-03 NO3,GAO1,ICAM1,IL1B,NO3,NO77,NO91,NO91RP1	140 (20)
FNIGR1		transmembrane receptor		1.048	bias 2.32E-03 Ccd2,C081,C9B,ICAM1,IL1B	151 (15)
NLRP3		other		0.840	2.35E-03 Cdc2,Csf3,CXCR3,GATA3,IL1B,MRC1,RELB	150 (15)
bezametene		chemical drug		1.411	2.40E-03 ALCAM,BMP6,Cdc2,DEPP1,DHRS3,ICAM1,IL1D1,IL1B,Neu,PNRC1	193 (18)
cytarabine		chemical drug	Activated	2.431	bias 2.44E-03 CD40,CD86,FAS,HLA-A,ICAM1,IL1B	188 (18)
black raspberry extract		chemical drug		2.46E-03	AKR1B10,BUB1,C044,KRT20,LAMB3,PLS3,SDC1,SLC30A1	1
RET		kinase	Activated	2.425	bias 2.46E-03 Cdc2,CSF1,CSF3,CXCL12,IL1B,KLK3,PTPN13,SCARA3	181 (17)
CCR2		G-protein coupled receptor	Activated	2.743	bias 2.46E-03 Cdc2,C081,CD40,C086,Csf1,CSF3,CXCL12,IL1B	184 (19)
BRD4		kinase	Activated	2.000	bias 2.49E-03 C081,CEBDP,CEBPAL1,ICAM1,IL1B,LPN2,NO3,NO91,NO91RP1	159 (11)
RORA		transcription regulator		1.609	bias 2.50E-03 Cdc2,C081,CSL1,ICAM1,IL1B,LPN2,NO3,NO91,NO91RP1	131 (13)
beta-cell dependent nuclear receptor		chemical drug		2.50E-03	Glycam1,ICAM1	1
lithium hydroxide		chemical drug		2.50E-03	Cd40,CD86,ICAM1,IL1B,NO3,NO91,NO91RP1	1
LYT5	1.199	transmembrane receptor		2.50E-03	CD40,CD86,ICAM1,IL1B	97 (7)
B3GNT2		enzyme		2.50E-03	CD14,IL1B	1
CYP2C8		enzyme		2.50E-03	Cd2,IL1B	137 (11)
SIRT4		enzyme		2.50E-03	Cd2,IL1B	1
Casein		group		2.50E-03	ICAM1,IL1B	1
cerotic acid		chemical - endogenous mammal		2.50E-03	CD04,IL1B	1
RNF6		transcription regulator		2.50E-03	BLNK,IL1B,NO3,NO91,NO91RP1	136 (7)
TAD2A2		kinase		2.50E-03	CD44,CSP3,CD44,CD86,ICAM1,IL1B	1
miR-328-3p (and other miRNAs)		mature microRNA		2.50E-03	CD44,CEBDP,CEBPAL1,ICAM1,IL1B,LPN2,NO3,NO91,NO91RP1	1
EGR1		other		2.50E-03	ICAM1,NFKBIA	1
FBXL5		enzyme		2.50E-03	FT1,SLC11A2	1
PTCH2		transmembrane receptor		2.50E-03	CXCL12,JA31	1
CFL1		other		2.50E-03	ICAM1,JUN	122 (12)
M3		other		2.50E-03	CEBDP,GSTP1	1
DEETGE-CAL-Tat		chemical reagent		2.50E-03	CD83,CSD2	1
ascomycin		chemical reagent		2.50E-03	CD83,CSD8	1
phenanthridine		chemical toxicant		2.50E-03	CD44,CEBDP	1
desoxyacetone		chemical - endogenous mammal		2.50E-03	ALAS1,CYBA	1
MAX		transcription regulator		2.51E-03	FT1,HADDG45B,HK2,HMGA1,IL1D1,KLF6,SLC2A3	1
COL18A1		other	Inhibited	-2.621	bias 2.51E-03 ANTR1,HK2,ICAM1,IL1D1,JUN,SERpine1	181 (17)
TCL1A		transcription regulator		2.51E-03	ACOD1,C086,CLEC4D,GDF15,IL1B,LY9,STEAP4	111 (7)
choline fenofibrate		chemical drug		2.51E-03	BLNK,BMP2,CAP3,CCNA2,CEBPAL1,IL1B,LYN,MAPK4	222 (23)
CX3CR1		G-protein coupled receptor		0.000	2.51E-03 CAVIN1,CDA4,IL1B	1
RC3H1		enzyme		2.51E-03 Ccd2,CD41,ICAM1,IL1B	160 (17)	
MALP-2s		chemical reagent	Activated	2.000	bias 2.51E-03 BCL2A1,CD40,CD86,ICAM1,IL1B	194 (21)
SNX2		enzyme		2.51E-03 bias 2.53E-03 C081,CD44,CD86,ICAM1,IL1B,NO3,NO91,NO91RP1	201 (18)	
VitaminD3-VDR-RXR		complex	Activated	2.207	bias 2.55E-03 CO14,IL1R1,KLF4,SEMA5B,SERPINB1B	1
MYBL2		transcription regulator		0.152	bias 2.55E-03 BIRC3,BU81,ICNA2,CEBPAL1,IL1B	1
SPHK1		kinase		1.432	bias 2.55E-03 BIRC3,C2H2,IL1B,JUN,SERpine1	174 (18)
IL12A		cytokine		1.091	bias 2.55E-03 CASP3,C086,FAS,ICAM1,IL1B	160 (16)
vincristine		chemical drug		1.467	bias 2.55E-03 FAS,GAP43,IL1B,JUN,SOD2	170 (20)
D-fructose		chemical - endogenous mammal	Activated	2.219	bias 2.55E-03 GMP,IL1B,NO3,NO91,NO91RP1	176 (14)
TAL1		transcription regulator		-1.066	bias 2.59E-03 BUB1,DOCK1,GATA3,HLA-A,ICAM1,JUN,MEST,NFKB1Z,PTK2,SLC2A3	131 (12)
Hdac		group		-0.426	bias 2.61E-03 BMP2,FOXP1,GATA3,HLA-A,ICAM1,JUN,MEST,NFKB1Z,PTK2	244 (22)
DKK1		growth factor	Inhibited	-2.369	bias 2.63E-03 G081,GATA3,HLA-A,ICAM1,JUN,MEST,NFKB1Z,PTK2	114 (9)
RHOA		enzyme		1.347	bias 2.70E-03 GDF15,ICAM1,IL1B,JUN,PDXK1,RND3,RUNX2	203 (21)
imatinib		chemical drug		0.392	bias 2.71E-03 BLNK,BMP2,CAP3,CCNA2,CEBPAL1,IL1B,LYN,MAPK4	1
Actin		group		2.72E-03	CAVIN1,CDA4,IL1B	1
Ptprd		phosphatase		2.72E-03	Cdc2,CEBDP,CXCL14	1
N12-(gamma-D-glutamyl)-meso		chemical reagent		2.72E-03	ICAM1,IL1B,MLKL	152 (15)
elastase		group		2.72E-03	GATA3,NFKBIA,TNFaIP3	133 (15)
PSMB10	0.446	peptidase		2.72E-03	GATA3,NFKBIA,TNFaIP3	85 (7)
Beta catenin/Tcf		complex		2.72E-03	CD44,JUN,JUNX2	1
ACVR1		peptidase		2.72E-03	CD44,IL1B,NO3,NO91,NO91RP1	169 (11)
Hsp27		protein		2.72E-03	CASPF1,CD44,C086,CSF1,IL1B	192 (18)
LRP6		transmembrane receptor		4.176	bias 2.78E-03 C086,GATA3,HK2,IL1B,SLC2A3	1
ADRA1B		G-protein coupled receptor		1.992	bias 2.87E-03 Cdc2,IL1B,SERpine1	205 (20)
TCF7		transcription regulator		1.961	bias 2.87E-03 FT1,GSTP1,NOO1,UGT1A7 (includes others)	118 (10)
Igm		complex		1.378	bias 2.87E-03 CEBPA,CEBDP,GATA3,LCK,Tcf7	123 (9)
SPDEF		transcription regulator		-1.119	bias 2.87E-03 BIRC3,CD40,CD44,FAS,IDS,NO3,NO91,NO91RP1	179 (20)
RASSF1		other		0.626	bias 2.88E-03 BIRC3,CD40,CD86,ICAM1,IL1B,NO3,NO91,NO91RP1	100 (9)
ANXA1		chemical reagent		2.88E-03	AMGG02,CAP3,CAV2,CCNA2,GDF15,IL1B,LITAF	137 (7)
other		group		2.88E-03	CD44,CD86,ICAM1,IL1B,NO3,NO91,NO91RP1	1
SAMS1		other	Activated	2.646	bias 2.89E-03 BAF7,CD40,NFKB1Z,DSL,SDC1,SLC3H12A	89 (6)
CpG ODN 2006		chemical reagent		2.89E-03	CD44,CD86,ICAM1,IL1B,NO3,NO91,NO91RP1	164 (18)
MIF		cytokine	Activated	2.742	bias 2.89E-03 C081,CD40,C086,CSF1,IL1B	194 (20)
platayquat		chemical toxicant		1.046	bias 2.89E-03 C081,CD40,C086,CSF1,IL1B,NO3,NO91,NO91RP1	1
C3		peptidase		1.378	bias 2.90E-03 C086,GATA3,IL1B,JUN,MAPK4	143 (16)
MYRF		transcription regulator		0.000	bias 2.90E-03 ANXA6,CFL16,HGDPS,MFSD1,RHO	1
PRKD1		kinase	Activated	2.190	bias 2.90E-03 Cdc2,C086,CEBDP,CXCL12,CYBA,GALNT3,JUN,RUNX2,Saa3,SDC4	204 (21)
valsatran		chemical drug	Inhibited	-2.202	bias 2.90E-03 Cdc2,CYBA,ICAM1,IL1B,SERpine1	175 (18)
PTH		other	Activated	2.296	bias 2.90E-03 C086,GAP43,GDF15,IL1B,JUN,PRKD3	154 (16)
EDN1		cytokine	Activated	2.748	bias 2.91E-03 ADAM19,ANXA6,BCL2A1,C086,CSF1,IL1B,JUN,PLC84,SDC1,SERpine1	176 (16)
DN1		group		1.445	bias 2.91E-03 ADAM19,ANXA6,BCL2A1,C086,CSF1,IL1B,JUN,PLC84,SDC1,SERpine1	173 (18)
mir-1550		microRNA		3.884	bias 2.92E-03 C081,CD40,C086,CSF1,IL1B,JUN,PLC84,SDC1,SERpine1	201 (20)
NR1		transcription regulator		0.166	bias 2.92E-03 CO44,F1R1,IC1,IC2,IC3,IC4,IC5,IC6,IC7,IC8,IC9,IC10,IC11,IC12,IC13,IC14,IC15,IC16,IC17,IC18,IC19,IC20,IC21,IC22,IC23,IC24,IC25,IC26,IC27,IC28,IC29,IC30,IC31,IC32,IC33,IC34,IC35,IC36,IC37,IC38,IC39,IC40,IC41,IC42,IC43,IC44,IC45,IC46,IC47,IC48,IC49,IC50,IC51,IC52,IC53,IC54,IC55,IC56,IC57,IC58,IC59,IC60,IC61,IC62,IC63,IC64,IC65,IC66,IC67,IC68,IC69,IC70,IC71,IC72,IC73,IC74,IC75,IC76,IC77,IC78,IC79,IC80,IC81,IC82,IC83,IC84,IC85,IC86,IC87,IC88,IC89,IC90,IC91,IC92,IC93,IC94,IC95,IC96,IC97,IC98,IC99,IC100,IC101,IC102,IC103,IC104,IC105,IC106,IC107,IC108,IC109,IC110,IC111,IC112,IC113,IC114,IC115,IC116,IC117,IC118,IC119,IC120,IC121,IC122,IC123,IC124,IC125,IC126,IC127,IC128,IC129,IC130,IC131,IC132,IC133,IC134,IC135,IC136,IC137	

PDLIM2	other	-1.890	3.41E-03	BST1.CRISPLD2.FBP1.RTN1.SCARA3.SLC43A3.STC2		
mir-210	microRNA	Inhibited	-2.368	bias	3.41E-03 CHD9.CXCL12.FGFLR1.KLF6.LASP1.RAD52.SCARA3	
FOXO4	transcription regulator		0.692	3.41E-03 ANXA3.FABP5.GADD45B.JAG1.LCP2.SERpine1.SOD2	150 (7)	
ciprofibrate	chemical drug		0.174	3.47E-03 ANXA12.GSTP1.KRT8.MGLL.NFKBIA.OAT.Saa3.SLC44.Vnn3	114 (8)	
L-trioiodothyronine	chemical - endogenous mammal	-0.730	bias	3.49E-03 APOA1.BMP4.CAMK4.CD44.CEBPA.CXCL12.FAS.GDF15.PD.D1	190 (19)	
LGALS1	other	1.710	bias	3.53E-03 APOA1.CAMK4.CD44.CEBPA.CXCL16.IFNB2.LILB.SERpine1	201 (23)	
GW665	chemical reagent		1.039	3.54E-03 APOA1.CAMK4.CD44.CEBPA.CXCL16.IFNB2.LILB.SERpine1	148 (7)	
RPTOR	other		0.136	3.62E-03 Cdc20.CORT.CD96.H2K11.LILB.LY75.MRC1	188 (21)	
TIRAP	other		0.762	3.68E-03 CD40.CD86.ICAM1.LILB	148 (17)	
VTN	other		1.199	3.68E-03 IL1B.RUNX2.SERpine1.SFN	154 (20)	
TAB1	enzyme		-0.762	3.68E-03 BIRC3.LILB.JUN.SERpine1	143 (18)	
butylated hydroxyanisol	chemical toxicant	1.896	bias	3.68E-03 GSTA3.GSTP1.JUN.NQO1	46 (3)	
selenium	chemical drug		-0.152	3.68E-03 APOA1.CEBPA.KLK3.MRC1	114 (7)	
Hedgehog	group			3.68E-03 CONA2.JAG1.LKL.KLK3.KRT19		
sebucylic acid	chemical drug	1.000	bias	3.68E-03 APOA1.CSF1.CSF3.GDF15.LILB	161 (20)	
ANKK1	complex		1.165	3.68E-03 APOA1.CSF1.CSF3.GDF15.LILB	202 (4)	
3MA002	chemical reagent	Activated	2.204	3.75E-03 ACO01.BCL2A1.CD40.CD86.FOSL1.JUN.LILB.Sea3	140 (15)	
stauroporine	chemical - kinase inhibitor		-1.238	3.75E-03 CASP3.CD28.FAS.FOSL1.ICAM1.LILB.NOO1.SERpine1	169 (20)	
rifampin	chemical drug	Activated	2.412	3.79E-03 ALAS1.CD14.CSF1.CYP3A7.GSTP1.LILB.PAD2.SERpine1.N. SOD2	26 (4)	
H89	chemical - kinase inhibitor		-1.795	3.79E-03 Cdc2.CD14.CD93.GSTP1.LILB.NFKBIA.OAT.Serpine1.SOD2	209 (16)	
daidzein	chemical drug		0.816	3.84E-03 CASP3.CD86.CXCR3.HLA.A.LCP2.NQO1.RASGRP1	169 (17)	
ARNT	transcription regulator		0.277	3.95E-03 CCR7.CD81.CSF3.CXR3.H2K11.NQO1.SERpine1.SLC2A3	182 (13)	
vornostat	chemical drug		-1.356	3.99E-03 BIRC3.BMF.CASP3.CD8A.CEBPA.FAS.ICAM1.LILB.JUN.KLF4	204 (18)	
9,10-dimethyl-1,2-benzanthracene	chemical toxicant			4.02E-03 IL1B.JUN.MRN.JUN.NQO1.SERpine1	182 (20)	
beta-apaptophlavone	chemical toxicant		1.350	4.05E-03 F10L.G3Pase.JUN.NQO1.SERpine1	208 (17)	
HDAC9	transcription regulator			4.05E-03 HK2.HMGC2.JUN.KLF6.PTPN12.RUNX2		
AGER	transmembrane receptor		1.449	4.05E-03 Cdc2.CSF1.FAS.ICAM1.LILB.SERpine1	186 (21)	
SHARPIN	other			4.05E-03 IL1B.MKL.TNFaiP3	120 (14)	
GAS2L3	other			4.05E-03 FAS.PTPN14.TMMSF1		
BMP10	growth factor			4.05E-03 ICAM1.ID1.NFKBIA	149 (7)	
PRF1	transporter			4.05E-03 Cdc2.CD44.LILB	137 (12)	
MAFG	transcription regulator			4.05E-03 GSTA3.GSTP1.NQO1		
EPH2	enzyme			4.05E-03 COG3.CD44.LILB	160 (19)	
MAML10	kinase			4.05E-03 CASP3.CD44.JUN	184 (17)	
CXCL2	cytokine			4.05E-03 Cdc2.CAM1.LILB	182 (18)	
VIPR1	G-protein coupled receptor			4.05E-03 Cdc2.CD40.CD86	119 (13)	
SMURF2	enzyme			4.05E-03 JUN.RUNX2.SERpine1	186 (17)	
MAML1	transcription regulator			4.05E-03 IL1B.LILR.RND3	66 (7)	
EFNB2	kinase			4.05E-03 IL1R.RUNX2.TIAM1		
DSP	other			4.05E-03 Cdc2.CEBPA.JUP		
BHLHA15	transcription regulator			4.05E-03 COKKAR.QJB2.KRT19		
cyclopiazonic acid	chemical - endogenous non-metabolite			4.05E-03 BCL2A1.CD22.FAS	88 (7)	
silicon dioxide	chemical drug			4.05E-03 COBLL1.CD44.JUN	208 (21)	
erythropoietin	other drug			4.05E-03 COBLL1.CD44.JUN	148 (17)	
CDK19	kinase		-1.414	bias	4.07E-03 CDB1.FAS.JUN.RHBDF2.SDC1.SFN.UPP1	
atrinavastatin	chemical drug		-1.671	4.09E-03 APOA1.BMP2.BMP6.Cd2.CD40.CYBA.GADD45B.ICAM1.JL17RD.JUN	204 (21)	
p38 Sapk	group			4.11E-03 CD83.CD86		
Mst1ks	group			4.11E-03 RELB.YAP1		
ATPase	group			4.11E-03 CD40.ICAM1		
Em	group			4.11E-03 CD44.CAM1		
CYF	group			4.11E-03 CD66.NQO1		
phorbatesterin	chemical drug			4.11E-03 COBLL1.CD44.CAM1		
FOXXK1	transcription regulator			4.11E-03 MCMB.SERpine1		
ZMW2	transcription regulator			4.11E-03 CD44.JUN		
Mucin	group			4.11E-03 CD83.CD86		
DCB 3503	chemical reagent			4.11E-03 Cdc2.L1B		
TDP2	transcription regulator			4.11E-03 KLK3.SYT1		
HADHA	enzyme			4.11E-03 Cdc2.L1B	95 (7)	
MAPKKAP5	kinase			4.11E-03 MAPK6.TNFaiP3		
Dmt1 (includes others)	other			4.11E-03 Cdc2.L1B		
ENR1K1	kinase			4.11E-03 IL1B.MRN.CAM1		
BCAR3	other			4.11E-03 IL1B.MRN.CAM1		
CES1	enzyme			4.11E-03 RALA.RRAS		
Cx3d	cytokine			4.11E-03 Cdc2.L1B		
ELF2	transcription regulator			4.11E-03 CEBPA.CEBPD		
4,4'-disothiocyanostilbene-2,2'	chemical drug			4.11E-03 CASP3.C62	128 (13)	
cimetidine	chemical drug			4.11E-03 FAS.GDF15		
cinnamyl-4,4-dihydroxy-alpha-c	chemical reagent			4.11E-03 Cd2.MRC1		
orlistat	chemical drug			4.11E-03 CASP3.CAM1		
retinoic aldehyde	chemical - endogenous mammal			4.11E-03 COBLL1.CD44.CAM1		
Sis63-Sis31	other	Activated	2.000	bias	4.14E-03 FTI1.CAM1.JUN.SOD2	144 (7)
HOXC9	transcription regulator		-1.000	4.14E-03 ADAM19.Cdc2.KRT19.NQO1		
SH4	peptidase		1.133	4.28E-03 BMP2.BMP4.HK2.HMG41.ID1.LAS1L.MCM3.RUNX2.SERpine1.YAP1	213 (26)	
miR-199a-5p (and other miRNA)	mature microRNA	Inhibited	-2.433	4.33E-03 ID3.JAG1.KLF4.LAMC2.RND1.ZBTB16		
methamphetamine	chemical drug	Activated	2.407	bias	4.33E-03 Cdc2.FAS.HOMER2.ICAM1.JL18.JUN	200 (18)
PELP1	other		0.000	4.35E-03 AHNAK2.BMP2.CSF3.GJ62.JL1B.KLK3.MPK4.MRC1	121 (7)	
GPER1	G-protein coupled receptor	Activated	2.236	bias	4.37E-03 CEBPD.JUN.NFKBIA.RND1.TNFaiP3	259 (21)
endosplin	biologic drug		0.447	4.37E-03 CLDN1.CP.SERpine1.SLC34A2.TNFRSF12A		
RB1	transcription regulator		4.473	4.41E-03 Cdc2.CAM1.JUN.SOD2	215 (20)	
Pof (complex)	complex		1.244	4.41E-03 COBLL1.CD44.CAM1.JUN.SERpine1	187 (20)	
NTRK2	kinase		1.964	4.63E-03 BMP2.CCN42.JAG1.Mcr1.SERpine1.SYT1	97 (7)	
KDM3A	transcription regulator		1.982	4.63E-03 ALCAM.CD9.GDF15.SERpine1	152 (15)	
ARHGAP31	other		0.000	4.63E-03 BMP2.GADD45B.GDF15.JUN		
SOST	other		1.980	bias	4.63E-03 Cdc2.CEBPA.LILB.SCD2	129 (12)
CYBB	enzyme	Activated	2.000	bias	4.63E-03 Cdc2.CYBA.CAM1.LILB	195 (17)
IL17RA	transmembrane receptor		1.992	bias	4.63E-03 Cdc2.CSF1.CXL12.LILB	153 (15)
SFRP1	transmembrane receptor		-1.413	4.74E-03 CAMP1.SAT3A.RUNX2.SERpine1.Tcf7	189 (16)	
MMP1	peptidase		1.422	4.85E-03 COBLL1.CD44.CAM1.JUN.SERpine1	152 (15)	
DN	other		0.836	4.74E-03 CASP3.CAM1.LILB.SCD1.SERpine1	153 (23)	
IL12 (family)	group	Activated	2.813	4.79E-03 ADAM19.CD44.CD86.GATA3.JL1B.NFKB1.SERpine1.SLC2A3	185 (20)	
FZD9	G-protein coupled receptor			4.85E-03 Cdc2.CX3L4.IPF16		
fontolizumab	biologic drug			4.85E-03 FAS.LAG3.TGM3		
GIP	other			4.85E-03 Cdc2.C8b.Tcf7		
CD70	cytokine			4.85E-03 BCL2A1.CD44.FAS	140 (19)	
IL1RAP	transmembrane receptor			4.85E-03 CD14.CD40.LILR1	134 (10)	
S1PR2	G-protein coupled receptor			4.85E-03 Cdc2.ICAM1.JUN	197 (20)	
KLF5	peptidase			4.85E-03 COBLL1.CD44.LILB		
7-nitroindazole	chemical reagent			4.85E-03 GTP1.NFKBIA.PRKG1		
phenyl-N-tert-butylurethane	chemical reagent			4.85E-03 COBLL1.CD83.CD86	169 (14)	
glutamyl-Se-methylselenocysteine	chemical - endogenous mammal			4.85E-03 GSTP1.JD1.JUN		
iI3	cytokine			4.94E-03 ADAM19.CD14.CD68.CSF1.CSF3.FAS	165 (19)	
MAP2K6	kinase		-0.763	bias	4.94E-03 Cdc2.CD40.CD83.CD86.JUN.RELB	138 (17)
doxycycline	chemical drug		1.000	4.94E-03 BMP2.CD86.CXCL12.SDC1.SCD2.XDH	127 (13)	
ESRRKA	ligand-dependent nuclear receptor		1.562	4.99E-03 ALAS1.CCR7.CEBPA.CSF1.HK2.KRT19.KRT20.KRT23.RUNX2	80 (6)	
acetaminophen	chemical drug	Activated	2.394	bias	4.99E-03 CASP3.C62.CSF1.FAS.GSTP1.HMG45B.ICAM1.LILB.JUN.NQO1	187 (19)
diethylthiouracilamine	chemical toxicant		0.555	5.02E-03 COBLL1.CD44.CAM1.JUN.NQO1		
Lethal outcome	other - endogenous mammal			5.14E-03 BUB1.GADD45B.F16.NFKBIA.SCD2	143 (7)	
CASP9	peptidase			5.14E-03 COBLL1.CD44.CSF1.FAS.L1B	139 (14)	
LPL	enzyme		1.792	5.14E-03 COBLL1.CD44.CSF1.ICAM1.LILB	208 (20)	
MAP3K1	kinase	Activated	2.176	bias	5.14E-03 BIRC3.FAS.HSPB1.JUN.SERpine1	146 (18)
RGS10	other			5.14E-03 Cdc8.CXCR2.FAS.L1B.L6ST	121 (10)	
DETA-NONcate	chemical reagent		0.365	5.14E-03 BIRC3.FAS.ICAM1.PRKG1.SERpine1	202 (23)	
ARRB2	other		-1.987	5.16E-03 Cdc2.L1B.NFKB1.SERpine1	182 (18)	
MARK2	kinase			5.16E-03 BAF1.CD44.NFKB1.Vnn3		
green tea polyphenol	chemical drug		1.467	5.16E-03 COBLL1.CD44.NFKB1.Vnn3	139 (15)	
bardoxolone	chemical drug		1.067	5.16E-03 COBLL1.CD44.NFKB1.Vnn3		
PD123074	chemical reagent	Activated	2.449	5.27E-03 COR7.CEBPA.DEP1.GATA3.KRT23.PRRS		
kaemic acid	chemical toxicant	Activated	2.919	bias	5.35E-03 CASP3.C62.FOSL1.GADD45B.GAP43.L1B.JUN.SCD1.SLC39A4	169 (18)
IL1RN	cytokine	Inhibited	-2.179	bias	5.52E-03 CD44.CD44.LILB.KLF6.OASL.RPK2.SERpine1	175 (19)
MOG	other		5.56E-03 Cdc2.CD40.CD44.CD86.ICAM1	156 (16)		
miR-34A-5p (and other miRNAs)	mature microRNA	Inhibited	-2.215	bias	5.56E-03 ICAM1.JAG1.KLF4.MCM3.NOTCH2	
BNP13L	other	0.000	bias	5.56E-03 BLNK.C62.CCA2.NFKBIA.PTK2B	110 (11)	
bicuculline	chemical - endogenous non-metabolite	Activated	2.191	bias	5.56E-03 GADD45B.HK2.JUN.NFKBIA.PTK2B	162 (12)
PRKE1	kinase		1.633	5.56E-03 ALAS1.CCR7.CEBPA.CSF1.HK2.JUN.NQO1	139 (17)	
COL5	cytokine	Activated	2.416	bias	5.61E-03 ALCAM.Cd44.CD44.HMG41.LILB	166 (19)
1-methyl-4-phenyl-1,2,3,6-tetra-	chemical toxicant	Activated	2.180	bias	5.61E-03 CASP3.C62.HSPB1.L1B.JUN.SCD2	171 (15)
rottelein	chemical toxicant	Inhibited	-2.415	bias	5.61E-03 APOBE3B.BIRC3.C62.CLDN4.ICAM1.JUN	195 (18)
Ctbp	group			5.73E-03 GATA3.JUP.PERF		
IFNW1	cytokine			5.73E-03 CD40.CD83.CD86		
GLIS2	transcription regulator			5.73E-03 Cdc2.TBP2.SERpine1		
S100B	other			5.73E-03 Cdc2.L1B.JUN	177 (19)	
TAF1	transcription regulator			5.73E-03 BCL2A1.CNA2.RUNX2	135 (7)	
PLA2G4A	enzyme			5.73E-03 COBLL1.CD44.LILB	154 (15)	
EGLN3	enzyme			5.73E-03 Cdc2.HAMP2.HAMP2.JUN.NQO1	150 (15)	
ACTN4	transcription regulator			5.73E-03 IL1B.PD1.JM1.SERpine1	115 (6)	
propionic acid	chemical - endogenous mammal			5.73E-03 COR7.JCAM1.LILB		
lisinopril	biologic drug			5.73E-03 Cdc2.L1B.JUN	165 (14)	
ZC3H12A	enzyme		0.105	bias	5.74E-03 Cdc2.CEBPA.CEBPD.LILB	171 (15)
SU6656	chemical toxicant			5.74E-03 Cdc2.CSF1.JL1R1.KRT8	166 (15)	
nicotinic acid	chemical - endogenous mammal		-1.192	5.74E-03 ANG.APOA1.CD68.LILB	156 (15)	
odium orthovanadate	chemical reagent		1.000	5.74E-03 COBLL1.CD44.CD86.NFKB1.SERpine1	220 (22)	
HSF1	transcription regulator		0.177	5.80E-03 BML.CD44.CD86.NFKB1.JUN.PG0.RUNX2.SERpine1.TCEA3	207 (1)	
THR8	G-protein dependent nuclear receptor		0.113	5.80E-03 APOA1.C2.CSF1.FOSL1.JD1.JUN.PG0.RUNX2.SERpine1.TCEA3	203 (22)	
fensamide	chemical drug		-0.651	5.97E-03 BCL2A1.CAM1.JUN.MAPKs.NFKBIA	164 (15)	
MED1	transcription regulator			6.04E-03 BCL11A.CEBPA.JUN.KRT19.RHOU.RUNX2.SERpine1.SERpine2	203 (15)	
WNT1	cytokine	Activated	2.016	bias	6.04E-03 BMP4.CEBPA.JUN.KRT19.RHOU.RUNX2.SERpine1.SERpine2	200 (20)
psychosine	chemical - endogenous mammal			6.08E-03 FOSL1.JL1B	213 (23)	
SERCA	group			6.08E-03 FOSL1.JUN	174 (15)	
N-hexanoylhomoserine lactone	chemical - endogenous non-metabolite			6.08E-03 CSF1.LILB		

CCAR1		transcription regulator		6.08E-03	CEBP _A ,CEBPD				
CCN6		growth factor		6.08E-03	BMP4,ICAM1				
C ₅		complex		6.08E-03	CD40,CD86	100 (7)			
PXN		other		6.08E-03	KLK3,VCX	136 (7)			
CSR _{P3}		other		6.08E-03	DMD,KRT7	104 (7)			
SDC4	0.444	other		6.08E-03	IL1B,IL1B				
WIF1-11		chemical reagent		6.08E-03	C03L1,IL1B				
PTPRR		phosphatase		6.08E-03	FOSL1,JUN				
PIP5K1B		kinase		6.08E-03	IL1B,PIP5K1C				
FGLF18		growth factor		6.08E-03	CSF1,RUNX2				
STX2		transporter		6.08E-03	BMP2,BMP4	130 (7)			
ABC _{B7}		transporter		6.08E-03	FTH1,FTL	36 (3)			
SERPIND1		other		6.08E-03	Cd2L1,IL1B	108 (7)			
ferrocinnitriacetate		chemical toxicant		6.08E-03	ID3,KLF4				
FC-99		chemical reagent		6.08E-03	CD44,CD86	106 (7)			
calcium chloride		chemical reagent		6.08E-03	CD44,CD86				
femic chloride		chemical reagent		6.08E-03	FTH1,FTL				
phenylaminal		chemical reagent		6.08E-03	ID1,RUNX2				
zofenoprid		chemical drug		6.08E-03	Cd2,CSE1				
NFATC1		transcription regulator		6.26E-03	B3GAT1,CD40,FAS,ICAM1,IL1B,NQO1,PLS3	187 (21)			
lipoxin A4		chemical - endogenous mammal	-1.982	bias	6.35E-03	Cd2,ICAM1,IL1B,SERpine1	198 (21)		
3-methyladenine		chemical toxicant	0.334	bias	6.35E-03	CD40,CD86,IL1B,RUNX2	187 (21)		
aspirin		chemical drug	-1.000	bias	6.35E-03	CASP3,LAMP3,SNF,XDH			
amiodarone		chemical drug		bias	6.35E-03	HIF1A,CAV1,SLC2A3,SOD2			
NO _x		transcription regulator		bias	6.35E-03	IL1B,CEBP _A ,CYP450,RELB	180 (17)		
SERPINF1		other	0.600	bias	6.47E-03	BCL2A1,CEBP _A ,CYBA,NFKBIA,SOD2	208 (20)		
luteolin		chemical drug	0.492	bias	6.47E-03	CASP3,FAS,ICAM1,JUN,SOD2	184 (19)		
EGR2		transcription regulator	1.823	bias	6.54E-03	CAMK4,GATA3,IDS,IL1B,IL7R,JUN,LAG3,LAMA2,ZBTB16	155 (13)		
potassium chloride		chemical drug	1.067	bias	6.59E-03	AMIGO2,CASP3,C62,IDS,IL3,IL1B	183 (19)		
THRA		ligand-dependent nuclear receptor	0.577	bias	6.61E-03	APOA1,BMP4,CAMK4,C2,CD44,CEBP _A ,JUN,SERpine1	184 (25)		
Pde4		group		bias	6.70E-03	CD14,CD40,ICAM1	129 (12)		
CDKS1R		kinase		bias	6.70E-03	CD14,IL1B,SERpine1	180 (14)		
TNFRSF11B		transmembrane receptor		bias	6.70E-03	CD44,CD86,RUNX2	118 (9)		
drubib		chemical drug		bias	6.70E-03	C044,CD86,FAS	116 (16)		
NT5E		phosphatase		bias	6.70E-03	Cd2L1,IL1B,SERpine1	175 (21)		
POCD4		other		bias	6.70E-03	CASP3,IL1B,JUN	199 (18)		
RARRES2		transmembrane receptor		bias	6.70E-03	Cd2,CNA2,IL1B	61 (4)		
PS-1145		chemical - kinase inhibitor		bias	6.70E-03	ICAM1,NFKBIA,TNFaIP3	109 (12)		
thiendiazine		chemical drug		bias	6.70E-03	DEPP1,HPN,SLC2A3			
vitamin K2		chemical drug		bias	6.70E-03	CD14,CSF1,SERPINB1			
magnesium		chemical - endogenous mammal		bias	6.70E-03	BMP6,PTP4A2,RUNX2			
CXCL8		cytokine	1.671	bias	6.73E-03	CD44,FAS,ICAM1,IL1B,KLK3,NFKBIA	174 (17)		
TGFA		growth factor	0.401	bias	6.73E-03	B3GAT1,G,GST,ICAM1,IL1B,NFKBIA	259 (24)		
spinatin		other - endogenous non-mam	1.513	bias	6.73E-03	CASP3,C044,ICAM1,IL1B,KLK3,SOD2	146 (16)		
SUZ2		enzyme	1.080	bias	6.90E-03	IRAK3,KLF4,LAMB3,LAMC2,LTAF,MATGB,Nes,PLCB4	79 (5)		
L- α -glutamic acid		chemical - endogenous mammal	Activated	2.571	bias	6.93E-03	CASP3,C2,CDD40498,IL1B,JUN,MCL1,RUNX2	202 (20)	
Mapk		group	Activated	2.000	bias	6.93E-03	APOA1,CLDN4,IL1B,IRAK3,ITGB7,JUN,RUNX2	221 (27)	
mif-13p (and other miRNAs w		mature microRNA	Inhibited	-3.123	bias	6.94E-03	CSPR1,LASP1,LRP1,MOV10,NOTCH2,OAT,PREX1,SDC4,SH2D4A,UNC93B1		
MAP2K4		kinase	1.996	bias	6.96E-03	CIRB3,CD44,ICAM1,IL1B,RN6	194 (18)		
PTK2		kinase	-0.371	bias	6.96E-03	BIRC3,C2,KRT8,PTK2B,SERPINB1	136 (7)		
CCL11		cytokine	2.190	bias	6.96E-03	BMP6,CXKL12,FAS,ICAM1,IL1B	121 (14)		
IMC-155-p (miRNAs w/seed U		chemical drug	Inhibited	-2.418	bias	6.96E-03	C044,CD86,ICAM1,IL1B,NFKBIA	159 (16)	
BCN1		transporter	-0.562	bias	6.96E-03	CD44,CD86,ICAM1,IL1B,NFKBIA	178 (18)		
dafammonide		chemical drug	-2.945	bias	6.96E-03	AMIGO2,C2,IL1B,PLXND1,POLR2A,B27B,SERPIN1,SLC30A1,TRIP13	116 (12)		
pravastatin		chemical drug	2.191	bias	6.98E-03	GAD65B,KM2,IL1B,RHO1,SLC2A3	176 (15)		
metformin		chemical drug	1	bias	6.98E-03	CD40,ICAM1,IL1B,RHO1,SLC2A3	150 (15)		
uranyl nitrate		chemical toxicant	-1.091	bias	6.98E-03	BMP2,CASP3,FTH1,GADD45B,NFKBIA,PARP14,RUNX2,SERpine1,SOD2	176 (15)		
TGF _{B2}		growth factor	-0.116	bias	6.98E-03	Cd244,Cle22 (includes others),CSRP1,ESD,FBP1,FTL,RACK1	209 (19)		
CP-55940		chemical reagent		bias	6.98E-03	CSF1,JUN,NFKBIA,TNFaIP3	86 (7)		
DLL4		other	0.000	bias	6.98E-03	GATA3,MCM3,REL,Tcf7			
TWIST2		transcription regulator	0.000	bias	6.98E-03	BCL11A,CD44,ICAM1,IL1B			
SUMO3		other	1.067	bias	6.98E-03	C044,CD86,ICAM1,IL1B,NFKBIA	100 (7)		
HSF2		transcription regulator		bias	7.01E-03	Hscab15,HSPB1,IL1B,JUN			
IL27RA		transmembrane receptor	-1.414	bias	7.01E-03	CD44,CD86,FAS,IL1B	166 (17)		
pentoxifyline		chemical drug	-1.091	bias	7.01E-03	Cd2,CAM1,IL1B,NFKBIA	147 (16)		
NR112		ligand-dependent nuclear receptor	0.218	bias	7.07E-03	ALAS1,ANG,CEBP _A ,CYP3A7,GSTP1,Hamp/Hamp2,HMGCS2,JUN,PGD	83 (8)		
FFAR3		G-protein coupled receptor	1.039	bias	7.14E-03	BCL11A,CRR2,FAS,ICAM1,IL1B,RN6			
spiroplactone		chemical drug	-2.418	bias	7.14E-03	BMP4,CASP3,C2,CRR7,ICAM1,IL1B	151 (16)		
BCN1		transporter	-0.562	bias	7.14E-03	C044,CD86,ICAM1,IL1B,NFKBIA			
mif-13p (miRNAs w/seed U		mature microRNA	Inhibited	-2.945	bias	7.14E-03	AMIGO2,C2,IL1B,PLXND1,POLR2A,B27B,SERPIN1,SLC30A1,TRIP13	116 (12)	
IL1RA		chemical drug	2.191	bias	7.14E-03	GAD65B,KM2,IL1B,RHO1,SLC2A3	176 (15)		
THZ1		chemical drug	1	bias	7.14E-03	CD40,ICAM1,SERpine1,SOD2	171 (18)		
sulfasalazine		chemical drug	-0.283	bias	7.14E-03	CASP3,FAS,NFKBIA,SOD2	195 (20)		
11,12-epoxyeicosatrienoic acid		chemical - endogenous mammal		bias	7.14E-03	CD44,ICAM1,NFKBIA	100 (8)		
ssRNA40		chemical reagent		bias	7.16E-03	CD83,CD86,IL1B	144 (16)		
WLS		ether		bias	7.16E-03	BMP4,C2,L36G			
MSR1		transmembrane receptor		bias	7.16E-03	ACOD1,CD40,IL1B	138 (15)		
GDF15	0.675	growth factor		bias	7.16E-03	GATA3,MCM3,REL,Tcf7	153 (9)		
TFAM		transcription regulator		bias	7.16E-03	FABP5,KM2,IL1B			
HOXA3		transcription regulator		bias	7.16E-03	J02,LCR,CD44,ICAM1,SERpine1			
CDON3		kinase		bias	7.16E-03	CEBP _A ,KLF4,MCM3	114 (7)		
IL1RA		transmembrane receptor		bias	7.16E-03	Cd2,C2b,CLCA1			
THZ1		chemical - kinase inhibitor		bias	7.16E-03	BIRC1,CD2,IQSEC1			
sulfasalazine		chemical drug		bias	7.16E-03	ICAM1,IL1B,NFKBIA	193 (21)		
1,2-dinitrofluorobenzene		chemical toxicant		bias	7.16E-03	CD83,CD86,IL1B	117 (7)		
CD28	5.675	transmembrane receptor	Activated	2.339	bias	7.16E-03	BCL11A,CAP3,C044,CD86,C066,CXCR3,GATA3,GZMA,HK2,HOMER2,IL1B	166 (18)	
3,4,5,3'-penta-chlorobiphenyl		chemical toxicant	1.461	bias	8.01E-03	BMP4,CD44,CYP3A7,GSTP1,IL1B,NQO1	122 (10)		
plicamycin		chemical drug	0.114	bias	8.02E-03	GJB2,CD1D1,Marks,SERpine1,SERpine2,SLC11A2,WWC1	147 (7)		
PTGES		enzyme	1.498	bias	8.03E-03	CD44,CD86,ICAM1,IL1B,NFKBIA	137 (7)		
chalcone		chemical drug	1	bias	8.03E-03	C044,CD86,ICAM1,IL1B,NFKBIA	190 (20)		
CLOCK		transcription regulator	0.239	bias	8.12E-03	AHNKA,C044,CEBP _A ,DTX4,GADD45B,HMGCS2,Hepa1b,ICAM1,D1,MAPK4			
E2F1		transcription regulator	1.269	bias	8.16E-03	BMP4,CASP3,CNA2,CD44,C044,CEBP _A ,FAS,HMGMA,Hepa1b,ICAM1	221 (21)		
NR114		ligand-dependent nuclear receptor	0.233	bias	8.23E-03	APOA1,C2,CBP _A ,FABP5,FAS,GSTA3,IL1B,KLF4,SDC1	198 (16)		
nicotinic acetylcholine receptor		complex	8.40E-03	bias	8.23E-03	ID1,JUN	137 (7)		
triamcinolone hexacetonide		chemical drug		bias	8.40E-03	ICAM1,IL1B	146 (7)		
ANKR042		transcription regulator		bias	8.40E-03	CSF3,IL1B			
SFRP5		transmembrane receptor		bias	8.40E-03	ICAM1,KLF4			
valine		chemical - endogenous mammal		bias	8.40E-03	J02,LCR,CD44,ICAM1,SERpine1	96 (7)		
uratamod		chemical drug		bias	8.40E-03	CD2,C2P,CFTR			
S _k		group		bias	8.40E-03	ICAM1,IL1B	196 (24)		
HNRNPR		other		bias	8.40E-03	Cad1,Neu			
TSC22D1		transcription regulator		bias	8.40E-03	Cd2,CAM1,IL1B,SERpine1	103 (10)		
C6		ether		bias	8.40E-03	Cd2L1,IL1B			
CHGA		other		bias	8.40E-03	FABP5,KM2,IL1B	146 (7)		
ERBIN		other		bias	8.40E-03	Ntg1,SERpine1			
KLKB1		peptidase		bias	8.40E-03	ICAM1,KLF4			
TSK		transmembrane receptor		bias	8.40E-03	J02,LCR,CD44,ICAM1,SERpine1			
testosporon		other - endogenous non-mam		bias	8.40E-03	IL1B,JUN			
WNT10B		other		bias	8.40E-03	CEBP _A ,RUNX2	130 (7)		
PILRA		other		bias	8.40E-03	Cd2L1,IL1B	82 (7)		
microrand		chemical drug		bias	8.40E-03	CASP3,JUN	111 (7)		
thienoylfluoracetone		chemical reagent		bias	8.40E-03	BIRC3,SERpine1			
AR-A014414		chemical reagent		bias	8.40E-03	CD44,GDF15			
6-methylsulfinylhexyl isothiocya		chemical reagent		bias	8.40E-03	GSTP1,NQO1	45 (3)		
zimelidine		chemical drug	0.114	bias	8.40E-03	DEPP1,HPN			
7SK		other		bias	8.40E-03	CD2,C2P,CFTR			
imidazepine		chemical drug		bias	8.40E-03	ICAM1,IL1B	142 (9)		
polyphosphate		chemical - endogenous mammal		bias	8.40E-03	BMP2,ICAM1			
BARS01		chemical reagent		bias	8.40E-03	BMP2,ICAM1,IL1B			
cyclospome		biologic drug		bias	8.40E-03	ICAM1,LAMA2			
mif-30c-5p (and other miRNAs		mature microRNA	Inhibited	-2.580	bias	8.41E-03	CNPB8,JUN,PTGFRN,PTPRK,RAB27B,RUNX2,SLC12A4		
BMPR1A		kinase	1.981	bias	8.45E-03	Hamp/Hamp2,I01,I03,SERpine1	173 (14)		
TFA4		transcription regulator	-0.762	bias	8.45E-03	CD44,CLDN4,GDF15,IDI1			
NEDD9		other	Activated	2.000	bias	8.45E-03	BMP4,GDF15,LRP1,SERpine1		
profilin		chemical drug	-1.962	bias	8.45E-03	CD44,GDF15,LRP1,SERpine1	175 (13)		
JFH1		oxidoreductase	Activated	2.219	bias	8.47E-03	CORT,CD40,C032,MKL1,OSL1,SP110	172 (17)	
EGF19		growth factor	1	bias	8.47E-03	AMYA2,STG3,FABP5,FBP1,I01,Saa3			
ITGB1		transmembrane receptor	1.175	bias	8.53E-03	ADAM19,ICAM1,IL1B,ITGA9,TGB7,JUN,SERpine1,TNFaIP3	196 (21)		
PKD1		ion channel	-1.406	bias	8.54E-03	CADM19,CAM1,IL1B,ITGB7,JUN,SERpine1,YAP1	93 (7)		
Smad2/3		group		bias	8.60E-03	APOA1,GATA1,IDI1,RUNX2,SERpine1			
mitomycin C		chemical drug	Activated	2.207	bias	8.60E-03	CASP3,FAS,ITPR1P2,JUN,NQO1	188 (18)	
MED12		transcription regulator		bias	8.91E-03	BMP4,GDF15,POLE4			
ITGAM		transmembrane receptor		bias	8.91E-03	CD28,CD6,IL1B	156 (19)		
ACKR1		G-protein							

NUPR1	transcription regulator	0.688	bias	9.57E-03	APOBEC3B,BUB1,CCNA2,CD68,FCHSD2,GDF15,HK2,KLF4,KLF6,LHFPL2			
PP1	chemical - kinase inhibitor	-1.953	bias	1.01E-02	CXCL16,IL1JUN,SERpine1			
HOTAIR	other	0.819	bias	1.01E-02	GDF15,ICAM1,LAMB3,LAMC2			
LGR4	transmembrane receptor	-1.091	bias	1.01E-02	CD14,HSD17B13,IL1B,OAT			
RCE1	peptidase			1.01E-02	Cd2,CXLO12,IL1T,RCN1			
SRE	kinase	Activated	2.547	bias	1.01E-02	Cd2,CXLO12,FOSL1,ICAM1,IL1JUN,KLK3		
PARGBP	other			1.02E-02	KRT8,TIAM1,TET2			
CatMII	complex			1.02E-02	BIRC3,CC4M,IL1B			
IKK (complex)	complex			1.02E-02	BIRC3,ICAM1,IL1B			
SALL4	transcription regulator			1.02E-02	CD44,CEBPAA,KRT19			
InG1	complex			1.02E-02	CD14,CD40,CD86			
IL2RA	transmembrane receptor			1.02E-02	CD86,G2M4,JUN			
miR-218-5p (and other miRNAs)	mature microRNA			1.02E-02	CASP3,LAMB3,RUNX2			
STK4	kinase			1.02E-02	FAS,L7R,YAP1			
IGFBP5	other			1.02E-02	RUNX1,SERpine1,SNF			
PLXNC1	enzyme			1.02E-02	O2AR,PLXNC1,SNF2			
SFTPB	other			1.02E-02	Cod2,CD44,IL1B			
GADD45A	other			1.02E-02	IL1B,JUN,NFKB			
CCN3	growth factor			1.02E-02	BMP4,RUNX2,SERpine1			
DYRK1A	kinase			1.02E-02	APOA1,MCM3,SERpine1			
ELF5	transcription regulator			1.02E-02	GATA3,ILK13,KRT8			
Gm21596/Hmgb1	transcription regulator			1.02E-02	CXCL12,IL1B,IL1RL1			
probuloc	chemical drug			1.02E-02	BMP2,CYBA,SERpine1			
agmatine	chemical - endogenous mammal			1.02E-02	BMP2,CMP,GADD45B,QJB2,IL1B,ITGB7,OLFML2B,SDC4,SERpine1			
lithium propionate	chemical - drug	0.000		1.03E-02	BCL2A1,CSPF1,IL1B,JUP,KLF4,LRP1,PIR,SDC1,SERpine1,SLC2A3			
WT1	transcription regulator	0.734		1.03E-02	Cd81,IL6ST,NFKBIA,PLS3,VCL			
MMP12	peptidase			1.03E-02	Cd2,CXLO12,EAS,FOSL1,IL1B			
gencibaline	chemical drug			1.03E-02	CASP3,Cx2C,CXCL12,HLA-A,PAD2,SOD2			
4-phenylbutyric acid	chemical - endogenous mammal	-0.816		1.03E-02	ALAS1,ALDH2,Cd2,FABP5,FBP1,GSTP1,HK2,HMGCS2,IL1B,MGLL			
TO-901317	chemical reagent	-1.755	bias	1.03E-02	ATM,CD44,HCK,D1,RHOU			
Laminin (complex)	complex			1.03E-02	Cd2,SEBP1,SERNE1			
SUMO2	enzyme	1.067		1.03E-02	CAV2,CXLO16,HMGA1,RNASE4			
ATR	transcription regulator			1.03E-02	FOXP1,HCK,JUN,SOD2			
SAH1M1	chemical - mammal	Inhibited	-2.000	bias	1.03E-02	Cd2,SEBP1,SERNE1		
UDP	chemical - endogenous mammal			1.03E-02	Cd2,SEBP1,SERNE1			
L-phenylalanine	chemical - endogenous mammal			1.03E-02	FAS,SOD2			
sakosaponin A	chemical - agent			1.03E-02	BMP4,JUN			
ganglioside GM3	chemical - endogenous mammal			1.03E-02	CD40,ICAM1			
Calicrein B	group			1.03E-02	B3GAT1,CXCR3			
Cyp4a14	enzyme			1.03E-02	Cd2,IL1B			
Ibdilast	chemical drug			1.03E-02	IL1B,NCIS1			
teclonemisin	chemical - endogenous non-mam			1.03E-02	ICAM1,IL1B			
GPR61	G-protein coupled receptor			1.03E-02	ICAM1,IL1B			
GSKTK1	kinase			1.03E-02	Cod2,TMEM173			
ADGRF5	G-protein coupled receptor			1.03E-02	Cod2,CSPF1			
LTPB4	G-protein coupled receptor			1.03E-02	BMP4,IDI1			
SMAD1/5	group			1.03E-02	ID1,IDI3			
IL26	cytokine			1.03E-02	ICAM1,IL1B			
ABC11	transporter			1.03E-02	CYBA,NQO1			
PDLIM7	other			1.03E-02	BMP2,RUNX2			
CDBA	8.241	other		1.03E-02	CASP3,IL1B			
SLC3A4	transporter			1.03E-02	CASP3,SLC2			
MAP2K12	kinase			1.03E-02	CASP3,UN			
CAV3	enzyme			1.03E-02	CAV2,DMO			
mir-326	microRNA			1.03E-02	NOTCH2,SMO			
levetiracetam	chemical drug			1.03E-02	GAP43,IL1B			
SMN1/SMN2	other			1.03E-02	Cd2,DMO			
LPA	other			1.03E-02	ICAM1,SERpine1			
RASSF10	other			1.03E-02	CASP3,JUN			
LY86	other			1.03E-02	CD144,CXCR12			
CCZ-771	chemical reagent			1.03E-02	CD44,CXCR12			
RBC1K1	transcription regulator			1.03E-02	ICAM1,TNFaIP3			
Ptx2e2s	other			1.03E-02	Cod2,Saa3			
ULBP1	transmembrane receptor			1.03E-02	Cd83,HLA-A			
niflumic acid	chemical drug			1.03E-02	CD86,FAS			
NCX4-0404	chemical drug			1.03E-02	GSTP1,NQO1			
mechlorethamine	chemical - drug			1.03E-02	CD40,IL1B			
benzolac acid	chemical - endogenous mammal			1.03E-02	CD68,IL1B			
SC58125	chemical drug			1.03E-02	FAS,GDF15			
acetone acid	chemical - endogenous mammal			1.03E-02	ICAM1,IL1B			
gadipine	local anesthetic			1.03E-02	FOSL1,JUN			
N,N-dimethylarginine	chemical - endogenous mammal			1.03E-02	ICAM1,SERpine1			
SOCS3	phosphatase	-1.687	bias	1.03E-02	Cd2,CD40,C9B6,ICAM1,IL1B,JUN			
tunicamycin	chemical - endogenous non-mam	1.553	bias	1.03E-02	BIRC3,C2,CEBPD,GADD45B,Hamp/Hamp2,ICAM1,IL1B,KLF4,NFKBIA,Nqo1			
12-(3-adamantan-1-ylureido) d	chemical reagent	0.000		1.03E-02	BIRC3,CASP3,CD40,FAS,RIPK2			
B2CL2	other			1.03E-02	CD2,CEBPB,HMG1,IL1RL1,MGLL			
NEUROG1	transcription regulator	-1.342		1.03E-02	AMIGO2,MEST,PPIC,PXDN,SLC4A3			
melibitolone	chemical reagent	Activated	3.360	bias	1.03E-02	BUB1,CAV2,CCNA2,GFRUL1,GDF15,HK1,HK2,HOMER2,KLK3,MGLL		
Nk8-RelA	complex			1.03E-02	ICAM1,IL1B,KRBIA			
POU5F-OD	complex			1.03E-02	CASP3,TNFSF12A			
MCP	other			1.03E-02	JAG1,Pres1 (includes others),RUNX2			
resolin D2	chemical - endogenous mammal			1.03E-02	Cod2,IL1B,JUN			
IFNK	cytokine			1.03E-02	CD40,CD83,CD86			
LTB	cytokine			1.03E-02	Cod2,Glycam1,IL1B			
hydrochloric acid	chemical - endogenous mammal			1.03E-02	BMF,CD40,CD44,C9B6,KLF4,SMO			
liporabinomannan	chemical - endogenous non-mam			1.03E-02	BMP2,ENPP1,FOSL1,HK2,SLC3A2,STC2			
dialyl triisulfide	chemical - endogenous non-mam			1.03E-02	BLNK,Cd2,Glycam1,ICAM1,IL1B,LYN,Saa3,SDC4			
lemonstat	chemical drug			1.03E-02	FAO,JUN,NQO1,RRAS			
NCOR1	transcription regulator			1.03E-02	ICAM1,IL1B,JUN,SERpine1			
mir-10	microRNA	-1.166	bias	1.03E-02	CON4A2,CEBPB,HK1,IL1B,KLK3,PDE9A			
phosphate	chemical - endogenous mammal	Activated	2.449	bias	1.03E-02	BMF,CD40,CD44,C9B6,KLF4,SMO		
JAK2	kinase	Activated	2.193	bias	1.03E-02	BLNK,Cd2,Glycam1,ICAM1,IL1B,LYN,Saa3,SDC4		
JO1	chemical reagent	Inhibited	-2.213	bias	1.03E-02	BIRC3,C2,CCNA2,MCM3,TNFaIP3		
ACVR1	kinase			1.03E-02	C1R,Hamp/Hamp2,ICAM1,I01			
miR-200b-3p (and other miRNA)	mature microRNA	-1.944	bias	1.03E-02	BST1,JAG1,PERP,PTPN13			
EEB	transcription regulator			1.03E-02	GATA3,KLF4,RUNX2,SCIN			
SLC1PLG	other	Activated	2.000	bias	1.03E-02	GATA3,KLF4,RUNX2,SCIN		
CALR	transcription regulator			1.03E-02	ICAM1,IL1B,NCIS1			
GABPA	transcription regulator			1.03E-02	Cod2,CEBPB,ICAM1,IL1B			
4-hydroxyonenal	chemical toxicant			1.03E-02	FASL17R,NQO1,RRAS			
N-193-5-difluorophenacyl-L-	chemical - protease inhibitor	Inhibited	-2.000	bias	1.03E-02	HK2,KLF4,PPIC,TNFaIP3,Tom1		
NCOA1	transcription regulator			1.03E-02	TNFaIP3,XDH			
CDX2	transcription regulator			1.03E-02	TNFaIP3,XDH			
E2F3	transcription regulator			1.03E-02	TNFaIP3,XDH			
HOXA9	transcription regulator			1.03E-02	TNFaIP3,XDH			
FGR2A	growth factor			1.03E-02	TNFaIP3,XDH			
DPY2A	other			1.03E-02	TNFaIP3,XDH			
miR-39b-3p (and other miRNAs)	mature microRNA	Inhibited	-2.182		1.03E-02	TNFaIP3,XDH		
TBP	transcription regulator			1.03E-02	TNFaIP3,XDH			
Wnt	group			1.03E-02	TNFaIP3,XDH			
ALB	transporter			1.03E-02	TNFaIP3,XDH			
RAC2	enzymes			1.03E-02	TNFaIP3,XDH			
TNC	other			1.03E-02	TNFaIP3,XDH			
OGT	enzymes	-0.928		1.03E-02	TNTA,GAP43,HMG1,JUN,JUP,NEK2			
butyryl ester B4	chemical - endogenous mammal			1.03E-02	TNTA,GAP43,HMG1,JUN,JUP,NEK2			
deoxycoformosterone acetate	chemical drug			1.03E-02	TDNA,GAP43,HMG1,JUN,JUP,NEK2			
Cip	group			1.03E-02	TDNA,GAP43,HMG1,JUN,JUP,NEK2			
dapomad	chemical drug			1.03E-02	TDI1,SERpine1,TRIP13			
GRHL2	transcription regulator			1.03E-02	TDMP,CEBPB,CAT,ICAM1,IL1B,RELB			
CD81	other			1.03E-02	TDNE,ICAM1,I01			
IL36G	cytokine			1.03E-02	CD83,CSF1,MRC1			
A2GP1	other			1.03E-02	CONN,ICAL,MRC3			
carvedilol	chemical drug			1.03E-02	DIS3,PPIC,TNFaIP3			
N2	chemical reagent			1.03E-02	HK2,KLF4,PPIC,TNFaIP3			
RUNX2	transcription regulator	2.637		1.03E-02	ICAM1,IL1B,JUN,JUP,NEK2			
TEAD1	transcription regulator	Activated	2.236	bias	1.03E-02	ARID5B,FJX1,LATS2,NFKBIZ,TRNP1		
F3	transmembrane receptor			1.03E-02	Cd2,DOCK4,ICAM1,IL1B,SERpine1			
uric acid	chemical - endogenous mammal			1.03E-02	CASP3,FAS,ICAM1,SOD2			
sodium bisulfide	chemical reagent			1.03E-02	Cd8,CXLO14,GADD45B,ICAM1			
ZMPSTE24	peptidase	-1.964	bias	1.03E-02	Cd8,CXLO14,GADD45B,ICAM1			
PP2CA	phosphatase	Activated	2.000	bias	1.03E-02	Cd8,CXLO14,GADD45B,ICAM1		
PKX4A	other			1.03E-02	Cd8,CXLO14,GADD45B,ICAM1			
dimethyltryptamine	chemical toxicant			1.03E-02	Cd8,CXLO14,GADD45B,ICAM1			
Ro31-8220	chemical - kinase inhibitor			1.03E-02	Cd8,CXLO14,GADD45B,ICAM1			
K+	chemical - endogenous mammal	-1.987	bias	1.03E-02	Cd8,CXLO14,GADD45B,ICAM1			
APC/APC2	group			1.03E-02	Cd8,CXLO14,GADD45B,ICAM1			
cytidylyl-3'-guanosine	chemical reagent			1.03E-02	Cd86,IL1B			
bacterial lipopolysaccharides	chemical - other			1.03E-02	IL1B,Saa3			
OLFM4	other			1.03E-02	Cd2,IL1B			
FBXO42	other			1.03E-02	Cd2,IL1B			
FAT1	other			1.03E-02	CD14,IL1B,JUN			

PHF8		enzyme		1.40E-02	CD14,IRAK3		
MEMO1		other		1.40E-02	JUN,STC2		
STK17A		kinase		1.40E-02	GSTO1,SO02		
nicotiforin		chemical reagent		1.40E-02	ICAM1,IL1B		
UNC5B		transmembrane receptor		1.40E-02	Cd2,YAP1		
SERPINB2		other		1.40E-02	CNNA2,CD14		
THBD		transmembrane receptor		1.40E-02	Cd2,IL1B		
TRG		other		1.40E-02	CAV2,IL1B		
DLX1		transcription regulator		1.40E-02	ARX,SERpine1		
OZ	0.893	peptidase		1.40E-02	CD86,CD86B		
PTGR		G-protein coupled receptor		1.40E-02	Cd2,IL1B		
HAS2		lysine		1.40E-02	Cd2,CD44		
CDKN2B		transcription regulator		1.40E-02	CD86,SERpine1		
ING4		transcription regulator		1.40E-02	Cd2,NFKBIA		
FKBP5		enzyme		1.40E-02	ICAM1,KLK3		
USP37		peptidase		1.40E-02	CEBPB,ZBTB16		
ST6GAL1		enzyme		1.40E-02	ICR3,SLC2A3		
COCH		other		1.40E-02	Cd2,IL1B		
IL22RA1		transmembrane receptor		1.40E-02	Hamp/Hamp2,SO02		
cyclic adenosine monophosphate		chemical - endogenous non-mam		1.40E-02	CD4,CD45,IL1B		
genes		other		1.40E-02	FOSL1,JUN		
6-aminonicotamide		chemical reagent		1.40E-02	Cd2,Saa3		
sulfuric sulfone		chemical - endogenous mammal		1.40E-02	NGO1,PRKG1		
bupivacaine		chemical drug		1.40E-02	FOSL1,HPGDS		
ketorolac		chemical drug		1.40E-02	Cd2,NFKBIA		
SR1078		chemical reagent		1.40E-02	Cd2,PAD2		
miR-182 inhibitor		chemical reagent		1.40E-02	CASP3,NFKBIA		
2,4-dinitrobenzenesulfonic acid		chemical reagent		1.40E-02	CD86,ICAM1		
YBA		transcription regulator	1.982	bias	1.42E-02	CD45,CD45R,IL1B,SLC2A3,STC2	
CD45R		transmembrane receptor	0.200	bias	1.42E-02	CD40,CSF1,IL1B,RUNX2,SERpine1	
CHD7		enzyme		1.45E-02	JAG1,PERP,POLE4		
Smad		complex		1.45E-02	ID1,IP3,SERpine1		
BCL2L11		other		1.45E-02	CASP3,C20,IL1B		
mir-124		microRNA		1.45E-02	CASP3,C20,RUNX2		
BTG2		transcribed regulator		1.45E-02	IL1B,NGO1,SO02		
BAG1		other		1.45E-02	Hspa1b,JUN,KLK3		
hemocyanin		biologic drug		1.45E-02	CD14,CD83,CD86		
aminothiprine		chemical drug		1.45E-02	CD45,CD45R,IL1B		
amiodarone		chemical - endogenous non-mam		1.45E-02	FAS,ICAM1,IL1B		
kaempferol		chemical toxicant		1.45E-02	ICAM1,JUN,RUNX2		
oscovitine		chemical drug	-1.954	bias	1.50E-02	CD44,CEBPB,Rae1/dRaet1e,RALA	
EGR3		transcription regulator	1.980		1.50E-02	ESD,JUN,PLXND1	
TEAD3		transcription regulator	Activated	2.000	bias	1.50E-02	ARID5B,FXJ1,NFKB1Z,TRNP1
ABC1A		transporter	-1.009		1.50E-02	APOA1,C20,CSF3,IL1B	
Sb202190		other		1.50E-02	Cd2,JUN,SERpine1,SO02		
Tsp53cor1		chemical - kinase inhibitor	-1.118	bias	1.50E-02	ICAM1,IL1B,SERpine1,SO02	
CD45R	1.365	chemical - kinase inhibitor	-1.980	bias	1.50E-02	CD2,C08,ICAM1,IL1B,MAPK6,SERpine1,XDH	
TSPY	1.108	other		1.51E-02	CD45,CD45R,IL1B,IL1B,SLC2A3		
EGR3	1.349	transcription regulator		1.51E-02	CCNA2,C02,CD45,IL1B,NOTCH2		
CD45		chemical drug	1.460		1.51E-02	DTX4,GATA3,ICAM1,IF16,RUNX2	
ADRA1D		G-protein coupled receptor		1.61E-02	ESD,GDF15,KRT19,NGO1,STC2		
herbimycin		chemical - kinase inhibitor		1.61E-02	CEBPB,FABP5,IL6ST,JUN		
Sb202190		chemical - kinase inhibitor	-1.118	bias	1.61E-02	ICAM1,IL1B,SERpine1,SO02	
Tsp53cor1		other		1.61E-02	CD2,JUN,SERpine1,SO02		
CD45R	1.365	other		1.61E-02	CD2,IL1B,PLA2G12A		
TSPY	1.108	other		1.56E-02	CD45,CD45R,IL1B,IL1B,SLC2A3		
FGF9		growth factor		1.56E-02	CCNA2,C02,GAD45B,JUN,NOTCH2		
HMG2		transcription regulator		1.61E-02	BMF1,CD45,IL1B,RUNX2		
K-252		chemical - kinase inhibitor		1.61E-02	CD14,JUN,SO02		
geranylgeranyl pyrophosphate		chemical - endogenous mammal		1.61E-02	BM2,ICAM1,IL1B		
inositol acid		chemical - endogenous mammal		1.61E-02	ICAM1,NFKBIA,SERpine1		
CEBPD	0.429	transcription regulator	0.447	bias	1.63E-02	CD2,CA1,C02,CD45,IL1B,Saa3	
Inoic acid		chemical - endogenous mammal	0.468	bias	1.68E-02	APOA1,C20,ICAM1,IL1B,NFKBIA	
ATM		kinase		1.68E-02	FAK1,JUN,SERpine1,TNFaIP3		
ET22		transcription regulator	Activated	2.236	bias	1.68E-02	CDX2,GATA3,IL1B,PLA2G16
1-(S)-hydroxymethyl-chiro-inositol		chemical - kinase inhibitor		1.73E-02	CDX2,IL1B		
THOC5		other		1.73E-02	APOA1,CEBPB		
DPY30		other		1.73E-02	CD1,IP3		
ADCY7		enzyme		1.73E-02	IL1R1,IL1RAK2		
FOXN1		transcription regulator		1.73E-02	G2MA,SERpine1		
SEMA4D		transmembrane receptor		1.73E-02	CD40,RRA8		
ITGA4		transmembrane receptor		1.73E-02	IL1B,TNFaIP3		
AMBP		other		1.73E-02	CD45,CD45R,IL1B		
AMBP		other		1.73E-02	F11R,ZNF703		
FRMD6		other		1.73E-02	BM2,RASSF4		
HLA-G		other		1.73E-02	CD8A,FA8		
LUM		other		1.73E-02	FAS,IL1B		
LY9	2.405	other		1.73E-02	CD81,ZBTB16		
Igkv1-117		other		1.73E-02	JUN,RELB		
Sry		transcription regulator		1.73E-02	IL1B,SO02		
NFKBIE		transcription regulator		1.73E-02	CSF3,ICAM1		
PAZG4		transcription regulator		1.73E-02	GOF15,ICAM1		
CD45		kinase		1.73E-02	ICAM1,SERpine1		
COP1		enzyme		1.73E-02	FAS,ICAM1		
S100P		other		1.73E-02	KRT19,KRT8		
CYBA	1.652	enzyme		1.73E-02	SERpine1,SO02		
zileuton		chemical drug		1.73E-02	Cd2,ICAM1		
astressin 2B		biologic drug		1.73E-02	Cd2,SLC2A3		
polyoxin B		biologic drug		1.73E-02	APOBEC3B,IL1B		
S-equal		chemical drug		1.73E-02	CD86,SERpine1		
monomorulin		chemical - endogenous non-mam		1.73E-02	BM2,CD86		
lysophosphatidylinositol		chemical - endogenous mammal	Activated	2.000	bias	1.73E-02	CD86,CD86B,IL1B,SO02
isoproterenol		chemical drug		1.860	bias	1.81E-02	CSF3,GATA3,IL1B,LAG3
E2F2		transcription regulator		1.78E-02	CCNA2,CD1,MCMB1,Rae1/dRaet1e,SERpine1		
PSEN1		peptidase	-0.762	1.78E-02	AMY2A,BASP1,C1R,CASP3,CD9,CTSZ,GADD45B,GSTP1,HK1,IL1B		
glutamine		chemical - endogenous mammal	Inhibited	2.000	bias	1.79E-02	FABP5,HK1,ICAM1,JUN,KLF4,NFKBIA
tetrodotoxin		chemical drug		1.79E-02	AMIGO2,FAS,FD1		
PRKDC		kinase		1.79E-02	BIRC3,KLK3,PREX1		
mr-23		microRNA		1.79E-02	PTK2B,RUNX2,SO02		
CC001G/LOC102723996		other		1.79E-02	CD45,CD45R,IL1B		
PNX2		phosphatase		1.79E-02	IL1B,LAG3,MRC1		
ESRRB		ligand-dependent nuclear recep		1.79E-02	H2K,Hsp10,POLE4		
ozone		chemical toxicant		1.79E-02	Cd2,IL1B,JUN		
PML		transcription regulator	-1.066	bias	1.81E-02	APOA1,FAS,FTL,HSPB1,IL1B,JUP,NGO1,TNFaIP3	
isoproterenol		chemical drug		1.860	bias	1.81E-02	ALDH3B1,CSF3,DRHRS3,FOSL1,IL1B,JUN,PRKD3,SO02
CDH11		kinase		1.81E-02	BIRC3,CEBPB,GADD45B,SERpine1		
ST22		transmembrane receptor		1.81E-02	CD45,CD45R,IL1B,SO02		
CD45R		kinase	1.067	bias	1.85E-02	APOA1,FABP5,ICAM1,SERpine1	
CD45R		transcription regulator	Activated	2.000	bias	1.85E-02	ALDH2,BDH2,SO02
AT45		transcription regulator		1.93E-02	GOF15,JAG1,JUN,KLF4,SO02,STC2,TNFRSF12A,XDH		
STAT4		transcription regulator	Activated	2.800	bias	1.94E-02	GATA3,Hsp10,LRP1,ME44bD (includes others),RCN3,SERpine1,SLC2A3,STC2,Tcf7
N-cor		group		1.95E-02	CD8,CD16,CD56,CD57		
Mir122a_b		group		1.95E-02	CD8,CD16,CD56,CD57		
CDH11		other		1.97E-02	CD9,JUP,PTK2B		
USP7		peptidase		1.97E-02	BMF,KLK3,POE9A		
PLA2R1		transmembrane receptor		1.97E-02	ALDH2,BDH2,SO02		
FABP4		transporter		1.97E-02	CD45,CD45R,IL1B		
CAT47		transmembrane receptor		1.97E-02	C5FL1,FTL,IL1B		
impramine		chemical drug		1.97E-02	DEPP1,HPM,SLC2A3		
BTM2		transmembrane receptor	1.342	bias	1.97E-02	GJB,Hsp10,IL1B,SLC2A3,STC2,Tcf7	
bradiamefon		chemical toxicant	1.000	bias	1.98E-02	ALAS1,CYP3A7,GSTA1,TST	
fish oils		chemical drug		1.98E-02	APOA1,C20,CEBPB,IL1B		
SQSTM1		transcription regulator		1.98E-02	IL1B,JUN,NFKBIA,NGO1		
CUL3		enzyme	-0.849	bias	1.98E-02	NGO1,PLS,Prss1 (includes others),TCEA3	
ADRA1A		G-protein coupled receptor		1.98E-02	CEBPB,FABP5,IL6ST,JUN		
transcription regulator			1.597	bias	2.04E-02	ANXA3,BMP2,FABP5,GADD45B,HMGCS2,ICAM1,JAG1,LCP2,NFKBIA,NTN4	
9-hydroxy-(S)-10,12-octadecad		chemical - endogenous mammal		2.02E-02	SERpine1		
acetoacetyl-coenzyme A		chemical - endogenous mammal		2.02E-02	IL1B		
endocannabinoid		chemical - endogenous mammal		2.02E-02	APOA1		
GPM53		other		2.02E-02	IL1B,JUN,NFKBIA,NGO1		
COMMD6		other		2.02E-02	NOTCH2		
resinhouse		biologic drug		2.02E-02	Cd2		
BDNF-AS		other		2.02E-02	CASP3		
BMP2/4		group		2.02E-02	Hamp/Hamp2		
Patred		group		2.02E-02	SMN1		
TRAK14		protein		2.02E-02	ALAS1		
methimazole		chemical drug		2.02E-02	ANTXR2		
G-actin		protein		2.02E-02	GATA3		
acidine half-mustard		chemical toxicant		2.02E-02	CD44		
WSX1-qp130		complex		2.02E-02	ICAM1		
bovine testicular hyaluronidase		biologic drug		2.02E-02	IL1B		
PMM2		enzyme		2.02E-02	IL1B		
NLRP2		other		2.02E-02	ICAM1		
IL1bos		other		2.02E-02	IL1B		
IL1b		other		2.02E-02	IL1B		

WFDC1	other		2.07E-02	ICAM1	
CMPK2	kinase		2.07E-02	IL1B	
PPIP5K1	phosphatase		2.07E-02	RUNX2	
SV2B	transporter		2.07E-02	SYT1	
SNORD21	other		2.07E-02	HLA-A	
DDO2	enzyme		2.07E-02	CDH1	
FNDC3B	other		2.07E-02	RUNX2	
CLPX	enzyme		2.07E-02	ALAS2	
DAGLA	enzyme		2.07E-02	IL1B	
UBN1	transcription regulator		2.07E-02	CNCNA2	
canaknumab	biologic drug		2.07E-02	IL1B	
DEPDCC1	transcription regulator		2.07E-02	TNFAIP3	
SGMS2	enzyme		2.07E-02	APOA1	
MYADM	other		2.07E-02	ICAM1	
MACR0D1	enzyme		2.07E-02	NFKBIA	
COX10	other		2.07E-02	B3GAT3	
MULT11	other		2.07E-02	CD44	
COMM09	other		2.07E-02	NOTCH2	
KIF26B	other		2.07E-02	NOQ1	
CLIC1	ion channel		2.07E-02	IL1B	
TCFL5	transcription regulator		2.07E-02	CD2	
PHF10	other		2.07E-02	CASP3	
DSC2	other		2.07E-02	CD44	
TMEM123	0.505		2.07E-02	CD44	
DPP6	peptidase		2.07E-02	NOQ1	
FAK1	transcription regulator		2.07E-02	JUN	
Testostosterone-AR dimer	complex		2.07E-02	KLUK3	
CELSR3	G-protein coupled receptor		2.07E-02	Nsp1	
gataparan	biologic drug		2.07E-02	CASP3	
tandutinib	chemical drug		2.07E-02	ID1	
FAS-A1	other		2.07E-02	FAS	
Oxi4503	chemical drug		2.07E-02	CXCL12	
black cohosh extract	chemical drug		2.07E-02	SERpine1	
G73	group		2.07E-02	BMP2	
EIF3j	translation regulator		2.07E-02	SERpine1	
ACBD3	other		2.07E-02	SLC11A2	
PRCC	other		2.07E-02	SERpine1	
cabazitaxel	chemical drug		2.07E-02	KLUK3	
DYNLRB1	other		2.07E-02	SERpine1	
NFE2L2	transcription regulator		2.07E-02	NOQ1	
FGF6	growth factor		2.07E-02	CSF3	
COL6A3	other		2.07E-02	WIF1	
RAAS7A	enzyme		2.07E-02	CD44	
MED7	transcription regulator		2.07E-02	TNFAIP3	
LINC00672	other		2.07E-02	LASP1	
SLC52A1	transporter		2.07E-02	ICAM1	
miR-615-5p (and other miRNAs)	mature microRNA		2.07E-02	KRT19	
miR-690 (miRNAs wised AAG)	mature microRNA		2.07E-02	CEBPB	
Mir690	microRNA		2.07E-02	CEBPB	
mir-1301	microRNA		2.07E-02	KLF6	
mir-613	microRNA		2.07E-02	RTKN	
AQUAPORIN	group		2.07E-02	IL1B	
CANX	group		2.07E-02	BRC3	
EPST11	other		2.07E-02	NFKBIA	
Rae11d/Rae11e	3.853	other	2.07E-02	HLA-A	
RNF14	transcription regulator		2.07E-02	KLUK3	
PLXNB1	transmembrane receptor		2.07E-02	KLUK3	
COL4A2	other		2.07E-02	FAS	
AXIN2	other		2.07E-02	BMP4	
PSMA1	peptidase		2.07E-02	GSTP1	
RNF43	enzyme		2.07E-02	JUN	
CTNNA1	other		2.07E-02	VCL	
SART3	other		2.07E-02	KLUK3	
MED21	transcription regulator		2.07E-02	TNFAIP3	
Uox	enzyme		2.07E-02	IL1B	
B3GAT2	enzyme		2.07E-02	B3GAT1	
PRDM14	transcription regulator		2.07E-02	POLE4	
PDPN	other		2.07E-02	CD44	
JAM2	other		2.07E-02	CXCL12	
RPN2	enzyme		2.07E-02	CD3TP1	
FAP	peptidase		2.07E-02	Cod1	
VPS4B	transporter		2.07E-02	CASP3	
ZC3H8	transcription regulator		2.07E-02	GATA3	
cytarabine/Idarubicin	chemical drug		2.07E-02	CEBPB	
GDF10	growth factor		2.07E-02	SERpine1	
F12	peptidase		2.07E-02	IL1B	
brimapant	biologic drug		2.07E-02	MLKL	
guercetin-3-methyl ether	chemical reagent		2.07E-02	IL1B	
guercetin-3,4'-dimethyl ether	chemical reagent		2.07E-02	IL1B	
COX10	other		2.07E-02	CD44	
SRRM1	other		2.07E-02	CD44	
HIST1H4B	other		2.07E-02	Hspa1b	
minozac free base	chemical reagent		2.07E-02	IL1B	
IGHMP2	enzyme		2.07E-02	APOA1	
Rhodobacter sphaeroides lipid	chemical - endogenous non-mam		2.07E-02	IL1B	
3-M-052	chemical drug		2.07E-02	Cd6	
ETP-4644	chemical reagent		2.07E-02	OASL	
ISG15	other		2.07E-02	HLA-H	
sintokamide A	chemical reagent		2.07E-02	KLUK3	
erteborel	chemical drug		2.07E-02	IL1B	
metabolite	chemical - endogenous mammal		2.07E-02	NOQ1	
lipophosphoglycan	chemical - endogenous non-mam		2.07E-02	IL1B	
3-hydroxybutyric acid	chemical - endogenous mammal		2.07E-02	IL1B	
SC-19220	chemical reagent		2.07E-02	ICAM1	
bathophenanthroline	chemical reagent		2.07E-02	CP	
RO31-9790	chemical - protease inhibitor		2.07E-02	GAP43	
A210606120	chemical reagent		2.07E-02	CD44	
fluor	chemical reagent		2.07E-02	CASP3	
1-(3-(1,4-dihydropyrimido[4,5-c]pyridin-2(1H)-yl)methyl)imidazo[4,5-c]pyridin-2(1H)-one	chemical - kinase inhibitor		2.07E-02	Cod1	
pentachlorophenol	chemical toxicant		2.07E-02	NOQ1	
SDM25N	chemical reagent		2.07E-02	CD86	
L18-muramyl dipeptide	chemical reagent		2.07E-02	ACOD1	
anti-miR-32 inhibitor	chemical reagent		2.07E-02	KLF4	
1-methylspiperidine	chemical reagent		2.07E-02	AMY2A	
leucyl-leucine-methyl ester	biologic drug		2.07E-02	IL1B	
2-methoxy-5-(2',3'-dimethoxyphenyl)benzoic acid	chemical reagent		2.07E-02	JUN	
zam	chemical reagent		2.07E-02	GSTP1	
17S-hydroperoxy-docosahexaenoic acid	chemical - endogenous mammal		2.07E-02	IL1B	
LIMP	chemical - endogenous mammal		2.07E-02	IL1B	
cladrubine	chemical drug		2.07E-02	IL1B	
2'-fucosylfucose	chemical - endogenous mammal		2.07E-02	ICAM1	
P2y Receptor	group		2.07E-02	SLC2A3	
fencitriptal	chemical drug	Activated	2.000	FT1H	
tetracycline	chemical drug	Activated	0.277	bias	
triploidie	chemical drug	Activated	0.277	bias	
CD44	other		2.08E-02	CSF1, JAC1, MAL, SERpine1, SOD2	
METTL3	enzyme		2.08E-02	CD9, SERpine1	
APOL1	transporter		2.08E-02	IFNGR2, IL1B	
Adaptor protein 1	complex		2.08E-02	CD44, SOD2	
T 0070907	chemical reagent		2.08E-02	Cd2, CEBPA	
PLCL2	enzyme		2.08E-02	ID1, RUNX2	
Atrial Natriuretic Peptide	group		2.08E-02	NPR2, SERpine1	
Kallikrein	group		2.08E-02	Cd2, ICAM1	
astagargin	chemical - endogenous non-mam		2.08E-02	CD44, IL1B	
McG	peptidase		2.08E-02	Cd2, CLDN1	
TXK	kinase		2.08E-02	CD44, ZBTB16	
DYRK1B	kinase		2.08E-02	CP, SOD2	
miR-208a-3p (and other miRNA)	mature microRNA		2.08E-02	CD14, RUNX2	
MAFF	transcription regulator		2.08E-02	GSTP1, NOQ1	
IL17RB	transmembrane receptor		2.08E-02	Cd2, CSF3	
VLDLR	transporter		2.08E-02	SERpine1, TNFAIP3	
ENTPD1	enzyme		2.08E-02	CD86, SERpine1	
CHRNL4	transmembrane receptor		2.08E-02	CD44, GATA3	
HSD17B3C	other		2.08E-02	IL1B, RNF43	
ascorbicurane	chemical drug		2.08E-02	CASP3, IL1B	
fernic ammonium citrate	chemical drug		2.08E-02	FT1H, FTL	
8-chlorophenylthio-adenosine 3'	chemical - kinase inhibitor	1.982	2.08E-02	BIRC3, CASP3, CEBPD, LPIN2	
IFN type 1	group	1.969	2.08E-02	Cd2, F116, GASL, XDH	
EPHB4	kinase	1.000	2.12E-02	CASP3, CHD9, GDF15, PTGFRN	
IGFBP2	other		2.12E-02	CEBPA, HMGC52, IL1B, NOQ1	
ARNTL	transcription regulator	0.591	2.12E-02	CD44, GATA3, IL1B, RNF43	
LMB11	other		2.12E-02	CD44, GATA3, IL1B, KLF4	
beta-Defensin A	chemical - endogenous non-mam	-0.130	2.17E-02	CTRB2, JUN, KLUK3	
GRP	growth factor		2.17E-02	CASP3, FAS, SFN	
ACTL6A	other		2.17E-02	CNCNA2, GATA3, JAG1	
DLL1	enzyme		2.17E-02	CD86, GATA3, JAG1	
CHADL	other		2.17E-02	Cd2, FAS, STEAP4	
CFLAR	other		2.17E-02	CSF3, GATA3, IL1B	
PD 123319	chemical drug		2.17E-02	Cd2, CYBA, SERpine1	
chrysotile asbestos	chemical toxicant		2.17E-02	CLCA1, CTSA, IL1B	

deoxynivalenol		chemical toxicant		2.17E-02	CLDN4,ICAM1,IL1B		
stearic acid		chemical - endogenous mammal		2.17E-02	ICAM1,IL1B,NFKBIA		
GnRH analog		biologic drug	0.577	2.18E-02	ACOT7,BCL2A1,CASP3,CD40,FAS,GAB1,GSTO1,JUN,NFKBIA,PLA2G16		
GNA12	enzyme		0.447	bias	2.19E-02	CNA2,GST3,GSTP1,LAMB3,VCL	
PAX3	transcription regulator		2.21E-02	BMP4,FLT3,IOD3,IL7R,LAMB3,MEST,PTPN14,PXDN,SNF			
FOXP3	transcription regulator	0.447	bias	2.21E-02	ICAM1,IL1B,IL17A,IL17B,IL17C,IL17R,LAT52,TNFAIPI3		
SNR (family)	group		1.969	bias	2.29E-02	BMP4,CDP,CAM1,IDI1	
RTN4	other				2.29E-02	GAP43,JUN,NOQ1,Tem1	
CCN2	growth factor	1.148	bias	2.31E-02	BCL2A1,CD44,JUN,SOD1,SERpine1,Tpm1		
RXRA	ligand-dependent nuclear receptor	0.000		2.33E-02	APOA1,C8B,CNA2,CEBPA,CEBD,CLMN,FABP5,FTL,HMGCS2,IL1B		
etanercept	biologic drug			2.37E-02	CD83,ICAM1,IL1B		
LPIN1	phosphatase			2.37E-02	CEBPAL,IL1B,LPIN2		
indican	chemical - endogenous mammal			2.37E-02	GATA3,ICAM1,IL1B		
LLGL2	other			2.37E-02	CRIM1,SERpine1,SH2D4A		
Focal adhesion kinase	group			2.37E-02	ICAM1,KLK3,KLK5		
CASE1	0.801	peptidase		2.37E-02	CD40,CDP,CAM1,RUNX2		
ROCK1	kinase			2.37E-02	CD44,ICAM1,LAMA2		
PRKCI	kinase			2.37E-02	CLDN1,HK1,HK2		
NOD4	transcription regulator			2.37E-02	FABP5,AG1,KLK3		
fenic acid	chemical - endogenous non-mam			2.37E-02	CASP3,CSF3,IL1B		
R/WIN_55_212	chemical reagent			2.37E-02	CASP3,ICAM1,IL1B		
glycymine acid	chemical drug			2.37E-02	APOA1,CASp3,CD40		
bardoxolone methyl	chemical drug			2.37E-02	BIRC3,C2,IL1B		
fucidine	chemical reagent			2.37E-02	CARD11,CXCL12,IL1B		
CO2	transmembrane receptor	0.762	bias	2.40E-02	CD40,CDP,CAM1,RELB		
ADM	other	-1.067		2.40E-02	Cdc2,ICAM1,IL1B,PRKG1		
phenethyl isothiocyanate	chemical drug			2.40E-02	BUB1,CYP2A7,GSTA3,KRT20,MAPK6,PLS3		
budesonide	chemical drug	1.342		2.41E-02	BTG3,Cdc2,CSF3,JUN,PDLM1		
ascorbic acid	chemical - endogenous mammal	-0.277		2.41E-02	APOA1,BMP,FAS,RUNX2,SERpine1		
FOXM1	transcription regulator	Activated	2.582	bias	2.43E-02	CNA2,CXL12,CXR3,JUN,Nek2,Nes,SOD2	
halofuginone	chemical drug			2.43E-02	C624a,CD4,COP,HK1,PLCB4,PTGFRN,PTK2B		
mocefinostat	chemical drug			2.47E-02	CASP3,IL1B		
WP1066	chemical drug			2.47E-02	CD40,CDP,CAM1		
TDRG1	1.150	enzyme		2.47E-02	CD44,COR6		
OLM12B	transmembrane receptor			2.47E-02	CXL12,LCBP2		
RGS2	other			2.47E-02	CEBPD,Vnn3		
ALOX12	enzyme			2.47E-02	FOSL1,JUN		
CST3	other			2.47E-02	IL1B,NFKBIA		
PLTP	enzyme			2.47E-02	APOA1,IL1B		
DBB2	other			2.47E-02	NFKBIA,SOD2		
BAP1	peptidase			2.47E-02	Cdc2,MCMB3		
ETV6	transcription regulator			2.47E-02	CARD11,CXCL12,IL1B		
NUMB	other			2.47E-02	CD38,IL1B,IL4		
ZBTB2	transcription regulator			2.47E-02	CSP2RB,GATA3		
HSPB8	kinase			2.47E-02	BMP4,ICAM1		
RIPK3	kinase			2.47E-02	Cdc2,IL1B		
PAX4	transcription regulator			2.47E-02	ARX,Nes		
AJUBA	transcription regulator			2.47E-02	BUB1,DOCK1		
ITGA3	other			2.47E-02	SERpine1,VCL		
CDH5	other			2.47E-02	ICAM1,TIAM1		
IРЕB2	translation regulator			2.47E-02	FT1H,FTL		
ELN	other			2.47E-02	ICAM1,IL1B		
PLCL1	enzyme			2.47E-02	ID1,RUNX2		
ACO1	enzyme			2.47E-02	FT1H,FTL		
pentylentetrazol	chemical drug			2.47E-02	IL1B,JUN		
toremifene	chemical drug			2.47E-02	CD86,KLK3		
D-sphingosine	chemical - endogenous mammal			2.47E-02	Cdc2,SERpine1		
KT5720	chemical - kinase inhibitor			2.47E-02	NFKBIA,PRKG1		
tin protoporphyrin IX	chemical reagent			2.47E-02	CD86,Hamp/Hamp2		
cucurbitacin B	chemical - endogenous non-mam			2.47E-02	CARD13,CCNA2		
lentiloid	chemical - endogenous mammal	1.519	bias	2.47E-02	APOA1,CD44,IL1B,LPIN2,NFKBIA,SERpine1		
TET2	enzyme	0.378	bias	2.51E-02	Cdc2,CELC4,D16,IL1B,IL1B,PLS3,RND3,ZBTB16		
NR4A1	ligand-dependent nuclear recep	-1.615	bias	2.53E-02	CEBPB,CSP1,CXL12,BP1,IK2,ICAM1,IL1B,JUP,KRT8,NFKBIA		
RS5020	chemical reagent	1.969	bias	2.53E-02	BIRC3,CEBPB,LCM2,NFKBIA,ZBTB16		
CDK9	kinase			2.55E-02	ALAS1,NFKBIA,STC2,TNFaiP3		
ZEB2	transcription regulator	-1.000	bias	2.55E-02	G2MA,IL7R,KRT19,Tcf7		
AKT2	kinase			2.55E-02	BUB1,Cdc2,RAK3,NOQ1		
VAV1	transcription regulator			2.59E-02	BCL2A1,JUN,RALA		
IFRD1	other			2.59E-02	CTSZ,HK1,LAMA2		
THBS4	other			2.59E-02	CD44,ICAM1		
laurestatine	chemical drug			2.59E-02	CORT1,HTR1,RACK1		
ERN1	kinase	1.404	bias	2.60E-02	ANG,C2,CEBPD,FAS,IL1B,JUN,TLNAGL1		
SPARC	other	-1.353		2.60E-02	CEBPB,CDN4,NOTCH2,PLET1,SERpine1,SLC3A4A2		
GAST	other	1.342	bias	2.65E-02	Hamp/Hamp2,JAG1,JUN,MCMB3,NFKBIA		
berberine	chemical drug	0.686		2.71E-02	BIRC3,CASP3,CD40,CD86,ICAM1,IL1B		
alefacept	biologic drug	-1.982	bias	2.71E-02	CD2,CDA,CYBA,IL7R		
oblimersen	biologic drug	Activated	2.000	bias	2.71E-02	CEBPD,GADD45B,IFI16,OASL	
CA1	enzyme	-1.067	bias	2.71E-02	BCL2A1,C2,IC1A1,SERpine1		
PLA2G1	transcription regulator	0.000	bias	2.71E-02	ICAT1,ICAT2,IL1B,IL4		
me-24	mRNA	-0.404		2.71E-02	CXCR3,CATP2,SERpine1,Tcf7		
CLEC11A	growth factor			2.71E-02	CXL12,IL1B,RUNX2,ZYX		
anisomycin	chemical - endogenous non-mam	1.966	bias	2.71E-02	IL1RL1,JUN,SCD1,SERpine1		
SP110	2.929	transcription regulator	-0.378		2.78E-02	BMP4,DMD,PAN1,PERP,RIPK2,TAB3,YAP1	
CARD9	other			2.81E-02	Cdc2,CSF3,IL1B		
IHH	enzyme			2.81E-02	BMP4,RUNX2,SMO		
PRKCZ	kinase			2.81E-02	CASP3,JUN,NFKBIA		
BECN1	other			2.81E-02	BMP1,IL1B,SOD2		
COX1	other			2.81E-02	CD38,IL1B,IL4		
X-3'-aminomethylbenzylacetate	chemical reagent			2.81E-02	CASP3,FA8,RIPK2		
hemocromone	chemical drug			2.81E-02	CASP3,CD44,FA8		
IFNA1/IFNA13	cytokine	1.131	bias	2.87E-02	CD40,CDD3,CD86,IL1B		
EBI3	cytokine	1.982	bias	2.87E-02	CD86,HLA-A,ICAM1,LAG3		
MDGA2	other			2.88E-02	BCL2A1,FAS		
FH	enzyme			2.88E-02	LTPB2,NOQ1		
CRBN	enzyme			2.88E-02	IL1B,JUN		
harmine	chemical - endogenous non-mam			2.88E-02	BMP2,RUNX2		
SOX4	transcription regulator			2.88E-02	CFGR1,IL1RA,NOQ2		
miR-210-3p (mRNAs w/seed_U	microRNA			2.88E-02	ILB,MRC1		
miR-127	microRNA			2.88E-02	IL1B,NOQ1		
HLA-A	1.061	other		2.88E-02	HLA-A,LAG3		
XRC5	enzyme			2.88E-02	KLK3,XDH		
CD180	other			2.88E-02	BCL2A1,CD86		
NLR4	other			2.88E-02	CD86,IL1B		
FRS2	other			2.88E-02	BMP4,CD44		
PLA2G2E	enzyme			2.88E-02	IL1B,SERpine1		
UGCG	enzyme			2.88E-02	ICAT1,ICAT2,IL1B		
POU4	monooxygenase			2.88E-02	ICAT2,IL1B,NOQ1		
SDC1	enzyme			2.88E-02	Cdc2,GALEN1		
CRY1	enzyme			2.88E-02	CEBPAL,IL1B		
CDK7	kinase			2.88E-02	STC2,TNFaiP3		
DUSP14	phosphatase			2.88E-02	NFKBIZ,Vnn3		
BHLHE41	transcription regulator			2.88E-02	GATA3,IKK2		
HSPA1A/HSPA1B	enzyme			2.88E-02	Hspa1b,IL1B		
2'-cyclic guanosine monophosphate A diglycerol ether	chemical reagent			2.88E-02	CD86,IL1B		
RV_538	other			2.88E-02	CASP1,CCR7,CYBA		
ethylene diaminetetraacetic acid	chemical drug			2.88E-02	BCL2A1,IL1B		
irootecan	chemical drug			2.88E-02	FAS,L		
isatoridine	chemical reagent			2.88E-02	CD40,CD86		
cyclomaltohextrin	chemical drug			2.88E-02	CSF3,IL1B		
topiramate	chemical drug			2.88E-02	CASP3,IL1B		
CNR1	G-protein coupled receptor	0.420	bias	2.88E-02	BMP2,BMP4,C2,C2b,CORO2A,NOD2,PTK2B		
ZAP70	kinase	1.982	bias	3.04E-02	ALAS1,ANG,CCR7,CYBA		
ELK1	transcription regulator	1.951	bias	3.04E-02	BCL2A1,CD44,IL1B,IL4,NOQ1,PTK2		
Ph	other			3.04E-02	APOA1,RAK2,RAK4,RRAS		
FBXO32	enzyme	1.109	bias	3.04E-02	ILB,KRT19,OAT,SOD2,Tcf7		
3M-011	chemical reagent			3.05E-02	CD40,CD83,CD86		
MALAT1	other			3.05E-02	Cdc2,FRMD8,Glycam1		
KEAP1	transcription regulator			3.05E-02	GSTP1,IL1B,NOQ1		
PPDK1	kinase			3.05E-02	ICAT1,IL1B,NOQ1,SERpine1		
TIMP1	cytokine			3.05E-02	ICAT2,IL1B,NOQ1		
lactic acid	chemical - endogenous mammal			3.05E-02	CXCL12,IL1B,NOQ1		
baflomycin A1	chemical drug			3.05E-02	IL1B,NOQ1		
TGF- β	growth factor	1.709	bias	3.15E-02	ADAM19,GATA3,JUN,LTBP2,SERpine1		
lithium	chemical drug	0.947		3.18E-02	CAMK4,CASP2,FAS,JUN,NCS1		
FBXW7	enzyme	0.577	bias	3.21E-02	HSPB1,JUN,NOQ1,SERpine1		
POU2AF1	transcription regulator			3.21E-02	B4GALT1,CD86,LD3,LCK		
zadarnol	chemical toxicant			3.21E-02	CXCL12,HSPB1,JUN,KLK3		
cadmium chloride	chemical toxicant			3.21E-02	Secretase gamma		
Secretase gamma	complex			3.29E-02	BATF,CD83,CD86		
ZBED6	transcription regulator			3.29E-02	CRIM1,UP1,WWC1		
CHRNA7	transmembrane receptor			3.29E-02	Cdc2,ID1,IL1B		
ANKK2	other			3.29E-02	ANXA1,FA8,JUN		
DNAse2	enzyme			3.29E-02	CP,HOXA11,HOXA11-2,Msf4a4b (includes others)		
SELP	transmembrane receptor			3.29E-02	BCL2A1,BST1,IL1B		
PRMT1	enzyme			3.29E-02	FTH1,FTL,MRC1		
ZBTB7B	transcription regulator			3.29E-02	CD8A,GATA3,KLF4		
PLAT	peptidase			3.29E-02	IL1B,JUN,SERpine1		
TYK2	kinase			3.29E-02	CSF3,Hamp/Hamp2,IL1B		
CCD42	enzyme			3.29E-02	CASP3,CD86,JUN		
MEIS1	transcription regulator			3.29E-02	CHD9,FLT3,RUNX2		

S-nitroso-N-acetylpenicillamine	chemical reagent		3.29E-02	CXCL12.FAS.PRKG1		
glycochenodeoxycholate	chemical - endogenous mammal		3.31E-02	BCL2A1.BIRC3		
MEG3	other		3.31E-02	GDF15.JUN		
Rac	group		3.31E-02	BMP2.CD9		
bel hac asan	chemical drug		3.31E-02	Cd2L1B		
SGPP1	phosphatase		3.31E-02	IL1B,IL3M3		
NF105D	transcription regulator		3.31E-02	GDF15.CD9		
TNFAIP1L2	other		3.31E-02	Cd2L1B		
CBS/CBSL	enzyme		3.31E-02	APOA1.CASP3		
TAC4	other		3.31E-02	CD86.IL1B		
COX411	enzyme		3.31E-02	SLC2A3.TSPAN8		
SRSF3	other		3.31E-02	CD44.JUN		
PIAS4	transcription regulator		3.31E-02	IL1B.SERpine1		
ATKN7	other		3.31E-02	BASP1.Marks		
CSF3R	transmembrane receptor		3.31E-02	CD44.CXCL12		
ACVR1B	kinase		3.31E-02	IL1A,IL1B,IL1NE1		
C532	G-protein coupled receptor		3.31E-02	Cd2.CSF3		
NPFF	other		3.31E-02	CEBPAl.D3		
ST14	peptidase		3.31E-02	ICAM1.IL1B		
ebselein	chemical drug		3.31E-02	ICAM1.IL1B		
clasto-lactacytin beta-lactone	chemical - protease inhibitor		3.31E-02	GSTP1.MAPK6		
N-3-oxododecanoyl-homoseri	chemical reagent		3.31E-02	CSF1.IL1B		
dimethyl fumarate	chemical drug		3.31E-02	CCR7.JUN		
polyamines	chemical - other		3.31E-02	CD44.CBP8A		
nickel chloride	chemical - pollutant		3.31E-02	IL1B.JUN		
spemarin	chemical - endogenous mammal		3.31E-02	IL1B.RUNX2		
anti-benz(a)pyrene-diol-epoxide	chemical toxicant		3.31E-02	GADD45B.JUN		
biochanin A	chemical toxicant		3.31E-02	CD86.RUNX2		
noscapine	chemical drug		3.31E-02	BIRC3.ICAM1		
cycloproterone acetate	chemical drug		3.31E-02	GA43.KLK3		
MAPK3	kinase	0.000	bias	3.32E-02	B4GALT1.BMP4.CD86.FOSL1.JUN	
HNRNPA2B1	other		3.38E-02	CP.GDF15.JUP.MEST.PLCB4.SEMA3B.SYT1		
S-hydroxytryptamine	chemical - endogenous mammal	1.954	bias	3.39E-02	AES.CAT1.CIC1.IL1B,IL3.RUNX2.SERpine1	
oxidase	chemical drug		3.47E-02	CD44.CAP3.GDP		
LSL-1	transcription regulator	1.387	bias	3.47E-02	BMP4.CCKAR.IL1B(ILRB3).PIRT	
NEYA	transcription regulator	Activated	2.000	bias	3.47E-02	CCNA2.FTH1.GAD045B.ICAM1.JUN
MAPK1	kinase	0.163	bias	3.48E-02	BCL11A.Cetn4/Gm7094.GATA3.IF16.IL1B.JUN.LAG3.OASL.PRKG1.PTPRK	
USP22	peptidase		3.55E-02	BCL2A1.CSF2RB.MRC1		
SETD2	enzyme		3.55E-02	ANG.JUN.SERpine1		
ABCGL1	transporter		3.55E-02	Cd2.CSF3.L1B		
PRKCQ	kinase		3.55E-02	CD44.FOSL1.GATA3		
formaldehyde	chemical - endogenous mammal		3.55E-02	FOXP1.IL1B		
methylmethanesulfone	chemical toxicant		3.55E-02	GDF15.JUN		
phenol 12,13-dibutylate	chemical - endogenous non-mam		3.55E-02	APOA1.C6.SERpine1		
AIRE	transcription regulator		3.58E-02	AKR1B10.BMP2.BMP4.KLK3		
ursolic acid	chemical drug		3.58E-02	CASP3.QDF15.IL1B.SOD2		
SBDS	other		3.62E-02	GADD45B.GAP43.ID1.IF16.ZNRF1		
MAPT	other		3.62E-02	ANXA6.BASP1.C1R.CASP3.GSTP1.HK1.IL1B.JUN.Press1 (includes others).SERpine1		
MAP4K4	kinase	Inhibited	-2.449	bias	3.64E-02	ALDH3B1.CEBPA.H8PD.MGLL.PLCB4.ST3GAL4
BDNF	growth factor	1.779	bias	3.64E-02	ACOT7.BMP2.CASP3.CAV2.CP.FTL.GA43.JUN.SEMA3E.SOD2	
STAT5B	transcription regulator	0.302	bias	3.70E-02	BIRC3.BMF.CASP3.FAS.GADD45B.Glycam1.GSTP1.Hmp/Hmp2.KRT19.NQO1	
Lh	complex	0.911	bias	3.72E-02	CD44.MAPK6.PLIN3.RUNX2.SOD2.TNFAIP3.TNFRSF12A.UPP1.VCL	
LSL-1	transcription regulator		3.74E-02	SERpine1.VCL		
NEYA	transcription regulator	Activated	2.000	bias	3.74E-02	CCNA2.FTH1.GAD045B.ICAM1.JUN
MAPK1	kinase		3.75E-02	BCL11A.Cetn4/Gm7094.GATA3.IF16.IL1B.JUN.LAG3.OASL.PRKG1.PTPRK		
USP22	peptidase		3.55E-02	BCL2A1.CSF2RB.MRC1		
SETD2	enzyme		3.55E-02	ANG.JUN.SERpine1		
ABCGL1	transporter		3.55E-02	Cd2.CSF3.L1B		
PRKCQ	kinase		3.55E-02	CD44.FOSL1.GATA3		
formaldehyde	chemical - endogenous mammal		3.55E-02	FOXP1.IL1B		
methylmethanesulfone	chemical toxicant		3.55E-02	GDF15.JUN		
phenol 12,13-dibutylate	chemical - endogenous non-mam		3.55E-02	APOA1.C6.SERpine1		
AIRE	transcription regulator		3.58E-02	AKR1B10.BMP2.BMP4.KLK3		
ursolic acid	chemical drug		3.58E-02	CASP3.QDF15.IL1B.SOD2		
SBDS	other		3.62E-02	GADD45B.GAP43.ID1.IF16.ZNRF1		
MAPT	other		3.62E-02	ANXA6.BASP1.C1R.CASP3.GSTP1.HK1.IL1B.JUN.Press1 (includes others).SERpine1		
L-685,458	chemical - protease inhibitor		3.77E-02	ID1.PTPRK		
Mn(III)-tetrakis(4-benzoic acid)	chemical reagent		3.77E-02	CD44.SERpine1		
benzod	other		3.77E-02	CD44.CD86		
IL1R1	transmembrane receptor	1.718	bias	3.77E-02	Cd2.CXK12.ICAM1.IL1B	
FL11	transcription regulator	1.969	bias	3.77E-02	Cd2.CSF3.CXR3.RACK1	
9-bromoguanosine 3',5'-cyclic n	chemical - kinase inhibitor		3.81E-02	BMP2.CD8A.SLC12A4		
TARDBP	transcription regulator		3.81E-02	CASP3.C2cJL1B		
IGFBP7	transporter		3.77E-02	CASP3.SOD2		
TAP1	transporter		3.77E-02	HLA-A,IL1B		
AIMP1	cytokine		3.77E-02	ICAM1.IL1B		
PNA	other		3.77E-02	GDF15.JUN		
CAPN3	peptidase		3.77E-02	FTH1.SOD2		
SLC2A1	transporter		3.77E-02	NOQ1.SERpine1		
BDXR2	G-protein coupled receptor		3.77E-02	CD44.ICAM1		
TREX1	enzyme		3.77E-02	IFI16.OASL		
PARK7	enzyme		3.77E-02	ICAM1.SOD2		
PDE5A	enzyme		3.77E-02	IL1B.PRKG1		
SPINT1	other		3.77E-02	PTK7.Tcf2		
L-685,458	chemical - protease inhibitor		3.77E-02	ID1.PTPRK		
Mn(III)-tetrakis(4-benzoic acid)	chemical reagent		3.77E-02	CD44.SERpine1		
benzod	other		3.77E-02	CD44.CD86		
IL1R1	transmembrane receptor	1.718	bias	3.77E-02	Cd2.CXK12.ICAM1.IL1B	
FL11	transcription regulator	1.969	bias	3.77E-02	Cd2.CSF3.CXR3.RACK1	
9-bromoguanosine 3',5'-cyclic n	chemical - kinase inhibitor		3.81E-02	BMP2.CD8A.SLC12A4		
TARDBP	transcription regulator		3.81E-02	CASP3.C2cJL1B		
IGFBP3	other		3.81E-02	ICAM1.IL1B.SERpine1		
GTF2B	transcription regulator		3.81E-02	BCL2A1.NFKBIA.TNFAIP3		
parthenolide	chemical drug		3.81E-02	CD44.IL1B.SOD2		
ZFH-X	transcription regulator		3.81E-02	CD44.IL1B.JUN		
3'-deazaneplanocin	chemical drug	0.711	bias	3.84E-02	ALCAM.C6.CCN3.CSF3.DOCK4.FOSL1.GADD45B.ID1.RASGRP1.SERpine1	
3-deazaneplanocin	chemical drug	0.687	bias	3.86E-02	FAS.KLF6.LAMB3.NOTCH2	
UCHL1	peptidase	1.000	bias	3.96E-02	ANXA6.DOCK10.MAPK6.SH2D4A	
GSK3B	kinase	Activated	2.433	bias	4.04E-02	BCL2A1.BIRC3.Cg2.IL1B.NFKBIZ.SERpine1
SOX4	transcription regulator	Activated	2.813	bias	4.05E-02	DEPP1.JX1.CASP3.Cg2.ILE8T.NQO1
POU2F2	transcription regulator	Activated	2.000	bias	4.05E-02	DCAF10.JUN.LCK.NFKBIA
flutamide	chemical drug	-0.784	bias	4.09E-02	CD44.IL1B.JUN.SOD2	
phorbol esters	chemical - other	Activated	2.219	bias	4.09E-02	CD44.IL1B.JUN.SOD2
3,4-dihydroxystyrene	chemical toxicant	1.980	bias	4.09E-02	CD83.CD86.CSF1	
RNASE2	enzyme		4.09E-02	GDF15.JUN		
TANK	other		4.09E-02	NFKBIZ.Vnn3.ZCH12		
CAMK4	kinase	1.814	bias	4.09E-02	ALCAM.C6.CCN3.CSF3.DOCK4.FOSL1.GADD45B.ID1.RASGRP1.SERpine1	
CD4	transmembrane receptor		4.09E-02	CASP3.C2cJL1B		
THBS1	other		4.09E-02	Cd2.L1B.LRP1		
POSTN	other		4.09E-02	Cd2.LCA1.RUNX2		
diphosphoryl lipid A	chemical toxicant		4.10E-02	CD44		
gentamicin C1	chemical drug		4.10E-02	CD44		
syngas	chemical - endogenous non-mam		4.10E-02	IL1B		
Cdx8	complex		4.10E-02	JUN		
Pdfra-Pdfrb	complex		4.10E-02	LCK		
endrin	chemical toxicant		4.10E-02	CEBPAl		
enkephalin, methionine	biologic drug		4.10E-02	MRC1		
T-type Calcium Channel	complex		4.10E-02	ENPP1		
Rps15a-ps4	other		4.10E-02	NFKBIA		
MBNL3	other		4.10E-02	CD44		
SLC4A4	transporter		4.10E-02	CD44		
ADM1	other		4.10E-02	NFKBIA		
POPC2	other		4.10E-02	IL1B		
SUCNR1	G-protein coupled receptor		4.10E-02	IL1B		
Snhg5	other		4.10E-02	KLF4		
SLC9A9	transporter		4.10E-02	FTH1		
GSTZ1	enzymes		4.10E-02	NOQ1		
Hsf3	other		4.10E-02	PROM2		
C1QL4	other		4.10E-02	CEBPAl		
GPR1	G-protein coupled receptor		4.10E-02	ICAM1		
LBH	transcription regulator		4.10E-02	IL1B		
METTL8	enzyme		4.10E-02	CEBPAl		
BATF2	other		4.10E-02	JUN		
lauroylcamitine	chemical - endogenous mammal		4.10E-02	CLDN4		
VANGL2	other		4.10E-02	SDC4		
CTDSP2	phosphatase		4.10E-02	ID1		
SV2A	transporter		4.10E-02	SYT1		
Rae1ta	other		4.10E-02	HLA-A		
AKNA	transcription regulator		4.10E-02	CDA		
annitin	chemical - endogenous non-mam		4.10E-02	CASP3		
HIP1	other		4.10E-02	KLF4		
LY_518674	chemical drug		4.10E-02	APOA1		
Inflammosome (Nalp3, Asc, Cas)	complex		4.10E-02	IL1B		
ETV7	transcription regulator		4.10E-02	BMP6		
clusterin antisense oligonucleo	biologic drug		4.10E-02	KLF4		
API1M1	transporter		4.10E-02	GDF15		
FAIM2	other		4.10E-02	CASP3		
IVNS1ABP	other		4.10E-02	SCD		
HL	transcription regulator		4.10E-02	SERpine1		
ZNF224	transcription regulator		4.10E-02	TNFAIP3		
CELA1	peptidase		4.10E-02	HLA-A		
cyproconazole	chemical drug		4.10E-02	GADD45B		
MLP	other		4.10E-02	HK1		
CALU	other		4.10E-02	IL1B		
NMB	other		4.10E-02	JUN		
LAMA3	other		4.10E-02	IL1B		
ARHGEF1	enzyme		4.10E-02	RUNX2		
mir-338	microRNA		4.10E-02	ALCAM		
mir-483-5p (miRNAs w/seed A)	mature microRNA		4.10E-02	JAG1		
mir-652	microRNA		4.10E-02	CASP3		
MIR585	microRNA		4.10E-02	LAMB3		
mir-1298-5p (and other miRNA)	mature microRNA		4.10E-02	IL1B		
Zingiber officiale ginger extract	chemical drug		4.10E-02	FTTH1		
NUBP1	other		4.10E-02	CASP3		
HIF1A-AS1	other		4.10E-02	CASP3		

N-acetylcytidine	chemical - endogenous mammal		4.10E-02	IL1B	
BORCS8-MEF2B	transcription regulator		4.10E-02	JUN	
STK38L	kinase		4.10E-02	YAP1	
NBR1	other		4.10E-02	GATA3	
abiraterone	chemical drug		4.10E-02	KLK3	
NOXO1	other		4.10E-02	SOD2	
IPF4	enzyme		4.10E-02	HLA-A	
SIGLEC11	other		4.10E-02	IL1B	
GSTF1	transcription regulator		4.10E-02	RUNX2	
FGB	other		4.10E-02	ICAM1	
poly-L-glutamic acid-peptidol 1	chemical reagent		4.10E-02	Cd2	
cyclo(Ieo-Asp-GR)-LLIILAKLKA	chemical reagent		4.10E-02	CASP3	
SLC7A11	transporter		4.10E-02	IL1B	
VANGL1	other		4.10E-02	JUN	
PLEKH1	other		4.10E-02	CDR1	
INDY	transcription regulator		4.10E-02	SERpine1	
RBM3	other		4.10E-02	CD44	
MYBP1	other		4.10E-02	Cd2	
CD88	other		4.10E-02	IL1B	
PLEKH2	other		4.10E-02	CD86	
PATZ1	transcription regulator		4.10E-02	KLK3	
ENC1	peptidase		4.10E-02	NQO1	
FOXL1	transcription regulator		4.10E-02	SDC1	
DRP2	other		4.10E-02	DMD	
FGF5	growth factor		4.10E-02	CD5	
SMC1A	transporter		4.10E-02	POLE4	
FRAT1	other		4.10E-02	JUN	
14,15-epoxyeicoso-5(Z)-enoic	chemical reagent		4.10E-02	Cd2	
IP09	transporter		4.10E-02	PTK2B	
nitrosifiedepine	chemical reagent		4.10E-02	ICAM1	
CRTAP	other		4.10E-02	SERpine1	
Acp5	phosphatase		4.10E-02	IL1B	
ST1	other		4.10E-02	Cd2	
APOC1	transporter		4.10E-02	CASP3	
CDK11B	kinase		4.10E-02	KLK3	
NLRP1	other		4.10E-02	IL1B	
RNF11	enzyme		4.10E-02	SERpine1	
CLEC2D	transmembrane receptor		4.10E-02	CD83	
COPS6	other		4.10E-02	SFN	
ZFYVE16	transporter		4.10E-02	SERpine1	
N-acetyl-sulfotyrosylcysteine-am	chemical reagent		4.10E-02	XDH	
ATB-346	chemical drug		4.10E-02	IL1B	
E-6540APP	chemical reagent		4.10E-02	CD54CA1	
verapin A	chemical reagent		4.10E-02	FAS	
hydroxyl radical	chemical toxicant		4.10E-02	KLF4	
trimellitic anhydride	chemical toxicant		4.10E-02	IL1B	
amsacrine	chemical drug		4.10E-02	JUN	
samorelate	chemical drug		4.10E-02	SERpine1	
methiothepin	chemical drug		4.10E-02	SERpine1	
sibutramine	chemical drug		4.10E-02	SERpine1	
2,5-hexanedione	chemical toxicant		4.10E-02	FANCI	
hexaazinone-neomycin B con	chemical reagent		4.10E-02	CD38A	
oxazepam	chemical drug		4.10E-02	GADD45B	
3,3'-iminodipropionitrile	chemical toxicant		4.10E-02	Cd2	
gliclazide	chemical drug		4.10E-02	SLC2A3	
chalcone-24	chemical reagent		4.10E-02	BIRC3	
trichosanthin	chemical drug		4.10E-02	JAG1	
terpenoid	chemical - endogenous mammal		4.10E-02	LRP1	
urushiol	chemical - endogenous non-mar		4.10E-02	IL1B	
phenol	chemical - endogenous mammal		4.10E-02	ICAM1	
sodium fluoride	chemical drug		4.10E-02	GSTP1	
cation	chemical - other		4.10E-02	IL1B	
echium oil	chemical drug		4.10E-02	ICAM1	
procaterol	chemical drug		4.10E-02	ICAM1	
Z-VAD-FMK	chemical reagent		4.10E-02	IL1B	
veneporfin	chemical drug		4.10E-02	YAP1	
KT 5926	chemical - kinase inhibitor		4.10E-02	CD14	
aluminum	chemical drug		4.10E-02	RUNX2	
lymphostin B56	chemical - kinase inhibitor		4.10E-02	ICAM1	
ibolome	chemical drug		4.10E-02	SERpine1	
flunitamide	chemical drug		4.10E-02	ICAM1	
fluorofolic acid	chemical reagent		4.10E-02	IL1B	
1-phenazinecarboxylic acid	chemical - endogenous non-mar		4.10E-02	ICAM1	
HDXD10	transcription regulator	0,000	4.17E-02	CD44,ICAM1,NCS1,SERpine1	
rotetone	chemical toxicant	0,832	4.17E-02	BIRC3,CASP3,IL1B,SOD2	
Interferon beta-1a	biologic drug		4.17E-02	GADD45B,GSTP1,IL1LRB3,MAL,NFKBIA,SERPINE1	
CREM	transcription regulator	1,131	4.18E-02	CMAK4,CDB8,CDB8,GADD45B,Marks,MEST,Tpm1	
aldosterone	chemical - endogenous mammal	Activated 2,578	4.18E-02	BMP2,CD92,CYBA,ICAM1,NFKBIA,SERpine1,ZBTB16	
epithilone B	chemical drug		4.25E-02	CD44,ICAM1	
selametinib	chemical drug		4.25E-02	JUN,RUNX2	
DPH5	enzyme		4.25E-02	IL1B,NFKBIA	
MDK	growth factor		4.25E-02	Cad1,Cd2	
NUP62	transporter		4.25E-02	PERP,WWC1	
LY96	transmembrane receptor		4.25E-02	CD40,CD86	
mir-204	microRNA		4.25E-02	IL1B,RUNX2	
FCGR1A	transmembrane receptor		4.25E-02	CSF1,IL1B	
HDAC9	transcription regulator		4.25E-02	CEBPB,ICAM1	
STM1	act. chaperone		4.25E-02	USTO1,NQO1	
10-hydrooleate	chemical - endogenous mammal		4.25E-02	Cd2,ICAM1	
CR2	transmembrane receptor		4.25E-02	FAS,IL1B	
BCL10	transcription regulator		4.25E-02	CD44,TNFaIP3	
CNR2	G-protein coupled receptor		4.25E-02	Cd2,IL1B	
Cux1	transcription regulator		4.25E-02	Cd8,CDA	
10,10 peptide	chemical reagent		4.25E-02	Cd2,IL1B	
3-aminobenzamide	chemical toxicant		4.25E-02	ICAM1,IL1B	
2-acetylaminofluorene	chemical toxicant		4.25E-02	JAG1,NOTCH2	
allyl sulfide	chemical drug		4.25E-02	CSF1,ICAM1,A3	
comstatin A	chemical drug		4.25E-02	ICAM1,NFKBIA	
mevastatin	chemical drug		4.25E-02	BMP4,KLF4	
indole	chemical - endogenous mammal		4.25E-02	CGN,TIP3	
farnesyl pyrophosphate	chemical - endogenous mammal		4.25E-02	ICAM1,SERpine1	
tetrandrine	chemical drug		4.25E-02	CASP3,JUN	
REST	transcription regulator	-1,400	4.30E-02	B3GAT1,CEBPB,CXCL12,GAP43,Nes,OAT,SYT1	
arsenic trioxide	chemical drug	1,672	4.34E-02	BCL2A1,CDA44,FAS,FTH1,MAPK4,MAPK6,MCM3,NFKBIA,NQO1,PIR	
CDKN1A	kinase	-0,116	4.35E-02	BUB1,CASP3,CONA,FAS,IL1B,JAG1,MCM3,SERpine1,SOD2	
rasagiline	chemical drug		4.37E-02	ITGB1,JUN,NOO1	
NS-001	other	0,462	4.37E-02	ITGB1,JUN,NOO1	
KRT14	other		4.37E-02	CXCL14,G3B2,KRT8	
APR-246	chemical drug		4.37E-02	CD81,GADD45B,VCL	
CIDEc	other		4.37E-02	Cd2,SDC1,SERpine1	
ethylene glycol tetraacetic acid	chemical reagent		4.37E-02	BIRC3,CD83,CD86	
NRA43	Igand-dependent nuclear recep		4.37E-02	BIRC3,CEBPB,FBP1,NQO1	
PLN	transporter		4.37E-02	APOA1,RACK1,RALA,RRAS	
25-hydroxycholesterol	chemical agent	1,000	4.37E-02	FOSL1,IL1B,JUN,NFKBIA	
ATP7C	transcription regulator	1,969	4.37E-02	FOSL1,IL1B,JUN,NFKBIA,NOO1	
LPE	enzymes		4.46E-02	CD44,ICAM1,JAG1	
BMI1	transcription regulator		4.59E-02	FAS,HCK,MCM3,SNF	
FOLR1	transporter		4.59E-02	BASP1,BIRC3,CDC1,CLCA1,ST3GL4	
KLF3	transcription regulator	-1,155	4.59E-02	ALDH3B1,ANXA6,ARHGEF3,GSTP1,ITGB7,LILRB3,NEURL3,PARP3,PDLM1,PTP4A2	
pregnenolone carbonitrile	chemical drug		4.67E-02	ALAS1,IMCGS2,UGT1A7 (includes others)	
INPP5D	phosphatase		4.67E-02	CD68,FAS,IRAK3	
ATP7B	transporter		4.67E-02	CFB,FBP5,TRIP13	
SERpine2	other	1,374	4.67E-02	Cd2,C8B,IL1B	
JAG2	growth factor		4.67E-02	CD44,FAS,IL1B,JAG1	
DDX17	chemical reagent		4.67E-02	CD44,FAS,SMO	
RORC	Igand-dependent nuclear recep		4.69E-02	CD28,GADD45B,GSTP1,IL1B,LPIN2,SLC2A3,ZBTB16	
3-deoxy-2-octulosonic acid(2)H	chemical - endogenous non-mar		4.75E-02	Cd2,IL1B	
pCPT-CAMP	chemical - kinase inhibitor		4.75E-02	JUN,PRK1	
Sod	group		4.75E-02	Cd2,ICAM1	
tricosan	chemical drug		4.75E-02	JUN,NOO1	
Angiotensin II receptor type 1	group		4.75E-02	GAP43,SERpine1	
ZC3H14	other		4.75E-02	BATF,Vnn3	
PFK1B	phosphatase		4.75E-02	CD44,CD44	
SMYD3	enzymes		4.75E-02	CEBPD,IL1RL1	
HSPB1	other	1,504	4.75E-02	Cd2,IL1B	
UCP2	transporter		4.75E-02	HK2,IL1B	
TNFRSF21	transmembrane receptor		4.75E-02	CASP3,CD28	
INHBB	growth factor		4.75E-02	Hamp/Hamp2,SERpine1	
PHB2	transcription regulator		4.75E-02	BMP2,IL6ST	
IL-17f dimer	complex		4.75E-02	CSF3,IL1B	
PHLPP1	enzyme		4.75E-02	CEBPD,Vnn3	
PSMB8	peptidase		4.75E-02	NEURL3,TNFaIP3	
LBH	transporter		4.75E-02	CD44,IL1B	
mir-515	microRNA		4.75E-02	CD44,SERpine1	
mir-7	microRNA		4.75E-02	KLF4,SLC2A3	
LAMA5	other		4.75E-02	Cd2,Csf3	
KLF10	transcription regulator		4.75E-02	GATA3,SERpine1	
DDX17	enzyme		4.75E-02	FOSL1,JUN	
Mir200	group		4.75E-02	JUN,LRP1	
CCAT2	other		4.75E-02	CASP3,LATS2	

GAB1	1.515	other			4.75E-02	CASP3,IL1B	
C5		other			4.75E-02	Cd2,IL1B	
batimastat		chemical - protease inhibitor			4.75E-02	ANG,SDC4	
cerulenin		chemical drug			4.75E-02	Cd2,IL1B	
pynvaldehyde		chemical - endogenous mammal			4.75E-02	ICAM1,NQO1	
bombezin		chemical - endogenous mammal			4.75E-02	KLK3,ZBTB18	
SMN2		transcription regulator	-0.317	bias	4.77E-02	CBP,CD44,CD45B,Hamp/Hamp2,RUNX2,SERpine1	
CD3E		transmembrane receptor			4.81E-02	FAS,JUN,LCP2,NFKBIA	
SGK1		kinase	Activated	2.000	bias	4.81E-02	CEBPB,SLC2A3,SLC34A2,SMO
sulindac		chemical drug			4.81E-02	CONNA2,IL1B,NQO1,SERPINB1	
INS		other	1.432		4.82E-02	APOA1,C22,FAD53,FAS,FOSL1,ICAM1,JUN	
cocaine		chemical drug	Activated	2.415	bias	4.85E-02	Cd2,FOSL1,GADD45B,ICAM1,JUN,LAMC2,MEST,Tpm1
PXR ligand-PXR-Reinoic acid-4		complex			4.97E-02	ALAS1,CYP3A7,UGT1A7 (includes others)	
FOXP1		transcription regulator			4.97E-02	DMD,GAP43,JUN	
propranolol		chemical drug			4.97E-02	HKG1,NFKBIA	
miR-124-3p (and other mRNAs)		mature microRNA	Inhibited	-2.978	bias	5.00E-02	B4GALT1,BMP4,C22,ODC47,CEBPB,F11R,JAG1,LITAF,TSC22D4
NRC2		ligand-dependent nuclear recep		1.984		5.89E-02	BCL2A1,BMP4,Cd2,ICAM1,IL1B,SERpine1
DNMT3A		enzyme	Inhibited	-2.000	2.09E-01	BLNK,IRF5,PLCB4,SDC4,Tcf7	